{
  "file_name": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
  "total_pages": 93,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "21.94206428527832": 4,
      "14.987749099731445": 16,
      "11.030982971191406": 1256,
      "19.51662254333496": 1,
      "17.02608299255371": 2,
      "11.99020004272461": 1209,
      "12.94941520690918": 17,
      "12.828953742980957": 2,
      "11.869691848754883": 46,
      "12.07383918762207": 1,
      "10.910422325134277": 1,
      "32.013832092285156": 2,
      "9.951866149902344": 750,
      "17.985300064086914": 15,
      "14.028532981872559": 43,
      "43.46063995361328": 1,
      "29.176517486572266": 1,
      "21.607894897460938": 10,
      "21.986534118652344": 1,
      "18.944515228271484": 1,
      "27.937164306640625": 1,
      "8.992650032043457": 220,
      "8.03343391418457": 4,
      "32.97304916381836": 1,
      "11.624929428100586": 1,
      "11.37490177154541": 1,
      "15.946965217590332": 2,
      "24.93961524963379": 2,
      "20.02363395690918": 1,
      "13.788712501525879": 19,
      "10.751672744750977": 13,
      "10.864259719848633": 21,
      "7.074217319488525": 2,
      "11.510591506958008": 42
    },
    "heading_sizes": [
      32.013832092285156,
      24.93961524963379,
      21.94206428527832,
      21.607894897460938,
      17.985300064086914,
      17.02608299255371,
      15.946965217590332,
      14.987749099731445,
      14.028532981872559,
      13.788712501525879,
      12.94941520690918,
      12.828953742980957,
      11.99020004272461,
      11.869691848754883,
      11.510591506958008
    ]
  },
  "table_analysis": {
    "total_tables": 8,
    "tables_info": [
      {
        "bbox": [
          83.95449829101562,
          123.08977508544922,
          535.5504760742188,
          740.4591674804688
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          65.48451232910156,
          263.8316650390625,
          528.913330078125,
          735.6729736328125
        ],
        "num_rows": 12,
        "num_cols": 3
      },
      {
        "bbox": [
          69.80216979980469,
          142.2845001220703,
          529.339111328125,
          331.54864501953125
        ],
        "num_rows": 8,
        "num_cols": 5
      },
      {
        "bbox": [
          64.52503204345703,
          213.72642517089844,
          529.9927368164062,
          601.7423706054688
        ],
        "num_rows": 9,
        "num_cols": 2
      },
      {
        "bbox": [
          81.79566955566406,
          215.76419067382812,
          511.85858154296875,
          373.0203552246094
        ],
        "num_rows": 6,
        "num_cols": 4
      },
      {
        "bbox": [
          89.35157012939453,
          470.8487243652344,
          486.3360900878906,
          532.3414916992188
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          113.45851135253906,
          193.2288360595703,
          479.9793701171875,
          302.3716125488281
        ],
        "num_rows": 5,
        "num_cols": 2
      },
      {
        "bbox": [
          92.46988677978516,
          157.02838134765625,
          500.0090026855469,
          736.9915771484375
        ],
        "num_rows": 3,
        "num_cols": 2
      }
    ]
  },
  "text_blocks": [
    {
      "text": "질병의 예후·예측에 사용되는",
      "font_size": 21.94206428527832,
      "font_name": "H2hdrM",
      "bbox": [
        150.75828552246094,
        263.2218933105469,
        443.998046875,
        285.1579284667969
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 허가·심사 가이드라인",
      "font_size": 21.94206428527832,
      "font_name": "H2hdrM",
      "bbox": [
        72.92047882080078,
        302.7786560058594,
        521.955322265625,
        324.7146911621094
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 21.94206428527832,
      "font_name": "H2hdrM",
      "bbox": [
        220.32058715820312,
        342.33544921875,
        381.86627197265625,
        364.271484375
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        85.75352478027344,
        378.33599853515625,
        509.47247314453125,
        399.5408630371094
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서 등록번호",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        67.88320922851562,
        125.72689056396484,
        166.82925415039062,
        140.39492797851562
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0882-01",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        67.88320922851562,
        147.06356811523438,
        165.66827392578125,
        161.7316131591797
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018. 8.",
      "font_size": 19.51662254333496,
      "font_name": "T3",
      "bbox": [
        256.78082275390625,
        524.4268798828125,
        337.1151428222656,
        548.4486083984375
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.02608299255371,
      "font_name": "H2hdrM",
      "bbox": [
        170.78744506835938,
        80.5648422241211,
        425.6492919921875,
        97.58624267578125
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.95449829101562,
        123.08977508544922,
        104.46343231201172,
        137.7578125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질병의 예후·예측에 사용되는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        260.2589416503906,
        108.70549774169922,
        409.37872314453125,
        123.37352752685547
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        178.82308959960938,
        123.08977508544922,
        487.19635009765625,
        152.02223205566406
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "< In Vitro Diagnostics Multivariate Index Assay, IVD-MIA >",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        178.82308959960938,
        123.08977508544922,
        487.19635009765625,
        152.02223205566406
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        167.7890625,
        154.85507202148438,
        429.0168762207031,
        169.52310180664062
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "등록대상",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        72.20086669921875,
        308.5271301269531,
        116.2166748046875,
        323.1951599121094
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        326.0279846191406,
        105.30292510986328,
        340.6960144042969
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        175.2327880859375,
        423.6513366699219,
        189.9008331298828
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        151.238037109375,
        191.77471923828125,
        297.5997314453125,
        206.4427490234375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        175.8321533203125,
        507.804443359375,
        205.84341430664062
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        175.8321533203125,
        507.804443359375,
        205.84341430664062
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        208.43649291992188,
        531.6714477539062,
        223.1045379638672
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        224.85855102539062,
        535.5512084960938,
        256.0685119628906
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        224.85855102539062,
        535.5512084960938,
        256.0685119628906
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        257.9423828125,
        526.6383666992188,
        286.3953552246094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        257.9423828125,
        526.6383666992188,
        286.3953552246094
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        151.238037109375,
        288.2692565917969,
        416.93505859375,
        319.3593444824219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        151.238037109375,
        288.2692565917969,
        416.93505859375,
        319.3593444824219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        280.477783203125,
        507.804443359375,
        310.60888671875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        280.477783203125,
        507.804443359375,
        310.60888671875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        318.47625732421875,
        507.804443359375,
        348.60736083984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        318.47625732421875,
        507.804443359375,
        348.60736083984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        318.47625732421875,
        507.804443359375,
        348.60736083984375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        347.7242736816406,
        451.71612548828125,
        362.3923034667969
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        363.0675048828125,
        210.643798828125,
        377.73553466796875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        347.7242736816406,
        507.804443359375,
        377.73553466796875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        347.7242736816406,
        507.804443359375,
        377.73553466796875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.8524475097656,
        507.804443359375,
        406.98358154296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.8524475097656,
        507.804443359375,
        406.98358154296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        376.8524475097656,
        507.804443359375,
        406.98358154296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        406.1004943847656,
        440.0824279785156,
        420.7685241699219
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        421.4437255859375,
        252.8639678955078,
        436.11175537109375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        406.1004943847656,
        502.40771484375,
        436.11175537109375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        406.1004943847656,
        502.40771484375,
        436.11175537109375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        440.5028991699219,
        528.8347778320312,
        471.59295654296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        440.5028991699219,
        528.8347778320312,
        471.59295654296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.64496612548828,
        506.4308166503906,
        127.65259552001953,
        521.098876953125
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        84.67411041259766,
        524.0516357421875,
        103.74420166015625,
        538.7196655273438
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        481.01861572265625,
        448.0770263671875,
        495.6866455078125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        496.4817199707031,
        432.84918212890625,
        511.1497497558594
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        481.01861572265625,
        534.4710693359375,
        511.1497497558594
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        481.01861572265625,
        534.4710693359375,
        511.1497497558594
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        519.616455078125,
        451.956298828125,
        534.2844848632812
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        534.959716796875,
        448.1968078613281,
        564.970947265625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것입니까? (민원인용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        534.959716796875,
        448.1968078613281,
        564.970947265625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        527.2880859375,
        535.5504760742188,
        557.29931640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        527.2880859375,
        535.5504760742188,
        557.29931640625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타 확인",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        69.44236755371094,
        593.3358764648438,
        118.97551727294922,
        608.00390625
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        610.8367919921875,
        105.30292510986328,
        625.5048217773438
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        574.8760375976562,
        434.6850280761719,
        589.5440673828125
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.6383514404297,
        590.3391723632812,
        337.0552978515625,
        605.0072021484375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        574.8760375976562,
        507.804443359375,
        605.0072021484375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        458.3915710449219,
        574.8760375976562,
        507.804443359375,
        605.0072021484375
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        134.0873260498047,
        614.9122924804688,
        531.6718139648438,
        629.580322265625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.51841735839844,
        631.4542236328125,
        372.0533752441406,
        646.1222534179688
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        216.0029296875,
        653.6300048828125,
        381.7624816894531,
        668.2980346679688
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018년 8월 22일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        250.06446838378906,
        674.1276245117188,
        336.2977294921875,
        688.795654296875
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        330.4209289550781,
        711.4068603515625,
        413.2167663574219,
        740.4591674804688
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        330.4209289550781,
        711.4068603515625,
        413.2167663574219,
        740.4591674804688
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "우 승 민",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        453.9539794921875,
        709.8485717773438,
        500.2488708496094,
        724.5166015625
      ],
      "page_num": 2,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 원 규",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        453.59417724609375,
        727.3494262695312,
        500.60870361328125,
        742.0174560546875
      ],
      "page_num": 2,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        100.0749282836914,
        536.8703002929688,
        114.74295806884766
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        117.69567108154297,
        532.9910888671875,
        132.36370849609375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        135.31640625,
        99.92084503173828,
        149.9844512939453
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        170.43801879882812,
        536.8703002929688,
        185.10606384277344
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        188.05877685546875,
        536.8704223632812,
        202.726806640625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        205.55966186523438,
        536.8703002929688,
        220.22769165039062
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        223.18038940429688,
        535.6710205078125,
        237.8484344482422
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서",
      "font_size": 11.99020004272461,
      "font_name": "H2gtrM",
      "bbox": [
        64.52503204345703,
        260.8541259765625,
        536.985107421875,
        272.8410339355469
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품",
      "font_size": 11.99020004272461,
      "font_name": "H2gtrM",
      "bbox": [
        81.19599151611328,
        280.0331726074219,
        532.9910888671875,
        292.02008056640625
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의약품안전처 지침서등의 관리에 관한 규정 제2조)",
      "font_size": 11.99020004272461,
      "font_name": "H2gtrM",
      "bbox": [
        81.19599151611328,
        299.21221923828125,
        362.9954528808594,
        311.1991271972656
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        65.72438049316406,
        397.6600341796875,
        542.7020874023438,
        414.8790283203125
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기심사부 체외진단기기과에 문의하시기 바랍니다.",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        82.87508392333984,
        418.5172424316406,
        408.9333801269531,
        435.7362365722656
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 전화번호 : 043-719-4654~4665",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        66.56392669677734,
        447.2857971191406,
        272.5555419921875,
        464.5047912597656
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 팩스번호 : 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        66.56392669677734,
        474.6159362792969,
        234.77435302734375,
        491.8349304199219
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제·개정 이력서",
      "font_size": 17.02608299255371,
      "font_name": "H2gtrE",
      "bbox": [
        233.75331115722656,
        90.63383483886719,
        361.125,
        107.65523529052734
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병의 예후·예측에 사용되는",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        203.88949584960938,
        151.02926635742188,
        390.8681640625,
        170.9586639404297
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서)",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        88.75189971923828,
        170.4480438232422,
        511.2763366699219,
        190.37744140625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA >",
      "font_size": 14.987749099731445,
      "font_name": "MalgunGothicBold",
      "bbox": [
        94.98851776123047,
        189.9866943359375,
        499.99755859375,
        209.9160919189453
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제․개정번호",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.39697265625,
        257.0536804199219,
        407.1795959472656,
        274.2726745605469
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.39697265625,
        257.0536804199219,
        407.1795959472656,
        274.2726745605469
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicBold",
      "bbox": [
        79.39697265625,
        257.0536804199219,
        407.1795959472656,
        274.2726745605469
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0882-01",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.4796371459961,
        328.0657653808594,
        223.63922119140625,
        342.7337951660156
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2018. 8. 22",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        74.4796371459961,
        328.0657653808594,
        223.63922119140625,
        342.7337951660156
      ],
      "page_num": 4,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병의 예후·예측에 사용되는 체외진단용 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        239.51019287109375,
        304.6065673828125,
        519.457275390625,
        320.5500793457031
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사 가이드라인 (민원인 안내서)",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        264.4566650390625,
        320.18951416015625,
        494.5107421875,
        336.1330261230469
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  >",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        236.27194213867188,
        335.97711181640625,
        522.2382202148438,
        350.6451416015625
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제정",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        367.0010986328125,
        350.1567687988281,
        388.5893859863281,
        366.10028076171875
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목  차",
      "font_size": 21.94206428527832,
      "font_name": "H2hdrM",
      "bbox": [
        397.82440185546875,
        87.97343444824219,
        463.668701171875,
        109.90946197509766
      ],
      "page_num": 5,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제 I부  개요",
      "font_size": 12.828953742980957,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        139.6824951171875,
        476.5179138183594,
        152.62835693359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        139.6824951171875,
        476.5179138183594,
        152.62835693359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 배경",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        166.51724243164062,
        476.5179138183594,
        178.50413513183594
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        166.51724243164062,
        476.5179138183594,
        178.50413513183594
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 목적",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        191.80960083007812,
        476.5179138183594,
        203.79649353027344
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        191.80960083007812,
        476.5179138183594,
        203.79649353027344
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 적용 범위",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        217.22183227539062,
        476.5179138183594,
        229.20872497558594
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        217.22183227539062,
        476.5179138183594,
        229.20872497558594
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 기본 용어 설명",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        242.63406372070312,
        476.5179138183594,
        254.62095642089844
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        242.63406372070312,
        476.5179138183594,
        254.62095642089844
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 관련 법령",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        267.9263916015625,
        476.2778625488281,
        279.9132995605469
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        267.9263916015625,
        476.2778625488281,
        279.9132995605469
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제 II부  허가·심사시 고려사항",
      "font_size": 12.828953742980957,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        305.3414611816406,
        476.2778625488281,
        318.2873229980469
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        305.3414611816406,
        476.2778625488281,
        318.2873229980469
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        332.1761779785156,
        457.50823974609375,
        344.1630859375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요 고려사항",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        357.4685363769531,
        476.2778625488281,
        369.4554443359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        357.4685363769531,
        476.2778625488281,
        369.4554443359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 공통 고려사항",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        382.8807678222656,
        476.2778625488281,
        394.86767578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        382.8807678222656,
        476.2778625488281,
        394.86767578125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 사용목적 설정시 주요 고려사항",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        408.2929992675781,
        476.2778625488281,
        420.2799072265625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        408.2929992675781,
        476.2778625488281,
        420.2799072265625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        433.5853576660156,
        476.2778625488281,
        445.572265625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        433.5853576660156,
        476.2778625488281,
        445.572265625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 알고리즘 설계 및 내부 검정(평가)",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        458.9975891113281,
        476.2778625488281,
        470.9844970703125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        458.9975891113281,
        476.2778625488281,
        470.9844970703125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 알고리즘 외부 검정(평가)",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        484.4098205566406,
        476.2778625488281,
        496.396728515625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "20",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        484.4098205566406,
        476.2778625488281,
        496.396728515625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 알고리즘 내부 및 외부 검정시 고려사항",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        509.7021484375,
        476.2778625488281,
        521.6890869140625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        509.7021484375,
        476.2778625488281,
        521.6890869140625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 소프트웨어 허가·심사시 고려사항",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        535.1143798828125,
        476.2778625488281,
        547.101318359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        535.1143798828125,
        476.2778625488281,
        547.101318359375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 소프트웨어 검증 및 유효성 확인 보고서 작성 예시",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        560.526611328125,
        476.2778625488281,
        572.5135498046875
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        560.526611328125,
        476.2778625488281,
        572.5135498046875
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제III부  Q & A",
      "font_size": 12.07383918762207,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        109.86045837402344,
        594.4246826171875,
        476.2778625488281,
        614.3540649414062
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "35",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        594.4246826171875,
        476.2778625488281,
        614.3540649414062
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<부 록>",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        629.3314208984375,
        486.05255126953125,
        676.0803833007812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        629.3314208984375,
        486.05255126953125,
        676.0803833007812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사 예시",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        629.3314208984375,
        486.05255126953125,
        676.0803833007812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41",
      "font_size": 11.869691848754883,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        629.3314208984375,
        486.05255126953125,
        676.0803833007812
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등)",
      "font_size": 10.910422325134277,
      "font_name": "H2hdrM",
      "bbox": [
        109.86045837402344,
        682.297607421875,
        428.7022705078125,
        693.3255615234375
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제 I 부  개 요",
      "font_size": 32.013832092285156,
      "font_name": "H2hdrM",
      "bbox": [
        188.8976287841797,
        314.7529602050781,
        406.09991455078125,
        346.7579650878906
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 7,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 7,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제  I 부  개요",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        70.75151062011719,
        181.22178649902344,
        88.73185729980469
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 배경",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        117.47161865234375,
        102.7845458984375,
        134.28720092773438
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        150.19586181640625,
        536.2293701171875,
        164.71124267578125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        150.19586181640625,
        536.2293701171875,
        164.71124267578125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        169.9742431640625,
        536.2293701171875,
        184.34654235839844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        189.75262451171875,
        536.2293701171875,
        204.1249237060547
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단백체학이 급속히 성장할 수 있었다. 융합 학문의 발달로 인한 유전체 및 단백질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        209.531005859375,
        536.2293701171875,
        223.90330505371094
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        229.30938720703125,
        536.2293701171875,
        243.6816864013672
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "맞춤의료 시대를 도래하게 하였다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        249.0877685546875,
        286.500732421875,
        263.4600830078125
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        278.8152770996094,
        536.2293701171875,
        293.3306579589844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        278.8152770996094,
        536.2293701171875,
        293.3306579589844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        298.59368896484375,
        484.1535949707031,
        312.96600341796875
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        328.3211975097656,
        536.2293701171875,
        342.8365783691406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        328.3211975097656,
        536.2293701171875,
        342.8365783691406
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다. 진단검사를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        348.0995788574219,
        536.2293701171875,
        362.4718933105469
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        367.8779602050781,
        536.2293701171875,
        382.2502746582031
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없었던 부분을 개척하고 있다. 이에 따라 질병의 예후를 진단할 수 있는 바이오",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        387.6563415527344,
        536.2293701171875,
        402.0286560058594
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마커 또는 다중 바이오마커의 개발까지 요구되고 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        407.4347229003906,
        399.2396240234375,
        421.8070373535156
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        437.2821044921875,
        536.2293701171875,
        451.7974853515625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        437.2821044921875,
        536.2293701171875,
        451.7974853515625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        457.06048583984375,
        536.1094970703125,
        471.43280029296875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        476.8388671875,
        536.2293701171875,
        491.211181640625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로써, 치료 방향의 선정에 도움이 될 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        496.6172790527344,
        362.8993225097656,
        510.9895935058594
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        526.3447875976562,
        536.1094970703125,
        540.8601684570312
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        526.3447875976562,
        536.1094970703125,
        540.8601684570312
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        546.1231689453125,
        536.2293701171875,
        560.4954223632812
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다. 이러한 진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        565.9015502929688,
        536.2293701171875,
        580.2738037109375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        585.6799926757812,
        536.2053833007812,
        600.05224609375
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        605.4583740234375,
        536.2293701171875,
        619.8426513671875
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        625.2367553710938,
        506.8213195800781,
        639.6090087890625
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        654.9642333984375,
        536.2293701171875,
        669.4796142578125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        654.9642333984375,
        536.2293701171875,
        669.4796142578125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        674.7426147460938,
        536.2293701171875,
        689.1148681640625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다. 서로 다른 상태에 대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        694.52099609375,
        536.2293701171875,
        708.8932495117188
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        714.2993774414062,
        474.3189392089844,
        728.671630859375
      ],
      "page_num": 7,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        744.1467895507812,
        536.2293701171875,
        758.6621704101562
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        744.1467895507812,
        536.2293701171875,
        758.6621704101562
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        70.1746826171875,
        796.536865234375
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개인별 맞춤 진단 및 치료에 이용할 수 있다. 이러한 결과는 환자의 치료 효과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        69.04454803466797,
        536.2293701171875,
        83.41683959960938
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        88.82292938232422,
        510.2994384765625,
        103.19522094726562
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        81.55580139160156,
        118.5504379272461,
        536.2293701171875,
        133.06582641601562
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        118.5504379272461,
        536.2293701171875,
        133.06582641601562
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        137.7294921875,
        536.2293701171875,
        152.10177612304688
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        156.90850830078125,
        536.2293701171875,
        171.2928009033203
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.54605102539062,
        176.08755493164062,
        433.5410461425781,
        190.45985412597656
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 목적",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        234.10415649414062,
        102.7845458984375,
        250.91973876953125
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민원인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서(가이드라인)는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        266.8283996582031,
        538.268310546875,
        281.3437805175781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        286.0074157714844,
        520.7337646484375,
        300.3916931152344
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        315.1355895996094,
        538.1483154296875,
        329.6509704589844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        315.1355895996094,
        538.1483154296875,
        329.6509704589844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상업화",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수입,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판매를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획하고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        334.31463623046875,
        538.1483154296875,
        348.68695068359375
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기업들에게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필수적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려사항들에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        353.4936828613281,
        538.268310546875,
        367.8779602050781
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방향을 제시하고자 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        372.6727294921875,
        229.53160095214844,
        387.0450439453125
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        401.9207458496094,
        538.1483154296875,
        416.4361267089844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        401.9207458496094,
        538.1483154296875,
        416.4361267089844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시로 설명함으로써 체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        421.09979248046875,
        538.1483154296875,
        435.48406982421875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)의 허가·심사에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        421.09979248046875,
        538.1483154296875,
        435.48406982421875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 보다 상세한 이해를 돕고자 한다. <부록 참고>",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        440.2788391113281,
        373.4176330566406,
        454.6511535644531
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 적용범위",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        498.29547119140625,
        132.16836547851562,
        515.1110229492188
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(In",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Vitro",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Diagnostic",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Multivariate",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Index",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assay,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        62.6060676574707,
        530.8998413085938,
        538.2442626953125,
        545.2720947265625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        90.07118225097656,
        550.078857421875,
        538.2442626953125,
        564.4511108398438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예후, 예측을 위하여 해석 함수를 사용한다. 해석 함수는 다양한 지표(수치)들을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        90.07118225097656,
        569.2579345703125,
        538.268310546875,
        583.6301879882812
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다. 결과의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        90.07118225097656,
        588.4369506835938,
        538.1483154296875,
        602.8092041015625
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        90.07118225097656,
        607.615966796875,
        538.1483154296875,
        621.9882202148438
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        90.07118225097656,
        626.7950439453125,
        496.6268615722656,
        641.1672973632812
      ],
      "page_num": 8,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.88483428955078,
        656.0430908203125,
        532.6072998046875,
        670.4153442382812
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        685.1712036132812,
        538.1483154296875,
        699.54345703125
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다. 알고리즘은 입력값을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        704.3502807617188,
        538.268310546875,
        718.7225341796875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        723.529296875,
        538.1483154296875,
        737.9015502929688
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따른",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등)를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        742.7083740234375,
        538.1483154296875,
        757.0806274414062
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.06468200683594,
        69.04454803466797,
        427.9040832519531,
        83.41683959960938
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        98.17271423339844,
        538.1483154296875,
        112.54500579833984
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.46176147460938,
        117.35175323486328,
        155.43576049804688,
        131.7240447998047
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        146.59979248046875,
        538.1483154296875,
        160.97207641601562
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        108.6611099243164,
        165.77883911132812,
        474.4628601074219,
        180.151123046875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.90747833251953,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병의 발생 및 재발의 위험을 예측하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        108.6611099243164,
        214.08602905273438,
        384.5115966796875,
        228.4583282470703
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.88483428955078,
        265.27008056640625,
        529.96875,
        279.64239501953125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        294.39825439453125,
        538.268310546875,
        308.77056884765625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.10357666015625,
        312.37860107421875,
        538.268310546875,
        344.73126220703125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종합하여 판독을 쉽게 하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.10357666015625,
        312.37860107421875,
        538.268310546875,
        344.73126220703125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        95.82806396484375,
        358.4082946777344,
        538.2678833007812,
        371.641845703125
      ],
      "page_num": 9,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        130.96902465820312,
        374.9502258300781,
        535.1322631835938,
        388.18377685546875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        401.3214111328125,
        538.268310546875,
        415.6937255859375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.30455017089844,
        419.3017578125,
        538.268310546875,
        451.6544189453125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수들에 대한 표준적인 해석을 제공하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.30455017089844,
        419.3017578125,
        538.268310546875,
        451.6544189453125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* (예, CFTR 유전자형 분석 등)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        95.82806396484375,
        465.3314514160156,
        252.44541931152344,
        478.56500244140625
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        491.70263671875,
        538.268310546875,
        506.074951171875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상의들",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "스스로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개별",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수들에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해석을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        509.6830139160156,
        538.1483154296875,
        524.0552978515625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        527.6633911132812,
        204.00942993164062,
        542.03564453125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* (예, 염색체 복제 수 결정 등)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        95.82806396484375,
        555.8325805664062,
        251.72581481933594,
        569.0661010742188
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 비록 여러",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        582.2037353515625,
        538.2442626953125,
        596.5759887695312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지 변수들을 측정하여 하나의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        582.2037353515625,
        538.2442626953125,
        596.5759887695312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 계산해 낼 수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        582.2037353515625,
        538.2442626953125,
        596.5759887695312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으나,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        582.2037353515625,
        538.2442626953125,
        596.5759887695312
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.34345245361328,
        600.18408203125,
        538.268310546875,
        650.51708984375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.34345245361328,
        600.18408203125,
        538.268310546875,
        650.51708984375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.34345245361328,
        600.18408203125,
        538.268310546875,
        650.51708984375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        95.82806396484375,
        664.1941528320312,
        440.8633117675781,
        677.4276733398438
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        690.5653686523438,
        538.1483154296875,
        704.9376220703125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        709.744384765625,
        538.1483154296875,
        724.1166381835938
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병등록정보의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자특이적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종합보고서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        728.9234008789062,
        538.1483154296875,
        743.295654296875
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        748.1024780273438,
        538.1483154296875,
        762.4747314453125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        70.1746826171875,
        796.536865234375
      ],
      "page_num": 10,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        69.04454803466797,
        414.61529541015625,
        83.41683959960938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        98.17271423339844,
        538.1483154296875,
        112.54500579833984
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자유롭게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자신들의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의학적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지식과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        116.15306854248047,
        538.268310546875,
        130.52536010742188
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        134.1334228515625,
        538.1483154296875,
        166.48605346679688
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 인구통계학적 위해도 계산법",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.06468200683594,
        134.1334228515625,
        538.1483154296875,
        166.48605346679688
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        95.82806396484375,
        181.12205505371094,
        431.98809814453125,
        194.35560607910156
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 기본 용어 설명",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        240.0976104736328,
        175.58433532714844,
        256.9132080078125
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        272.82183837890625,
        538.1483154296875,
        287.20611572265625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해를 돕기 위해 사용되는 것이므로 단순 참고용임.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.98851776123047,
        292.0008850097656,
        385.8069152832031,
        306.3731994628906
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간섭물질(Interfering",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "substances)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "존재하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부물질(혈액",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        321.1290588378906,
        538.268310546875,
        335.6444396972656
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        340.3080749511719,
        538.1483154296875,
        354.6803894042969
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위음성 결과를 야기할 수 있는 물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        359.48712158203125,
        292.5214538574219,
        373.85943603515625
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        388.73516845703125,
        538.1483154296875,
        403.25054931640625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        388.73516845703125,
        538.1483154296875,
        403.25054931640625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        407.9142150878906,
        538.1483154296875,
        422.2865295410156
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        427.0932312011719,
        394.4662170410156,
        441.4655456542969
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교차반응(Cross-reactivity)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이외에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공유되었거나,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        456.2214050292969,
        538.268310546875,
        470.7367858886719
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원 결정기를 가진 항원과 항체가 반응하는 현상",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        475.40045166015625,
        370.4792175292969,
        489.77276611328125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기질효과(Matrix",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "effect)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이외에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        504.5285949707031,
        538.1483154296875,
        519.0440063476562
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질의 측정에 영향을 미치는 경우. 검체의 점성, 표면장력, 혼탁도, 이온",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        523.7077026367188,
        538.1483154296875,
        538.0799560546875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "강도, pH 등이 기질효과의 주된 요인이다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        542.88671875,
        327.51849365234375,
        557.2589721679688
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조물질(Internal",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "튜브에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.134765625,
        538.1483154296875,
        586.650146484375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염기서열을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "넣어서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "염기서열과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증폭되게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        591.3137817382812,
        538.2442626953125,
        605.68603515625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        610.4928588867188,
        538.268310546875,
        624.8651123046875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의한 증폭 방해를 동정하기 위한 목적으로 사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        629.671875,
        358.4857177734375,
        644.0441284179688
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조물질(Control/Control",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "material)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용되는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        658.800048828125,
        538.2442626953125,
        673.3154296875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        677.9790649414062,
        538.268310546875,
        692.351318359375
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체를 이용한 리간드-결합 분석",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        697.1581420898438,
        272.4923095703125,
        711.5303955078125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        716.337158203125,
        538.268310546875,
        730.721435546875
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        112.97876739501953,
        735.5162353515625,
        538.268310546875,
        749.8884887695312
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        112.97876739501953,
        754.6952514648438,
        502.6475830078125,
        769.0675048828125
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        93.50906372070312
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        93.50906372070312
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        98.17271423339844,
        538.268310546875,
        112.54500579833984
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        117.35175323486328,
        538.268310546875,
        131.7240447998047
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 측정 결과의 동등을 평가하는 시험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        136.53079223632812,
        316.5084533691406,
        150.903076171875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        165.77883911132812,
        463.18896484375,
        180.29421997070312
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        165.77883911132812,
        463.18896484375,
        180.29421997070312
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        194.906982421875,
        538.1483154296875,
        209.42237854003906
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        194.906982421875,
        538.1483154296875,
        209.42237854003906
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        214.08602905273438,
        538.1483154296875,
        228.4583282470703
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 특성을 가짐",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        233.26507568359375,
        202.57020568847656,
        247.6373748779297
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        262.39324951171875,
        538.1483154296875,
        276.90863037109375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        262.39324951171875,
        538.1483154296875,
        276.90863037109375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성하는 다양한 단백질이 형성되는 과정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        281.572265625,
        322.5052185058594,
        295.944580078125
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        310.8203125,
        538.1483154296875,
        325.335693359375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        310.8203125,
        538.1483154296875,
        325.335693359375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정물질이나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고물질에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상응하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        329.9993591308594,
        538.1483154296875,
        344.3716735839844
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관계를 확립하는 일련의 조작",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        349.17840576171875,
        256.54095458984375,
        363.55072021484375
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        378.3065490722656,
        538.268310546875,
        392.8219299316406
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정물질(Calibrator / Calibration material) :",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        378.3065490722656,
        538.268310546875,
        392.8219299316406
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정과정을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        378.3065490722656,
        538.268310546875,
        392.8219299316406
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보정하거나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        378.3065490722656,
        538.268310546875,
        392.8219299316406
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        378.3065490722656,
        538.268310546875,
        392.8219299316406
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응을 비교하기 위해서 사용되는 체외진단용 시약",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        397.485595703125,
        376.4759521484375,
        411.85791015625
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 보정물질에서",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양은",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조과정에서",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인된",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한계(limit)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내에",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        426.733642578125,
        538.2462158203125,
        440.0877990722656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        442.1967468261719,
        436.5630798339844,
        455.41925048828125
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        462.574462890625,
        536.7091064453125,
        475.9286193847656
      ],
      "page_num": 11,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        482.95220947265625,
        480.5795593261719,
        496.3063659667969
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        508.1246643066406,
        411.3770446777344,
        522.6400756835938
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        508.1246643066406,
        411.3770446777344,
        522.6400756835938
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        537.3727416992188,
        538.268310546875,
        551.8881225585938
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        537.3727416992188,
        538.268310546875,
        551.8881225585938
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "행하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상물을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확하게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        556.5518188476562,
        538.1483154296875,
        570.924072265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        575.7308349609375,
        538.1483154296875,
        590.1030883789062
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석법임을 입증하는 과정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        594.9098510742188,
        238.5507049560547,
        609.2821044921875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도(Analytical",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "specificity)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질만",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        624.0380249023438,
        538.1483154296875,
        638.5534057617188
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        643.2171020507812,
        430.44671630859375,
        657.58935546875
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        672.3452758789062,
        538.268310546875,
        686.8606567382812
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        672.3452758789062,
        538.268310546875,
        686.8606567382812
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확률 범위 내에서 분포할 것으로 예상되는 구간",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        691.5242919921875,
        358.4857177734375,
        705.8965454101562
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        720.7723388671875,
        538.1483154296875,
        735.2877197265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        720.7723388671875,
        538.1483154296875,
        735.2877197265625
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        739.9513549804688,
        421.93133544921875,
        754.3236083984375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        70.1746826171875,
        796.536865234375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F a)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측도(PPV)는",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관심대상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건(진단",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준으로",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정되는)의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        79.11354064941406,
        538.2682495117188,
        92.46769714355469
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유병률에 맞추어 해석",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        117.41636657714844,
        94.57664489746094,
        227.39675903320312,
        107.79915618896484
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F b) PPV의 추정값 [추정 유병률은  ×",
      "font_size": 43.46063995361328,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        125.38297271728516,
        385.1571960449219,
        144.74603271484375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "      ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        125.38297271728516,
        385.1571960449219,
        144.74603271484375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        315.6081848144531,
        121.491455078125,
        473.5689697265625,
        144.74603271484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "은  ×",
      "font_size": 29.176517486572266,
      "font_name": "HyhwpEQ",
      "bbox": [
        315.6081848144531,
        121.491455078125,
        473.5689697265625,
        144.74603271484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        315.6081848144531,
        121.491455078125,
        473.5689697265625,
        144.74603271484375
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        443.3389587402344,
        122.09078979492188,
        510.9226379394531,
        138.60548400878906
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로 계산",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        443.3389587402344,
        122.09078979492188,
        510.9226379394531,
        138.60548400878906
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단정확도기준",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        298.6381530761719,
        155.4700927734375,
        368.559326171875,
        167.3990936279297
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        176.80677795410156,
        481.658935546875,
        188.73577880859375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        176.80677795410156,
        481.658935546875,
        188.73577880859375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        176.80677795410156,
        481.658935546875,
        188.73577880859375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법 X",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        101.58494567871094,
        208.69192504882812,
        133.29107666015625,
        220.6209259033203
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        198.02359008789062,
        509.7232666015625,
        209.9525909423828
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "# 진양성 TP",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        198.02359008789062,
        509.7232666015625,
        209.9525909423828
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "# 위양성 FP",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        198.02359008789062,
        509.7232666015625,
        209.9525909423828
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진양성 + 위양성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        198.02359008789062,
        509.7232666015625,
        209.9525909423828
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        219.3602752685547,
        509.7232666015625,
        231.28927612304688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "# 위음성 FN",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        219.3602752685547,
        509.7232666015625,
        231.28927612304688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "# 진음성 TN",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        219.3602752685547,
        509.7232666015625,
        231.28927612304688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위음성 + 진음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        219.3602752685547,
        509.7232666015625,
        231.28927612304688
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        240.57708740234375,
        475.7689514160156,
        252.50608825683594
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진양성 + 위음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        240.57708740234375,
        475.7689514160156,
        252.50608825683594
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위양성 + 진음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        240.57708740234375,
        475.7689514160156,
        252.50608825683594
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        240.57708740234375,
        475.7689514160156,
        252.50608825683594
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교방법",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        313.6300354003906,
        278.2159423828125,
        353.56793212890625,
        290.14495849609375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        298.9532775878906,
        481.658935546875,
        310.8822937011719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        298.9532775878906,
        481.658935546875,
        310.8822937011719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        277.5295715332031,
        298.9532775878906,
        481.658935546875,
        310.8822937011719
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후보 검사법",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        89.95124816894531,
        330.1192321777344,
        144.88148498535156,
        342.0482482910156
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        319.69061279296875,
        484.99505615234375,
        331.61962890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        319.69061279296875,
        484.99505615234375,
        331.61962890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        319.69061279296875,
        484.99505615234375,
        331.61962890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a + b",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        319.69061279296875,
        484.99505615234375,
        331.61962890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        340.427978515625,
        484.9627990722656,
        352.35699462890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        340.427978515625,
        484.9627990722656,
        352.35699462890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        340.427978515625,
        484.9627990722656,
        352.35699462890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c + d",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        340.427978515625,
        484.9627990722656,
        352.35699462890625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        189.6172332763672,
        361.1653137207031,
        474.6194763183594,
        373.0943298339844
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a + c",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        361.1653137207031,
        474.6194763183594,
        373.0943298339844
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b + d",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        361.1653137207031,
        474.6194763183594,
        373.0943298339844
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        189.6172332763672,
        361.1653137207031,
        474.6194763183594,
        373.0943298339844
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 양성 일치율(Percent Positive Agreement, PPA) =  ×",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        405.6366882324219,
        409.0554504394531,
        424.999755859375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        405.6366882324219,
        409.0554504394531,
        424.999755859375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        394.9459533691406,
        402.3445129394531,
        400.2051696777344,
        412.29364013671875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 음성 일치율(Percent Negative Agreement, PNA) =  ×",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        440.2788391113281,
        417.0910949707031,
        459.64190673828125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        440.2788391113281,
        417.0910949707031,
        459.64190673828125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        402.8616638183594,
        436.9866638183594,
        408.03338623046875,
        446.935791015625
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 총 일치율(Overall percent agreement) =  ×",
      "font_size": 21.986534118652344,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        474.9209899902344,
        363.3502197265625,
        494.2840576171875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        84.91397857666016,
        474.9209899902344,
        363.3502197265625,
        494.2840576171875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        340.6153869628906,
        471.0294494628906,
        361.97833251953125,
        481.57794189453125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        503.9292907714844,
        538.2442626953125,
        518.4447021484375
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        503.9292907714844,
        538.2442626953125,
        518.4447021484375
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        523.1083374023438,
        538.1483154296875,
        537.4805908203125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구 조직에서 시행된 국제적인 임상시험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        542.2874145507812,
        322.5052185058594,
        556.65966796875
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 9.951866149902344,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        571.535400390625,
        538.268310546875,
        585.9076538085938
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        571.535400390625,
        538.268310546875,
        585.9076538085938
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전체를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "집약하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해석하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영역(초고속",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서열",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발전은",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        590.7144775390625,
        538.2678833007812,
        605.0867309570312
      ],
      "page_num": 12,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        610.0133666992188,
        488.08074951171875,
        623.2359008789062
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무재발",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생존률(Distant",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Recurrence-Free",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Survival,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DRFS)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        637.46337890625,
        538.1483154296875,
        651.978759765625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전까지의 생존 기간",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        656.0430908203125,
        202.57020568847656,
        670.4153442382812
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        684.5718994140625,
        538.1483154296875,
        699.0872802734375
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        684.5718994140625,
        538.1483154296875,
        699.0872802734375
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성으로 나온 검사 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        703.151611328125,
        232.553955078125,
        717.5238647460938
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        731.680419921875,
        538.268310546875,
        746.19580078125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        731.680419921875,
        538.268310546875,
        746.19580078125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성으로 나온 검사 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        750.2600708007812,
        232.553955078125,
        764.63232421875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        129.32666015625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        129.32666015625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        129.32666015625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분하는 기준값을 의미",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.268310546875,
        129.32666015625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성율),",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도(질병",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표현형이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성율)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.1483154296875,
        175.35635375976562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물의 효능을 정확하게 예측하는 분석법임을 검증",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        178.96441650390625,
        376.4759521484375,
        193.3367156982422
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과가 양성으로 나오는 비율",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성이란",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        252.8037109375,
        538.268310546875,
        285.1563720703125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        288.764404296875,
        538.1483154296875,
        321.1170959472656
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단 근거를 제공할 수 있는 성능",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        288.764404296875,
        538.1483154296875,
        321.1170959472656
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        334.7940979003906,
        538.1483154296875,
        367.14678955078125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        334.7940979003906,
        538.1483154296875,
        367.14678955078125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 결과가 음성으로 나오는 비율",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        334.7940979003906,
        538.1483154296875,
        367.14678955078125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        380.7039489746094,
        538.1483154296875,
        413.0566101074219
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        380.7039489746094,
        538.1483154296875,
        413.0566101074219
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사이의 일치도의 근접성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        380.7039489746094,
        538.1483154296875,
        413.0566101074219
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정밀도(Precision)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험:",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일정기간",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동안",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.61376953125,
        538.1483154296875,
        441.129150390625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        444.5941162109375,
        534.2144775390625,
        458.9664306640625
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확도(Accuracy)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험: 표준물질의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목표",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실측 결과(정량검사의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        472.6434631347656,
        538.268310546875,
        487.1588439941406
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        490.6238098144531,
        538.268310546875,
        522.9764404296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복 측정 결과를 기술하는 시험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        490.6238098144531,
        538.268310546875,
        522.9764404296875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        536.53369140625,
        538.1483154296875,
        568.8862915039062
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        536.53369140625,
        538.1483154296875,
        568.8862915039062
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공할 수 있는 능력",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        536.53369140625,
        538.1483154296875,
        568.8862915039062
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사(Diagnostic",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "test)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개개의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        582.4434814453125,
        538.268310546875,
        596.9588623046875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        600.423828125,
        436.4434509277344,
        614.7960815429688
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진양성(True",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Positive,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TP)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성판정이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        628.4732055664062,
        538.1483154296875,
        642.9885864257812
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일치하는 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        646.4535522460938,
        169.94789123535156,
        660.8258056640625
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진음성(True",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Negative,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "TN)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성판정이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        674.3829956054688,
        538.1483154296875,
        688.8983764648438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일치하는 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        692.3634033203125,
        169.94789123535156,
        706.7356567382812
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        720.2928466796875,
        538.1483154296875,
        752.6454467773438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고물질/참고제작(Reference Material, RM / Reference preparation)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        720.2928466796875,
        538.1483154296875,
        752.6454467773438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        720.2928466796875,
        538.1483154296875,
        752.6454467773438
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가 또는 물질에 값을 할당하기 위해서 사용되는 물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        756.2535400390625,
        417.373779296875,
        770.6257934570312
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인증참고물질(Certified",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Reference",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Material,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CRM)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술적으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과정으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공인되었고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인증서나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인증기관에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발행된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서류가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있거나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        87.02489471435547,
        538.268310546875,
        101.39718627929688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        107.82156372070312,
        105.00524139404297,
        413.65582275390625,
        119.37753295898438
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        97.62709045410156,
        122.98558807373047,
        538.1483154296875,
        137.35787963867188
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성값이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공인되며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성값이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표현되는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단위의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        140.9659423828125,
        538.1483154296875,
        155.33824157714844
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정확한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구현에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추적을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있고,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그것에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공인된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        158.9462890625,
        538.268310546875,
        173.31858825683594
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        176.9266357421875,
        415.57476806640625,
        191.29893493652344
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준참고물질(Standard",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Reference",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Material,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SRM)은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인증참고물질(CRM)의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        97.62709045410156,
        194.906982421875,
        538.1483154296875,
        209.27928161621094
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하나로써",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국립표준기술",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구소(National",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Institute",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Science",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.2947998046875,
        212.88735961914062,
        538.2562255859375,
        227.2596435546875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Technology, NIST)에서 인증하고 배포한 인증참고물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        230.86770629882812,
        415.09503173828125,
        245.239990234375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        258.79718017578125,
        538.1483154296875,
        309.13018798828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        258.79718017578125,
        538.1483154296875,
        309.13018798828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        258.79718017578125,
        538.1483154296875,
        309.13018798828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정할 수 있는 분석물질 값의 범위",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        258.79718017578125,
        538.1483154296875,
        309.13018798828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        322.8072204589844,
        538.2462158203125,
        337.1795349121094
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        322.8072204589844,
        538.2462158203125,
        337.1795349121094
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국제 표준품을 이용하여 측정할 것을 권장)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        93.0695571899414,
        340.9074401855469,
        311.05670166015625,
        354.12994384765625
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도/분석적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도(Specificity/Analytical",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "specificity)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하고자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        367.27862548828125,
        538.268310546875,
        381.79400634765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        385.25897216796875,
        472.4239501953125,
        399.63128662109375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판정기준치(Cut-off",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "value)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정성검사에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계치",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성으로,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계치",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        413.1884460449219,
        538.1483154296875,
        427.7038269042969
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미만을 음성으로 판정하는 경계값. 정량검사에서는 측정 결과가 임상적 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정점(Decision",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "point)의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는지(양성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        431.1687927246094,
        538.17236328125,
        463.5214538574219
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하는데 사용되는 측정물질의 정량값",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        467.1294860839844,
        316.5084533691406,
        481.5018005371094
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵산추출(Nucleic",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "acid",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "extraction)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵산을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증폭하고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석하기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "핵산을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        495.0589599609375,
        538.268310546875,
        509.5743408203125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생물학적 물질로부터 분리하는 것",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        513.0393676757812,
        280.5279541015625,
        527.41162109375
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 부록에 사용된 용어",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        76.63846588134766,
        563.0247192382812,
        207.36761474609375,
        577.4089965820312
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        590.9542236328125,
        538.1483154296875,
        623.3068237304688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        590.9542236328125,
        538.1483154296875,
        623.3068237304688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감지되는 시점의 사이클 수(cycle number)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        590.9542236328125,
        538.1483154296875,
        623.3068237304688
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        84.91397857666016,
        637.103759765625,
        518.8388061523438,
        650.4579467773438
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "F 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        663.5947875976562,
        538.2682495117188,
        676.948974609375
      ],
      "page_num": 14,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        101.3450698852539,
        680.016845703125,
        381.6331787109375,
        693.2393798828125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        706.3880615234375,
        463.18896484375,
        720.9034423828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        706.3880615234375,
        463.18896484375,
        720.9034423828125
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        734.4373779296875,
        538.268310546875,
        766.7899780273438
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        734.4373779296875,
        538.268310546875,
        766.7899780273438
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        734.4373779296875,
        538.268310546875,
        766.7899780273438
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        129.32666015625
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        129.32666015625
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        129.32666015625
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "활동을 하기 위한 체계적인 검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        129.32666015625
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포주를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세포들이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "클론에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유래하므로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모두",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        143.00372314453125,
        538.2442626953125,
        175.35635375976562
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        178.96441650390625,
        421.3316345214844,
        193.3367156982422
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화가 제품 성능에 미치는 영향을 평가하는 실험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        206.89389038085938,
        538.268310546875,
        239.2465362548828
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        84.91397857666016,
        252.923583984375,
        307.371337890625,
        266.2777404785156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최악의 상황을 고려하여 시험해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        252.923583984375,
        307.371337890625,
        266.2777404785156
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        279.2947692871094,
        538.1483154296875,
        311.6474304199219
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        279.2947692871094,
        538.1483154296875,
        311.6474304199219
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        279.2947692871094,
        538.1483154296875,
        311.6474304199219
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "역가(Titer)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시스템에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정해진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내는데",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "희석율에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        325.324462890625,
        538.1483154296875,
        339.83984375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        343.3048095703125,
        538.268310546875,
        375.657470703125
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 백분율이 결합하는 항체의 희석율",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        343.3048095703125,
        538.268310546875,
        375.657470703125
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F 역가는 주로 분석물질 농도에 비례",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        84.91397857666016,
        389.3345031738281,
        277.28973388671875,
        402.68865966796875
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        415.7056884765625,
        527.1142578125,
        430.2210693359375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        415.7056884765625,
        527.1142578125,
        430.2210693359375
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        443.6351623535156,
        538.1483154296875,
        493.9681701660156
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        443.6351623535156,
        538.1483154296875,
        493.9681701660156
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        443.6351623535156,
        538.1483154296875,
        493.9681701660156
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        443.6351623535156,
        538.1483154296875,
        493.9681701660156
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        507.6452331542969,
        538.268310546875,
        557.9782104492188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        507.6452331542969,
        538.268310546875,
        557.9782104492188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        507.6452331542969,
        538.268310546875,
        557.9782104492188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값으로 보고할 수 있는 분석물질 값의 범위",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        507.6452331542969,
        538.268310546875,
        557.9782104492188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        571.535400390625,
        538.268310546875,
        603.8880004882812
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        571.535400390625,
        538.268310546875,
        603.8880004882812
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        571.535400390625,
        538.268310546875,
        603.8880004882812
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        617.4452514648438,
        501.17236328125,
        631.9606323242188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        617.4452514648438,
        501.17236328125,
        631.9606323242188
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        645.4945678710938,
        471.704345703125,
        660.0099487304688
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        645.4945678710938,
        471.704345703125,
        660.0099487304688
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        673.5438842773438,
        538.2678833007812,
        686.8980712890625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절 단 된",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조 각 이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서 로",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위 치 를",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바 꾸 어",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 동 하 는",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "현 상 이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일 어 난 다 .",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        101.3450698852539,
        690.0858154296875,
        538.2462158203125,
        703.308349609375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        101.3450698852539,
        706.5078735351562,
        458.5767517089844,
        719.7304077148438
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이(Metastasis)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내지",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조직에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "암병소를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원발소라",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        732.8790893554688,
        538.2442626953125,
        747.3944702148438
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        750.8594360351562,
        457.3121337890625,
        765.231689453125
      ],
      "page_num": 15,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        111.3463134765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        111.3463134765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "x축에, 관측치의 빈도를 곡선의 y축에 표시",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        78.9936752319336,
        538.1483154296875,
        111.3463134765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        125.14324188232422,
        531.5298461914062,
        138.4973907470703
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        151.514404296875,
        538.1483154296875,
        183.8670654296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        151.514404296875,
        538.1483154296875,
        183.8670654296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합적인 기능을 발휘하는 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        151.514404296875,
        538.1483154296875,
        183.8670654296875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다. 온열과 진동 기능이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        198.38319396972656,
        538.2678833007812,
        211.93963623046875
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        215.5244598388672,
        538.2677612304688,
        228.74697875976562
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        102.90422821044922,
        232.90545654296875,
        516.0255737304688,
        246.1279754638672
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        259.8759765625,
        413.1760559082031,
        274.391357421875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        259.8759765625,
        413.1760559082031,
        274.391357421875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        287.8054504394531,
        468.4660949707031,
        302.3208312988281
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        76.63846588134766,
        287.8054504394531,
        468.4660949707031,
        302.3208312988281
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F",
      "font_size": 11.030982971191406,
      "font_name": "Wingdings-Regular",
      "bbox": [
        84.91397857666016,
        315.97467041015625,
        400.80072021484375,
        329.3288269042969
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        315.97467041015625,
        400.80072021484375,
        329.3288269042969
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        342.3458557128906,
        538.268310546875,
        374.6985168457031
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        342.3458557128906,
        538.268310546875,
        374.6985168457031
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도수의 변화 및 측정된 양의 값의 변화계수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        342.3458557128906,
        538.268310546875,
        374.6985168457031
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "F 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        389.2146301269531,
        538.14794921875,
        402.77105712890625
      ],
      "page_num": 16,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분해능(resolution)에 비하여 큰 차이여야 함",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        407.1949768066406,
        324.3042297363281,
        420.41748046875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        434.16552734375,
        538.268310546875,
        466.5181884765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        434.16552734375,
        538.268310546875,
        466.5181884765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적으로 사용하는 단일가닥 핵산",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        434.16552734375,
        538.268310546875,
        466.5181884765625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        480.1952209472656,
        538.1483154296875,
        512.5478515625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        480.1952209472656,
        538.1483154296875,
        512.5478515625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        480.1952209472656,
        538.1483154296875,
        512.5478515625
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        526.1050415039062,
        538.2442626953125,
        558.4577026367188
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        526.1050415039062,
        538.2442626953125,
        558.4577026367188
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        526.1050415039062,
        538.2442626953125,
        558.4577026367188
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항암화학요법(Chemotherapy)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항암제를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "암을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요법으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        572.014892578125,
        538.268310546875,
        586.5302734375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전신에 퍼져있는 암세포에 작용하는 치료 방법",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        589.9952392578125,
        352.48895263671875,
        604.3674926757812
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        618.0446166992188,
        535.030029296875,
        632.5599975585938
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        618.0446166992188,
        535.030029296875,
        632.5599975585938
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 관련 법령",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        78.75393676757812,
        139.24478149414062,
        95.56951904296875
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        111.3582992553711,
        538.268310546875,
        125.87368774414062
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        111.3582992553711,
        538.268310546875,
        125.87368774414062
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        130.537353515625,
        538.1483154296875,
        144.90963745117188
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다루어 질 것이다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        149.71636962890625,
        180.9579315185547,
        164.0886688232422
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법」제3조 (제조업의 허가의 신청절차)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        178.96441650390625,
        361.6280212402344,
        193.3487091064453
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법」제29조 (수입업 허가신청 등)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        208.09259033203125,
        333.68316650390625,
        222.47686767578125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제5조 (제조허가의 절차)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        237.22076416015625,
        361.6280212402344,
        251.60504150390625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제6조 (제조인증의 절차)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        266.4687805175781,
        361.6280212402344,
        280.8530578613281
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제7조 (제조신고의 절차)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        295.5969543457031,
        361.6280212402344,
        309.9812316894531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제9조 (기술문서 등의 심사)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        324.7251281738281,
        378.2989807128906,
        339.1094055175781
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        353.97314453125,
        406.1239013671875,
        368.357421875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        383.101318359375,
        461.8936767578125,
        397.485595703125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제30조 (수입허가 신청 등)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        412.2294921875,
        372.6620178222656,
        426.61376953125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제42조 (용기 등의 기재사항)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        441.4775085449219,
        383.81597900390625,
        455.8617858886719
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        470.6056823730469,
        389.45294189453125,
        484.9899597167969
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기법 시행규칙」제44조 (기재사항의 표시방법)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        499.7338562011719,
        389.45294189453125,
        514.1181640625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기 허가․신고․심사 등에 관한 규정」",
      "font_size": 11.99020004272461,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        528.98193359375,
        354.7677307128906,
        543.3662109375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기 품목 및 품목별 등급에 관한 규정」",
      "font_size": 11.99020004272461,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        558.110107421875,
        354.6477966308594,
        572.494384765625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 「의료기기 안정성시험 기준」",
      "font_size": 11.99020004272461,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        587.23828125,
        265.53607177734375,
        601.62255859375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제Ⅱ부  허가·심사시 고려사항",
      "font_size": 32.013832092285156,
      "font_name": "H2hdrM",
      "bbox": [
        65.60444641113281,
        257.575439453125,
        529.39453125,
        289.5804443359375
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 19,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 15 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제 Ⅱ 부  허가·심사시 고려사항",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        70.75151062011719,
        335.45819091796875,
        88.73185729980469
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        117.47161865234375,
        536.4699096679688,
        134.3012237548828
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        150.19586181640625,
        538.268310546875,
        164.71124267578125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        150.19586181640625,
        538.268310546875,
        164.71124267578125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        171.77227783203125,
        538.1483154296875,
        186.1445770263672
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        193.34869384765625,
        484.1535949707031,
        207.7209930419922
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        224.87423706054688,
        538.268310546875,
        239.38963317871094
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        224.87423706054688,
        538.268310546875,
        239.38963317871094
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        246.45065307617188,
        538.1243286132812,
        260.8229675292969
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        268.0270690917969,
        492.90887451171875,
        282.3993835449219
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        299.5526123046875,
        538.268310546875,
        314.0679931640625
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        299.5526123046875,
        538.268310546875,
        314.0679931640625
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성을 동시에 검토해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        321.1290588378906,
        271.50885009765625,
        335.5013732910156
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        352.77447509765625,
        538.268310546875,
        367.28985595703125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        352.77447509765625,
        538.268310546875,
        367.28985595703125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        374.35089111328125,
        512.5781860351562,
        388.72320556640625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        405.8764343261719,
        538.268310546875,
        420.3918151855469
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        405.8764343261719,
        538.268310546875,
        420.3918151855469
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        427.4528503417969,
        538.268310546875,
        441.8251647949219
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해야 한다. 국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        449.0292663574219,
        538.268310546875,
        463.4015808105469
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        470.6056823730469,
        538.268310546875,
        484.9779968261719
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(optimization)를 수행하는 것을 권고한다. 다만, 각 바이오마커들에 대한 인종적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        492.1820983886719,
        538.268310546875,
        506.5544128417969
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        513.758544921875,
        537.8844604492188,
        528.1307983398438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        545.2841186523438,
        538.268310546875,
        559.7994995117188
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        545.2841186523438,
        538.268310546875,
        559.7994995117188
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        566.8605346679688,
        538.1483154296875,
        581.2327880859375
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        588.4369506835938,
        538.268310546875,
        602.8092041015625
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다. 그렇지만 사용목적이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        610.0133666992188,
        538.1483154296875,
        624.3856201171875
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        631.5897827148438,
        538.1483154296875,
        645.9620361328125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하도록 권고한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        653.1661987304688,
        186.83474731445312,
        667.5384521484375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        684.8116455078125,
        538.1483154296875,
        699.3270263671875
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        684.8116455078125,
        538.1483154296875,
        699.3270263671875
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        706.3880615234375,
        538.1483154296875,
        720.7603149414062
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        727.9644775390625,
        177.12001037597656,
        742.3367309570312
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 16 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<알고리즘 도출 및 내부 검정단계의 고려사항>",
      "font_size": 11.99020004272461,
      "font_name": "T23",
      "bbox": [
        178.94302368164062,
        511.3611755371094,
        450.2599792480469,
        525.7454833984375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.42611694335938,
        536.8932495117188,
        530.3525390625,
        551.2655029296875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        117.05655670166016,
        552.4762573242188,
        506.9412536621094,
        566.8485107421875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.42611694335938,
        578.0083618164062,
        530.3525390625,
        592.380615234375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.97714233398438,
        593.59130859375,
        530.3525390625,
        623.5465698242188
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가를 제시한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.97714233398438,
        593.59130859375,
        530.3525390625,
        623.5465698242188
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.42611694335938,
        634.8262329101562,
        530.232666015625,
        649.198486328125
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과적합(overfitting)이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생길",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과적합을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방지하기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내부",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.6967544555664,
        650.4092407226562,
        530.3525390625,
        664.781494140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        116.6967544555664,
        665.9921875,
        500.8245849609375,
        680.3644409179688
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 적절한 internal validation 방법은 split-sample, cross-validation including",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.42611694335938,
        691.5242919921875,
        530.2806396484375,
        705.8965454101562
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.73727416992188,
        707.1072387695312,
        530.3525390625,
        752.6454467773438
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.73727416992188,
        707.1072387695312,
        530.3525390625,
        752.6454467773438
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정(validation)하는 방법 등을 권고한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.73727416992188,
        707.1072387695312,
        530.3525390625,
        752.6454467773438
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 공통 고려사항",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        78.75393676757812,
        168.62860107421875,
        95.56951904296875
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        110.03974151611328,
        538.268310546875,
        141.19369506835938
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        110.03974151611328,
        538.268310546875,
        141.19369506835938
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "접근법을 적용하는 것이 타당하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        110.03974151611328,
        538.268310546875,
        141.19369506835938
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 체외진단용 의료기기의 사용목적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        153.55218505859375,
        283.7662048339844,
        167.9244842529297
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        180.28298950195312,
        439.68170166015625,
        194.6552734375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        87.912353515625,
        207.13363647460938,
        462.61328125,
        221.50592041015625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        233.86441040039062,
        538.1483154296875,
        248.3798065185547
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        233.86441040039062,
        538.1483154296875,
        248.3798065185547
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        253.04345703125,
        442.5361633300781,
        267.427734375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        282.171630859375,
        538.1483154296875,
        296.5439453125
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발한 경우, 조합의료기기로 허가․심사한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        104.34345245361328,
        298.9532775878906,
        356.4228210449219,
        313.3375549316406
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        325.8039245605469,
        538.1483154296875,
        340.1762390136719
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․",
      "font_size": 11.99020004272461,
      "font_name": "T16",
      "bbox": [
        104.46338653564453,
        342.5856018066406,
        538.1483154296875,
        373.73956298828125
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심사한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        104.46338653564453,
        342.5856018066406,
        538.1483154296875,
        373.73956298828125
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        386.2179260253906,
        538.2678833007812,
        399.45147705078125
      ],
      "page_num": 20,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(소프트웨어)의 검정을 다시 해야한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        108.18136596679688,
        401.5611572265625,
        299.5755615234375,
        414.7836608886719
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        76.63846588134766,
        426.853515625,
        538.268310546875,
        474.7891540527344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.853515625,
        538.268310546875,
        474.7891540527344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.853515625,
        538.268310546875,
        474.7891540527344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        426.853515625,
        538.268310546875,
        474.7891540527344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 사용목적 설정시 주요 고려사항",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        78.75393676757812,
        285.56524658203125,
        95.56951904296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        76.63846588134766,
        111.3582992553711,
        538.268310546875,
        125.7305908203125
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        76.63846588134766,
        130.537353515625,
        402.4778747558594,
        144.90963745117188
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 사용목적",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.88483428955078,
        159.78536987304688,
        136.24615478515625,
        174.1576690673828
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 측정 항목 및 검출 항목",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        188.91354370117188,
        233.75331115722656,
        203.2858428955078
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        99.90585327148438,
        218.04171752929688,
        225.8376007080078,
        232.55709838867188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구체적인 사용 검체",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        218.04171752929688,
        225.8376007080078,
        232.55709838867188
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        99.90585327148438,
        247.28973388671875,
        377.31549072265625,
        261.80511474609375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출 · 측정의 대상이 되는 유전자명, 단백질명",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        247.28973388671875,
        377.31549072265625,
        261.80511474609375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        99.90585327148438,
        276.41790771484375,
        537.308837890625,
        290.93328857421875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        276.41790771484375,
        537.308837890625,
        290.93328857421875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 임상적 의의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        305.54608154296875,
        167.7890625,
        319.91839599609375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        99.90585327148438,
        334.7940979003906,
        538.268310546875,
        349.3094787597656
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        334.7940979003906,
        538.268310546875,
        349.3094787597656
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        117.89610290527344,
        353.97314453125,
        538.1483154296875,
        368.345458984375
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        117.89610290527344,
        373.1521911621094,
        538.1483154296875,
        387.5245056152344
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사용 의료기기(IVD-MIA)임을 명확히 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        117.89610290527344,
        392.33123779296875,
        354.2640075683594,
        406.70355224609375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        99.90585327148438,
        421.45941162109375,
        538.1483154296875,
        435.97479248046875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        421.45941162109375,
        538.1483154296875,
        435.97479248046875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기입한다. 암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        117.89610290527344,
        440.638427734375,
        538.2442626953125,
        455.0107421875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        117.89610290527344,
        459.8174743652344,
        455.4891357421875,
        474.1897888183594
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가",
      "font_size": 14.028532981872559,
      "font_name": "T12",
      "bbox": [
        56.609317779541016,
        517.8341064453125,
        447.3570556640625,
        534.649658203125
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 알고리즘 설계 및 내부 검정(평가)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.88483428955078,
        550.558349609375,
        282.1111145019531,
        564.9306030273438
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        85.87345886230469,
        579.6865234375,
        471.20062255859375,
        594.0587768554688
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        608.814697265625,
        538.1483154296875,
        623.1869506835938
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "군을 어떤 방법으로 선별하였는지 확인해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.06468200683594,
        627.9937133789062,
        374.892822265625,
        642.365966796875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.87020874023438,
        657.2417602539062,
        538.1483154296875,
        671.614013671875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 바이오마커를 1차 선별한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.85720825195312,
        676.4207763671875,
        296.8151550292969,
        690.7930297851562
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.37747192382812,
        705.5489501953125,
        538.268310546875,
        719.9212036132812
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.85720825195312,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.85720825195312,
        743.9070434570312,
        201.82662963867188,
        758.279296875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "18",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<그림 1> 마이크로어레이를 이용한 바이오마커 선별",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        163.71127319335938,
        374.11114501953125,
        454.4337158203125,
        388.48345947265625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        104.46338653564453,
        394.4888916015625,
        537.97607421875,
        406.41790771484375
      ],
      "page_num": 22,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        425.2951965332031,
        538.268310546875,
        439.6675109863281
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2차 선별한다. 특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        114.4179916381836,
        444.4742431640625,
        538.268310546875,
        458.8465576171875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        114.4179916381836,
        463.6532897949219,
        538.1483154296875,
        478.0256042480469
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3차 선별을 추가할 수도 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        114.4179916381836,
        482.83233642578125,
        267.7908630371094,
        497.20465087890625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 임상적 정보가 확보된 검체란?",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        130.84909057617188,
        526.3447875976562,
        299.7425231933594,
        539.5783081054688
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        125.45201110839844,
        550.6781616210938,
        528.43359375,
        592.4405517578125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        125.45201110839844,
        550.6781616210938,
        528.43359375,
        592.4405517578125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인되는 검체를 의미한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        125.45201110839844,
        550.6781616210938,
        528.43359375,
        592.4405517578125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        613.0100708007812,
        538.268310546875,
        627.38232421875
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        114.4179916381836,
        632.1891479492188,
        528.0498046875,
        646.5614013671875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        124.37259674072266,
        97.57337188720703,
        448.07684326171875,
        110.8069076538086
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자를",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선별할",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자의",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "콕스비례위험비(cox",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "proportional",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        121.90677642822266,
        524.7089233398438,
        135.14031982421875
      ],
      "page_num": 23,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성,",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "되는 것이 바람직하다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.85558319091797,
        136.17117309570312,
        524.715576171875,
        220.96652221679688
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        245.7314453125,
        538.268310546875,
        260.103759765625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        115.1375961303711,
        264.9104919433594,
        538.268310546875,
        279.2828063964844
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘의 임상적 성능이 떨어질 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        115.1375961303711,
        284.08953857421875,
        349.5865478515625,
        298.46185302734375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        313.2176818847656,
        538.268310546875,
        327.5899963378906
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환자의 잔여검체를 충분히 확보한다. 다음으론 선별된 바이오마커와 질환과의 연관",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.66436004638672,
        332.396728515625,
        538.1483154296875,
        346.76904296875
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.66436004638672,
        351.5757751464844,
        406.075927734375,
        365.9480895996094
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<그림 2> 통계적 방법을 이용한 알고리즘 도출",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        178.70314025878906,
        545.4039916992188,
        439.44183349609375,
        559.7762451171875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        93.54930114746094,
        565.78173828125,
        526.94140625,
        577.710693359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        596.5880126953125,
        538.268310546875,
        610.9602661132812
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정)을",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통하여",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델의",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이어스(bias,",
      "font_size": 11.869691848754883,
      "font_name": "T14",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편향성)를",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인한다.",
      "font_size": 11.869691848754883,
      "font_name": "T14",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘의",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과적합",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        103.7437744140625,
        615.76708984375,
        538.2686157226562,
        630.1393432617188
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(overfitting)에 대한 평가를 반드시 수행하여야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        103.7437744140625,
        634.9461059570312,
        387.8457946777344,
        649.318359375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 내부 검정에서 교차검정 기법을 사용한다. 대표적인 교차검정 기법으로는 Leave",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        85.87345886230469,
        664.0742797851562,
        538.2443237304688,
        678.446533203125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        683.2533569335938,
        538.1483154296875,
        697.6256103515625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다. 과적합",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        702.432373046875,
        538.1483154296875,
        716.8046264648438
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(overfitting) 되었을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "dropout",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기법",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "과적합",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        102.90422821044922,
        721.6113891601562,
        538.1483154296875,
        735.983642578125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.90422821044922,
        740.7904663085938,
        538.2442626953125,
        755.1627197265625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 24,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        102.90422821044922,
        69.04454803466797,
        465.6836242675781,
        83.41683959960938
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        98.17271423339844,
        538.1483154296875,
        112.54500579833984
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        114.4179916381836,
        117.35175323486328,
        538.1483154296875,
        131.7240447998047
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        114.4179916381836,
        136.53079223632812,
        534.7661743164062,
        150.903076171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        109.86045837402344,
        165.77883911132812,
        538.1483154296875,
        180.151123046875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성을 검정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        109.86045837402344,
        184.95785522460938,
        187.81820678710938,
        199.3301544189453
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<그림 3> LOOCV 개념도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        237.95103454589844,
        475.04083251953125,
        380.1939392089844,
        489.41314697265625
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        98.94637298583984,
        495.4185791015625,
        532.4590454101562,
        507.34759521484375
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        528.142822265625,
        538.1483154296875,
        542.5150756835938
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        552.1166381835938,
        538.268310546875,
        566.4888916015625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "법. 이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        576.0904541015625,
        538.1483154296875,
        590.4627075195312
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성을 검정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        600.0642700195312,
        125.57194519042969,
        614.4365234375
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 알고리즘의 외부 검정(평가)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.88483428955078,
        663.2352294921875,
        244.93125915527344,
        677.6074829101562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        692.3634033203125,
        538.1483154296875,
        706.7356567382812
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분하는 능력을 평가한다. 알고리즘 계산으로 도출되는 분류, 점수, 지수 등이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        98.5865707397461,
        711.5424194335938,
        538.1483154296875,
        725.9146728515625
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 유효성이 있는지 확인한다. 단, 내부 검정에 모집된 검체를 사용하지 않고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        98.5865707397461,
        730.721435546875,
        538.1483154296875,
        745.0936889648438
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 새로 모집한 검체로 평가해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        98.5865707397461,
        749.9005126953125,
        330.7567443847656,
        764.2727661132812
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 알고리즘의 내부 및 외부 검정시 고려사항",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.88483428955078,
        78.9936752319336,
        329.9411926269531,
        93.365966796875
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.87345886230469,
        108.24170684814453,
        375.39654541015625,
        122.61399841308594
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        136.17117309570312,
        538.1483154296875,
        150.54347229003906
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        154.15155029296875,
        538.268310546875,
        204.48452758789062
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        154.15155029296875,
        538.268310546875,
        204.48452758789062
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        154.15155029296875,
        538.268310546875,
        204.48452758789062
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        218.04171752929688,
        538.1483154296875,
        232.41400146484375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        236.02206420898438,
        538.1483154296875,
        286.3550720214844
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        236.02206420898438,
        538.1483154296875,
        286.3550720214844
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        236.02206420898438,
        538.1483154296875,
        286.3550720214844
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        300.0321044921875,
        538.1483154296875,
        314.4044189453125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석 및 임상 데이터 검토가 이뤄져야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        318.012451171875,
        360.8604431152344,
        332.384765625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.90585327148438,
        345.9419250488281,
        538.2442626953125,
        360.3142395019531
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예방 등)이 있는 것이 바람직하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        363.9222717285156,
        306.0501403808594,
        378.2945861816406
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        391.85174560546875,
        538.1483154296875,
        406.22406005859375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        409.83209228515625,
        538.1483154296875,
        442.1847839355469
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        409.83209228515625,
        538.1483154296875,
        442.1847839355469
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        455.86181640625,
        538.268310546875,
        470.234130859375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려할 것을 권장한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        473.8421630859375,
        243.32412719726562,
        488.2144775390625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        111.05980682373047,
        501.7716369628906,
        538.1483154296875,
        516.1439208984375
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        120.41474151611328,
        519.7520141601562,
        538.1483154296875,
        552.1046142578125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부 검정(Internal validation)을 실시한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        120.41474151611328,
        519.7520141601562,
        538.1483154296875,
        552.1046142578125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        111.65948486328125,
        565.661865234375,
        538.1723022460938,
        580.0341186523438
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Set)를 통하여 알고리즘을 평가한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.09382629394531,
        583.6422119140625,
        315.0452575683594,
        598.0144653320312
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상",
      "font_size": 11.99020004272461,
      "font_name": "T17",
      "bbox": [
        121.37422180175781,
        611.6915283203125,
        538.1483154296875,
        626.0758056640625
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부를 식약처에 확인받아야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T17",
      "bbox": [
        139.24453735351562,
        629.671875,
        324.00439453125,
        644.05615234375
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        111.89935302734375,
        657.6013793945312,
        538.268310546875,
        671.9736328125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        675.5817260742188,
        538.1483154296875,
        707.9463500976562
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·심사자료 중 개발경위의 자료로 요구된다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        123.65298461914062,
        675.5817260742188,
        538.1483154296875,
        707.9463500976562
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        111.89935302734375,
        721.4915161132812,
        538.1483154296875,
        735.86376953125
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수 이상을 가지고 시행하는 것이 바람직하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        123.65298461914062,
        738.87255859375,
        400.6788635253906,
        753.2448120117188
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        111.89935302734375,
        78.9936752319336,
        538.2682495117188,
        93.365966796875
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        121.85395812988281,
        96.49454498291016,
        538.1482543945312,
        125.67066192626953
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        121.85395812988281,
        96.49454498291016,
        538.1482543945312,
        125.67066192626953
      ],
      "page_num": 26,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        112.13922119140625,
        138.32882690429688,
        538.1483154296875,
        152.7011260986328
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.57357025146484,
        155.7098388671875,
        538.1483154296875,
        187.463134765625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.57357025146484,
        155.7098388671875,
        538.1483154296875,
        187.463134765625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.90585327148438,
        200.42095947265625,
        500.584716796875,
        214.7932586669922
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        227.7510986328125,
        538.1483154296875,
        242.12339782714844
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘 결과값의 일관성을 평가한다. 예를 들어, 발현량이 높으면 예후가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        245.13211059570312,
        538.17236328125,
        294.26641845703125
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        245.13211059570312,
        538.17236328125,
        294.26641845703125
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        245.13211059570312,
        538.17236328125,
        294.26641845703125
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        307.3441162109375,
        538.1483154296875,
        321.7164306640625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        324.7251281738281,
        534.8861083984375,
        339.0974426269531
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        352.05523681640625,
        538.268310546875,
        366.42755126953125
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려돼야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.09382629394531,
        369.4362487792969,
        200.74720764160156,
        383.8085632324219
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상적 민감도와 특이도(Clinical Sensitivity & Specificity)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        111.89935302734375,
        396.7663879394531,
        456.7364501953125,
        411.1387023925781
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Sensitivity와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Specificity는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가지의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다룬다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질환의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        419.181884765625,
        538.268310546875,
        433.55419921875
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        436.5628967285156,
        538.268310546875,
        520.459228515625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "두 그룹으로 나눈다. 따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        436.5628967285156,
        538.268310546875,
        520.459228515625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저위험군으로 나눠지면 총 4가지 그룹이 만들어진다. 이 4가지 그룹의 각 수를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        436.5628967285156,
        538.268310546875,
        520.459228515625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        436.5628967285156,
        538.268310546875,
        520.459228515625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        124.85233306884766,
        436.5628967285156,
        538.268310546875,
        520.459228515625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<그림 4 민감도와 특이도 계산>",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        227.75656127929688,
        745.105712890625,
        404.1209716796875,
        759.4779663085938
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 23 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        121.85395812988281,
        74.19891357421875,
        538.2678833007812,
        87.43244934082031
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "걸린 것으로 나타났는가”를 의미(Sensitivity = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        139.96414184570312,
        93.977294921875,
        399.58056640625,
        113.3403549194336
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 4,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        139.96414184570312,
        93.977294921875,
        399.58056640625,
        113.3403549194336
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        385.4710998535156,
        90.68511962890625,
        404.6429443359375,
        107.21083068847656
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ")",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        385.4710998535156,
        90.68511962890625,
        404.6429443359375,
        107.21083068847656
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치명적인",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병을",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "test하거나",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고위험군을",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선별하는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중요하게",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        114.23516082763672,
        538.2677612304688,
        127.46869659423828
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야할",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라서,",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이런",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘을",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통해",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "치료를",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        128.4995574951172,
        538.2674560546875,
        141.7331085205078
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받아야 하는 고위험군을 매우 잘 규정해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        142.88385009765625,
        538.267822265625,
        184.64620971679688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        142.88385009765625,
        538.267822265625,
        184.64620971679688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발병)할 것이라고 구분한 사람의 비율을 의미한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        142.88385009765625,
        538.267822265625,
        184.64620971679688
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        121.85395812988281,
        205.09585571289062,
        538.2678833007812,
        218.32940673828125
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없다고 나타나는가”를 의미(Specificity = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        139.96414184570312,
        224.87423706054688,
        371.7556457519531,
        244.2373046875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        139.96414184570312,
        224.87423706054688,
        371.7556457519531,
        244.2373046875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        357.5262451171875,
        221.58206176757812,
        376.6980895996094,
        238.1077880859375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ")",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        357.5262451171875,
        221.58206176757812,
        376.6980895996094,
        238.1077880859375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우의 고려 대상이다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석결과",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발(또는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발병)하지",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않을",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이라고",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분한",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람의",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.20401000976562,
        245.13211059570312,
        538.2682495117188,
        301.27874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율을 의미한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        140.44387817382812,
        303.2685546875,
        227.46153259277344,
        316.5021057128906
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 예측도(Predictive values)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        111.65948486328125,
        339.82861328125,
        263.76104736328125,
        354.200927734375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.6935043334961,
        360.4460754394531,
        538.1243896484375,
        390.4013671875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.6935043334961,
        360.4460754394531,
        538.1243896484375,
        390.4013671875
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        121.85395812988281,
        396.6465148925781,
        538.1488647460938,
        409.88006591796875
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        139.96414184570312,
        411.0307922363281,
        538.2678833007812,
        438.52874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도에 대한 예측도를 나타냄",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        139.96414184570312,
        411.0307922363281,
        538.2678833007812,
        438.52874755859375
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Positive Predictive Value(PPV) = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.36273193359375,
        449.1491394042969,
        430.763671875,
        469.4711608886719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.36273193359375,
        449.1491394042969,
        430.763671875,
        469.4711608886719
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        416.53424072265625,
        446.81591796875,
        421.79345703125,
        456.7650451660156
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될",
      "font_size": 11.030982971191406,
      "font_name": "T24",
      "bbox": [
        121.85395812988281,
        475.64019775390625,
        538.2682495117188,
        488.8737487792969
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        139.96414184570312,
        489.90460205078125,
        538.1041870117188,
        517.5223999023438
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘 특이도에 대한 예측도를 나타냄",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        139.96414184570312,
        489.90460205078125,
        538.1041870117188,
        517.5223999023438
      ],
      "page_num": 27,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Negative Predictive Value(NPV) = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        211.92514038085938,
        528.142822265625,
        435.0813293457031,
        548.46484375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        211.92514038085938,
        528.142822265625,
        435.0813293457031,
        548.46484375
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        420.8518981933594,
        525.8095703125,
        426.02362060546875,
        535.7587280273438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Likelihood ratios",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        111.65948486328125,
        554.5140380859375,
        218.55755615234375,
        568.8862915039062
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        575.1314697265625,
        538.1483154296875,
        605.0867309570312
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        123.65298461914062,
        575.1314697265625,
        538.1483154296875,
        605.0867309570312
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Likelihood ratio positive = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.96241760253906,
        615.886962890625,
        401.2596740722656,
        636.2089233398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        216.96241760253906,
        615.886962890625,
        401.2596740722656,
        636.2089233398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        387.1501770019531,
        613.5536499023438,
        440.59832763671875,
        636.2089233398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        387.1501770019531,
        613.5536499023438,
        440.59832763671875,
        636.2089233398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        387.1501770019531,
        613.5536499023438,
        440.59832763671875,
        636.2089233398438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        426.7287292480469,
        613.5536499023438,
        445.7096252441406,
        629.3764038085938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        426.7287292480469,
        613.5536499023438,
        445.7096252441406,
        629.3764038085938
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Likelihood ratio negative = ",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        215.40325927734375,
        646.9330444335938,
        402.8188171386719,
        667.3748779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": " ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        215.40325927734375,
        646.9330444335938,
        402.8188171386719,
        667.3748779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        389.0691223144531,
        644.5997314453125,
        442.0375671386719,
        667.3748779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 21.607894897460938,
      "font_name": "HyhwpEQ",
      "bbox": [
        389.0691223144531,
        644.5997314453125,
        442.0375671386719,
        667.3748779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "  ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        389.0691223144531,
        644.5997314453125,
        442.0375671386719,
        667.3748779296875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        427.9280700683594,
        644.5997314453125,
        447.2687683105469,
        660.4224853515625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        427.9280700683594,
        644.5997314453125,
        447.2687683105469,
        660.4224853515625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- AUC(Area Under the ROC Curve)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        115.85720825195312,
        690.3256225585938,
        323.4886779785156,
        704.6978759765625
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        710.9430541992188,
        538.268310546875,
        756.4812622070312
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "값에서 1에 근접할수록 이상적인 성능이라 하겠다. 따라서 예후 예측에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        124.85233306884766,
        710.9430541992188,
        538.268310546875,
        756.4812622070312
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 정확도를 AUC로 평가할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        124.85233306884766,
        710.9430541992188,
        538.268310546875,
        756.4812622070312
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        88.51203155517578,
        101.8886489868164,
        525.1956787109375,
        115.12218475341797
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        105.30292510986328,
        119.38953399658203,
        525.3145751953125,
        132.62307739257812
      ],
      "page_num": 28,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        105.30292510986328,
        137.01026916503906,
        525.3161010742188,
        150.2438201904297
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        105.30292510986328,
        154.63101196289062,
        525.2477416992188,
        167.86456298828125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "reviewer)가 동의할 수 있는 내용이어야 한다. (마커 선정, 모델 개발, 판단 기준(decision",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        105.30292510986328,
        172.1318817138672,
        525.2750854492188,
        185.3654327392578
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "rule)이 알고리즘 개발의 핵심)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        105.30292510986328,
        189.75262451171875,
        237.93328857421875,
        202.98617553710938
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(예,",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.030982971191406,
      "font_name": "T24",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기(IVD-MIA)는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변수",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선택",
      "font_size": 11.030982971191406,
      "font_name": "T24",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기법을",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이용하는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "logistic",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        94.02903747558594,
        217.32249450683594,
        525.2483520507812,
        230.55604553222656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "regression을 적용하여 질병의 유무를 예측한다. 결과가 yes/no로 나오는 경우엔 로지스틱",
      "font_size": 11.030982971191406,
      "font_name": "T24",
      "bbox": [
        117.77616882324219,
        234.9432373046875,
        525.1953125,
        248.17678833007812
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다. 질병과 관련있는",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        252.44412231445312,
        525.1952514648438,
        265.67767333984375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        270.0648498535156,
        525.1956787109375,
        283.29840087890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예측할 수 있다. 로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        287.68560791015625,
        525.1956787109375,
        300.9191589355469
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "도 사용 가능하다. 이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        305.18646240234375,
        525.1958618164062,
        318.4200134277344
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        322.8072204589844,
        525.1953125,
        336.040771484375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있다. 바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다. 내부",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        340.4279479980469,
        525.1954956054688,
        353.6614990234375
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        357.9288330078125,
        525.1958618164062,
        371.1623840332031
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알고리즘의 검정을 실시한다. 단, 검정에 대한 성공 기준을 질병 및 대상군에 따라",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        375.549560546875,
        525.3154296875,
        388.7831115722656
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "달리 설정해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        117.77616882324219,
        393.1703186035156,
        213.30918884277344,
        406.40386962890625
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "25",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 29,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        79.75677490234375,
        78.9936752319336,
        448.7727966308594,
        93.3779525756836
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정>",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        116.6967544555664,
        480.6746826171875,
        478.1208801269531,
        495.0469970703125
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상검체를 이용한 시험시 유의 사항",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        509.9226989746094,
        302.59600830078125,
        524.2949829101562
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        541.4483032226562,
        538.268310546875,
        555.820556640625
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        563.0247192382812,
        538.1483154296875,
        577.39697265625
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        584.6011352539062,
        415.67071533203125,
        598.973388671875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        616.126708984375,
        538.268310546875,
        630.4989624023438
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        637.703125,
        538.1483154296875,
        652.0753784179688
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토해야 한다. 개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        659.279541015625,
        538.268310546875,
        673.6517944335938
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 성능시험을 수행할 수 있다. 이때, 그 타당성은 식약처에 문의하기를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        122.81343841552734,
        680.85595703125,
        538.1483154296875,
        695.2282104492188
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권고한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        702.432373046875,
        171.84288024902344,
        716.8046264648438
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        734.0777587890625,
        538.1483154296875,
        748.4500122070312
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명확히 제시하여 검체 수집의 편향성을 배제해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        122.81343841552734,
        755.6542358398438,
        419.6285705566406,
        770.0264892578125
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 30,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 26 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.88483428955078,
        78.9936752319336,
        534.454345703125,
        93.3779525756836
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        82.87508392333984,
        110.63909149169922,
        538.268310546875,
        125.01138305664062
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같은 분석적 성능 시험이 요구된다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        82.87508392333984,
        132.21551513671875,
        273.9075622558594,
        146.58779907226562
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 정확도(Accuracy)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        163.74105834960938,
        193.5990753173828,
        178.11334228515625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 정밀도(Precision)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        195.2666015625,
        192.39971923828125,
        209.63890075683594
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 재현성(Repeatability)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        226.91201782226562,
        213.6282196044922,
        241.28431701660156
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 특이도(Specificity)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        258.43756103515625,
        198.5164031982422,
        272.80987548828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        289.9631042480469,
        421.2117004394531,
        304.3354187011719
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        321.6085205078125,
        538.268310546875,
        335.9808349609375
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.90585327148438,
        343.1849365234375,
        490.6300964355469,
        357.5572509765625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 분석적 판별기준(Analytical Cut-off)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        374.7104797363281,
        295.303955078125,
        389.0827941894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        406.23602294921875,
        538.1483154296875,
        420.60833740234375
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시하여야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.90585327148438,
        427.8124694824219,
        191.8720245361328,
        442.1847839355469
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        101.58494567871094,
        459.4578857421875,
        386.4065856933594,
        473.8421630859375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        116.57682037353516,
        490.9834289550781,
        284.4858093261719,
        505.4988098144531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준물질 및 내부 표준물질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.57682037353516,
        490.9834289550781,
        284.4858093261719,
        505.4988098144531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        116.57682037353516,
        522.5089721679688,
        518.2391357421875,
        537.0243530273438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.57682037353516,
        522.5089721679688,
        518.2391357421875,
        537.0243530273438
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        116.57682037353516,
        554.1544189453125,
        261.69818115234375,
        568.6697998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응 조건 및 분석 조건",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.57682037353516,
        554.1544189453125,
        261.69818115234375,
        568.6697998046875
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        116.57682037353516,
        585.6799926757812,
        371.0788879394531,
        600.1953735351562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비특이적 반응이 발생할 가능성과 억제 방법",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.57682037353516,
        585.6799926757812,
        371.0788879394531,
        600.1953735351562
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "§",
      "font_size": 11.99020004272461,
      "font_name": "Wingdings-Regular",
      "bbox": [
        116.57682037353516,
        617.2055053710938,
        476.3818054199219,
        631.7208862304688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        116.57682037353516,
        617.2055053710938,
        476.3818054199219,
        631.7208862304688
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        670.7869262695312,
        538.1483154296875,
        685.1591796875
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.90585327148438,
        694.0415649414062,
        461.6058349609375,
        708.413818359375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "27",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.88483428955078,
        78.9936752319336,
        527.2342529296875,
        93.3779525756836
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.4828872680664,
        108.24170684814453,
        538.1483154296875,
        122.62598419189453
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        86.59307098388672,
        125.62271881103516,
        134.66302490234375,
        139.99501037597656
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        70.64171600341797,
        152.95285034179688,
        527.2342529296875,
        167.32513427734375
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        180.28298950195312,
        538.1483154296875,
        194.6552734375
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기로 허가·심사한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        101.94474792480469,
        197.66397094726562,
        246.0826416015625,
        212.0482635498047
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        84.91397857666016,
        225.11398315429688,
        538.2442626953125,
        239.4862823486328
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        100.98526763916016,
        242.4949951171875,
        527.2102661132812,
        256.8672790527344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁. 타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        70.88158416748047,
        269.8251037597656,
        529.6329345703125,
        284.1974182128906
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        297.1552429199219,
        538.268310546875,
        311.5275573730469
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때의 성능으로 심사가 이루어져야 한다. 타사의 시약과 장비에서 알고리즘의 결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        108.06143188476562,
        314.5362548828125,
        538.268310546875,
        346.2895812988281
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판정에 영향을 주는 중대한 변경*이 없어야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        108.06143188476562,
        314.5362548828125,
        538.268310546875,
        346.2895812988281
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        108.06143188476562,
        353.2539367675781,
        538.2682495117188,
        366.48748779296875
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.73564910888672,
        369.7958679199219,
        538.2682495117188,
        398.97198486328125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "영향을 주는 변경",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        118.73564910888672,
        369.7958679199219,
        538.2682495117188,
        398.97198486328125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        411.6301574707031,
        538.1483154296875,
        426.0144348144531
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가받은 알고리즘의 검정을 다시 평가해야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        126.53142547607422,
        429.0111389160156,
        394.0824279785156,
        443.3834533691406
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        99.90585327148438,
        456.3412780761719,
        538.1483154296875,
        470.7255554199219
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리 계획을 확보하고 있어야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        126.41149139404297,
        473.7222900390625,
        319.123046875,
        488.0946044921875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂. 소프트웨어의 허가·심사시 성능 평가",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        70.88158416748047,
        501.0523986816406,
        303.31561279296875,
        515.4367065429688
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        528.50244140625,
        538.1483154296875,
        542.88671875
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다. 소프트웨어의 명칭,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        101.58494567871094,
        545.8834838867188,
        538.2442626953125,
        612.3987426757812
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        101.58494567871094,
        545.8834838867188,
        538.2442626953125,
        612.3987426757812
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·",
      "font_size": 11.99020004272461,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        545.8834838867188,
        538.2442626953125,
        612.3987426757812
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심사 시 검토가 이루어져야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        101.58494567871094,
        545.8834838867188,
        538.2442626953125,
        612.3987426757812
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        84.91397857666016,
        625.3566284179688,
        538.268310546875,
        639.7288818359375
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 성능)이 우선적으로 검정되어야 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        99.78591918945312,
        642.7376098632812,
        325.719482421875,
        657.10986328125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        91.39047241210938,
        674.1432495117188,
        534.55029296875,
        701.6411743164062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다음 각 호와 같다.",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        91.39047241210938,
        674.1432495117188,
        534.55029296875,
        701.6411743164062
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 성능에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        102.42449188232422,
        702.7919311523438,
        534.5503540039062,
        730.2898559570312
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        102.42449188232422,
        702.7919311523438,
        534.5503540039062,
        730.2898559570312
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        127.73077392578125,
        731.32080078125,
        534.5505981445312,
        758.9385986328125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출하여야 하고, (이하 생략)",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        127.73077392578125,
        731.32080078125,
        534.5505981445312,
        758.9385986328125
      ],
      "page_num": 31,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 32,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<작성 예시>",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        56.609317779541016,
        74.91812133789062,
        133.52842712402344,
        90.44020080566406
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 검증 및 유효성확인 보고서",
      "font_size": 17.985300064086914,
      "font_name": "T12",
      "bbox": [
        128.21051025390625,
        108.12184143066406,
        465.82635498046875,
        129.68028259277344
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Software Verification & Validation Report)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        108.06143188476562,
        136.89039611816406,
        486.7922058105469,
        158.44883728027344
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품명",
      "font_size": 18.944515228271484,
      "font_name": "T12",
      "bbox": [
        267.4550476074219,
        261.4342956542969,
        326.34326171875,
        284.14251708984375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev. 0",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        274.7710876464844,
        323.4065856933594,
        320.01654052734375,
        341.3719482421875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구분",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        442.55633544921875,
        440.2816162109375,
        455.7788391113281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        442.55633544921875,
        440.2816162109375,
        455.7788391113281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검토",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        442.55633544921875,
        440.2816162109375,
        455.7788391113281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        442.55633544921875,
        440.2816162109375,
        455.7788391113281
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성명",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        475.16070556640625,
        445.79840087890625,
        488.3942565917969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김○○",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        153.9965362548828,
        475.16070556640625,
        445.79840087890625,
        488.3942565917969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이○○",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        153.9965362548828,
        475.16070556640625,
        445.79840087890625,
        488.3942565917969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "박○○",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        153.9965362548828,
        475.16070556640625,
        445.79840087890625,
        488.3942565917969
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서명",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        507.76507568359375,
        176.66372680664062,
        520.9876098632812
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일자",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        153.9965362548828,
        540.3694458007812,
        453.93084716796875,
        553.5919799804688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.08.01",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        153.9965362548828,
        540.3694458007812,
        453.93084716796875,
        553.5919799804688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.08.02",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        153.9965362548828,
        540.3694458007812,
        453.93084716796875,
        553.5919799804688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018.08.03",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        153.9965362548828,
        540.3694458007812,
        453.93084716796875,
        553.5919799804688
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개정 이력(Revision History)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        197.29307556152344,
        79.95262145996094,
        397.5245361328125,
        97.9179916381836
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "날짜",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        98.10682678222656,
        115.31398010253906,
        424.4501953125,
        128.53648376464844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개정 버전",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        98.10682678222656,
        115.31398010253906,
        424.4501953125,
        128.53648376464844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인자",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        98.10682678222656,
        115.31398010253906,
        424.4501953125,
        128.53648376464844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        98.10682678222656,
        115.31398010253906,
        424.4501953125,
        128.53648376464844
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 34,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 30 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목 차(Contents)",
      "font_size": 27.937164306640625,
      "font_name": "T11",
      "bbox": [
        194.29469299316406,
        241.05657958984375,
        400.5065002441406,
        274.54400634765625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 소개(Introduction)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        74.4796371459961,
        326.8827819824219,
        221.22010803222656,
        344.84814453125
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 시스템 정보(System Information)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        74.4796371459961,
        371.8336486816406,
        330.0011291503906,
        389.79901123046875
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 검사 장비 & 검사 도구(Test Equipments & Tools)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        74.4796371459961,
        416.7845153808594,
        457.0122985839844,
        434.7498779296875
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 검증 & 유효성 확인(Verification & Validation)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        74.4796371459961,
        461.85528564453125,
        421.1517333984375,
        479.8206481933594
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 미해결 오류 (Unresolved Anomalies)",
      "font_size": 14.987749099731445,
      "font_name": "T11",
      "bbox": [
        74.4796371459961,
        506.8061218261719,
        353.6283264160156,
        524.771484375
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "31",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 31 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 소개(Introduction)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        66.56392669677734,
        68.20545959472656,
        242.48397827148438,
        89.76390075683594
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        119.9888687133789,
        538.1483154296875,
        134.37315368652344
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)를 다룬다. IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        143.96267700195312,
        538.1483154296875,
        158.3349609375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        168.77554321289062,
        537.2847900390625,
        183.14784240722656
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 시스템 정보(System Information)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        66.56392669677734,
        245.01223754882812,
        373.0962829589844,
        266.5706787109375
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 소프트웨어 버전(Software Version)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        290.80218505859375,
        264.96038818359375,
        305.17449951171875
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보드(Boards)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        116.81668853759766,
        327.8417053222656,
        453.1800537109375,
        339.7707214355469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 버전(Software Version)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        116.81668853759766,
        327.8417053222656,
        453.1800537109375,
        339.7707214355469
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시스템 제어부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.93824768066406,
        355.0519714355469,
        178.94253540039062,
        366.9809875488281
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(System Control Board)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        91.87020874023438,
        360.5659484863281,
        378.19500732421875,
        378.0089416503906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.00",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        91.87020874023438,
        360.5659484863281,
        378.19500732421875,
        378.0089416503906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터 분석 모듈",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        106.50228118896484,
        387.7762145996094,
        186.3789825439453,
        399.7052307128906
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Data Analysis Module(GUI))",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        78.43749237060547,
        393.2901916503906,
        378.19500732421875,
        410.7331848144531
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1.00",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        78.43749237060547,
        393.2901916503906,
        378.19500732421875,
        410.7331848144531
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 안전성 등급",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        91.51040649414062,
        420.5004577636719,
        508.84100341796875,
        443.4574279785156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Software Safety Level)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        91.51040649414062,
        420.5004577636719,
        508.84100341796875,
        443.4574279785156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "C",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        91.51040649414062,
        420.5004577636719,
        508.84100341796875,
        443.4574279785156
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 하드웨어 버전(Hardware Version)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        480.4349365234375,
        260.1629943847656,
        494.8072509765625
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보드(Boards)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        132.16836547851562,
        517.3546142578125,
        462.4351501464844,
        529.2835693359375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Version",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        132.16836547851562,
        517.3546142578125,
        462.4351501464844,
        529.2835693359375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Remarks",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        132.16836547851562,
        517.3546142578125,
        462.4351501464844,
        529.2835693359375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PC부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        150.27854919433594,
        544.9244384765625,
        173.3060760498047,
        556.8534545898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(PC BOARD)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        131.44876098632812,
        550.4384765625,
        342.45458984375,
        567.8814086914062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev 1.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        131.44876098632812,
        550.4384765625,
        342.45458984375,
        567.8814086914062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시스템 제어부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        129.4098663330078,
        578.367919921875,
        194.29421997070312,
        590.2969360351562
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(System Control Board)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        107.34182739257812,
        583.8819580078125,
        342.45458984375,
        601.3248901367188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev 1.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        107.34182739257812,
        583.8819580078125,
        342.45458984375,
        601.3248901367188
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "USB 부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        144.76153564453125,
        611.8114013671875,
        178.82308959960938,
        623.7403564453125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(USB",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        125.93174743652344,
        617.3253173828125,
        342.45458984375,
        634.768310546875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BOARD)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        125.93174743652344,
        617.3253173828125,
        342.45458984375,
        634.768310546875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev 1.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        125.93174743652344,
        617.3253173828125,
        342.45458984375,
        634.768310546875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전원공급부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        136.84584045410156,
        645.2548828125,
        186.73831176757812,
        657.183837890625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Power Supply BOARD)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        105.30292510986328,
        650.768798828125,
        342.45458984375,
        668.2117919921875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev 1.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        105.30292510986328,
        650.768798828125,
        342.45458984375,
        668.2117919921875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전원제어부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        136.84584045410156,
        678.6982421875,
        186.73831176757812,
        690.6272583007812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Power Control Board)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        108.9009780883789,
        684.2122802734375,
        342.45458984375,
        701.6552124023438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Rev 1.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        108.9009780883789,
        684.2122802734375,
        342.45458984375,
        701.6552124023438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 32 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연번",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        66.4439926147461,
        276.53778076171875,
        86.95246124267578,
        288.466796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        106.98201751708984,
        265.62969970703125,
        127.49049377441406,
        299.4947509765625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        106.98201751708984,
        265.62969970703125,
        127.49049377441406,
        299.4947509765625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        106.98201751708984,
        265.62969970703125,
        127.49049377441406,
        299.4947509765625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        187.93814086914062,
        276.53778076171875,
        368.79937744140625,
        288.466796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험방법",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        187.93814086914062,
        276.53778076171875,
        368.79937744140625,
        288.466796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        434.6444396972656,
        263.8316650390625,
        455.15289306640625,
        275.76068115234375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        428.7676086425781,
        276.53778076171875,
        514.8805541992188,
        301.29278564453125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        428.7676086425781,
        276.53778076171875,
        514.8805541992188,
        301.29278564453125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        428.7676086425781,
        276.53778076171875,
        514.8805541992188,
        301.29278564453125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        428.7676086425781,
        276.53778076171875,
        514.8805541992188,
        301.29278564453125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TID-1",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        65.48451232910156,
        327.12249755859375,
        88.43287658691406,
        337.9017028808594
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SRS-1",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        317.1733703613281,
        128.9718017578125,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(초기",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        317.1733703613281,
        128.9718017578125,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화면)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        317.1733703613281,
        128.9718017578125,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "System이 초기화하는 동안 필요한",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보를 Controller Firmware로부",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "터 전달받고, 화면에는 진행 상",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "태를 보여준다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(메인화면->System Log->",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자모드)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        302.30963134765625,
        273.8118896484375,
        362.5947265625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장비를",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        307.2242431640625,
        412.6963195800781,
        318.0034484863281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "켜고",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        307.2242431640625,
        412.6963195800781,
        318.0034484863281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Self",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        307.2242431640625,
        412.6963195800781,
        318.0034484863281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Test화면을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        307.2242431640625,
        412.6963195800781,
        318.0034484863281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        317.1733703613281,
        412.6963195800781,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Service의 Log화면에서 System",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        317.1733703613281,
        412.6963195800781,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Log를",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        317.1733703613281,
        412.6963195800781,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인,",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        317.1733703613281,
        412.6963195800781,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초기사용자모드",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        317.1733703613281,
        412.6963195800781,
        347.73095703125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "00화면으로 자동전환 된다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        346.90087890625,
        394.1783752441406,
        357.6800842285156
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        322.0880126953125,
        439.2286376953125,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        322.0880126953125,
        439.2286376953125,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        322.0880126953125,
        466.5738220214844,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        322.0880126953125,
        466.5738220214844,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(시험보고서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        480.9393310546875,
        322.0880126953125,
        528.913330078125,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TX-1 참고)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        480.9393310546875,
        322.0880126953125,
        528.913330078125,
        342.81634521484375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TID-2",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        65.48451232910156,
        399.88299560546875,
        88.43287658691406,
        410.6622009277344
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SRS-2",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        389.9338684082031,
        128.9718017578125,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(부가",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        389.9338684082031,
        128.9718017578125,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        389.9338684082031,
        128.9718017578125,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저장화면에서 사용자가 파라미터를",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        389.9338684082031,
        273.8113098144531,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저장 가능하고 재소환시 저장된",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        389.9338684082031,
        273.8113098144531,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화면이 나타난다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        389.9338684082031,
        273.8113098144531,
        420.611328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 화면에서 저장 화면을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        365.2408447265625,
        412.6963195800781,
        385.84930419921875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "클릭하면,",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        365.2408447265625,
        412.6963195800781,
        385.84930419921875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자설정화면으로",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        365.2408447265625,
        412.6963195800781,
        385.84930419921875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전환한다. 출력관련 파라미터를",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정하고 M1의 저장 버튼을 3",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초 누르면 삐삐 소리를 울린다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다시 다른 파라미터로 변경하고",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "M1을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "누르면",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이전에",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저장된",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        385.01922607421875,
        412.6963195800781,
        435.4750671386719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "값으로 나타난다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        434.5251159667969,
        353.7602844238281,
        445.3043212890625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        394.9683532714844,
        439.2286376953125,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        394.9683532714844,
        439.2286376953125,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        394.9683532714844,
        466.5738220214844,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        394.9683532714844,
        466.5738220214844,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(시험보고서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        480.9393310546875,
        394.9683532714844,
        528.913330078125,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TX-2 참고)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        480.9393310546875,
        394.9683532714844,
        528.913330078125,
        415.5768127441406
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TID-3",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        65.48451232910156,
        475.40045166015625,
        88.43287658691406,
        486.1796569824219
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SRS-3",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        465.4513244628906,
        128.9718017578125,
        476.23052978515625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(주",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        475.40045166015625,
        123.53305053710938,
        486.1796569824219
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.98201751708984,
        485.2297058105469,
        127.95864868164062,
        496.0089111328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파라미터를 입력한 알고리즘의",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        460.5367126464844,
        273.8121643066406,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "산술식의 결과와 소프트웨어에서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        460.5367126464844,
        273.8121643066406,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "산출된",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        460.5367126464844,
        273.8121643066406,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과가",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        460.5367126464844,
        273.8121643066406,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일치하는지를",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        460.5367126464844,
        273.8121643066406,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인한다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        490.26422119140625,
        182.37315368652344,
        501.0434265136719
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알고리즘",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        450.58758544921875,
        412.6963195800781,
        461.3667907714844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검정에서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        450.58758544921875,
        412.6963195800781,
        461.3667907714844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자에",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        450.58758544921875,
        412.6963195800781,
        461.3667907714844
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 바이오마커의 정량 또는",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        460.5367126464844,
        412.6963195800781,
        510.8726806640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성 결과를 알고리즘으로 산",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        460.5367126464844,
        412.6963195800781,
        510.8726806640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출하였을 때, 소프트웨어의 파",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        460.5367126464844,
        412.6963195800781,
        510.8726806640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라미터를 입력한 값과 동일한",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        460.5367126464844,
        412.6963195800781,
        510.8726806640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과가 나타난다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        460.5367126464844,
        412.6963195800781,
        510.8726806640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        470.365966796875,
        439.2286376953125,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        470.365966796875,
        439.2286376953125,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        470.365966796875,
        466.5738220214844,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        470.365966796875,
        466.5738220214844,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(시험보고서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        480.9393310546875,
        470.365966796875,
        528.913330078125,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TX-3 참고)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        480.9393310546875,
        470.365966796875,
        528.913330078125,
        491.09429931640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TID-4",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        65.48451232910156,
        549.958984375,
        88.43287658691406,
        560.7382202148438
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SRS-4",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        106.02253723144531,
        525.1461181640625,
        128.9718017578125,
        575.6019897460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(기기",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        525.1461181640625,
        128.9718017578125,
        575.6019897460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버전",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        525.1461181640625,
        128.9718017578125,
        575.6019897460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        525.1461181640625,
        128.9718017578125,
        575.6019897460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        106.02253723144531,
        525.1461181640625,
        128.9718017578125,
        575.6019897460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "초기화)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        102.54442596435547,
        574.7718505859375,
        132.5161895751953,
        585.5510864257812
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시스템의 H/W, S/W버전은 초",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        144.161865234375,
        530.1806030273438,
        273.8118896484375,
        580.5166015625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기설정 버전과 동일하다. 기기",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        530.1806030273438,
        273.8118896484375,
        580.5166015625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정화면에서 광조사 된 pulse",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        530.1806030273438,
        273.8118896484375,
        580.5166015625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "count는 사용자화면에서 카운터와",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        144.161865234375,
        530.1806030273438,
        273.8118896484375,
        580.5166015625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동일하다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        144.161865234375,
        530.1806030273438,
        273.8118896484375,
        580.5166015625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기설정화면에서 초기화 버튼을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "누른다. 비밀번호를 누른다. 기",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기의 “Pulse count”가 0이 된다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "H/W, S/W버전을 확인한다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자 화면에서 광조사 파라미",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "터를 최소 설정하여 안전한 곳",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 1시간 shot을 한다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다시 기기설정화면으로 진입한다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        284.0060729980469,
        515.3168334960938,
        412.6963195800781,
        595.38037109375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        545.0443725585938,
        439.2286376953125,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        423.2506103515625,
        545.0443725585938,
        439.2286376953125,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]P",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        545.0443725585938,
        466.5738220214844,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[ ]F",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        450.7157287597656,
        545.0443725585938,
        466.5738220214844,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(시험보고서",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        480.9393310546875,
        545.0443725585938,
        528.913330078125,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TX-3 참고)",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        480.9393310546875,
        545.0443725585938,
        528.913330078125,
        565.65283203125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자 직급",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        615.886962890625,
        500.96807861328125,
        627.81591796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자 성명",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        615.886962890625,
        500.96807861328125,
        627.81591796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 일자",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        615.886962890625,
        500.96807861328125,
        627.81591796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서명",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        615.886962890625,
        500.96807861328125,
        627.81591796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        615.886962890625,
        500.96807861328125,
        627.81591796875
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구원",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        83.59469604492188,
        634.4666748046875,
        327.2227478027344,
        646.4055786132812
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김○○",
      "font_size": 9.951866149902344,
      "font_name": "T19",
      "bbox": [
        83.59469604492188,
        634.4666748046875,
        327.2227478027344,
        646.4055786132812
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2014.9.1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        83.59469604492188,
        634.4666748046875,
        327.2227478027344,
        646.4055786132812
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "책임연구원",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        654.8443603515625,
        327.2227478027344,
        666.7832641601562
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이○○",
      "font_size": 9.951866149902344,
      "font_name": "T19",
      "bbox": [
        73.52015686035156,
        654.8443603515625,
        327.2227478027344,
        666.7832641601562
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2014.9.1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        73.52015686035156,
        654.8443603515625,
        327.2227478027344,
        666.7832641601562
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "총 시험 횟수",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        81.31592559814453,
        703.7509155273438,
        149.55917358398438,
        716.9734497070312
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Total Test Cases)",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        68.4828872680664,
        721.3716430664062,
        162.9377899169922,
        734.5941772460938
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 결과(Test Results)",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        238.9105224609375,
        703.7509155273438,
        501.3935546875,
        717.0933227539062
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(결함률)",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        238.9105224609375,
        703.7509155273438,
        501.3935546875,
        717.0933227539062
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Defect Rate",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        204.9689178466797,
        721.3716430664062,
        510.6808776855469,
        735.6729736328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pass",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        204.9689178466797,
        721.3716430664062,
        510.6808776855469,
        735.6729736328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Fail",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        204.9689178466797,
        721.3716430664062,
        510.6808776855469,
        735.6729736328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Total",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        204.9689178466797,
        721.3716430664062,
        510.6808776855469,
        735.6729736328125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 검사 장비 & 검사 도구(Test Equipments & Tools)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        66.56392669677734,
        68.20545959472656,
        514.2578735351562,
        89.76390075683594
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        68.4828872680664,
        103.92642211914062,
        521.4774169921875,
        115.85542297363281
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "테스트 & 툴",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        68.4828872680664,
        103.92642211914062,
        521.4774169921875,
        115.85542297363281
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        68.4828872680664,
        103.92642211914062,
        521.4774169921875,
        115.85542297363281
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장비관리번호",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        68.4828872680664,
        103.92642211914062,
        521.4774169921875,
        115.85542297363281
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T12",
      "bbox": [
        68.4828872680664,
        103.92642211914062,
        521.4774169921875,
        115.85542297363281
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        122.02664184570312,
        375.755859375,
        133.9556427001953
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Visual Studio 2018",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        122.02664184570312,
        375.755859375,
        133.9556427001953
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램 컴파일러",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        122.02664184570312,
        375.755859375,
        133.9556427001953
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        136.89039611816406,
        375.755859375,
        148.81939697265625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IAR Embedded workbench IDE",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        136.89039611816406,
        375.755859375,
        148.81939697265625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램 다운로드",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        136.89039611816406,
        375.755859375,
        148.81939697265625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        151.63429260253906,
        370.71905517578125,
        163.56329345703125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IAR 에뮬레이터",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        151.63429260253906,
        370.71905517578125,
        163.56329345703125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램 디버거",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        151.63429260253906,
        370.71905517578125,
        163.56329345703125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        165.53909301757812,
        365.68182373046875,
        177.4680938720703
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Personal Computer",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        165.53909301757812,
        365.68182373046875,
        177.4680938720703
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로그램 개발",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        165.53909301757812,
        365.68182373046875,
        177.4680938720703
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        179.3240203857422,
        360.04486083984375,
        191.25302124023438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Power Meter",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        179.3240203857422,
        360.04486083984375,
        191.25302124023438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Power 측정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        179.3240203857422,
        360.04486083984375,
        191.25302124023438
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        193.2288360595703,
        355.72723388671875,
        205.1578369140625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Fluorescence scan",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        76.5185317993164,
        193.2288360595703,
        355.72723388671875,
        205.1578369140625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신호 측정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        76.5185317993164,
        193.2288360595703,
        355.72723388671875,
        205.1578369140625
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 검증 및 유효성 확인(Verification & Validation)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        66.56392669677734,
        232.7855987548828,
        514.4977416992188,
        254.3440399169922
      ],
      "page_num": 36,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 결과",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        66.56392669677734,
        678.3386840820312,
        124.9722671508789,
        693.8737182617188
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "33",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 37,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 33 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        797.1734008789062,
        518.2831420898438,
        812.6821899414062
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "No",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        69.80216979980469,
        142.2845001220703,
        314.6659851074219,
        158.45782470703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상현상",
      "font_size": 8.992650032043457,
      "font_name": "T12",
      "bbox": [
        69.80216979980469,
        142.2845001220703,
        314.6659851074219,
        158.45782470703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Explanation -Disposition",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        69.80216979980469,
        142.2845001220703,
        314.6659851074219,
        158.45782470703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Description",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        238.19090270996094,
        153.07272338867188,
        286.24200439453125,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Acceptable",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.94281005859375,
        142.2845001220703,
        368.0639953613281,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Deviation",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        326.94281005859375,
        142.2845001220703,
        368.0639953613281,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        395.1858215332031,
        142.2845001220703,
        418.9698486328125,
        153.063720703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Performance",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        381.3932800292969,
        153.07272338867188,
        432.5872802734375,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        449.5163879394531,
        142.2845001220703,
        475.368408203125,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Safety",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        449.5163879394531,
        142.2845001220703,
        475.368408203125,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        498.6897277832031,
        142.2845001220703,
        522.4727783203125,
        153.063720703125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "End User",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        491.9733581542969,
        153.07272338867188,
        529.339111328125,
        163.85194396972656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        73.52015686035156,
        211.0893096923828,
        78.47755432128906,
        223.018310546875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자가 파라메터 버튼을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        194.0679168701172,
        198.85250854492188,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반복적으로 빠르게 누르면",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        194.0679168701172,
        198.85250854492188,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "화면이",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        194.0679168701172,
        198.85250854492188,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "느리게",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        194.0679168701172,
        198.85250854492188,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "움직이며",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        194.0679168701172,
        198.85250854492188,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "멈춤 현상을 일으킨다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        94.62871551513672,
        229.1895294189453,
        186.8107452392578,
        239.96875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Low Priority –",
      "font_size": 8.992650032043457,
      "font_name": "T19",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용자가 빠르게 여러 번",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동일 버튼을 누르면 일어날",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "현상을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반적",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        182.4406280517578,
        315.5489807128906,
        228.34146118164062
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        229.1895294189453,
        315.5489807128906,
        239.96875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        229.1895294189453,
        315.5489807128906,
        239.96875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일어나지",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        229.1895294189453,
        315.5489807128906,
        239.96875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않는",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        229.1895294189453,
        315.5489807128906,
        239.96875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것으로 보인다",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        240.9366912841797,
        267.5749816894531,
        251.71591186523438
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Y",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        211.0893096923828,
        514.747802734375,
        223.018310546875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        211.0893096923828,
        514.747802734375,
        223.018310546875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        211.0893096923828,
        514.747802734375,
        223.018310546875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        211.0893096923828,
        514.747802734375,
        223.018310546875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        73.52015686035156,
        290.92205810546875,
        78.47755432128906,
        302.85107421875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동작 중 측정가능 범위가",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        262.27337646484375,
        198.85223388671875,
        284.79974365234375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "벗어난",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        262.27337646484375,
        198.85223388671875,
        284.79974365234375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파라미터를 잘못",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        262.27337646484375,
        198.85223388671875,
        284.79974365234375
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "입력하고",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        285.6478271484375,
        198.85223388671875,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계산 아이콘을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        285.6478271484375,
        198.85223388671875,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "더블 클릭할 경우, 알고",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        297.3949890136719,
        198.85223388671875,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "리즘",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        297.3949890136719,
        198.85223388671875,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과치가 산출되는",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        94.62871551513672,
        297.3949890136719,
        198.85223388671875,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오류가 나타남",
      "font_size": 8.992650032043457,
      "font_name": "T18",
      "bbox": [
        94.62871551513672,
        320.7694396972656,
        153.03704833984375,
        331.54864501953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Low Priority –",
      "font_size": 8.992650032043457,
      "font_name": "T19",
      "bbox": [
        209.0467071533203,
        262.27337646484375,
        315.5486755371094,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "알고리즘의 안전한 연산이",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        262.27337646484375,
        315.5486755371094,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능하도록",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        262.27337646484375,
        315.5486755371094,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파라미터의",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        262.27337646484375,
        315.5486755371094,
        296.4270324707031
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정량값을 하나씩 입력하면",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        297.3949890136719,
        315.5486755371094,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오류현상을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        297.3949890136719,
        315.5486755371094,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "막을수",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        297.3949890136719,
        315.5486755371094,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있을",
      "font_size": 8.992650032043457,
      "font_name": "T15",
      "bbox": [
        209.0467071533203,
        297.3949890136719,
        315.5486755371094,
        319.9213562011719
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것으로 보인다.",
      "font_size": 8.992650032043457,
      "font_name": "T14",
      "bbox": [
        209.0467071533203,
        320.7694396972656,
        268.48651123046875,
        331.54864501953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Y",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        290.92205810546875,
        514.747802734375,
        302.85107421875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        290.92205810546875,
        514.747802734375,
        302.85107421875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        290.92205810546875,
        514.747802734375,
        302.85107421875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "N",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        344.21343994140625,
        290.92205810546875,
        514.747802734375,
        302.85107421875
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 미해결 오류(Unresolved Anomalies)",
      "font_size": 17.985300064086914,
      "font_name": "T11",
      "bbox": [
        65.60444641113281,
        95.17597961425781,
        395.9989318847656,
        116.73442077636719
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "34",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        75.69152069091797,
        796.536865234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<작성 예시>",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        133.52842712402344,
        84.4467544555664
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<별지제13호서식>",
      "font_size": 12.94941520690918,
      "font_name": "T14",
      "bbox": [
        431.526123046875,
        94.93624877929688,
        538.1890869140625,
        110.45832824707031
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기 소프트웨어 적합성 확인보고서",
      "font_size": 17.985300064086914,
      "font_name": "T23",
      "bbox": [
        123.05330657958984,
        127.42074584960938,
        470.623779296875,
        148.99716186523438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        79.39697265625,
        153.91180419921875,
        110.33985900878906,
        165.8507537841797
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(품목분류번호)",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        65.84431457519531,
        169.9742431640625,
        124.381591796875,
        180.762451171875
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자분석기구 [A22500.01(3)]",
      "font_size": 8.992650032043457,
      "font_name": "T24",
      "bbox": [
        137.6853790283203,
        161.4635467529297,
        519.0877075195312,
        173.40249633789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 명칭 및 버전",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        137.6853790283203,
        161.4635467529297,
        519.0877075195312,
        173.40249633789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MFDS-IVD-MIA-SW(1.00)",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        137.6853790283203,
        161.4635467529297,
        519.0877075195312,
        173.40249633789062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        184.4783935546875,
        120.89332580566406,
        196.41734313964844
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용형태",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        191.6705322265625,
        311.2313232421875,
        209.48306274414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내장형",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        74.11982727050781,
        191.6705322265625,
        311.2313232421875,
        209.48306274414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 독립형",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        74.11982727050781,
        191.6705322265625,
        311.2313232421875,
        209.48306274414062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        64.52503204345703,
        216.24368286132812,
        125.70087432861328,
        253.163330078125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능적 특성",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        64.52503204345703,
        216.24368286132812,
        125.70087432861328,
        253.163330078125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(중복선택 가능)",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        216.24368286132812,
        125.70087432861328,
        253.163330078125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 제어",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        213.72642517089844,
        436.9231872558594,
        224.51463317871094
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 측정",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        213.72642517089844,
        436.9231872558594,
        224.51463317871094
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 분석",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        213.72642517089844,
        436.9231872558594,
        224.51463317871094
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 진단",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        229.4292755126953,
        468.4660949707031,
        240.2174835205078
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 데이터 변환",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        229.4292755126953,
        468.4660949707031,
        240.2174835205078
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 데이터 전송",
      "font_size": 8.992650032043457,
      "font_name": "T24",
      "bbox": [
        136.00628662109375,
        229.4292755126953,
        468.4660949707031,
        240.2174835205078
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 데이터 수신",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        245.01223754882812,
        436.9231872558594,
        255.80044555664062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 표시",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        245.01223754882812,
        436.9231872558594,
        255.80044555664062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        245.01223754882812,
        436.9231872558594,
        255.80044555664062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        66.32405090332031,
        262.63299560546875,
        123.41270446777344,
        287.5177917480469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 등급",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        66.32405090332031,
        262.63299560546875,
        123.41270446777344,
        287.5177917480469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ A",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        260.11572265625,
        425.2205505371094,
        270.9039306640625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ B",
      "font_size": 8.992650032043457,
      "font_name": "T24",
      "bbox": [
        136.00628662109375,
        260.11572265625,
        425.2205505371094,
        270.9039306640625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ C",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        260.11572265625,
        425.2205505371094,
        270.9039306640625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-RM-Software Safety Class",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        276.41790771484375,
        337.7171630859375,
        288.35687255859375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        293.7989196777344,
        120.89332580566406,
        305.7378845214844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용목적",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        306.7447814941406,
        115.61659240722656,
        318.6837463378906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량",
      "font_size": 9.951866149902344,
      "font_name": "T24",
      "bbox": [
        136.00628662109375,
        294.2784118652344,
        529.9927368164062,
        318.2042541503906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        294.2784118652344,
        529.9927368164062,
        318.2042541503906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        324.2456359863281,
        120.89332580566406,
        336.1846008300781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "운영환경",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        337.1914978027344,
        115.61659240722656,
        349.1304626464844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(독립형",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        80.71625518798828,
        350.2572326660156,
        109.50065612792969,
        361.0454406738281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어에",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        69.08255767822266,
        362.00439453125,
        121.25428009033203,
        372.7926025390625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한함)",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        85.2737808227539,
        373.7515563964844,
        105.07205963134766,
        384.5397644042969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용된 SOUP",
      "font_size": 8.03343391418457,
      "font_name": "T17",
      "bbox": [
        230.63499450683594,
        337.7908630371094,
        408.378662109375,
        347.4283142089844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버전",
      "font_size": 8.03343391418457,
      "font_name": "T17",
      "bbox": [
        230.63499450683594,
        337.7908630371094,
        408.378662109375,
        347.4283142089844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Window 7",
      "font_size": 8.03343391418457,
      "font_name": "T24",
      "bbox": [
        237.95103454589844,
        350.1373596191406,
        273.0320129394531,
        359.7748107910156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Network(LANs)",
      "font_size": 8.03343391418457,
      "font_name": "T17",
      "bbox": [
        229.91539001464844,
        361.884521484375,
        281.1072998046875,
        371.52197265625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        489.0655212402344,
        120.89332580566406,
        501.0044860839844
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        84.67411041259766,
        505.1279602050781,
        105.0631332397461,
        517.06689453125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        148.83934020996094,
        397.3657531738281,
        195.61309814453125,
        408.1539611816406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발 계획",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        151.35797119140625,
        411.7500305175781,
        193.0953369140625,
        422.5382385253906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증,",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        390.1736145019531,
        530.0467529296875,
        400.9618225097656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        404.5578918457031,
        468.5110778808594,
        415.3460998535156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-SDP : Software Development Plan",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        418.9421691894531,
        434.245361328125,
        429.7303771972656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        148.83934020996094,
        440.7583312988281,
        195.61309814453125,
        451.5465393066406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "요구사항 분석",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        141.8831024169922,
        455.1426086425781,
        202.56991577148438,
        465.9308166503906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        433.5661926269531,
        529.9927368164062,
        444.3544006347656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        447.9504699707031,
        518.0442504882812,
        458.7386779785156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-SRS : Software Requirement Specification",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        462.3347473144531,
        463.7481689453125,
        473.1229553222656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 구현",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        137.2056427001953,
        498.5351867675781,
        207.2476806640625,
        509.3233947753906
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        476.9587707519531,
        529.992431640625,
        487.7469787597656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상세설계에 대한 내용은 아래문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        491.3430480957031,
        410.22265625,
        502.1312561035156
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-SA : Software Architecture",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        505.727294921875,
        401.169677734375,
        516.5155029296875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-SDS : Software Design Specification",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        520.111572265625,
        441.44085693359375,
        530.8997802734375
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 검증",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        138.1651153564453,
        541.0886840820312,
        206.4078369140625,
        551.8768920898438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 유효성확인",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        142.72264099121094,
        555.4729614257812,
        201.85061645507812,
        566.2611694335938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        540.6091918945312,
        464.19342041015625,
        551.3973999023438
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· Software Verification & Validation",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        554.8736572265625,
        374.1870422363281,
        566.8125610351562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 배포",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        137.2056427001953,
        590.9541625976562,
        207.2476806640625,
        601.7423706054688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상)",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        576.5698852539062,
        530.0017700195312,
        587.3580932617188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목록 및 잔여위험 평가여부는 아래 문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        590.9541625976562,
        437.2080383300781,
        601.7423706054688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-Release : Software Release",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        219.24118041992188,
        605.3384399414062,
        407.40594482421875,
        616.1266479492188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        627.873779296875,
        120.89332580566406,
        639.812744140625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지보수",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        640.9395751953125,
        115.61659240722656,
        652.8784790039062
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 문제해결",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        66.32405090332031,
        653.8853759765625,
        123.41236877441406,
        665.8243408203125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립,",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        619.9624633789062,
        530.0467529296875,
        630.7506713867188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        634.3467407226562,
        470.6698913574219,
        645.1349487304688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-Maintenance : Software Maintenance",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        648.7310180664062,
        359.31146240234375,
        659.5192260742188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-PR : Software Problem Resolution",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        663.1152954101562,
        349.8099060058594,
        673.9035034179688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        685.0513916015625,
        120.89332580566406,
        696.9902954101562
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험관리",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        697.9971923828125,
        115.61659240722656,
        709.9361572265625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        677.7393188476562,
        530.1126708984375,
        688.5275268554688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        692.1235961914062,
        385.3961181640625,
        702.9118041992188
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· MFDS-IVD-MIA-RM : Software Risk Management",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        706.5078735351562,
        345.9054260253906,
        717.2960815429688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        68.84268951416016,
        728.4439697265625,
        120.89332580566406,
        740.3828735351562
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "형상관리",
      "font_size": 9.951866149902344,
      "font_name": "T23",
      "bbox": [
        74.11982727050781,
        741.3897705078125,
        115.61659240722656,
        753.3287353515625
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        721.1318969726562,
        513.4417114257812,
        731.9201049804688
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래 문서를 참조한다.",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        735.5161743164062,
        228.04141235351562,
        746.3043823242188
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· MFDS-IVD-MIA-CM : Software Configuration Management",
      "font_size": 8.992650032043457,
      "font_name": "T17",
      "bbox": [
        136.00628662109375,
        749.9004516601562,
        380.0869140625,
        760.6886596679688
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅲ부  Q & A",
      "font_size": 32.97304916381836,
      "font_name": "T26",
      "bbox": [
        173.90574645996094,
        213.72642517089844,
        419.32574462890625,
        253.28318786621094
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Q1. 체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        87.3844985961914,
        522.4728393554688,
        101.75679016113281
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A1. 현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를",
      "font_size": 11.624929428100586,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        124.30416107177734,
        538.1483154296875,
        138.67645263671875
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받고 사용되는 IVD-MIA 제품은 다음과 같습니다.",
      "font_size": 11.37490177154541,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        143.48318481445312,
        342.6926574707031,
        157.85548400878906
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 국내 허가 제품(수입1, 제조 3)",
      "font_size": 11.869691848754883,
      "font_name": "T14",
      "bbox": [
        66.56392669677734,
        162.6622314453125,
        241.97317504882812,
        177.03453063964844
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 14,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품명",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        141.76316833496094,
        191.4307861328125,
        511.1629638671875,
        205.80308532714844
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상 환자군",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        141.76316833496094,
        191.4307861328125,
        511.1629638671875,
        205.80308532714844
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사대상",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        141.76316833496094,
        191.4307861328125,
        511.1629638671875,
        205.80308532714844
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진단 기법",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        141.76316833496094,
        191.4307861328125,
        511.1629638671875,
        205.80308532714844
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가 현황",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        141.76316833496094,
        191.4307861328125,
        511.1629638671875,
        205.80308532714844
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        215.76419067382812,
        185.15565490722656,
        237.927978515625
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Progensa",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        215.76419067382812,
        185.15565490722656,
        237.927978515625
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PCA 3 Assay",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        123.05330657958984,
        231.34716796875,
        198.1805877685547,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전립선 반복",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        215.76419067382812,
        297.5587158203125,
        230.13648986816406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생검 결정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        237.5912322998047,
        231.34716796875,
        291.5619812011719,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2개",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        332.3398742675781,
        215.76419067382812,
        350.33013916015625,
        230.13648986816406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        323.3447570800781,
        215.76419067382812,
        508.98016357421875,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "qRT-PCR",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        215.76419067382812,
        508.98016357421875,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2015.4.30.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        215.76419067382812,
        508.98016357421875,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(수입)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        467.6265563964844,
        231.34716796875,
        499.5532531738281,
        245.71946716308594
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        261.4342956542969,
        207.76339721679688,
        281.800048828125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "GenesWell™ BCT",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        261.4342956542969,
        207.76339721679688,
        281.800048828125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        240.589599609375,
        251.84475708007812,
        288.5635986328125,
        281.800048828125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "타 장기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        240.589599609375,
        251.84475708007812,
        288.5635986328125,
        281.800048828125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전이 위험도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        283.0107116699219,
        297.5587158203125,
        297.3830261230469
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9개",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        332.3398742675781,
        259.6362609863281,
        350.33013916015625,
        274.0085754394531
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        323.3447570800781,
        259.6362609863281,
        508.98016357421875,
        289.5915222167969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "qRT-PCR",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        259.6362609863281,
        508.98016357421875,
        289.5915222167969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2016.11.2.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        259.6362609863281,
        508.98016357421875,
        289.5915222167969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제조)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        467.6265563964844,
        275.2192077636719,
        499.5532531738281,
        289.5915222167969
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        300.3916931152344,
        198.99615478515625,
        324.2336730957031
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "AptoDetectTM-",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        300.3916931152344,
        198.99615478515625,
        324.2336730957031
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Lung",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        146.56056213378906,
        317.65283203125,
        174.67332458496094,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비소세포성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        302.06988525390625,
        297.5587158203125,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐암 위험도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        302.06988525390625,
        297.5587158203125,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7개",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        332.3398742675781,
        302.06988525390625,
        350.33013916015625,
        316.44219970703125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단백질",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        323.3447570800781,
        302.06988525390625,
        508.98016357421875,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Microarray",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        302.06988525390625,
        508.98016357421875,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017.9.26.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        302.06988525390625,
        508.98016357421875,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제조)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        467.6265563964844,
        317.65283203125,
        499.5532531738281,
        332.025146484375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        343.0650634765625,
        214.2279052734375,
        365.2288818359375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "nProfiler I stomach",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        81.79566955566406,
        343.0650634765625,
        214.2279052734375,
        365.2288818359375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "cancer assay",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        126.29154968261719,
        343.0650634765625,
        350.33013916015625,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위암 예후",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        126.29154968261719,
        343.0650634765625,
        350.33013916015625,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9개",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        126.29154968261719,
        343.0650634765625,
        350.33013916015625,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전자",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        323.3447570800781,
        343.0650634765625,
        511.85858154296875,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "qRT-PCR",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        343.0650634765625,
        511.85858154296875,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017.11.10.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        323.3447570800781,
        343.0650634765625,
        511.85858154296875,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(제조)",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        467.6265563964844,
        358.6480407714844,
        499.5532531738281,
        373.0203552246094
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 미국 허가 제품",
      "font_size": 11.869691848754883,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        408.9930114746094,
        160.8328399658203,
        423.3653259277344
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "37",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 37 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Q2.",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다중진단(Multiplex",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "assays)과",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        82.11026763916016,
        534.7901611328125,
        96.48255920410156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(IVD-MIA)의 가장 큰 차이점은 무엇인가요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        96.54767608642578,
        101.289306640625,
        351.4455261230469,
        115.6615982055664
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A2.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다중진단은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다수의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단순히",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        133.4141845703125,
        538.1483154296875,
        147.78648376464844
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cut-off",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수치를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        152.59323120117188,
        538.268310546875,
        166.9655303955078
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도출합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반해,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다수의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        171.77227783203125,
        538.268310546875,
        186.1445770263672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이오마커에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입력값으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "알고리즘의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수식을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        190.95132446289062,
        538.268310546875,
        205.3236083984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계산합니다. 그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        210.13037109375,
        538.1483154296875,
        224.50265502929688
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상의의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도울",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있습니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다중진단과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        229.30938720703125,
        538.268310546875,
        243.6816864013672
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        248.48843383789062,
        538.268310546875,
        262.8607482910156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "돕는 결과를 생성하는 알고리즘 포함 여부입니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        267.66748046875,
        363.9787292480469,
        282.039794921875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q3. 체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        334.07489013671875,
        514.760986328125,
        348.44720458984375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어떻게 이루어지나요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        89.47151184082031,
        353.2539367675781,
        214.11996459960938,
        367.6262512207031
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A3. 체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        381.18341064453125,
        538.268310546875,
        395.55572509765625
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        400.3624572753906,
        538.268310546875,
        414.7347717285156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가장",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상적입니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하지만,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        419.54150390625,
        538.268310546875,
        433.913818359375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        438.7205505371094,
        538.268310546875,
        453.0928649902344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있습니다. 이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        457.8995666503906,
        538.268310546875,
        472.2718811035156
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과치)가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명확해야",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        477.07861328125,
        538.1483154296875,
        491.450927734375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자군",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명확하게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의돼야",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수와의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        496.2576599121094,
        538.268310546875,
        510.6299743652344
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.63034057617188,
        515.4367065429688,
        538.268310546875,
        529.8089599609375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.63034057617188,
        534.6157836914062,
        448.05316162109375,
        548.988037109375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        90.5509262084961,
        553.7947998046875,
        538.268310546875,
        568.1670532226562
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 민원인 안내서(가이드라인)을 참고하시면 됩니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        90.5509262084961,
        572.973876953125,
        377.4114685058594,
        587.3461303710938
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q4. 체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        620.0823364257812,
        514.760986328125,
        634.45458984375
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떻게 이루어지나요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        89.47151184082031,
        639.2614135742188,
        214.11996459960938,
        653.6336669921875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A4. 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        66.56392669677734,
        667.1908569335938,
        538.268310546875,
        681.5631103515625
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정은 허용기준(acceptability criteria)을 충족해야 합니다. 또한, 알고리즘은 독립",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        686.3699340820312,
        538.1483154296875,
        700.7421875
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적인 검체를 이용해 검정을 진행합니다. 알고리즘의 검정을 시행하기 이전에 알",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        705.5489501953125,
        538.268310546875,
        719.9212036132812
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고리즘의 핵심 구성 요소인 사용변수(바이오마커),",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통계모델",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        91.99014282226562,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        724.72802734375,
        538.1483154296875,
        739.1002807617188
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(decision rule) 등이 결정돼야 합니다. 검체군은 알고리즘으로 예측하고자 하는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        743.9070434570312,
        538.268310546875,
        758.279296875
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "38",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 38 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        69.04454803466797,
        538.1483154296875,
        83.41683959960938
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        88.22358703613281,
        166.925537109375,
        102.59587860107422
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        107.40262603759766,
        538.268310546875,
        121.77491760253906
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        126.58167266845703,
        538.1483154296875,
        140.95396423339844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험해야 합니다. 알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        145.76071166992188,
        538.1483154296875,
        160.13299560546875
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단계와 무관하게 진행할 수 있어야 합니다. 만약 알고리즘 개발 단계에서 사용했던",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        164.93975830078125,
        538.1483154296875,
        179.31204223632812
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용해야",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다면(예,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "gene",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "expression",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "microarray",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험에서",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        184.1187744140625,
        538.268310546875,
        198.49107360839844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        203.29782104492188,
        538.2442626953125,
        217.6701202392578
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        222.47686767578125,
        536.565185546875,
        236.84915161132812
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        241.65591430664062,
        538.1483154296875,
        256.0281982421875
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        260.8349304199219,
        538.2442626953125,
        275.2072448730469
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        280.01397705078125,
        538.1483154296875,
        294.38629150390625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        299.1930236816406,
        538.184326171875,
        313.5653381347656
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reviewer)가 동의할 수 있는 내용이어야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        318.3720703125,
        351.9852294921875,
        332.744384765625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        337.55108642578125,
        538.1483154296875,
        351.92340087890625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "logistic regression을 적용할 수 있습니다. 질병과 관련 있는 지표와 바이오마커들의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        356.7301330566406,
        538.1483154296875,
        371.1024475097656
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        375.9091796875,
        538.1483154296875,
        390.281494140625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "습니다. 로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다. 이러한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        395.0882263183594,
        538.1483154296875,
        409.4605407714844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법으로",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생성된",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능은",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cross-validation을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통하여",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내부",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        414.26727294921875,
        538.268310546875,
        428.63958740234375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(internal validation 임상시험)이 시행되어야 합니다. 바이오마커의 선택과 적합 모",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        433.4462890625,
        538.1483154296875,
        447.818603515625
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "델의 선정 등 모든 경위를 검정에 사용합니다. 성공적인 결과를 확인한 경우(성공",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        452.6253356933594,
        538.1483154296875,
        466.9976501464844
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        471.80438232421875,
        538.1483154296875,
        486.17669677734375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해 알고리즘의 검정을 계획합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        91.99014282226562,
        490.9834289550781,
        277.02587890625,
        505.3557434082031
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q5.",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기(IVD-MIA)는",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상(환자,",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자)을",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        538.0919799804688,
        534.9100341796875,
        552.4642333984375
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "왜 명확히 설정해야 하나요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        93.0695571899414,
        557.27099609375,
        256.6968688964844,
        571.6432495117188
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A4. 체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        585.3203735351562,
        538.268310546875,
        599.692626953125
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        604.4993896484375,
        538.1483154296875,
        618.8716430664062
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다. 따라서, 환자군의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        623.6784057617188,
        538.1483154296875,
        638.0506591796875
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        642.8574829101562,
        535.1259765625,
        657.229736328125
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        662.0364990234375,
        538.1483154296875,
        676.4087524414062
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관찰하여 유방암의 예후를 예측하는 검사입니다. 만약 이 검사의 알고리즘 개발과",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        681.215576171875,
        538.1483154296875,
        695.5878295898438
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        700.3945922851562,
        538.1483154296875,
        714.766845703125
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자 발현 양상에 영향을 줄 수 있습니다. 유전적 요소만이 검사 결과에 영향을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        719.5736083984375,
        538.1483154296875,
        733.9458618164062
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        738.752685546875,
        538.1483154296875,
        753.1249389648438
      ],
      "page_num": 42,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 39 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(IVD-MIA)에 문제가 있는 것입니다. 그러한 이유로 MammaPrint 제품은 알고리즘",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        69.04454803466797,
        538.1483154296875,
        83.41683959960938
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        88.22358703613281,
        538.1468505859375,
        102.59587860107422
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "expression",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "profiling",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "predicts",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "clinical",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "outcome",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cancer.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Nature,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2002)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        107.52249908447266,
        538.215087890625,
        120.74501037597656
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "415(6871):530-6.\"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        125.14324188232422,
        538.2683715820312,
        138.36575317382812
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        142.64410400390625,
        538.1483154296875,
        155.8666229248047
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        160.14498901367188,
        538.1517944335938,
        174.51727294921875
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "clinical utility of a 70-gene prognostic signature for women with node-negative breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        179.4438934326172,
        538.2457885742188,
        192.66641235351562
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cancer. JNCI, (2006) 98(17):1183-1192.\"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        196.94476318359375,
        538.268310546875,
        211.3170623779297
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        216.12380981445312,
        534.0465087890625,
        230.49609375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q6. 체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        263.2323303222656,
        534.9100341796875,
        277.6046447753906
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있나요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        89.47151184082031,
        282.4113464355469,
        132.56414794921875,
        296.7836608886719
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A6. 체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        61.64658737182617,
        310.3408508300781,
        489.3108215332031,
        324.7131652832031
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Chapter 1. 사용변수(바이오마커)의 선별 근거 및 선별된 사용변수",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        84.91397857666016,
        341.50677490234375,
        453.4742431640625,
        355.87908935546875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        360.6858215332031,
        487.41583251953125,
        375.0700988769531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 선별에 사용된 통계적 분석 방법들을 제시",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        379.8648681640625,
        337.4970703125,
        394.2491455078125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        399.04388427734375,
        536.948974609375,
        413.42816162109375
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        418.2229309082031,
        511.40283203125,
        432.6072082519531
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Chapter 2. 진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        85.39372253417969,
        456.5810241699219,
        532.9910888671875,
        470.9533386230469
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        475.76007080078125,
        538.1483154296875,
        490.14434814453125
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 기술",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        104.10357666015625,
        494.9390869140625,
        158.07432556152344,
        509.3114013671875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 알고리즘 개발 모델과 discovery set에 대한 설명",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        514.1181640625,
        373.83740234375,
        528.50244140625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        533.2971801757812,
        529.39306640625,
        547.6814575195312
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        552.4762573242188,
        535.509765625,
        566.8605346679688
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        571.6552734375,
        517.2796630859375,
        586.03955078125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        85.63359069824219,
        590.8343505859375,
        361.4841003417969,
        605.2186279296875
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        85.63359069824219,
        610.0133666992188,
        525.8909301757812,
        624.3976440429688
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Q7. 체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고",
      "font_size": 11.99020004272461,
      "font_name": "T12",
      "bbox": [
        64.52503204345703,
        657.1218872070312,
        534.9100341796875,
        671.494140625
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는데 식약처의 임상시험 계획 승인 대상인가요?",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        93.0695571899414,
        676.3009033203125,
        391.7436828613281,
        690.6731567382812
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "A7. 「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        704.3502807617188,
        538.268310546875,
        718.7345581054688
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 계획 승인 대상을 정하고 있습니다. 여기에는 ‘이미 확릭된 의학적 진단",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        723.529296875,
        538.1483154296875,
        737.9015502929688
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        742.7083740234375,
        538.1483154296875,
        757.0926513671875
      ],
      "page_num": 43,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "40",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 40 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 없는 시험’이 포함됩니다. 개발중인 IVD-MIA는 기존의 의학적 진단방법 또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        69.04454803466797,
        538.268310546875,
        83.41683959960938
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        88.22358703613281,
        538.1483154296875,
        102.60786437988281
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상일 수 있습니다. 임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        86.11332702636719,
        107.40262603759766,
        538.1483154296875,
        121.77491760253906
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반드시 협의하여 주시기 바랍니다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        86.11332702636719,
        126.58167266845703,
        274.9869689941406,
        140.95396423339844
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<부 록>",
      "font_size": 15.946965217590332,
      "font_name": "MalgunGothicBold",
      "bbox": [
        56.609317779541016,
        67.03621673583984,
        115.21659851074219,
        88.2410888671875
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단다지표검사용 의료기기",
      "font_size": 24.93961524963379,
      "font_name": "YetR-HM",
      "bbox": [
        107.94149780273438,
        208.36228942871094,
        486.93743896484375,
        234.75595092773438
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[IVD-MIA] 허가·심사 예시",
      "font_size": 24.93961524963379,
      "font_name": "YetR-HM",
      "bbox": [
        136.24615478515625,
        248.27867126464844,
        458.5118713378906,
        274.6723327636719
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>",
      "font_size": 14.028532981872559,
      "font_name": "YetR-HM",
      "bbox": [
        73.99989318847656,
        288.28118896484375,
        542.0877075195312,
        306.9016418457031
      ],
      "page_num": 45,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        73.42176818847656,
        796.536865234375
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목   차",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        262.41778564453125,
        75.2354736328125,
        332.4598083496094,
        95.25359344482422
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅰ부.  제품 개요 ··············································································· 4",
      "font_size": 14.987749099731445,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        139.97105407714844,
        509.94873046875,
        154.95468139648438
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 제품 개요 ···································································································· 4",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        175.36834716796875,
        509.9955139160156,
        192.1979522705078
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료 ······················· 5",
      "font_size": 14.987749099731445,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        216.8070831298828,
        509.94873046875,
        231.79071044921875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 제조허가 및 수입허가 신청서 ··································································5",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        252.2043914794922,
        509.9955139160156,
        269.03399658203125
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 기술문서에 관한 자료 ················································································5",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        281.572265625,
        509.9955139160156,
        298.4018859863281
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목 ······················· 6",
      "font_size": 14.987749099731445,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        323.01104736328125,
        509.94873046875,
        337.9946594238281
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 명칭 ·············································································································· 6",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        358.4083251953125,
        509.9955139160156,
        375.2379150390625
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 분류번호(등급) ··························································································· 7",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        387.7762451171875,
        509.9955139160156,
        404.6058349609375
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 모양 및 구조 ······························································································ 7",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        417.14410400390625,
        509.9955139160156,
        433.9737243652344
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 원재료 ·········································································································· 9",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        446.51202392578125,
        509.9955139160156,
        463.3416442871094
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 제조방법 ······································································································11",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        475.87994384765625,
        509.9951477050781,
        492.70953369140625
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 사용목적(성능) ···························································································11",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        505.24786376953125,
        509.9951477050781,
        522.0774536132812
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 사용방법 ······································································································13",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        534.6157836914062,
        509.9951477050781,
        551.4453735351562
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 사용 시 주의사항 ······················································································14",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        563.983642578125,
        509.9951477050781,
        580.813232421875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9. 포장단위 ······································································································15",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        593.3515625,
        509.9951477050781,
        610.18115234375
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10. 저장방법 및 사용기간 ············································································15",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        622.719482421875,
        509.9951477050781,
        639.549072265625
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11. 시험규격 ····································································································16",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        652.08740234375,
        509.9951477050781,
        668.9169921875
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12. 제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        681.4552612304688,
        509.9951477050781,
        698.2848510742188
      ],
      "page_num": 46,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅳ부.  기술문서 등의 심사를 위한 제출자료 ···························18",
      "font_size": 14.987749099731445,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        80.75576782226562,
        509.94873046875,
        95.73939514160156
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 기본원칙 및 성능시험 자료의 요건 ·····················································18",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        116.15306091308594,
        509.9951477050781,
        132.982666015625
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        145.52096557617188,
        509.9951477050781,
        162.35057067871094
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 원재료 및 제조방법에 관한 자료 ··························································22",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        174.8888702392578,
        509.9951477050781,
        191.71847534179688
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 사용목적에 관한 자료 ··············································································22",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        204.25677490234375,
        509.9951477050781,
        221.0863800048828
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 저장방법과 사용기간(유효기간)에 관한 자료 ·····································23",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        233.6246795654297,
        509.9951477050781,
        250.45428466796875
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 성능시험에 관한 자료 ··············································································23",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        262.99261474609375,
        509.9951477050781,
        279.82220458984375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        292.3604736328125,
        509.9951477050781,
        309.1900939941406
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 이미 허가받은 제품과 비교한 자료 ······················································24",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        321.7283935546875,
        509.9951477050781,
        338.5580139160156
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅴ부.  성능에 관한 세부사항 ····················································· 25",
      "font_size": 14.987749099731445,
      "font_name": "H2hdrM",
      "bbox": [
        56.609317779541016,
        363.1671447753906,
        509.94873046875,
        378.1507568359375
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 분석적 성능시험에 관한 자료 ································································25",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        398.564453125,
        509.9951477050781,
        415.39404296875
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상적 성능시험에 관한 자료 ································································36",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        427.93231201171875,
        509.9951477050781,
        444.7619323730469
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        457.30023193359375,
        509.9951477050781,
        474.1298522949219
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        486.66815185546875,
        509.9951477050781,
        503.49774169921875
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        516.0360717773438,
        509.9951477050781,
        532.8656616210938
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 상관성 평가 ································································································43",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        545.4039916992188,
        509.9951477050781,
        562.2335815429688
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 소프트웨어 성능 자료 ··············································································46",
      "font_size": 14.028532981872559,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        574.7718505859375,
        509.9951477050781,
        591.6014404296875
      ],
      "page_num": 47,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        73.42176818847656,
        796.536865234375
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 4 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅰ부. 제품 개요",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        74.4796371459961,
        81.89932250976562,
        222.8392333984375,
        99.87966918945312
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 제품에 대한 개요",
      "font_size": 12.94941520690918,
      "font_name": "T12",
      "bbox": [
        76.63846588134766,
        136.2910614013672,
        200.77175903320312,
        151.81312561035156
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        172.85110473632812,
        538.1483154296875,
        187.223388671875
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        196.82489013671875,
        538.1243896484375,
        211.1971893310547
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        220.7987060546875,
        538.1483154296875,
        235.17098999023438
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        244.77249145507812,
        529.3690795898438,
        259.1448059082031
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        281.692138671875,
        538.1483154296875,
        296.064453125
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        305.66595458984375,
        538.268310546875,
        320.03826904296875
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류된다. 유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        329.6397399902344,
        538.1243286132812,
        344.0120544433594
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        353.6135559082031,
        467.3627014160156,
        367.9858703613281
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        389.5742492675781,
        538.268310546875,
        403.9465637207031
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분화도가",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "호르몬",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수용체(HR,",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에스트로겐",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수용체",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "프로게스테론",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        413.54803466796875,
        538.1483154296875,
        427.92034912109375
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        437.5218505859375,
        538.1483154296875,
        451.8941650390625
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정에 중요한 역할을 한다. 조기 유방암 환자 중 HR 양성, HER2 음성, 림프절",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        68.60282135009766,
        461.4956359863281,
        538.1483154296875,
        475.8679504394531
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        485.4694519042969,
        538.1483154296875,
        499.8417663574219
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        509.4432678222656,
        538.1483154296875,
        523.8155517578125
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처방 받고 있다. 본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        533.4170532226562,
        538.1483154296875,
        547.789306640625
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        557.390869140625,
        538.1483154296875,
        571.7631225585938
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수를 제공 한다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        581.3646850585938,
        167.52520751953125,
        595.7369384765625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를",
      "font_size": 11.99020004272461,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        605.3385009765625,
        538.268310546875,
        619.7107543945312
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선택하는데",
      "font_size": 11.99020004272461,
      "font_name": "T18",
      "bbox": [
        68.60282135009766,
        605.3385009765625,
        538.268310546875,
        619.7107543945312
      ],
      "page_num": 48,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.",
      "font_size": 11.99020004272461,
      "font_name": "T14",
      "bbox": [
        68.60282135009766,
        629.312255859375,
        386.4065856933594,
        643.6845092773438
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅱ부. 신청서 기재 항목 및 기술문서 제출자료",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        74.4796371459961,
        81.89932250976562,
        493.172119140625,
        99.87966918945312
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        151.3426971435547,
        291.9224853515625,
        166.08657836914062
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조허가 및 수입허가 신청서",
      "font_size": 14.028532981872559,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        151.3426971435547,
        291.9224853515625,
        166.08657836914062
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 9,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 명칭(제품명, 품목명, 모델명)",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        186.3962860107422,
        217.76449584960938,
        199.6298370361328
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 분류번호(등급)",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        208.4521942138672,
        153.71920776367188,
        221.6857452392578
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 모양 및 구조-외형",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        230.38821411132812,
        171.915283203125,
        243.62176513671875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 모양 및 구조-작용원리",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        252.32424926757812,
        191.70484924316406,
        265.55780029296875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 원재료",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        274.380126953125,
        116.74563598632812,
        287.6136779785156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 제조방법",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        296.316162109375,
        126.58015441894531,
        309.5497131347656
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용목적(성능)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        318.252197265625,
        160.8817596435547,
        331.4857482910156
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        340.3080749511719,
        130.36900329589844,
        353.5416259765625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용 시 주의사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        362.2441101074219,
        174.38516235351562,
        375.4776611328125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 포장단위",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        384.1801452636719,
        130.36900329589844,
        397.4136962890625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 저장방법 및 사용기간",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        406.2360534667969,
        186.06790161132812,
        419.4696044921875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 시험규격",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        428.17205810546875,
        126.58015441894531,
        441.4056091308594
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        450.10809326171875,
        293.80328369140625,
        463.3416442871094
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 허가조건",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        472.16400146484375,
        130.36900329589844,
        485.3975524902344
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 비고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        494.1000061035156,
        108.4212417602539,
        507.33355712890625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        567.0484008789062,
        236.63572692871094,
        581.912109375
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술문서에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        567.0484008789062,
        236.63572692871094,
        581.912109375
      ],
      "page_num": 49,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        602.4616088867188,
        390.02862548828125,
        615.6951293945312
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 원재료 및 제조방법에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        624.5175170898438,
        251.26382446289062,
        637.7510375976562
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용목적에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        646.4534912109375,
        196.33358764648438,
        659.68701171875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 사용기간 또는 유효기간에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        668.3895263671875,
        273.21160888671875,
        681.623046875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 성능시험에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        690.4454345703125,
        196.33358764648438,
        703.678955078125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 취급자 안전에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        712.3814697265625,
        212.76434326171875,
        725.614990234375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 이미 허가받은 제품과 비교한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        734.3175048828125,
        262.2978515625,
        747.551025390625
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        73.42176818847656,
        796.536865234375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 6 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅲ부. 제조허가 및 수입허가 신청서 기재 항목",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        74.4796371459961,
        103.9552230834961,
        477.1014404296875,
        121.9355697631836
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 명칭",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        144.442138671875,
        97.26728057861328,
        158.82643127441406
      ],
      "page_num": 50,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        168.5358123779297,
        350.38385009765625,
        181.7693634033203
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        190.47183227539062,
        538.2682495117188,
        203.70538330078125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.1522216796875,
        212.52774047851562,
        489.1486511230469,
        225.76129150390625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        234.46376037597656,
        535.8034057617188,
        247.6973114013672
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        256.3997802734375,
        538.197265625,
        269.6333312988281
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불가하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.51203155517578,
        278.4556884765625,
        135.1005401611328,
        291.6892395019531
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        322.3277282714844,
        538.2020874023438,
        335.561279296875
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.79566955566406,
        344.3836364746094,
        411.3108215332031,
        357.6171875
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        366.3196716308594,
        538.2697143554688,
        379.55322265625
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "취소된 날로부터 1년이 지난 경우",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.51203155517578,
        388.25567626953125,
        258.9396667480469,
        401.4892272949219
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        410.31158447265625,
        498.20965576171875,
        423.5451354980469
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        432.24761962890625,
        538.2698364257812,
        445.4811706542969
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분하는 경우",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.11170196533203,
        454.18365478515625,
        160.59295654296875,
        467.4172058105469
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.24626541137695,
        498.1755676269531,
        538.1483154296875,
        511.40911865234375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.03716278076172,
        523.5877685546875,
        402.4356384277344,
        536.8212890625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        62.00639343261719,
        573.213623046875,
        104.5334243774414,
        585.1525268554688
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 7 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 분류번호(등급)",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        69.04454803466797,
        158.12229919433594,
        83.42882537841797
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        93.13821411132812,
        538.2678833007812,
        106.37174987792969
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.19599151611328,
        115.0742416381836,
        127.90443420410156,
        128.3077850341797
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 모양 및 구조",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        158.9462890625,
        147.04031372070312,
        173.33058166503906
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 모양 및 구조 - 작용원리",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        183.0399627685547,
        208.44668579101562,
        196.2735137939453
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        78.07768249511719,
        204.97598266601562,
        538.2687377929688,
        218.20953369140625
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정항목에 대한 임상적 배경을 포함하여 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        78.07768249511719,
        227.03187561035156,
        338.5102844238281,
        240.2654266357422
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        270.9039306640625,
        339.3498229980469,
        284.1374816894531
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        292.9598388671875,
        466.9606628417969,
        306.1933898925781
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① FFPE 처리된 유방암 조직에서 RNA 추출",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        314.8958740234375,
        305.7139892578125,
        328.1294250488281
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② RNA 교잡반응",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        336.8318786621094,
        167.18905639648438,
        350.0654296875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 형광표지자를 이용한 각 유전자들의 정량(Scanning)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        358.8877868652344,
        356.13494873046875,
        372.121337890625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        380.8238220214844,
        467.0268859863281,
        394.057373046875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        402.75982666015625,
        497.3704528808594,
        415.9933776855469
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프노드 전이유무",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        91.99014282226562,
        434.7681579589844,
        480.8194274902344,
        445.7961120605469
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BCA Score Range",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        91.99014282226562,
        434.7681579589844,
        480.8194274902344,
        445.7961120605469
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험 수준",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        91.99014282226562,
        434.7681579589844,
        480.8194274902344,
        445.7961120605469
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프노드 전이 음성",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        89.35157012939453,
        470.8487243652344,
        188.29794311523438,
        481.8766784667969
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0-60",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        284.1260070800781,
        454.3067932128906,
        478.0605773925781,
        465.3347473144531
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저위험군",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        284.1260070800781,
        454.3067932128906,
        478.0605773925781,
        465.3347473144531
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61-100",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        277.5295715332031,
        470.8487243652344,
        486.3360900878906,
        481.8766784667969
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중간 위험군",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        277.5295715332031,
        470.8487243652344,
        486.3360900878906,
        481.8766784667969
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "101-160",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        274.2913513183594,
        487.510498046875,
        478.0605773925781,
        498.5384521484375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고위험군",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        274.2913513183594,
        487.510498046875,
        478.0605773925781,
        498.5384521484375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프노드 전이 양성",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        89.35157012939453,
        503.69281005859375,
        188.29794311523438,
        514.7207641601562
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1-3개 림프노드)",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        94.38884735107422,
        521.3135375976562,
        183.10232543945312,
        532.3414916992188
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0-60",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        284.1260070800781,
        504.17230224609375,
        478.0605773925781,
        515.2002563476562
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저위험군",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        284.1260070800781,
        504.17230224609375,
        478.0605773925781,
        515.2002563476562
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61-160",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        277.5295715332031,
        520.8341064453125,
        478.0605773925781,
        531.862060546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고위험군",
      "font_size": 11.030982971191406,
      "font_name": "Batang",
      "bbox": [
        277.5295715332031,
        520.8341064453125,
        478.0605773925781,
        531.862060546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        568.7783813476562,
        538.2682495117188,
        582.0119018554688
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Index Score) 판단표에 대한 설명 포함).",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        590.8342895507812,
        282.6209716796875,
        604.0678100585938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 모양 및 구조 – 외형",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        634.7063598632812,
        185.65936279296875,
        647.9398803710938
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다. 만일 체외진단다지표검사용 의료기기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.841064453125,
        656.7622680664062,
        538.2677001953125,
        669.9957885742188
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        127.8507080078125,
        678.6983032226562,
        538.2681884765625,
        691.9318237304688
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성품의 외관사진 및 구성표를 따로 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        127.8507080078125,
        700.63427734375,
        350.38385009765625,
        713.8677978515625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        722.690185546875,
        140.513916015625,
        735.9237060546875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        744.865966796875,
        538.2345581054688,
        756.7949829101562
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        73.42176818847656,
        796.536865234375
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 8 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        105.90260314941406,
        125.38298034667969,
        464.987548828125,
        137.31198120117188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        105.90260314941406,
        125.38298034667969,
        464.987548828125,
        137.31198120117188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세부구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.90260314941406,
        125.38298034667969,
        464.987548828125,
        137.31198120117188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외관상 특징",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.90260314941406,
        125.38298034667969,
        464.987548828125,
        137.31198120117188
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        148.63755798339844,
        479.9793701171875,
        167.03948974609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reference Sample",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        148.63755798339844,
        479.9793701171875,
        167.03948974609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.45851135253906,
        148.63755798339844,
        479.9793701171875,
        167.03948974609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "붉은색캡 바이알내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.45851135253906,
        148.63755798339844,
        479.9793701171875,
        167.03948974609375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무색액상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        417.4937438964844,
        161.5834197998047,
        457.43206787109375,
        173.51242065429688
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        186.7559051513672,
        118.41590881347656,
        198.68490600585938
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Primer",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        149.55894470214844,
        197.30438232421875,
        180.1076202392578,
        209.23338317871094
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "set",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        158.6739959716797,
        210.37010192871094,
        171.01373291015625,
        222.29910278320312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cancer Related",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        199.451904296875,
        180.28297424316406,
        479.9793701171875,
        205.1578369140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Gens primer set",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        199.451904296875,
        180.28297424316406,
        479.9793701171875,
        205.1578369140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        199.451904296875,
        180.28297424316406,
        479.9793701171875,
        205.1578369140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파란색캡 바이알내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        199.451904296875,
        180.28297424316406,
        479.9793701171875,
        205.1578369140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무색액상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        417.4937438964844,
        193.2288360595703,
        457.43206787109375,
        205.1578369140625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        213.12709045410156,
        272.505126953125,
        231.5290069580078
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reference Gens",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        213.12709045410156,
        272.505126953125,
        231.5290069580078
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "primer set",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        213.2444305419922,
        213.12709045410156,
        479.9793701171875,
        238.12181091308594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        213.2444305419922,
        213.12709045410156,
        479.9793701171875,
        238.12181091308594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보라색캡 바이알내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        213.2444305419922,
        213.12709045410156,
        479.9793701171875,
        238.12181091308594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무색액상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        417.4937438964844,
        226.19281005859375,
        457.43206787109375,
        238.12181091308594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        245.97119140625,
        247.6785888671875,
        264.3731384277344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reference Gens",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        245.97119140625,
        247.6785888671875,
        264.3731384277344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "primer set",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        188.41787719726562,
        245.97119140625,
        474.942138671875,
        270.8460693359375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단일구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        188.41787719726562,
        245.97119140625,
        474.942138671875,
        270.8460693359375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "흰색캡 바이알내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        188.41787719726562,
        245.97119140625,
        474.942138671875,
        270.8460693359375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무색액상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        417.4937438964844,
        258.91705322265625,
        457.43206787109375,
        270.8460693359375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        277.4967346191406,
        359.80450439453125,
        295.898681640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prep Sol",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        277.4967346191406,
        359.80450439453125,
        295.898681640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3개 바이알로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.45851135253906,
        277.4967346191406,
        359.80450439453125,
        295.898681640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        319.86663818359375,
        290.4425964355469,
        339.77587890625,
        302.3716125488281
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "녹색캡 바이알내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        399.98321533203125,
        277.4967346191406,
        474.942138671875,
        289.4257507324219
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "무색액상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        417.4937438964844,
        290.4425964355469,
        457.43206787109375,
        302.3716125488281
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        310.3408508300781,
        470.9847412109375,
        322.2698669433594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prep Plate",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        310.3408508300781,
        470.9847412109375,
        322.2698669433594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3*96well/kit",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        310.3408508300781,
        470.9847412109375,
        322.2698669433594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "흰색의 PP재질",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.45851135253906,
        310.3408508300781,
        470.9847412109375,
        322.2698669433594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        331.6775207519531,
        460.6684265136719,
        343.6065368652344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "BCA Risk Score(Software)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        331.6775207519531,
        460.6684265136719,
        343.6065368652344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CD",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        331.6775207519531,
        460.6684265136719,
        343.6065368652344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Mini Disk",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.45851135253906,
        331.6775207519531,
        460.6684265136719,
        343.6065368652344
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pack,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cartridge(s)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Prep",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Plate),",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체와",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "probe의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼성화(hybridization)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "디지털",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        113.09870147705078,
        69.4041519165039,
        538.1483154296875,
        81.3331527709961
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        113.09870147705078,
        90.26136016845703,
        455.2233581542969,
        102.20030975341797
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        372.0733947753906,
        538.148193359375,
        384.0123596191406
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해서는 색, 성상, 액성, 냄새 등을 기재한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        137.80531311035156,
        392.09149169921875,
        344.52337646484375,
        404.0205078125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        540.1297607421875,
        538.1487426757812,
        552.0587158203125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있는 컬러사진을 첨부한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        136.9657745361328,
        560.0279541015625,
        274.36138916015625,
        571.9569702148438
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        70.76165008544922,
        69.4041519165039,
        323.89453125,
        81.3331527709961
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 소프트웨어 주요기능",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        316.45416259765625,
        178.94253540039062,
        328.3831787109375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        97.26728057861328,
        352.025634765625,
        406.33929443359375,
        361.9747619628906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        97.26728057861328,
        352.025634765625,
        406.33929443359375,
        361.9747619628906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주요기능",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        97.26728057861328,
        352.025634765625,
        406.33929443359375,
        361.9747619628906
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        381.7531433105469,
        480.42608642578125,
        391.7022705078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터의 수집",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        381.7531433105469,
        480.42608642578125,
        391.7022705078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에서 측정한 데이터를 수집한다.",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        381.7531433105469,
        480.42608642578125,
        391.7022705078125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        408.72369384765625,
        467.9528503417969,
        418.6728210449219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터의 저장 및 삭제",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        408.72369384765625,
        467.9528503417969,
        418.6728210449219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수집된 데이터를 저장 및 삭제한다.",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        408.72369384765625,
        467.9528503417969,
        418.6728210449219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        435.6942138671875,
        514.6076049804688,
        445.6433410644531
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "데이터의 표시",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        435.6942138671875,
        514.6076049804688,
        445.6433410644531
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        435.6942138671875,
        514.6076049804688,
        445.6433410644531
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        462.54486083984375,
        493.019287109375,
        472.4939880371094
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "디바이스 등록 및 해제",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        462.54486083984375,
        493.019287109375,
        472.4939880371094
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연동되는 의료기기를 등록 및 해제할 수 있다.",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        104.34345245361328,
        462.54486083984375,
        493.019287109375,
        472.4939880371094
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 원재료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        70.76165008544922,
        518.0738525390625,
        124.01278686523438,
        532.4581298828125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 원재료는 다음 양식의 표를 사용하여 기재한다.",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        61.52665328979492,
        542.16748046875,
        294.2395935058594,
        555.4010009765625
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련번호",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "배합목적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원재료명 또는 성분명",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분량",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        573.4533081054688,
        512.7217407226562,
        586.6868286132812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        67.52340698242188,
        628.832763671875,
        410.9510192871094,
        642.0662841796875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 명칭",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        667.3107299804688,
        107.82122802734375,
        680.5442504882812
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다. 두 세트 이상이 함께 사용",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        689.2467651367188,
        538.1484375,
        702.4802856445312
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        711.3026733398438,
        444.29296875,
        724.5361938476562
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 10 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 배합목적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        69.16441345214844,
        129.88926696777344,
        82.39794921875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        91.1004409790039,
        359.13909912109375,
        104.33397674560547
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        113.15634155273438,
        413.7757568359375,
        126.38987731933594
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 원재료명 및 성분명",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        157.02838134765625,
        184.81982421875,
        170.26193237304688
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 구성 시약의 원재료명 또는 성분명을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        179.0842742919922,
        337.0710754394531,
        192.3178253173828
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 분량",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        213.0072021484375,
        107.82122802734375,
        226.24075317382812
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.95612335205078,
        234.9432373046875,
        538.2698364257812,
        248.17678833007812
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "범위를 설정할 수 있다. 주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.07605743408203,
        256.9991455078125,
        538.2676391601562,
        270.2326965332031
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.07605743408203,
        278.9351501464844,
        439.8553466796875,
        292.168701171875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        300.8711853027344,
        475.7159118652344,
        314.104736328125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 규격",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        334.9139709472656,
        107.82122802734375,
        348.14752197265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        81.91560363769531,
        356.8500061035156,
        538.2682495117188,
        370.08355712890625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 경우 자사규격 등을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.91560363769531,
        378.7860412597656,
        247.71951293945312,
        392.01959228515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        400.8419189453125,
        526.0886840820312,
        414.0754699707031
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 비고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        434.7648620605469,
        107.82122802734375,
        447.9984130859375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        456.7008972167969,
        364.53619384765625,
        469.9344482421875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 소프트웨어 원재료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        490.7436828613281,
        179.302490234375,
        503.97723388671875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다. 소프",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        512.6796875,
        538.2682495117188,
        525.9132080078125
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        81.67573547363281,
        534.61572265625,
        538.2682495117188,
        547.8492431640625
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        556.671630859375,
        538.267822265625,
        569.9051513671875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작성하지 않아도 된다. 하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        578.607666015625,
        538.268798828125,
        591.8411865234375
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        600.543701171875,
        538.14794921875,
        613.7772216796875
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        622.599609375,
        485.4306640625,
        635.8331298828125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 11 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        90.67086029052734,
        69.4041519165039,
        334.0577087402344,
        81.34310150146484
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분품의 명칭",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부분품 관리번호",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격 또는 특성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        92.17926025390625,
        523.0364990234375,
        117.05411529541016
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        102.06468200683594,
        133.8936767578125,
        107.02207946777344,
        145.8226776123047
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암 예후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        120.94781494140625,
        190.45677185058594,
        158.88839721679688
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도 측정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        120.94781494140625,
        190.45677185058594,
        158.88839721679688
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        120.94781494140625,
        190.45677185058594,
        158.88839721679688
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MFDS-IVD-MIA-01",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        215.40325927734375,
        127.42074584960938,
        488.19500732421875,
        152.2956085205078
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭 : MFDS-IVD-MIA-01",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        215.40325927734375,
        127.42074584960938,
        488.19500732421875,
        152.2956085205078
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버전 : 2.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        215.40325927734375,
        127.42074584960938,
        488.19500732421875,
        152.2956085205078
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1EA",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        215.40325927734375,
        127.42074584960938,
        488.19500732421875,
        152.2956085205078
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정)",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        91.63034057617188,
        194.90699768066406,
        334.8972473144531,
        206.845947265625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일련",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부분품의 명칭",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부분품 관리번호",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격 또는 특성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        216.24368286132812,
        523.0364990234375,
        241.1185302734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        102.06468200683594,
        292.0008850097656,
        107.02207946777344,
        303.9299011230469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암 예후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        272.5821228027344,
        190.45677185058594,
        310.40283203125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위험도 측정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        272.5821228027344,
        190.45677185058594,
        310.40283203125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소프트웨어",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        135.52655029296875,
        272.5821228027344,
        190.45677185058594,
        310.40283203125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다운로드 형태)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        127.25102996826172,
        311.5395202636719,
        198.79898071289062,
        323.4685363769531
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MFDS-IVD-MIA-02",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        215.40325927734375,
        292.0008850097656,
        302.1536560058594,
        303.9299011230469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "명칭 : MFDS-IVD-MIA-02",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        316.6283874511719,
        253.04345703125,
        435.7626953125,
        290.9840393066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "버전 : 2.0",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        316.6283874511719,
        253.04345703125,
        435.7626953125,
        290.9840393066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "운영환경",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        316.6283874511719,
        253.04345703125,
        435.7626953125,
        290.9840393066406
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- OS: Windows 7 64bit",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        326.5830078125,
        292.0008850097656,
        452.6343994140625,
        342.8873291015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- CPU: Core 2 Duo 3.0G 이상",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        326.5830078125,
        292.0008850097656,
        452.6343994140625,
        342.8873291015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- RAM : 4Gbyte",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        326.5830078125,
        292.0008850097656,
        452.6343994140625,
        342.8873291015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Network : 10/100Mbps",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        326.5830078125,
        292.0008850097656,
        452.6343994140625,
        342.8873291015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1EA",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        469.42559814453125,
        292.0008850097656,
        488.19500732421875,
        303.9299011230469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 제조방법",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        386.8172607421875,
        122.4536361694336,
        401.2015380859375
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. '제조원의 제조방법에 따른다.’라고 기재한다.",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        61.52665328979492,
        410.9109191894531,
        282.9656982421875,
        424.14447021484375
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다.(대부분의 체외진단용 의료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        432.9668273925781,
        538.2682495117188,
        446.20037841796875
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기는 비멸균의료기기에 해당됨)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        454.9028625488281,
        242.0777587890625,
        468.13641357421875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        61.52665328979492,
        488.8257751464844,
        538.1971435546875,
        502.059326171875
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.",
      "font_size": 10.751672744750977,
      "font_name": "T16",
      "bbox": [
        79.27703094482422,
        510.88165283203125,
        450.99462890625,
        524.1151733398438
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 사용목적(성능)",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        554.6339111328125,
        158.12229919433594,
        569.0181884765625
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.24626541137695,
        578.7275390625,
        538.2682495117188,
        591.9610595703125
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구체적으로 기재한다. 검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.39534759521484,
        600.783447265625,
        538.25390625,
        614.0169677734375
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어만을 사용하도록 분명히 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.39534759521484,
        622.719482421875,
        314.1634826660156,
        635.9530029296875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        644.895263671875,
        123.40208435058594,
        656.8341674804688
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        100.74539947509766,
        664.913330078125,
        538.1488037109375,
        676.8423461914062
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        100.74539947509766,
        684.9315185546875,
        538.148193359375,
        696.8604736328125
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        100.74539947509766,
        704.8297119140625,
        455.51263427734375,
        716.7587280273438
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        100.74539947509766,
        724.847900390625,
        536.8991088867188,
        736.77685546875
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.66273498535156,
        744.865966796875,
        538.0274658203125,
        756.7949829101562
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단독 투여된 환자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        114.6578598022461,
        69.4041519165039,
        194.89437866210938,
        81.3331527709961
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.66273498535156,
        89.42227172851562,
        538.1483154296875,
        101.35127258300781
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독 투여된 환자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        114.05818176269531,
        109.32052612304688,
        183.97979736328125,
        121.24952697753906
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        110.70000457763672,
        130.177734375,
        413.0062561035156,
        142.1067352294922
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        70.76165008544922,
        163.02183532714844,
        538.1483154296875,
        176.25538635253906
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        87.07280731201172,
        185.07772827148438,
        527.6478271484375,
        198.311279296875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        86.23326110839844,
        208.09259033203125,
        538.0283813476562,
        220.0315399169922
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래와 같다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        135.04681396484375,
        229.1895294189453,
        192.44577026367188,
        241.1185302734375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        125.69187927246094,
        249.2076416015625,
        538.1478271484375,
        261.13665771484375
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단독 투여된 환자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        134.3271942138672,
        269.22576904296875,
        214.2039031982422,
        281.15478515625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        300.8711853027344,
        415.7484130859375,
        314.104736328125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 검사항목",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        344.86309814453125,
        129.88926696777344,
        358.0966491699219
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 검사하고자 하는 유전자에 대해 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        366.79913330078125,
        313.8036804199219,
        380.0326843261719
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        388.85504150390625,
        538.2678833007812,
        402.0885925292969
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자 수를 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        103.26403045654297,
        410.7910461425781,
        215.81680297851562,
        424.02459716796875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼",
      "font_size": 9.951866149902344,
      "font_name": "T19",
      "bbox": [
        85.75352478027344,
        433.805908203125,
        438.00262451171875,
        445.744873046875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 측정원리",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        466.7698974609375,
        129.88926696777344,
        480.0034484863281
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 측정에 사용된 검사원리를 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        488.7059020996094,
        286.33856201171875,
        501.939453125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : ∼ 정량 PCR법으로 ∼",
      "font_size": 9.951866149902344,
      "font_name": "T19",
      "bbox": [
        85.75352478027344,
        511.7207946777344,
        237.8311004638672,
        523.6597290039062
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        544.6847534179688,
        538.1490478515625,
        557.9182739257812
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요성을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        156.51516723632812,
        566.6207885742188,
        254.4358673095703,
        579.8543090820312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 성능",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.24626541137695,
        610.6126708984375,
        103.98397827148438,
        623.84619140625
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.40022277832031,
        632.5487060546875,
        538.2227783203125,
        645.7822265625
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직선성/측정범위, 측정소급성, 검체안정성, 판별기준",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        88.99176788330078,
        654.4847412109375,
        538.2677001953125,
        667.71826171875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.99176788330078,
        654.4847412109375,
        538.2677001953125,
        667.71826171875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과값(Index Score)등을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.99176788330078,
        654.4847412109375,
        538.2677001953125,
        667.71826171875
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.99176788330078,
        676.5406494140625,
        137.25936889648438,
        689.774169921875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.40022277832031,
        698.4766845703125,
        538.197265625,
        711.710205078125
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일치도 등의 정보를 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.71138000488281,
        720.4127197265625,
        244.00152587890625,
        733.646240234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 사용방법",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        69.04454803466797,
        122.4536361694336,
        83.42882537841797
      ],
      "page_num": 57,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        93.13821411132812,
        538.2682495117188,
        106.37174987792969
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.79566955566406,
        115.0742416381836,
        534.1243286132812,
        128.3077850341797
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 검체준비 및 저장방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        149.11703491210938,
        195.73358154296875,
        162.3505859375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 검체대상 및 채취방법 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        171.0530548095703,
        228.71603393554688,
        184.28660583496094
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 검체 종류별 사용 가능한 항응고제",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        192.9890899658203,
        278.1289367675781,
        206.22264099121094
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 사용하는 검체의 종류별 필요 분량",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        215.04498291015625,
        278.1292724609375,
        228.27853393554688
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 검체 보관조건, 방법 및 사용기간 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        236.9810028076172,
        286.1649169921875,
        250.2145538330078
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 냉동 및 해동된 검체의 사용 가능성 및 제한점",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        81.67573547363281,
        258.9170227050781,
        338.5765075683594,
        272.15057373046875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 원심분리 조건 등을 포함한 검체 전처리과정 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        280.9729309082031,
        344.093505859375,
        294.20648193359375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        86.59307098388672,
        307.1043701171875,
        538.148193359375,
        319.0433349609375
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자의 품질(DNA 또는 RNA Quality)을 기재한다.",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        102.06468200683594,
        327.12249755859375,
        343.40411376953125,
        339.06146240234375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검사 전 준비사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        358.8877868652344,
        173.78546142578125,
        372.121337890625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        380.8238220214844,
        493.946044921875,
        394.057373046875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        402.75982666015625,
        387.0299377441406,
        415.9933776855469
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        424.81573486328125,
        371.0788879394531,
        438.0492858886719
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        446.75177001953125,
        538.2689819335938,
        459.9853210449219
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "웨어의 회사명, 모델명, 허가 번호 등을 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        468.6877746582031,
        307.993408203125,
        481.92132568359375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        490.7436828613281,
        362.2037048339844,
        503.97723388671875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 소프트웨어의 사용전 준비사항을 기재",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        512.6796875,
        293.7208251953125,
        525.9132080078125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 1. 사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        534.85546875,
        538.0284423828125,
        546.79443359375
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용해야만 한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        145.36122131347656,
        554.8736572265625,
        223.74880981445312,
        566.8026123046875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        130.72914123535156,
        574.8917236328125,
        538.1483154296875,
        586.8207397460938
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어를 사용할 수 있도록 한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        145.0014190673828,
        594.7900390625,
        317.4180603027344,
        606.718994140625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        626.5552368164062,
        538.1483154296875,
        639.7887573242188
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        648.4912719726562,
        538.2227172851562,
        661.7247924804688
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법 등)을 상세하게 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        670.5471801757812,
        240.88320922851562,
        683.7807006835938
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        86.83293914794922,
        693.56201171875,
        423.2506103515625,
        705.5009765625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 소프트웨어 조작방법 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        86.95287322998047,
        714.658935546875,
        229.26583862304688,
        726.597900390625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        95.7081298828125,
        734.6771240234375,
        538.1483154296875,
        746.6060791015625
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나타난다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        110.58007049560547,
        754.6951904296875,
        153.82672119140625,
        766.6242065429688
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 14 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        95.7081298828125,
        69.4041519165039,
        509.1941223144531,
        81.3331527709961
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        95.7081298828125,
        89.42227172851562,
        508.4745178222656,
        101.35127258300781
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        95.7081298828125,
        109.32052612304688,
        417.923583984375,
        121.24952697753906
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 계산 아이콘을 클릭한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        95.7081298828125,
        129.33865356445312,
        221.47006225585938,
        141.2676544189453
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 데이터 불러오기 및 저장을 실행한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        95.7081298828125,
        149.35678100585938,
        281.43756103515625,
        161.28578186035156
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 결과판정",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        181.00218200683594,
        129.88926696777344,
        194.23573303222656
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        203.05807495117188,
        538.2682495117188,
        216.2916259765625
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 판정하는 기준과 해석을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        224.99411010742188,
        293.17486572265625,
        238.2276611328125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        246.93014526367188,
        538.148681640625,
        260.1636962890625
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        103.14409637451172,
        268.98602294921875,
        188.47161865234375,
        282.2195739746094
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 그대로 보고 또는 재검사 필요 여부",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        92.5898208618164,
        290.92205810546875,
        290.4825744628906,
        304.1556091308594
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        92.5898208618164,
        312.85809326171875,
        452.27508544921875,
        326.0916442871094
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 결과 판독을 위한 알고리즘 제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        92.5898208618164,
        334.9139709472656,
        262.8977355957031,
        348.14752197265625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        356.8500061035156,
        538.2682495117188,
        370.08355712890625
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        378.7860412597656,
        147.81365966796875,
        392.01959228515625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        400.8419189453125,
        538.2227172851562,
        414.0754699707031
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정량값 판정 등의 기준을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        422.7779541015625,
        275.4244689941406,
        436.0115051269531
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        444.7139892578125,
        538.1484375,
        457.9475402832031
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 방법을 상세히 기재하고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        466.7698974609375,
        246.10757446289062,
        480.0034484863281
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        488.7059020996094,
        536.1632080078125,
        501.939453125
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 정도관리",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        522.6288452148438,
        130.36900329589844,
        535.8623657226562
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 사용자가 정도관리를 할 수 있는 방법을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        544.6847534179688,
        356.74041748046875,
        557.9182739257812
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        566.6207885742188,
        538.1490478515625,
        579.8543090820312
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하는 과정을 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        588.5567626953125,
        236.68548583984375,
        601.790283203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        610.6126708984375,
        444.65277099609375,
        623.84619140625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 사용 시 주의사항",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        654.3649291992188,
        172.22665405273438,
        668.7492065429688
      ],
      "page_num": 58,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 다음의 사항을 포함하여 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        678.4585571289062,
        254.31593322753906,
        691.6920776367188
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        71.24138641357422,
        700.5144653320312,
        538.1483154296875,
        713.7479858398438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함을 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.71300506591797,
        722.450439453125,
        155.96923828125,
        735.6839599609375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        744.386474609375,
        538.1481323242188,
        757.6199951171875
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 15 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        80.71625518798828,
        69.16441345214844,
        538.2682495117188,
        82.39794921875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함을 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        91.1004409790039,
        149.85255432128906,
        104.33397674560547
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.88158416748047,
        113.15634155273438,
        538.2682495117188,
        126.38987731933594
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전 등의 주의사항을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.23326110839844,
        135.0923614501953,
        240.16360473632812,
        148.32591247558594
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        157.02838134765625,
        533.8843994140625,
        170.26193237304688
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        179.0842742919922,
        429.660888671875,
        192.3178253173828
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        201.0203094482422,
        538.1483154296875,
        214.2538604736328
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.83293914794922,
        222.95632934570312,
        133.54139709472656,
        236.18988037109375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        245.01223754882812,
        538.1493530273438,
        258.24578857421875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.47313690185547,
        266.9482727050781,
        133.0616455078125,
        280.18182373046875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.36132049560547,
        288.88427734375,
        493.10650634765625,
        302.1178283691406
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        310.940185546875,
        369.2136535644531,
        324.1737365722656
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 포장단위",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        354.6923522949219,
        122.4536361694336,
        369.0766296386719
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.24626541137695,
        378.7860412597656,
        538.2683715820312,
        392.01959228515625
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우는 ‘제조원 포장단위’로 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        83.11495208740234,
        400.8419189453125,
        279.6221923828125,
        414.0754699707031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. 저장방법 및 사용기간",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        444.5941162109375,
        204.00942993164062,
        458.9783935546875
      ],
      "page_num": 59,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        468.6877746582031,
        538.1482543945312,
        481.92132568359375
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.79566955566406,
        490.7436828613281,
        465.1616516113281,
        503.97723388671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        524.6666259765625,
        538.2682495117188,
        537.900146484375
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서로 다른 경우 가장 짧은 기한으로 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        546.6026611328125,
        316.80206298828125,
        559.836181640625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        568.6585083007812,
        538.197265625,
        581.8920288085938
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 사용기간(유효기간) 등이 포함되도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        590.5945434570312,
        311.7647705078125,
        603.8280639648438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        612.5305786132812,
        493.7061767578125,
        625.7640991210938
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        634.5864868164062,
        538.2682495117188,
        647.8200073242188
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "같이 저장방법과 사용기간을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        656.5225219726562,
        278.6627197265625,
        669.7560424804688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        678.4585571289062,
        538.2675170898438,
        691.6920776367188
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(온도 등) 및 유의사항 등을 병기하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.02253723144531,
        700.5144653320312,
        327.95599365234375,
        713.7479858398438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        722.450439453125,
        538.2686157226562,
        735.6839599609375
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.74214935302734,
        744.386474609375,
        538.2698364257812,
        757.6199951171875
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 16 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(유효기간) 설정하여 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.74214935302734,
        69.16441345214844,
        250.5979461669922,
        82.39794921875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 멸균의료기기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        91.1004409790039,
        183.14041137695312,
        104.33397674560547
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        100.74539947509766,
        113.15634155273438,
        538.1483154296875,
        126.38987731933594
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예측되는 의료기기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        118.13597106933594,
        135.0923614501953,
        204.96780395507812,
        148.32591247558594
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        157.02838134765625,
        538.2682495117188,
        170.26193237304688
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        105.54280090332031,
        179.0842742919922,
        431.10009765625,
        192.3178253173828
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.75352478027344,
        201.0203094482422,
        538.2020874023438,
        214.2538604736328
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        105.06305694580078,
        222.95632934570312,
        373.05157470703125,
        236.18988037109375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11. 시험규격",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        268.86614990234375,
        129.050048828125,
        283.25042724609375
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        292.9598388671875,
        538.2678833007812,
        306.1933898925781
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        314.8958740234375,
        533.2847290039062,
        328.1294250488281
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        336.8318786621094,
        538.2682495117188,
        350.0654296875
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.07605743408203,
        358.8877868652344,
        165.444091796875,
        372.121337890625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험항목",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        380.8238220214844,
        130.72882080078125,
        394.057373046875
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.55580139160156,
        402.75982666015625,
        374.1309814453125,
        415.9933776855469
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.55580139160156,
        424.81573486328125,
        538.269287109375,
        438.0492858886719
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험항목을 설정할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        446.75177001953125,
        243.0420379638672,
        459.9853210449219
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험기준",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        71.6011962890625,
        468.6877746582031,
        130.72915649414062,
        481.92132568359375
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        81.55580139160156,
        490.7436828613281,
        538.2682495117188,
        503.97723388671875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        512.6796875,
        536.5230102539062,
        525.9132080078125
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        534.61572265625,
        130.72882080078125,
        547.8492431640625
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.55580139160156,
        556.671630859375,
        535.6834716796875,
        569.9051513671875
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.55580139160156,
        578.607666015625,
        538.2682495117188,
        591.8411865234375
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        600.543701171875,
        518.7726440429688,
        613.7772216796875
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        622.599609375,
        489.0287170410156,
        635.8331298828125
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.58494567871094,
        644.5355834960938,
        480.6332702636719,
        657.7691040039062
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12. 제조원(수입 또는 제조공정 전부 위탁의 경우)",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        690.3256225585938,
        345.820556640625,
        704.7098999023438
      ],
      "page_num": 60,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제조원의 제조국, 제조사명 및 주소를 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        714.4192504882812,
        322.7987976074219,
        727.6527709960938
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        736.4751586914062,
        538.2686767578125,
        749.7086791992188
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 17 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재한다. 다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.79566955566406,
        69.16441345214844,
        449.8099670410156,
        82.39794921875
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        113.15634155273438,
        111.53955078125,
        126.38987731933594
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        83.95449829101562,
        135.0923614501953,
        397.2026672363281,
        148.31488037109375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 제조의뢰자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        82.03553771972656,
        157.02838134765625,
        150.75830078125,
        170.2509002685547
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 상호 : (주)오송진단시약(주)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        92.11007690429688,
        179.0842742919922,
        244.8525848388672,
        192.30679321289062
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 주소 : 충북 청원군 오송읍 오송생명2로 187",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        92.11007690429688,
        201.0203094482422,
        329.0792236328125,
        214.24282836914062
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 제조자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        82.03553771972656,
        245.01223754882812,
        128.8101806640625,
        258.2347412109375
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 상호 : MFDS",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        97.02741241455078,
        266.9482727050781,
        178.13902282714844,
        280.1707763671875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제조국 : 미국",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        97.02741241455078,
        288.88427734375,
        180.38223266601562,
        302.1067810058594
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 주소 : 0000 U.S Highway 000, CA 0000, USA",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        97.02741241455078,
        310.940185546875,
        347.6287841796875,
        324.1626892089844
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 18 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅳ부. 기술문서 등 심사를 위한 제출자료",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        74.4796371459961,
        81.89932250976562,
        436.55755615234375,
        99.87966918945312
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        60.926979064941406,
        129.88613891601562,
        316.2725830078125,
        144.63002014160156
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기본원칙 및 성능시험 자료의 요건",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        60.926979064941406,
        129.88613891601562,
        316.2725830078125,
        144.63002014160156
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 기본원칙",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        167.57687377929688,
        122.4536361694336,
        181.96115112304688
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        191.6705322265625,
        538.1488647460938,
        204.90408325195312
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 심사의뢰서’를 작성하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        213.60655212402344,
        252.03717041015625,
        226.84010314941406
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        241.53602600097656,
        537.1226806640625,
        254.7695770263672
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        269.58538818359375,
        538.1488647460938,
        282.8189392089844
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한하여 번역물을 요구할 수 있다. 다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        291.5213928222656,
        538.1483154296875,
        304.75494384765625
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        81.43586730957031,
        313.4574279785156,
        143.25611877441406,
        326.69097900390625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 분석적 성능시험에 관한 자료의 요건",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        379.3853759765625,
        284.9655456542969,
        393.7696533203125
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 인정범위",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.00639343261719,
        403.35919189453125,
        125.21179962158203,
        416.5927429199219
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        431.4085388183594,
        380.79296875,
        444.64208984375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        453.34454345703125,
        538.2686157226562,
        466.5780944824219
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.34832000732422,
        475.28057861328125,
        538.2682495117188,
        488.5141296386719
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인한 자료 또는 이를 공증한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.34832000732422,
        497.33648681640625,
        266.2558898925781,
        510.5700378417969
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        519.2725219726562,
        538.2677612304688,
        532.5060424804688
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리시스템 하에서 실시된 시험자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.1052017211914,
        541.2085571289062,
        308.5921936035156,
        554.4420776367188
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        563.264404296875,
        538.1488647460938,
        576.4979248046875
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.10845184326172,
        585.200439453125,
        538.1483154296875,
        598.4339599609375
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.10845184326172,
        607.136474609375,
        377.9158020019531,
        620.3699951171875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 기재내용",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        64.88483428955078,
        651.12841796875,
        128.09024047851562,
        664.3619384765625
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 업체명 및 주소",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        673.064453125,
        171.98678588867188,
        686.2979736328125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        695.120361328125,
        369.75927734375,
        708.3538818359375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 시험검사품의 모델명, 상품명(해당 경우에 한함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        717.0563354492188,
        336.9463195800781,
        730.2898559570312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 시험일자 및 시험성적서 발급일자",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        738.9923706054688,
        265.4158020019531,
        752.2258911132812
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 19 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 시험책임자의 서명 또는 직인",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        69.16441345214844,
        243.46804809570312,
        82.39794921875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        91.1004409790039,
        427.3283996582031,
        104.33397674560547
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        113.15634155273438,
        502.6965026855469,
        126.38987731933594
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        135.0923614501953,
        356.255859375,
        148.32591247558594
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        67.88320922851562,
        179.0842742919922,
        508.93310546875,
        192.3178253173828
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험시설개요",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        201.0203094482422,
        161.07235717773438,
        214.2538604736328
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        91.15059661865234,
        222.95632934570312,
        538.2681274414062,
        236.18988037109375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기재되어 있어야 함",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        91.15059661865234,
        245.01223754882812,
        192.73553466796875,
        258.24578857421875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 주요설비",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        266.9482727050781,
        139.00433349609375,
        280.18182373046875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        91.0306625366211,
        288.88427734375,
        538.1478271484375,
        302.1178283691406
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 증빙자료를 함께 제출하여야 함",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        91.0306625366211,
        310.940185546875,
        281.7273254394531,
        324.1737365722656
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 연구 인력구성",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        332.876220703125,
        166.46945190429688,
        346.1097717285156
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        354.8122253417969,
        535.989501953125,
        368.0457763671875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) 시험자의 연구경력",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        376.8681335449219,
        188.53781127929688,
        390.1016845703125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        90.7907943725586,
        398.8041687011719,
        538.1480102539062,
        412.0377197265625
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        90.91072845458984,
        420.74017333984375,
        538.2679443359375,
        433.9737243652344
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 자료를 제출",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        90.91072845458984,
        442.79608154296875,
        182.78115844726562,
        456.0296325683594
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 임상적 성능시험에 관한 자료의 요건",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        486.54827880859375,
        284.9655456542969,
        500.93255615234375
      ],
      "page_num": 63,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 인정범위",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.24626541137695,
        510.6419677734375,
        126.89026641845703,
        523.87548828125
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 식약처장이 지정한 임상시험기관에서 시험한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        532.6978149414062,
        355.3673095703125,
        545.9313354492188
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        554.6338500976562,
        431.6451110839844,
        567.8673706054688
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기 임상시험",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        442.9199523925781,
        554.6338500976562,
        538.3872680664062,
        567.8673706054688
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관리기준",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        95.10845184326172,
        576.5698852539062,
        140.08407592773438,
        589.8034057617188
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에 의하여 실시한 것으로 판단되는 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        145.9608917236328,
        576.5698852539062,
        354.8872375488281,
        589.8034057617188
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        598.6257934570312,
        538.2682495117188,
        611.8593139648438
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        94.86858367919922,
        620.5618286132812,
        538.2682495117188,
        633.7953491210938
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받아 승인하였음을 확인한 자료 또는 이를 공증한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        94.86858367919922,
        642.4978637695312,
        377.9154968261719,
        655.7313842773438
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        664.5537109375,
        502.287353515625,
        677.7872314453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        61.88645935058594,
        708.42578125,
        516.3739013671875,
        721.6593017578125
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.39859771728516,
        730.481689453125,
        157.47396850585938,
        743.7152099609375
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        752.417724609375,
        373.357666015625,
        765.6512451171875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 사용방법과 그 설정 사유",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        69.16441345214844,
        233.39349365234375,
        82.39794921875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        91.1004409790039,
        367.84063720703125,
        104.33397674560547
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 병용사용의 유무",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        86.35319519042969,
        113.15634155273438,
        189.37734985351562,
        126.38987731933594
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        135.0923614501953,
        395.0655822753906,
        148.32591247558594
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 유효성 평가기준, 평가방법 및 해석방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        157.02838134765625,
        307.3930969238281,
        170.26193237304688
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상결과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        75.91885375976562,
        179.0842742919922,
        135.04647827148438,
        192.3178253173828
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        201.0203094482422,
        536.8779907226562,
        214.2538604736328
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 증례기록 요약",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        222.95632934570312,
        178.46328735351562,
        236.18988037109375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 기타 임상시험성적의 확인에 필요한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.35319519042969,
        245.01223754882812,
        315.7888488769531,
        258.24578857421875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상평가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        75.91885375976562,
        266.9482727050781,
        135.04681396484375,
        280.18182373046875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        92.34994506835938,
        288.88427734375,
        538.2677001953125,
        302.1178283691406
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        92.34994506835938,
        310.940185546875,
        518.0530395507812,
        324.1737365722656
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 이미 허가받은 제품과의 동등비교",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        75.31917572021484,
        332.876220703125,
        259.77886962890625,
        346.1097717285156
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        354.8122253417969,
        538.3887329101562,
        368.0457763671875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        105.78266906738281,
        376.8681335449219,
        437.216796875,
        390.1016845703125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.87345886230469,
        398.8041687011719,
        538.3878173828125,
        412.0377197265625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출자료가 면제될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        105.18299102783203,
        420.74017333984375,
        241.24301147460938,
        433.9737243652344
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        457.8995666503906,
        534.484130859375,
        471.13311767578125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 4등급 체외진단용 의료기기의 시험",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        67.52340698242188,
        488.3463134765625,
        255.2504119873047,
        501.5798645019531
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        67.28353118896484,
        514.4777221679688,
        538.2648315429688,
        527.7112426757812
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        81.91560363769531,
        536.4137573242188,
        538.1448974609375,
        549.6472778320312
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "코, 입, 항문관 또는 질에 들어가는 침습적인 시험. 다만, 정맥채혈 등 피험자에게 중대한 위험을",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        81.91560363769531,
        558.4696655273438,
        538.2974243164062,
        571.7031860351562
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외)",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        81.91560363769531,
        580.4057006835938,
        357.091552734375,
        593.6392211914062
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        67.28353118896484,
        602.3417358398438,
        538.296875,
        615.5752563476562
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과를 확인할 수 없는 시험",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        81.91560363769531,
        624.3976440429688,
        220.2293243408203,
        637.6311645507812
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        67.28353118896484,
        646.3336181640625,
        538.1448974609375,
        659.567138671875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함)",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        83.11495208740234,
        668.2696533203125,
        422.0963439941406,
        681.503173828125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험",
      "font_size": 10.864259719848633,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        690.3255615234375,
        538.297119140625,
        703.55908203125
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계획승인을 받고 실시해야함)",
      "font_size": 10.864259719848633,
      "font_name": "T17",
      "bbox": [
        99.3061752319336,
        712.2615966796875,
        238.32000732421875,
        725.4951171875
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "21",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        73.35983276367188,
        538.1481323242188,
        86.59336853027344
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.96099853515625,
        95.29586029052734,
        352.1828918457031,
        108.5293960571289
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시",
      "font_size": 10.864259719848633,
      "font_name": "T17",
      "bbox": [
        72.56067657470703,
        121.54717254638672,
        538.2969970703125,
        134.7807159423828
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관(IRB)의 임상시험계획승인을 받고 실시해야함)",
      "font_size": 10.864259719848633,
      "font_name": "T17",
      "bbox": [
        91.63034057617188,
        143.48318481445312,
        332.58892822265625,
        156.71673583984375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        61.88645935058594,
        165.41921997070312,
        538.2969970703125,
        178.65277099609375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시한 자료",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        82.87508392333984,
        187.47511291503906,
        141.43209838867188,
        200.7086639404297
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        72.56067657470703,
        209.4111328125,
        448.58551025390625,
        222.64468383789062
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        73.52015686035156,
        231.34716796875,
        366.5501403808594,
        244.58071899414062
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        73.52015686035156,
        253.403076171875,
        472.57061767578125,
        266.6366271972656
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        61.88645935058594,
        286.3670349121094,
        538.2969970703125,
        299.6005859375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        81.07605743408203,
        308.3030700683594,
        443.90911865234375,
        321.53662109375
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 임상적 성능시험에 관한 자료 요건(상기의 3. 임상적 성능시험에 관한 자료의 요건의 가.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        61.88645935058594,
        330.2391052246094,
        538.2020874023438,
        343.47265625
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인정범위 1)∼4) 중 어느 하나)에 해당하는 자료",
      "font_size": 10.864259719848633,
      "font_name": "T16",
      "bbox": [
        82.9950180053711,
        352.29498291015625,
        327.93096923828125,
        365.5285339355469
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        64.0452880859375,
        425.48309326171875,
        473.9870910644531,
        440.2269592285156
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        64.0452880859375,
        425.48309326171875,
        473.9870910644531,
        440.2269592285156
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 개발경위",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        463.1737976074219,
        122.4536361694336,
        477.5580749511719
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        487.2674865722656,
        538.2678833007812,
        500.50103759765625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 자료 및 내부 검정(Internal Validation) 결과 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        509.2034912109375,
        360.88409423828125,
        522.43701171875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        531.1395263671875,
        538.14794921875,
        544.373046875
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등의 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        553.1954345703125,
        131.68829345703125,
        566.428955078125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        575.1314697265625,
        535.5101318359375,
        588.364990234375
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        597.0675048828125,
        377.6753234863281,
        610.301025390625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 측정원리․방법",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        640.9395751953125,
        160.233154296875,
        655.3238525390625
      ],
      "page_num": 65,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        665.033203125,
        372.51812744140625,
        678.2667236328125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        686.96923828125,
        477.03521728515625,
        700.2027587890625
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        709.025146484375,
        441.0547180175781,
        722.2586669921875
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "22",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 국내․외에서 사용현황",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        69.04454803466797,
        204.00942993164062,
        83.42882537841797
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        93.13821411132812,
        441.0547180175781,
        106.37174987792969
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        115.0742416381836,
        434.2843017578125,
        128.3077850341797
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.16034698486328,
        137.130126953125,
        538.1477661132812,
        150.36367797851562
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련된 유해사례보고 요약",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        88.75189971923828,
        159.066162109375,
        222.23989868164062,
        172.29971313476562
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 제조국에서 사용되지 않는 경우는 그 사유",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        181.00218200683594,
        302.47607421875,
        194.23573303222656
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        254.1903076171875,
        302.9598083496094,
        269.0540466308594
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료 및 제조방법에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        254.1903076171875,
        302.9598083496094,
        269.0540466308594
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 원재료의 성분 또는 분량을 확인할 수 있는 근거자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        289.9631042480469,
        378.5148620605469,
        304.3473815917969
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 의료기기의 성분과 분량을 확인할 수 있는 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        314.0567626953125,
        322.9846496582031,
        327.2903137207031
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        335.9927978515625,
        538.197265625,
        349.2263488769531
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 활성도를 확인 할 수 있는 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        357.9288330078125,
        258.1001281738281,
        371.1623840332031
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 프라이머, 프로브에 대한 자료(염기서열)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        379.9847412109375,
        284.6546630859375,
        393.2182922363281
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라. 원료물질의 품질 확인 근거자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        401.9207458496094,
        240.58926391601562,
        415.154296875
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 제조공정의 흐름도를 포함한 제조공정에 관한 자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        445.7928161621094,
        366.5213623046875,
        460.1770935058594
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        469.886474609375,
        538.1487426757812,
        483.1200256347656
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품질관리 시험의 단계를 확인할 수 있는 자료)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        491.822509765625,
        317.15704345703125,
        505.0560607910156
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        513.758544921875,
        538.1482543945312,
        526.9920654296875
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        535.814453125,
        129.10379028320312,
        549.0479736328125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        557.7504272460938,
        538.2682495117188,
        570.9839477539062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 자료도 포함",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.27540588378906,
        579.6864624023438,
        170.18777465820312,
        592.9199829101562
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        652.9944458007812,
        238.3148193359375,
        667.7383422851562
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용목적에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        652.9944458007812,
        238.3148193359375,
        667.7383422851562
      ],
      "page_num": 66,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        688.7672729492188,
        538.2678833007812,
        702.0007934570312
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원리 및 정성 또는 정량 등)에 대한 근거자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        710.7033081054688,
        301.036865234375,
        723.9368286132812
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 해당제품의 제품설명서(instructions for user)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        732.7592163085938,
        299.0468444824219,
        745.9927368164062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 23 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        98.360595703125,
        372.5220947265625,
        113.22434997558594
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저장방법과 사용기간(유효기간)에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        98.360595703125,
        372.5220947265625,
        113.22434997558594
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        134.25328063964844,
        538.14794921875,
        147.48683166503906
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성적서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        156.18930053710938,
        104.5829849243164,
        169.4228515625
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 구성 제품별로 구분하여 안정성 시험 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        178.12533569335938,
        284.6057434082031,
        191.35888671875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        200.1812286376953,
        538.2684936523438,
        213.41477966308594
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료도 가능)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        222.11724853515625,
        136.17515563964844,
        235.35079956054688
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        244.05328369140625,
        479.5538330078125,
        257.2868347167969
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        266.10919189453125,
        538.1497802734375,
        279.3427429199219
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.6011962890625,
        288.0451965332031,
        119.50898742675781,
        301.27874755859375
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        309.9812316894531,
        538.2227172851562,
        323.21478271484375
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "open vial/bottle stability) 안정성 자료를 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        70.76165008544922,
        332.0371398925781,
        315.3628234863281,
        345.27069091796875
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 제품사용방법과 관련하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        353.97314453125,
        538.2677612304688,
        367.2066955566406
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당되는 경우, 개봉후의 유효기간에 관한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        353.97314453125,
        538.2677612304688,
        367.2066955566406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        353.97314453125,
        538.2677612304688,
        367.2066955566406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함한다",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        353.97314453125,
        538.2677612304688,
        367.2066955566406
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(on-board, reconstitution, openvial/bottle).",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.24138641357422,
        375.9091796875,
        290.17578125,
        389.1427307128906
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        397.965087890625,
        460.6041259765625,
        411.1986389160156
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9. 저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        419.9010925292969,
        536.1632080078125,
        433.1346435546875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        471.1531982421875,
        238.3148193359375,
        485.8970642089844
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능시험에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        471.1531982421875,
        238.3148193359375,
        485.8970642089844
      ],
      "page_num": 67,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 성능시험에 관한 자료는 다음의 자료를 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        506.926025390625,
        320.2801818847656,
        520.1595458984375
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 분석적 성능시험에 관한 자료(시험성적서)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        62.12632751464844,
        528.9818725585938,
        293.05010986328125,
        542.2153930664062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        77.59794616699219,
        550.9179077148438,
        453.88775634765625,
        564.1514282226562
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        72.0809326171875,
        572.8539428710938,
        445.7273864746094,
        586.0874633789062
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 분석적 특이도(교차반응 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        72.0809326171875,
        594.9098510742188,
        227.5656280517578,
        608.1433715820312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정밀도(반복, 재현성 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        72.0809326171875,
        616.8458862304688,
        208.1361541748047,
        630.0794067382812
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        72.0809326171875,
        638.7819213867188,
        400.5118713378906,
        652.0154418945312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 임상적 성능시험에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        682.7738037109375,
        227.51669311523438,
        696.00732421875
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        77.83781433105469,
        704.7098388671875,
        538.2678833007812,
        717.943359375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험한 자료로서 다음의 평가항목을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        77.83781433105469,
        726.7657470703125,
        316.32232666015625,
        739.999267578125
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.9982681274414,
        748.7017822265625,
        538.2683715820312,
        761.935302734375
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.9982681274414,
        69.16441345214844,
        538.1485595703125,
        82.39794921875
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가 제출할 것을 요구 할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.9982681274414,
        91.1004409790039,
        250.3580780029297,
        104.33397674560547
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상적 민감도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        113.15634155273438,
        156.51516723632812,
        126.38987731933594
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 임상적 특이도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        135.0923614501953,
        156.51483154296875,
        148.32591247558594
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        168.05633544921875,
        535.0789184570312,
        181.28988647460938
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        189.9923553466797,
        477.874755859375,
        203.2259063720703
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        212.0482635498047,
        367.89434814453125,
        225.2818145751953
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        245.01223754882812,
        353.80792236328125,
        258.24578857421875
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        266.9482727050781,
        381.393310546875,
        280.18182373046875
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바. 국내·외 허가 제품과의 상관성 시험에 대한 시험성적서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        288.88427734375,
        358.1255798339844,
        302.1178283691406
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사. 소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        310.940185546875,
        538.2682495117188,
        324.1737365722656
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어를 추가로 제공할 경우에 한함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.99664306640625,
        332.876220703125,
        292.93017578125,
        346.1097717285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        406.0643310546875,
        402.86566162109375,
        420.9280700683594
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기의 취급자 안전에 관한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        406.0643310546875,
        402.86566162109375,
        420.9280700683594
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        453.82403564453125,
        538.2682495117188,
        467.0575866699219
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.28028106689453,
        475.87994384765625,
        538.2682495117188,
        489.1134948730469
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증하는 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.28028106689453,
        497.8159484863281,
        207.90109252929688,
        511.04949951171875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        519.751953125,
        479.67376708984375,
        532.9854736328125
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 13.788712501525879,
      "font_name": "H2hdrM",
      "bbox": [
        63.68548583984375,
        593.0599365234375,
        316.2725830078125,
        607.8038330078125
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이미 허가받은 제품과 비교한 자료",
      "font_size": 13.788712501525879,
      "font_name": "HYwulM",
      "bbox": [
        63.68548583984375,
        593.0599365234375,
        316.2725830078125,
        607.8038330078125
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        640.8197021484375,
        538.2227172851562,
        654.05322265625
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        71.841064453125,
        662.7556762695312,
        537.4824829101562,
        675.9891967773438
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제Ⅴ부. 성능에 관한 세부사항",
      "font_size": 17.985300064086914,
      "font_name": "H2hdrM",
      "bbox": [
        74.4796371459961,
        81.89932250976562,
        321.78558349609375,
        99.87966918945312
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM",
      "font_size": 7.074217319488525,
      "font_name": "T29",
      "bbox": [
        56.609317779541016,
        119.02991485595703,
        538.2183227539062,
        133.82176208496094
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Breast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        142.52423095703125,
        538.2677612304688,
        155.75778198242188
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설명하였다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        164.58013916015625,
        114.23184967041016,
        177.81369018554688
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 분석적 성능시험에 관한 자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        208.33233642578125,
        241.1892852783203,
        222.71661376953125
      ],
      "page_num": 69,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 분석적 성능시험에 관한 자료의 작성 시 권장사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        232.42599487304688,
        325.8630676269531,
        245.6595458984375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 분석적 민감도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        254.48187255859375,
        150.5184326171875,
        267.7154235839844
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 최소검출한계(Limit of detection)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        276.41790771484375,
        251.07293701171875,
        289.6514587402344
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 일반사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        298.35394287109375,
        139.48406982421875,
        311.5874938964844
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 표준물질, 국제표준품을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        320.4098205566406,
        538.1483154296875,
        333.64337158203125
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용하여 측정할 것을 권장하며,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        320.4098205566406,
        538.1483154296875,
        333.64337158203125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일관되게 검출되는 최소",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        320.4098205566406,
        538.1483154296875,
        333.64337158203125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도값으로 설정할 수 있다. 일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.66598510742188,
        342.3458557128906,
        538.2682495117188,
        355.57940673828125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.66598510742188,
        364.2818908691406,
        443.0935974121094,
        377.51544189453125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "②",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질, 국제표준품을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구할 수",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는 항목이나",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아형의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에는 국내·외 허가된",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        386.3377990722656,
        538.2682495117188,
        399.57135009765625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.66598510742188,
        408.2738037109375,
        459.5246887207031,
        421.5073547363281
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        430.2098388671875,
        538.2682495117188,
        443.4433898925781
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.66598510742188,
        452.2657470703125,
        140.857421875,
        465.4992980957031
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        74.9593734741211,
        474.2017517089844,
        139.48406982421875,
        487.435302734375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        496.1377868652344,
        538.1475830078125,
        509.371337890625
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        98.10682678222656,
        518.1936645507812,
        392.00128173828125,
        531.4271850585938
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        540.1296997070312,
        538.14794921875,
        553.3632202148438
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 검사하여 분석적 민감도를 판정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        98.10682678222656,
        562.0657348632812,
        320.5200500488281,
        575.2992553710938
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        584.1216430664062,
        139.48406982421875,
        597.3551635742188
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        606.0576782226562,
        538.2682495117188,
        619.2911987304688
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상 반복 검사를 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        627.9937133789062,
        236.5655517578125,
        641.2272338867188
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        650.049560546875,
        538.183349609375,
        663.2830810546875
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "analysis)으로 산정하여 최소검출한계를 결정한다. 계산된 값이 실제로 측정되지 않은",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        671.985595703125,
        538.2682495117188,
        685.2191162109375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        693.921630859375,
        538.2227172851562,
        707.1551513671875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        715.9775390625,
        395.1195983886719,
        729.2110595703125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "26",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 26 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        69.16441345214844,
        139.48406982421875,
        82.39794921875
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        91.1004409790039,
        538.102783203125,
        104.33397674560547
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "계산법을 함께 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.66598510742188,
        113.15634155273438,
        223.2527618408203,
        126.38987731933594
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        135.0923614501953,
        483.7515563964844,
        148.32591247558594
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        157.02838134765625,
        529.4468383789062,
        170.26193237304688
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        179.0842742919922,
        394.10638427734375,
        192.3178253173828
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        221.27818298339844,
        538.1463623046875,
        233.20718383789062
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        241.1764373779297,
        538.2175903320312,
        253.10543823242188
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        261.1945495605469,
        538.1488037109375,
        273.1235656738281
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        281.2126770019531,
        151.54794311523438,
        293.1416931152344
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        301.1109313964844,
        538.1483154296875,
        313.0399475097656
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "권장한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        321.1290588378906,
        151.54794311523438,
        333.0580749511719
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표 1. RNA input 양에 따른 ROR score 차이점",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        148.35958862304688,
        352.89434814453125,
        388.3495178222656,
        366.1278991699219
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        273.8116149902344,
        573.6929931640625,
        538.2147216796875,
        585.6220092773438
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        613.729248046875,
        421.4017028808594,
        625.6582641601562
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가) 50% 이상의 암조직을 포함하는 검체여야 함",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        633.6275634765625,
        331.5003662109375,
        645.5565185546875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(암 조직 주변 정상세포가 50% 이상이면 안됨)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        128.21051025390625,
        653.6456298828125,
        343.0807800292969,
        665.5746459960938
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        673.663818359375,
        531.31201171875,
        685.5927734375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        692.2435302734375,
        391.1080322265625,
        705.4910278320312
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(라) 전체 암 면적은 최소 24mm2이상이 되어야 함",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        712.1417846679688,
        338.936279296875,
        725.5091552734375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        128.21051025390625,
        728.5638427734375,
        380.62042236328125,
        745.5272827148438
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(마) RNA 양은 최소 125 ng 이상이어야 함",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        753.49658203125,
        307.2734375,
        765.425537109375
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        106.6222152709961,
        69.4041519165039,
        406.0466613769531,
        81.3331527709961
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        106.6222152709961,
        89.42227172851562,
        459.2979431152344,
        101.35127258300781
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 측정범위(Measurement range)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        131.13668823242188,
        238.60098266601562,
        144.3702392578125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 일반사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        153.0727081298828,
        139.48406982421875,
        166.30625915527344
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 정성검사는 생략할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        175.0087432861328,
        236.44561767578125,
        188.24229431152344
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        197.30438232421875,
        538.1478271484375,
        209.2433319091797
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적용되지 않는다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        217.20263671875,
        188.9676513671875,
        229.1316375732422
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 판정기준치(cut-off value)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        258.9170227050781,
        215.57235717773438,
        272.15057373046875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        280.9729309082031,
        395.8392028808594,
        294.20648193359375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        302.9089660644531,
        538.2682495117188,
        316.14251708984375
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전문가 그룹의 자문 등을 거칠 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        324.8450012207031,
        329.9949035644531,
        338.07855224609375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        346.90087890625,
        532.3252563476562,
        360.1344299316406
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        368.8369140625,
        538.14794921875,
        382.0704650878906
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.54605102539062,
        390.77294921875,
        146.25450134277344,
        404.0065002441406
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        412.8288269042969,
        538.2451782226562,
        426.0623779296875
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "number) 등으로 설정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.98689270019531,
        434.7648620605469,
        230.3289337158203,
        447.9984130859375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        456.7008972167969,
        373.89111328125,
        469.9344482421875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        478.75677490234375,
        529.326904296875,
        491.9903259277344
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        96.54767608642578,
        500.93255615234375,
        538.1478271484375,
        512.8715209960938
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근거를 제시한다.(임상적 민감도 참고)",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        111.53955078125,
        520.95068359375,
        284.6445007324219,
        532.8895874023438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        540.848876953125,
        538.1483154296875,
        552.787841796875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다. 림프절 전이 음성은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        560.8670654296875,
        538.1478271484375,
        572.7960205078125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        580.8851318359375,
        538.2183837890625,
        592.8141479492188
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각각의 판정 기준 점수는 40점과 60점이다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        600.783447265625,
        308.9026794433594,
        612.71240234375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 2> Breast Cancer Alarm score 범위 및 위험도 분류",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        141.52330017089844,
        633.7474365234375,
        403.3409423828125,
        645.6763916015625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다. 림프절 전이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ROR score가 25였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10%",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이하)으로,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ROR",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "41-60는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중위험군(10년",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        69.4041519165039,
        538.1483154296875,
        146.30215454101562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도 20% 이하)으로,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "40",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초과는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고위험군(10년",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험도가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20%",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        147.31900024414062,
        538.1483154296875,
        185.25958251953125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "초과)으로 설정하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        186.27642822265625,
        197.36312866210938,
        198.20542907714844
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<그림 1. TransATAC 임상 연구 결과>",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        228.23629760742188,
        506.6862487792969,
        406.60540771484375,
        518.615234375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 분석적 특이도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        549.359619140625,
        150.51809692382812,
        562.5931396484375
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 간섭반응",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        571.41552734375,
        129.050048828125,
        584.6490478515625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        593.3515625,
        538.2682495117188,
        606.5850830078125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.82806396484375,
        615.28759765625,
        180.91571044921875,
        628.5211181640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        637.3434448242188,
        538.2686767578125,
        650.5769653320312
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.06793212890625,
        659.2794799804688,
        538.1487426757812,
        672.5130004882812
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검토하고, 자료를 제시하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.06793212890625,
        681.2155151367188,
        271.70648193359375,
        694.4490356445312
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다. 간섭 물질의 가능성 있는 모든 물질의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        703.2714233398438,
        538.2682495117188,
        716.5049438476562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목록을 제시하고 자료를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        95.58819580078125,
        725.2074584960938,
        268.58819580078125,
        738.4409790039062
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        747.1434936523438,
        400.3967590332031,
        760.3770141601562
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "29",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        69.16441345214844,
        538.2682495117188,
        82.39794921875
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "세트를 준비한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        91.1004409790039,
        181.75526428222656,
        104.33397674560547
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 분석물질 약양성 검체(간섭물질 없음)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        113.15634155273438,
        286.2138366699219,
        126.38987731933594
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 분석물질 약양성 검체 + 간섭물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        135.0923614501953,
        267.4547424316406,
        148.32591247558594
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 분석물질 음성 검체 + 간섭물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        157.02838134765625,
        256.54095458984375,
        170.26193237304688
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 분석물질 음성 검체(간섭물질 없음)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        179.0842742919922,
        275.1798095703125,
        192.3178253173828
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바) 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        74.9593734741211,
        201.0203094482422,
        139.48406982421875,
        214.2538604736328
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.39372253417969,
        222.95632934570312,
        538.14794921875,
        236.18988037109375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합성된 유전자를 활용한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        85.39372253417969,
        245.01223754882812,
        220.0145263671875,
        258.24578857421875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        266.9482727050781,
        139.48406982421875,
        280.18182373046875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        288.88427734375,
        538.2682495117188,
        302.1178283691406
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 실험프로토콜을 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        310.940185546875,
        253.23651123046875,
        324.1737365722656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        332.876220703125,
        434.2184143066406,
        346.1097717285156
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        354.8122253417969,
        526.5684204101562,
        368.0457763671875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        376.8681335449219,
        494.6656494140625,
        390.1016845703125
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        398.8041687011719,
        538.2675170898438,
        412.0377197265625
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위양성 결과를 보이는지 확인한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.42774200439453,
        420.74017333984375,
        262.71136474609375,
        433.9737243652344
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        442.79608154296875,
        538.2682495117188,
        456.0296325683594
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.02741241455078,
        464.73211669921875,
        396.43890380859375,
        477.9656677246094
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑦ 각 검체별로 3번 반복검사를 시행한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        486.66815185546875,
        291.3758239746094,
        499.9017028808594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        530.6600341796875,
        139.48406982421875,
        543.8935546875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        552.5960693359375,
        505.6996765136719,
        565.82958984375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 경향이 있다면 경향을 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        574.6519775390625,
        258.3937072753906,
        587.885498046875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(높은 농도의 X물질은 분석물질의 결과를 감소시킴)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.66761016845703,
        596.8277587890625,
        334.8052673339844,
        608.7567138671875
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        616.6061401367188,
        538.2682495117188,
        629.8396606445312
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.02741241455078,
        638.5421752929688,
        385.4048767089844,
        651.7756958007812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        660.7178955078125,
        139.07470703125,
        672.6568603515625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        680.736083984375,
        538.1483154296875,
        692.6650390625
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ROR score로 확인하였다. 정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        700.754150390625,
        538.1478271484375,
        712.6831665039062
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        720.6524658203125,
        538.1483154296875,
        732.5814208984375
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        740.6705322265625,
        161.5025634765625,
        752.5995483398438
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 30 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "<그림 2. 정상조직 포함에 따른 ROR score 비교>",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        177.1439971923828,
        269.22576904296875,
        405.64593505859375,
        281.15478515625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다. 10개의 파라핀 포매",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        96.54767608642578,
        312.1388854980469,
        538.1483154296875,
        324.0679016113281
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        332.1570129394531,
        538.1201782226562,
        344.0860290527344
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        352.1751403808594,
        430.1569519042969,
        364.1041564941406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 3> DNase 처리 유무에 따른 ROR score 차이 비교",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        162.87173461914062,
        394.1292724609375,
        418.93292236328125,
        406.05828857421875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다. 괴사, 출혈, 유관 상피",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        96.54767608642578,
        543.845703125,
        538.1483154296875,
        555.774658203125
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        563.86376953125,
        538.1094970703125,
        575.7927856445312
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교한 결과, 영향을 거의 미치지 않음을 확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        583.7620849609375,
        353.8782958984375,
        595.6910400390625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 교차반응",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        69.92210388183594,
        623.5585327148438,
        129.04971313476562,
        636.7920532226562
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 일반사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        645.4945678710938,
        139.48406982421875,
        658.7280883789062
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        667.4306030273438,
        538.2675170898438,
        680.6641235351562
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 교차반응에 대한 자료를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        689.4865112304688,
        297.1327209472656,
        702.7200317382812
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        74.9593734741211,
        711.4225463867188,
        139.48406982421875,
        724.6560668945312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        733.3585205078125,
        538.102783203125,
        746.592041015625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        755.4144287109375,
        401.5960998535156,
        768.64794921875
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "31",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 31 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        69.16441345214844,
        139.48406982421875,
        82.39794921875
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 준비된 시험물질을 3회 반복 측정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        91.1004409790039,
        291.3758239746094,
        104.33397674560547
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 위양성률을 계산한다. 위양성을 보이는 검체에 대해 원인을 분석 조사한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        113.15634155273438,
        475.3561096191406,
        126.38987731933594
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        135.0923614501953,
        139.48406982421875,
        148.32591247558594
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        157.02838134765625,
        494.42578125,
        170.26193237304688
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        179.0842742919922,
        357.340087890625,
        192.3178253173828
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정밀도(반복, 재현성, 안정성 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        222.95632934570312,
        237.04049682617188,
        236.18988037109375
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 일반사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        245.01223754882812,
        139.48406982421875,
        258.24578857421875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        266.9482727050781,
        516.61376953125,
        280.18182373046875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        288.88427734375,
        538.2678833007812,
        302.1178283691406
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.02741241455078,
        310.940185546875,
        143.73587036132812,
        324.1737365722656
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        332.876220703125,
        538.14794921875,
        346.1097717285156
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가를 수행하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.02741241455078,
        354.8122253417969,
        220.61419677734375,
        368.0457763671875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 반복성",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        376.8681335449219,
        128.5703125,
        390.1016845703125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 실험방법 및 기타 세부사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        398.8041687011719,
        233.75296020507812,
        412.0377197265625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        420.74017333984375,
        515.654296875,
        433.9737243652344
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        442.79608154296875,
        422.22491455078125,
        456.0296325683594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        464.73211669921875,
        498.8633728027344,
        477.9656677246094
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        486.66815185546875,
        515.4144287109375,
        499.9017028808594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 결과제시방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        508.72406005859375,
        162.39132690429688,
        521.9575805664062
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        530.6600341796875,
        382.88623046875,
        543.8935546875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.876708984375,
        552.5960693359375,
        140.44387817382812,
        565.82958984375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        574.6519775390625,
        537.6024169921875,
        587.885498046875
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        596.5880126953125,
        538.1483154296875,
        609.821533203125
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.8620834350586,
        618.5240478515625,
        446.691650390625,
        631.757568359375
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        640.5799560546875,
        422.22491455078125,
        653.8134765625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        662.5159912109375,
        515.2944946289062,
        675.74951171875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        684.4519653320312,
        520.8115234375,
        697.6854858398438
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        706.5078735351562,
        482.6721496582031,
        719.7413940429688
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        728.4439086914062,
        140.44354248046875,
        741.6774291992188
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        750.3799438476562,
        533.8843994140625,
        763.6134643554688
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "32",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 32 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        69.16441345214844,
        535.443603515625,
        82.39794921875
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "⑤ 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        91.1004409790039,
        140.44354248046875,
        104.33397674560547
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        113.15634155273438,
        394.7597961425781,
        126.38987731933594
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        107.94149780273438,
        135.0923614501953,
        456.3526611328125,
        148.32591247558594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        157.02838134765625,
        394.7597961425781,
        170.26193237304688
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 재현성",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        201.0203094482422,
        128.5703125,
        214.2538604736328
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 시험물질 : 반복성 평가와 동일하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        222.95632934570312,
        277.943115234375,
        236.18988037109375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        245.01223754882812,
        140.44354248046875,
        258.24578857421875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        266.9482727050781,
        482.4322814941406,
        280.18182373046875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        288.88427734375,
        474.6365051269531,
        302.1178283691406
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        310.940185546875,
        465.8812561035156,
        324.1737365722656
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        332.876220703125,
        383.845703125,
        346.1097717285156
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        354.8122253417969,
        532.205322265625,
        368.0457763671875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        376.8681335449219,
        140.44354248046875,
        390.1016845703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        398.8041687011719,
        446.4517822265625,
        412.0377197265625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        420.74017333984375,
        538.14794921875,
        433.9737243652344
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변환할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.50065612792969,
        442.79608154296875,
        189.0712890625,
        456.0296325683594
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        464.97186279296875,
        139.07470703125,
        476.91082763671875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        484.989990234375,
        428.234619140625,
        496.91900634765625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        504.8882141113281,
        538.1478271484375,
        516.8171997070312
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다. 5개 그룹에 대한 임상적",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        525.7454833984375,
        538.1483154296875,
        537.6744384765625
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보 및 ROR score은 아래 표와 같다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        546.8424072265625,
        285.5153503417969,
        558.7713623046875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 4> 재현성 시험에 사용된 RNA 혼합물 정보",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        205.08885192871094,
        588.7965087890625,
        429.72711181640625,
        600.7255249023438
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "33",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 33 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        110.70000457763672,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        110.70000457763672,
        89.42227172851562,
        409.6480712890625,
        101.35127258300781
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 3. RNA 혼합물에 대한 재현성 실험 디자인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        204.84898376464844,
        291.7611389160156,
        429.96649169921875,
        303.6901550292969
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        312.73822021484375,
        538.1090087890625,
        324.67718505859375
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Signature",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assay",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nCounter",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Analysis",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "System",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "using",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "formalin-fixed",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "paraffin-embedded",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        332.75634765625,
        538.21240234375,
        344.68536376953125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "breast tumor specimens, Nielsen et al. BMC Cancer 2014, 14:177)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        352.65460205078125,
        403.6476135253906,
        364.5836181640625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 5> RNA 혼합물에 대한 재현성 시험 결과",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        210.0061798095703,
        394.6087646484375,
        424.6898193359375,
        406.53778076171875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        630.990478515625,
        408.3254089355469,
        642.91943359375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        109.02091217041016,
        651.008544921875,
        538.1478271484375,
        662.9375610351562
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        109.02091217041016,
        670.9068603515625,
        538.1483154296875,
        682.8358154296875
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        109.02091217041016,
        690.9249267578125,
        465.4178466796875,
        702.8538818359375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 34 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림 4. RNA 추출에 대한 재현성 실험 디자인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        209.88624572753906,
        270.7840881347656,
        424.9296875,
        282.7131042480469
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        291.7611389160156,
        538.2294311523438,
        303.7001037597656
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        311.7792663574219,
        538.1348266601562,
        323.7082824707031
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "tumor specimens, Nielsen et al. BMC Cancer 2014, 14:177)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        331.7973937988281,
        369.3471374511719,
        343.7264099121094
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 6> RNA 추출에 대한 재현성 시험 결과",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        195.01431274414062,
        373.7515563964844,
        399.6234130859375,
        385.6805725097656
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 강건성(robustness)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        585.919677734375,
        170.35662841796875,
        599.1531982421875
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        607.9755859375,
        538.2678833007812,
        621.2091064453125
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용과정에 대한 신뢰도를 보여주는 지표가 된다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.15872192382812,
        629.91162109375,
        326.03704833984375,
        643.1451416015625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 시험물질 :　반복성 평가와 동일하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        651.8475952148438,
        283.4601135253906,
        665.0811157226562
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        673.9035034179688,
        140.44354248046875,
        687.1370239257812
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        695.8395385742188,
        460.72406005859375,
        709.0730590820312
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        717.7755737304688,
        465.4015197753906,
        731.0090942382812
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        739.8314819335938,
        361.7776794433594,
        753.0650024414062
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "35",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 35 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        69.16441345214844,
        537.9622192382812,
        82.39794921875
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        91.1004409790039,
        532.205322265625,
        104.33397674560547
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        113.15634155273438,
        140.44354248046875,
        126.38987731933594
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        135.0923614501953,
        498.8633728027344,
        148.32591247558594
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        157.02838134765625,
        521.1713256835938,
        170.26193237304688
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        179.3240203857422,
        139.07470703125,
        191.26296997070312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다. 동일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        199.22227478027344,
        538.1483154296875,
        211.15127563476562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에서",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12개월",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주기적으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "RNA를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추출하여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ROR",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "score를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ROR",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        219.2404022216797,
        538.1912841796875,
        231.16940307617188
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "score에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        111.53955078125,
        239.25852966308594,
        538.1478271484375,
        251.18753051757812
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        111.53955078125,
        259.1567687988281,
        164.02117919921875,
        271.0857849121094
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        289.9631042480469,
        538.2682495117188,
        303.1966552734375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고려해야할 항목이다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        113.09870147705078,
        311.8991394042969,
        220.25439453125,
        325.1326904296875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        334.0749206542969,
        486.2865295410156,
        346.0138854980469
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        353.853271484375,
        538.14794921875,
        367.0868225097656
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        110.46013641357422,
        375.789306640625,
        453.767822265625,
        389.0228576660156
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        397.84521484375,
        538.2682495117188,
        411.0787658691406
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 검체에 혼합하여 사용하였다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        107.82156372070312,
        419.78125,
        269.78753662109375,
        433.0148010253906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        89.95124816894531,
        441.7172546386719,
        538.2678833007812,
        454.9508056640625
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실험하였다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        108.54117584228516,
        463.7731628417969,
        166.2836456298828,
        477.0067138671875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        315.4290466308594,
        485.9489440917969,
        538.21533203125,
        497.8879089355469
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 정확도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        527.663330078125,
        108.06143188476562,
        540.8968505859375
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        549.599365234375,
        538.2682495117188,
        562.8328857421875
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        97.02741241455078,
        571.6552734375,
        538.1483154296875,
        584.8887939453125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반복 측정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        97.02741241455078,
        593.59130859375,
        171.2009735107422,
        606.8248291015625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        615.52734375,
        527.407958984375,
        628.7608642578125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        637.5831909179688,
        423.544189453125,
        650.8167114257812
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        659.5192260742188,
        456.1665344238281,
        672.7527465820312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.876708984375,
        681.4552612304688,
        490.3479919433594,
        694.6887817382812
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "36",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 임상적 성능시험에 관한 자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        69.04454803466797,
        241.1892852783203,
        83.42882537841797
      ],
      "page_num": 80,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        56.609317779541016,
        93.13821411132812,
        320.34637451171875,
        106.37174987792969
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "❍ 체외진단용",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다지표",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유효성을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입증하기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람에서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        115.0742416381836,
        538.2682495117188,
        128.3077850341797
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        135.45196533203125,
        529.9265747070312,
        148.68551635742188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        155.82969665527344,
        538.2682495117188,
        169.06324768066406
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적 근거를 제시한다. 이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        176.08755493164062,
        538.1339721679688,
        189.32110595703125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다. 가급적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        196.4652862548828,
        538.2682495117188,
        209.69883728027344
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        216.843017578125,
        538.2682495117188,
        230.07656860351562
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        237.1008758544922,
        502.46142578125,
        250.3344268798828
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 질병의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주된",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "목적이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아니어서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도와",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        257.4786071777344,
        538.2678833007812,
        270.712158203125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        277.8563537597656,
        531.0059814453125,
        291.08990478515625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        298.11419677734375,
        538.14794921875,
        311.3477478027344
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단되는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내에서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "우리나라",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사람",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유래의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        318.491943359375,
        538.14794921875,
        331.7254943847656
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제출해야 한다. 이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        338.8696594238281,
        538.102783203125,
        352.10321044921875
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국내 유병률을 고려하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        359.1275329589844,
        255.1554718017578,
        372.361083984375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        379.5052490234375,
        538.2682495117188,
        392.7388000488281
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에 대한 원인을 분석하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        399.88299560546875,
        282.6205749511719,
        413.1165466308594
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 추가 검사 수행",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        93.0695571899414,
        420.1408386230469,
        189.25741577148438,
        433.3743896484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 다른 방법이나 표지자의 이용",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        440.5185852050781,
        260.6184387207031,
        453.75213623046875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 환자의 임상상태나 진단명 검토",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        93.0695571899414,
        460.89630126953125,
        271.65277099609375,
        474.1298522949219
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 추적 검사 수행",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        93.0695571899414,
        481.1541748046875,
        189.25741577148438,
        494.3877258300781
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        501.53192138671875,
        436.4971923828125,
        514.7654418945312
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다.(예,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        76.63846588134766,
        521.9096069335938,
        538.2227172851562,
        535.1431274414062
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        542.16748046875,
        538.2682495117188,
        555.4010009765625
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가능한 서류 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        93.0695571899414,
        562.5452270507812,
        174.19454956054688,
        575.7787475585938
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.59307098388672,
        582.9229736328125,
        538.2682495117188,
        596.156494140625
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "통계적으로 타당한 근거를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        101.70487976074219,
        603.1807861328125,
        285.7388916015625,
        616.414306640625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        96.54767608642578,
        623.5585327148438,
        161.192626953125,
        636.7920532226562
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 양성 임상 검체를 이용하여 평가한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        643.936279296875,
        312.6043395996094,
        657.1697998046875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다.(예, 기허가 진단",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        664.1941528320312,
        538.2682495117188,
        677.4276733398438
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.65298461914062,
        684.5718383789062,
        506.89422607421875,
        697.8053588867188
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        704.9495849609375,
        538.2678833007812,
        718.18310546875
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.41311645507812,
        725.2074584960938,
        197.4667510986328,
        738.4409790039062
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨",
      "font_size": 11.030982971191406,
      "font_name": "T24",
      "bbox": [
        119.45526123046875,
        745.46533203125,
        486.33642578125,
        759.849609375
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "37",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 37 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        69.16441345214844,
        161.19229125976562,
        82.39794921875
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        88.94280242919922,
        422.46478271484375,
        102.17633819580078
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        108.72118377685547,
        538.2682495117188,
        121.95471954345703
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.65298461914062,
        128.4995574951172,
        170.2415008544922,
        141.7331085205078
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        148.2779541015625,
        538.2682495117188,
        161.51150512695312
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석 방법을 미리 확립하고 이를 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.41311645507812,
        168.05633544921875,
        340.309326171875,
        181.28988647460938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        187.834716796875,
        425.1033630371094,
        201.06826782226562
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        207.61309814453125,
        161.19229125976562,
        220.84664916992188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        227.39149475097656,
        538.2227172851562,
        240.6250457763672
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.77291870117188,
        247.16986083984375,
        538.2682495117188,
        260.4034118652344
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.77291870117188,
        266.9482727050781,
        208.98049926757812,
        280.18182373046875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        286.7266540527344,
        447.05145263671875,
        299.960205078125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        306.5050354003906,
        490.9476623535156,
        319.73858642578125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        326.2834167480469,
        538.14794921875,
        339.5169677734375
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제외)을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.53305053710938,
        346.0617980957031,
        212.81842041015625,
        359.29534912109375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상적 특이도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.59307098388672,
        385.6185607910156,
        173.185791015625,
        398.85211181640625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가) 시험물질",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        96.54767608642578,
        405.3969421386719,
        161.192626953125,
        418.6304931640625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        425.17535400390625,
        407.35296630859375,
        438.4089050292969
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        444.9537353515625,
        538.102783203125,
        458.1872863769531
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유병율을 고려하여 통계적으로 타당한 근거를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        126.41149139404297,
        464.73211669921875,
        395.1195983886719,
        477.9656677246094
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        484.510498046875,
        161.19229125976562,
        497.7440490722656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        504.28887939453125,
        538.268798828125,
        517.5223999023438
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확립한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.77291870117188,
        524.0672607421875,
        168.20260620117188,
        537.30078125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        543.8456420898438,
        538.268798828125,
        557.0791625976562
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법을 미리 확립하고 이를 명시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.65298461914062,
        563.6240234375,
        303.60919189453125,
        576.8575439453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        583.4024047851562,
        409.8716125488281,
        596.6359252929688
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        603.1807861328125,
        538.2682495117188,
        616.414306640625
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인토록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.53305053710938,
        622.9591674804688,
        194.1085662841797,
        636.1926879882812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        642.737548828125,
        161.19229125976562,
        655.9710693359375
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        662.5159912109375,
        430.74029541015625,
        675.74951171875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        682.2943725585938,
        472.3577575683594,
        695.5278930664062
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        702.07275390625,
        538.268798828125,
        715.3062744140625
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제외)을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        123.41311645507812,
        721.8511352539062,
        208.26089477539062,
        735.0846557617188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "38",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 38 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 임상적 유용성",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.59307098388672,
        69.16441345214844,
        173.185791015625,
        82.39794921875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        91.1004409790039,
        477.03521728515625,
        104.33397674560547
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        113.15634155273438,
        534.3641967773438,
        126.38987731933594
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        135.0923614501953,
        513.6154174804688,
        148.32591247558594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        157.02838134765625,
        365.6156005859375,
        170.26193237304688
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        179.0842742919922,
        433.3788757324219,
        192.3178253173828
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        201.0203094482422,
        490.8277282714844,
        214.2538604736328
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        222.95632934570312,
        433.0190734863281,
        236.18988037109375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        245.01223754882812,
        495.9849548339844,
        258.24578857421875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        266.9482727050781,
        417.7873229980469,
        280.18182373046875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 레지스트리 연구 등을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        288.88427734375,
        276.983642578125,
        302.1178283691406
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 2차원 자료를 이용한 후향적 분석은 부적절하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        310.940185546875,
        355.1812438964844,
        324.1737365722656
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        332.876220703125,
        538.1483154296875,
        346.1097717285156
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        122.4536361694336,
        354.8122253417969,
        165.68397521972656,
        368.0457763671875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.54767608642578,
        376.8681335449219,
        411.0709533691406,
        390.1016845703125
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 연구 설계 또는 자료원에 따른 위계",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        106.6222152709961,
        398.8041687011719,
        295.75970458984375,
        412.0377197265625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        420.74017333984375,
        409.626953125,
        433.9737243652344
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 무작위 배정 단일암 연구",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        442.79608154296875,
        252.82296752929688,
        456.0296325683594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 무작위 배정 없는 대조군 연구",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        464.73211669921875,
        280.2880859375,
        477.9656677246094
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱ 코호트 연구 또는 환자-대조군 연구",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        486.66815185546875,
        308.4728088378906,
        499.9017028808594
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        508.72406005859375,
        538.2682495117188,
        521.9575805664062
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미발표 연구, 회사자료, 가이드라인, 전문가 의견 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.3304443359375,
        530.6600341796875,
        388.82928466796875,
        543.8935546875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 임상문헌의 내적타당도 확보를 위한 평가항목",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        106.6222152709961,
        552.5960693359375,
        342.6553649902344,
        565.82958984375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        574.6519775390625,
        492.0932922363281,
        587.885498046875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        596.5880126953125,
        538.2227172851562,
        609.821533203125
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전향적 연구여부 등",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        129.05006408691406,
        618.5240478515625,
        227.99642944335938,
        631.757568359375
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        640.5799560546875,
        494.6119384765625,
        653.8134765625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료분석",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "담보할",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충분한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        662.5159912109375,
        538.2227172851562,
        675.74951171875
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        126.77129364013672,
        684.4519653320312,
        538.2682495117188,
        697.6854858398438
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        126.77129364013672,
        706.5078735351562,
        538.2682495117188,
        719.7413940429688
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추정 결과와 95% 신뢰구간 제시 여부.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        126.77129364013672,
        728.4439086914062,
        320.9997863769531,
        741.6774291992188
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 비용효과분석 관련 이슈",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        106.6222152709961,
        750.3799438476562,
        238.4307861328125,
        763.6134643554688
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "39",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 39 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        69.16441345214844,
        538.2682495117188,
        82.39794921875
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 관련해서 사회적 관점이 요구될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        127.8507080078125,
        91.1004409790039,
        361.2979431152344,
        104.33397674560547
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        113.15634155273438,
        538.1484375,
        126.38987731933594
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        129.05006408691406,
        135.0923614501953,
        533.5245971679688,
        148.32591247558594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다. 경우에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        157.02838134765625,
        538.2684936523438,
        170.26193237304688
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        130.00953674316406,
        179.0842742919922,
        538.2683715820312,
        192.3178253173828
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보다 효과적인 방법일 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        130.00953674316406,
        201.0203094482422,
        282.0209045410156,
        214.2538604736328
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉱",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경로의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이해",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": ":",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상적",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경로에서",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유전자",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "효과가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지점을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        222.95632934570312,
        538.2682495117188,
        236.18988037109375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        131.56869506835938,
        245.01223754882812,
        466.4809265136719,
        258.24578857421875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        266.9482727050781,
        538.2682495117188,
        280.18182373046875
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비용 포함한다. 사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        136.24615478515625,
        288.88427734375,
        538.2682495117188,
        302.1178283691406
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        136.24615478515625,
        310.940185546875,
        538.2682495117188,
        324.1737365722656
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다. 매우 배우기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        136.24615478515625,
        332.876220703125,
        538.2682495117188,
        346.1097717285156
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        136.24615478515625,
        354.8122253417969,
        538.2678833007812,
        368.0457763671875
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "때문에 제외하는 경우가 많다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        136.24615478515625,
        376.8681335449219,
        287.29803466796875,
        390.1016845703125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        109.86045837402344,
        398.8041687011719,
        538.2107543945312,
        412.0377197265625
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        420.74017333984375,
        538.2682495117188,
        433.9737243652344
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        442.79608154296875,
        538.2020874023438,
        456.0296325683594
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선호도에",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "간접측정법(the",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EuroQol",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "five-dimensional",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[EQ-5D]",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        128.9301300048828,
        464.73211669921875,
        538.1943969726562,
        477.9656677246094
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "questionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        486.66815185546875,
        538.2682495117188,
        499.9017028808594
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        508.72406005859375,
        538.2682495117188,
        521.9575805664062
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        530.6600341796875,
        538.2020874023438,
        543.8935546875
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        552.5960693359375,
        538.2227172851562,
        565.82958984375
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        574.6519775390625,
        538.2682495117188,
        587.885498046875
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        596.5880126953125,
        538.14794921875,
        609.821533203125
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        128.9301300048828,
        618.5240478515625,
        153.57054138183594,
        631.757568359375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다. 그러나 이에 대한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        640.5799560546875,
        538.14794921875,
        653.8134765625
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구가 부족하다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        127.13109588623047,
        662.5159912109375,
        212.33868408203125,
        675.74951171875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        109.86045837402344,
        684.4519653320312,
        538.0821533203125,
        697.6854858398438
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        103.02416229248047,
        706.7476806640625,
        538.1478271484375,
        718.6865844726562
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Breast Cancer Alarm을 통한 ROR",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        103.02416229248047,
        706.7476806640625,
        538.1478271484375,
        718.6865844726562
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "score의 임상적 유용성을 입증하기 위하여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        103.02416229248047,
        706.7476806640625,
        538.1478271484375,
        718.6865844726562
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ABSCG 임상 시험을 시행하였다. ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        726.6458740234375,
        538.1483154296875,
        738.5748901367188
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        746.6640625,
        538.1483154296875,
        758.593017578125
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "40",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 40 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "병용",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "투여한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "군을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대상으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성(1-3개)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유방암",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        69.4041519165039,
        538.1478271484375,
        81.3331527709961
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        89.42227172851562,
        538.1089477539062,
        101.35127258300781
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Survival, DRFS)를 확인하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        109.32052612304688,
        258.76983642578125,
        121.24952697753906
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        129.33865356445312,
        538.1478271484375,
        141.2676544189453
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조직",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시료를",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다변량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cox의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비례",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모형을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무재발",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생존율의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        149.35678100585938,
        538.1478271484375,
        161.28578186035156
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위험비(HR)을 비교 평가하였다. 이때 다변량 변수로 Breast Cancer Alarm Score 외에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        169.25503540039062,
        538.1483154296875,
        181.1840362548828
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나이,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종양의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등급,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "종양의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "크기,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보조요법을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        189.2731475830078,
        538.1483154296875,
        201.2021484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가하였다. 또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        209.29127502441406,
        538.1116943359375,
        221.22027587890625
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Alarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        229.1895294189453,
        537.498779296875,
        241.1185302734375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        249.2076416015625,
        538.1483154296875,
        261.13665771484375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        269.22576904296875,
        538.2183227539062,
        281.15478515625
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저위험군으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분류된",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실제로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10년",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격전이가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "없는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        289.1240234375,
        538.1478271484375,
        301.05303955078125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성예측도(NPV)는 96.6%이다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        309.14215087890625,
        259.48944091796875,
        321.0711669921875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        329.1602783203125,
        538.1483154296875,
        341.08929443359375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "양성예측도(PPV)는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "24.2%이었으며,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저위험군",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "재발이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일어나지",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "않는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비율인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        349.8976135253906,
        538.1483154296875,
        361.8266296386719
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성예측도(NPV)는 94.2%이다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        371.11444091796875,
        259.48944091796875,
        383.04345703125
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.01603698730469,
        391.0126953125,
        538.1478271484375,
        402.94171142578125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.01603698730469,
        411.0307922363281,
        450.066162109375,
        422.9598083496094
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        103.02416229248047,
        450.9471740722656,
        491.49365234375,
        462.8761901855469
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        116.33695220947266,
        470.9653015136719,
        538.1492309570312,
        482.8943176269531
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Breast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        116.33695220947266,
        490.9834289550781,
        538.1478271484375,
        502.9124450683594
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        116.33695220947266,
        510.8816833496094,
        538.2183837890625,
        522.8106689453125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        116.33695220947266,
        530.8997802734375,
        538.1483154296875,
        542.8287963867188
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        116.33695220947266,
        550.91796875,
        538.1116943359375,
        562.846923828125
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Alarm 모델의 통계적 유의성을 판단하였다. 아래 표는 검정통계량(test statistic), α=0.05",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        116.33695220947266,
        570.816162109375,
        538.188720703125,
        582.7451782226562
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        116.33695220947266,
        590.8343505859375,
        413.2461242675781,
        602.7633056640625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Null Model",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        102.54442596435547,
        659.5192260742188,
        424.227783203125,
        674.7426147460938
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alternate Model",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        102.54442596435547,
        659.5192260742188,
        424.227783203125,
        674.7426147460938
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ΔLR χ2",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        102.54442596435547,
        659.5192260742188,
        424.227783203125,
        674.7426147460938
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "χ2 Critical Value",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        102.54442596435547,
        659.5192260742188,
        424.227783203125,
        674.7426147460938
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Degrees of freedom)",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        337.017333984375,
        663.9544067382812,
        504.9440002441406,
        679.297607421875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "χ2 p-value",
      "font_size": 8.992650032043457,
      "font_name": "T22",
      "bbox": [
        337.017333984375,
        663.9544067382812,
        504.9440002441406,
        679.297607421875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CTS",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        692.9627075195312,
        260.3039245605469,
        708.18603515625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CTS + Breast Cancer",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        692.9627075195312,
        260.3039245605469,
        708.18603515625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Alarm score",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        188.53781127929688,
        697.3978271484375,
        503.1872863769531,
        712.7410888671875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "53.49",
      "font_size": 8.992650032043457,
      "font_name": "T29",
      "bbox": [
        188.53781127929688,
        697.3978271484375,
        503.1872863769531,
        712.7410888671875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.84 (df = 1)",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        188.53781127929688,
        697.3978271484375,
        503.1872863769531,
        712.7410888671875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "p < 0.0001",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        188.53781127929688,
        697.3978271484375,
        503.1872863769531,
        712.7410888671875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CTS",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        728.8035278320312,
        503.1872863769531,
        739.5917358398438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CTS + Risk Groups",
      "font_size": 8.992650032043457,
      "font_name": "T29",
      "bbox": [
        118.25590515136719,
        728.8035278320312,
        503.1872863769531,
        739.5917358398438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "34.12",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        728.8035278320312,
        503.1872863769531,
        739.5917358398438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.99 (df = 2)",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        728.8035278320312,
        503.1872863769531,
        739.5917358398438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "p < 0.0001",
      "font_size": 8.992650032043457,
      "font_name": "T16",
      "bbox": [
        118.25590515136719,
        728.8035278320312,
        503.1872863769531,
        739.5917358398438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        177.98353576660156,
        632.1890869140625,
        426.9681396484375,
        644.1181030273438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "41",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 41 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상정보",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기반",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점수(Clinical",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Treatment",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Score,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CTS)는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의사가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "처방을",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        91.34017944335938,
        538.1478271484375,
        103.26918029785156
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.37584686279297,
        111.3582992553711,
        538.1483154296875,
        123.28730010986328
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태, 보조 요법)의 최적화된 조합이다. 모든 조합 중에서 세 가지 변수(나이, 치료요법",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        131.3764190673828,
        538.1478271484375,
        143.305419921875
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        151.27467346191406,
        538.1478271484375,
        163.20367431640625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자에 한에서 중요한 예후 인자로 작용한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        171.2928009033203,
        325.8135070800781,
        183.2218017578125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        191.31092834472656,
        538.1478271484375,
        203.23992919921875
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군). 점수와 위험군 분류 모두",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.37584686279297,
        211.2091827392578,
        538.1483154296875,
        223.13818359375
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원격",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "무재발",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생존율(Distant",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Recurrence",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Free",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Survival,",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "DRFS)에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        118.37584686279297,
        231.22731018066406,
        538.1478271484375,
        243.15631103515625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보임을 알 수 있다(p < 0.0001).",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        118.37584686279297,
        251.24542236328125,
        271.96185302734375,
        263.1744384765625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) Breast Cancer Alarm score의 위험도 추정",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        103.02416229248047,
        293.1995849609375,
        310.991455078125,
        305.12860107421875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다. 아래의 표와",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        116.33695220947266,
        313.09783935546875,
        538.1483154296875,
        325.02685546875
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절",
      "font_size": 9.951866149902344,
      "font_name": "T18",
      "bbox": [
        116.33695220947266,
        333.115966796875,
        538.1483154296875,
        345.04498291015625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "음성환자의 비율을 보여준다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        116.33695220947266,
        353.1340637207031,
        248.69528198242188,
        365.0630798339844
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<그림 5. 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율>",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        115.85720825195312,
        619.4830322265625,
        435.1499328613281,
        631.4119873046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "42",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 42 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Risk Group",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        119.09545135498047,
        97.38794708251953,
        271.0519714355469,
        121.63894653320312
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Number of",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        119.09545135498047,
        97.38794708251953,
        271.0519714355469,
        121.63894653320312
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Patients (%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        119.09545135498047,
        97.38794708251953,
        271.0519714355469,
        121.63894653320312
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Number of Events",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        290.8423767089844,
        91.63423156738281,
        383.5517272949219,
        104.3778076171875
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Through",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        313.7499694824219,
        103.14165496826172,
        360.6443786621094,
        127.39265441894531
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10 Years",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        313.7499694824219,
        103.14165496826172,
        360.6443786621094,
        127.39265441894531
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Estimated Percent Without",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        388.7093200683594,
        97.38794708251953,
        520.9971313476562,
        110.13151550292969
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Recurrence at 10 years",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        396.7449645996094,
        108.89537048339844,
        512.9612426757812,
        121.63894653320312
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 15,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Low",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        136.60595703125,
        128.91348266601562,
        515.1201782226562,
        141.6570587158203
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "487 (47%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        136.60595703125,
        128.91348266601562,
        515.1201782226562,
        141.6570587158203
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        136.60595703125,
        128.91348266601562,
        515.1201782226562,
        141.6570587158203
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96.6% [94.4% - 97.9%]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        136.60595703125,
        128.91348266601562,
        515.1201782226562,
        141.6570587158203
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Intermediate",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        118.13597106933594,
        143.29776000976562,
        515.1201782226562,
        156.0413360595703
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "335 (32%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        118.13597106933594,
        143.29776000976562,
        515.1201782226562,
        156.0413360595703
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        118.13597106933594,
        143.29776000976562,
        515.1201782226562,
        156.0413360595703
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "90.4% [86.3% - 93.3%]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        118.13597106933594,
        143.29776000976562,
        515.1201782226562,
        156.0413360595703
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        135.646484375,
        157.5621795654297,
        515.1201782226562,
        170.30575561523438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "225 (21%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        135.646484375,
        157.5621795654297,
        515.1201782226562,
        170.30575561523438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "32",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        135.646484375,
        157.5621795654297,
        515.1201782226562,
        170.30575561523438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "84.3% [78.4% - 88.6%]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        135.646484375,
        157.5621795654297,
        515.1201782226562,
        170.30575561523438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Total",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        134.9268798828125,
        171.9464569091797,
        344.3333740234375,
        184.69003295898438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1,047 (100%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        134.9268798828125,
        171.9464569091797,
        344.3333740234375,
        184.69003295898438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        134.9268798828125,
        171.9464569091797,
        344.3333740234375,
        184.69003295898438
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        143.32232666015625,
        70.84258270263672,
        475.18243408203125,
        82.7715835571289
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다. 아래의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        120.77454376220703,
        196.22555541992188,
        538.1492309570312,
        208.15455627441406
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        120.77454376220703,
        216.24368286132812,
        538.1488037109375,
        228.1726837158203
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결절 양성 환자의 비율을 보여준다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        120.77454376220703,
        236.14193725585938,
        283.11663818359375,
        248.07093811035156
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<그림 6. 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율>",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        156.87498474121094,
        486.30853271484375,
        476.167724609375,
        498.237548828125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Risk Group",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        96.90747833251953,
        560.0823364257812,
        236.87066650390625,
        584.333251953125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Number of",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        96.90747833251953,
        560.0823364257812,
        236.87066650390625,
        584.333251953125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Patients (%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        96.90747833251953,
        560.0823364257812,
        236.87066650390625,
        584.333251953125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Number of",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        262.5377197265625,
        554.448486328125,
        318.42706298828125,
        567.1920166015625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Events Through",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        250.78408813476562,
        565.8359985351562,
        330.1810607910156,
        578.5795288085938
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10 Years",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        267.0952453613281,
        577.3434448242188,
        313.8697204589844,
        590.0869750976562
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Estimated Percent Without Distant",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        335.098388671875,
        560.0823364257812,
        506.2444763183594,
        584.333251953125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Recurrence at 10 years [95% CI]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-BoldMT",
      "bbox": [
        335.098388671875,
        560.0823364257812,
        506.2444763183594,
        584.333251953125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Low",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        114.53792572021484,
        597.361572265625,
        481.05853271484375,
        610.1051025390625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "158 (41%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        114.53792572021484,
        597.361572265625,
        481.05853271484375,
        610.1051025390625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        114.53792572021484,
        597.361572265625,
        481.05853271484375,
        610.1051025390625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "94.2% [88.1% - 97.2%]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        114.53792572021484,
        597.361572265625,
        481.05853271484375,
        610.1051025390625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        113.45851135253906,
        617.2598266601562,
        481.05853271484375,
        630.0033569335938
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "224 (59%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        113.45851135253906,
        617.2598266601562,
        481.05853271484375,
        630.0033569335938
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "46",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        113.45851135253906,
        617.2598266601562,
        481.05853271484375,
        630.0033569335938
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75.8% [68.9% - 81.4%]",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPSMT",
      "bbox": [
        113.45851135253906,
        617.2598266601562,
        481.05853271484375,
        630.0033569335938
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Total",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        112.85883331298828,
        637.2779541015625,
        297.6786804199219,
        650.021484375
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "382 (100%)",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        112.85883331298828,
        637.2779541015625,
        297.6786804199219,
        650.021484375
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "53",
      "font_size": 11.510591506958008,
      "font_name": "TimesNewRomanPS-ItalicMT",
      "bbox": [
        112.85883331298828,
        637.2779541015625,
        297.6786804199219,
        650.021484375
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        127.97064208984375,
        530.6600341796875,
        459.830810546875,
        542.5890502929688
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        273.09197998046875,
        665.27294921875,
        538.2152099609375,
        677.2119140625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        708.0662231445312,
        385.11126708984375,
        722.4505004882812
      ],
      "page_num": 86,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        732.1598510742188,
        538.2686157226562,
        745.3933715820312
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        754.0958862304688,
        370.4129943847656,
        767.3294067382812
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "43",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 43 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        69.16441345214844,
        538.1483154296875,
        82.39794921875
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용된 경우, 이에 관한 자료를 제출 한다.(단, 표준물질에 관한 자료와 중복될 경우 이를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        91.1004409790039,
        538.2686157226562,
        104.33397674560547
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생략한다.)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        113.15634155273438,
        130.89801025390625,
        126.38987731933594
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        135.0923614501953,
        535.6834716796875,
        148.32591247558594
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        178.96441650390625,
        385.11126708984375,
        193.3487091064453
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        73.04041290283203,
        203.05807495117188,
        504.2604675292969,
        216.2916259765625
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        224.99411010742188,
        396.43408203125,
        238.2276611328125
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 출처 및 근거 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        246.93014526367188,
        174.744873046875,
        260.1636962890625
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        82.15547180175781,
        268.98602294921875,
        411.6706237792969,
        282.2195739746094
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        65.72438049316406,
        290.92205810546875,
        476.3815002441406,
        304.1556091308594
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 표준물질 관리방법 및 관리기록서(정도관리 포함)",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        65.72438049316406,
        312.85809326171875,
        331.06951904296875,
        326.0916442871094
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        356.7301330566406,
        405.0204772949219,
        371.1144104003906
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        380.8238220214844,
        538.2227172851562,
        394.057373046875
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용기한, 주의사항 등을 기재한다. 이는 원심분리 조건 등을 포함한 검체 전 처리 과정",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        402.75982666015625,
        538.267822265625,
        415.9933776855469
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        424.81573486328125,
        418.9866638183594,
        438.0492858886719
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 검체 취급 및 보관조건에 대한 시험 결과를 제시한다. 이는 제시된 시간, 온도, 습도 등의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        446.75177001953125,
        538.2682495117188,
        459.9853210449219
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        468.6877746582031,
        538.1483154296875,
        481.92132568359375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증해야 한다. 이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        79.51690673828125,
        490.7436828613281,
        538.1483154296875,
        503.97723388671875
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        512.6796875,
        520.0919189453125,
        525.9132080078125
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        534.61572265625,
        538.2680053710938,
        547.8492431640625
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요약하여 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        79.51690673828125,
        556.671630859375,
        176.95785522460938,
        569.9051513671875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 상관성 평가",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        600.423828125,
        141.04356384277344,
        614.80810546875
      ],
      "page_num": 87,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 일반사항",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        59.967498779296875,
        624.5175170898438,
        123.05297088623047,
        637.7510375976562
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 국내",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        65.72438049316406,
        646.5733642578125,
        102.66478729248047,
        659.806884765625
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        107.82156372070312,
        646.5733642578125,
        538.2686767578125,
        659.806884765625
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다. 다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        668.5093994140625,
        538.14794921875,
        681.742919921875
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        690.4454345703125,
        160.28689575195312,
        703.678955078125
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        65.72438049316406,
        712.5013427734375,
        538.2678833007812,
        725.73486328125
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사의 결과로 제시할 수 있다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        80.71625518798828,
        734.4373779296875,
        237.28515625,
        747.6708984375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        65.72438049316406,
        756.3734130859375,
        396.67877197265625,
        769.60693359375
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "44",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 44 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가) 시험물질 검체",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        69.16441345214844,
        166.94918823242188,
        82.39794921875
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        91.1004409790039,
        538.14794921875,
        104.33397674560547
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험을 수행한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        113.15634155273438,
        202.50401306152344,
        126.38987731933594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        99.90585327148438,
        135.0923614501953,
        538.2682495117188,
        148.32591247558594
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등이 밝혀진 검체를 사용할 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        157.02838134765625,
        334.31256103515625,
        170.26193237304688
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        179.0842742919922,
        525.60888671875,
        192.3178253173828
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        201.0203094482422,
        538.1483154296875,
        214.2538604736328
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상의 검체를 시험하도록 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        222.95632934570312,
        301.3304443359375,
        236.18988037109375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나) 시험방법",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        245.01223754882812,
        139.48406982421875,
        258.24578857421875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        266.9482727050781,
        383.312255859375,
        280.18182373046875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외 허가 제품과의 비교시험을",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        388.7093200683594,
        266.9482727050781,
        538.1475830078125,
        280.18182373046875
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        288.88427734375,
        164.0048828125,
        302.1178283691406
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        310.940185546875,
        421.26544189453125,
        324.1737365722656
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        332.876220703125,
        382.76629638671875,
        346.1097717285156
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        354.8122253417969,
        415.7484130859375,
        368.0457763671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        376.8681335449219,
        538.2682495117188,
        390.1016845703125
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자료를 제공하여야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        398.8041687011719,
        240.88320922851562,
        412.0377197265625
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다) 결과판독",
      "font_size": 11.030982971191406,
      "font_name": "T29",
      "bbox": [
        74.9593734741211,
        420.74017333984375,
        139.48440551757812,
        433.9737243652344
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        442.79608154296875,
        538.2682495117188,
        456.0296325683594
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 결과 자료(raw data)를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        96.66761016845703,
        464.73211669921875,
        279.98199462890625,
        477.9656677246094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라) 결과제시",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        486.66815185546875,
        139.48406982421875,
        499.9017028808594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        508.72406005859375,
        443.2135314941406,
        521.9575805664062
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        530.6600341796875,
        538.269287109375,
        543.8935546875
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "바이어스(bias, 편향성)를 제시한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        552.5960693359375,
        294.13433837890625,
        565.82958984375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        574.6519775390625,
        538.1483154296875,
        587.885498046875
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제시(신뢰구간과 함께) 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        117.29642486572266,
        596.5880126953125,
        260.4326171875,
        609.821533203125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        99.90585327148438,
        618.5240478515625,
        465.2815856933594,
        631.757568359375
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        66.56392669677734,
        662.5159912109375,
        500.60870361328125,
        675.74951171875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        83.11495208740234,
        684.4519653320312,
        473.26318359375,
        697.6854858398438
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "45",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유사점 및 차이점",
      "font_size": 12.94941520690918,
      "font_name": "T12",
      "bbox": [
        235.43240356445312,
        80.67183685302734,
        343.37506103515625,
        96.19391632080078
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항 목",
      "font_size": 11.030982971191406,
      "font_name": "T12",
      "bbox": [
        99.66598510742188,
        112.67686462402344,
        452.3710021972656,
        125.89937591552734
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Prosigna",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        99.66598510742188,
        112.67686462402344,
        452.3710021972656,
        125.89937591552734
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "MammaPrint",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        99.66598510742188,
        112.67686462402344,
        452.3710021972656,
        125.89937591552734
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        95.22838592529297,
        157.02838134765625,
        128.3304443359375,
        170.2509002685547
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신청 제품(ProsignaTM Breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        163.83120727539062,
        142.76397705078125,
        312.407958984375,
        155.9864959716797
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cancer Prognostic Gene",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        177.02406311035156,
        157.02838134765625,
        299.23583984375,
        170.2509002685547
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Signature Assay)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        195.49404907226562,
        171.41265869140625,
        280.8318176269531,
        184.6351776123047
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가 받은 제품(MammaPrint,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        341.9346923828125,
        149.95611572265625,
        490.15203857421875,
        163.1786346435547
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K062694, K070675)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        369.27984619140625,
        164.22052001953125,
        462.8941345214844,
        177.4430389404297
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용목적",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        411.0307922363281,
        133.8471221923828,
        424.2532958984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ProsignaTM",
      "font_size": 7.074217319488525,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        194.90699768066406,
        322.056640625,
        209.68780517578125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        194.90699768066406,
        322.056640625,
        209.68780517578125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cancer",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        194.90699768066406,
        322.056640625,
        209.68780517578125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prognostic Gene Signature Assay",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        210.7296905517578,
        322.0260009765625,
        252.6009063720703
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 침윤성 파라핀 포매된 유방암",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        210.7296905517578,
        322.0260009765625,
        252.6009063720703
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체를",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        210.7296905517578,
        322.0260009765625,
        252.6009063720703
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상으로",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        210.7296905517578,
        322.0260009765625,
        252.6009063720703
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "NanoString",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        210.7296905517578,
        322.0260009765625,
        252.6009063720703
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "nCounterⓇ Dx 분석 시스템을 사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용하는 체외 진단 검사이다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이러한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성분석은",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질병의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "윈격",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        154.2364044189453,
        253.64279174804688,
        322.0259094238281,
        295.5140075683594
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "재발 위험을 평가하기 위해서 위험",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "군 분류와 구체적인 점수에 필요",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 임상적 요인들와 함께 유전자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발현 데이터를 이용한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ProsignaTM",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cancer",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        296.555908203125,
        322.056640625,
        367.0757751464844
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Prognostic Gene Signature Assay",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        368.1177062988281,
        322.0260009765625,
        424.2532958984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "는 수술과 함께 국소적인 치료를",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        368.1177062988281,
        322.0260009765625,
        424.2532958984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "받은 여성 유방암 환자를 대상으",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        368.1177062988281,
        322.0260009765625,
        424.2532958984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        368.1177062988281,
        322.0260009765625,
        424.2532958984375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 내분비보조치료만 받은 호르몬",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        154.2364044189453,
        439.67950439453125,
        322.0270690917969,
        510.0794982910156
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수용체 양성, 림프절 전이 음성,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        439.67950439453125,
        322.0270690917969,
        510.0794982910156
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Stage 1 또는 2 유방암인 폐경",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        439.67950439453125,
        322.0270690917969,
        510.0794982910156
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 여성의 윈격 무재발 생존율에",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        439.67950439453125,
        322.0270690917969,
        510.0794982910156
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 예후 지표",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        439.67950439453125,
        322.0270690917969,
        510.0794982910156
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 내분비보조치료만 받은 호르몬",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        154.2364044189453,
        525.5056762695312,
        322.02557373046875,
        552.9926147460938
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수용체 양성,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        525.5056762695312,
        322.02557373046875,
        552.9926147460938
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프절 전이 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        525.5056762695312,
        322.02557373046875,
        552.9926147460938
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1-3개), Stage",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        554.0345458984375,
        322.0254821777344,
        567.257080078125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        554.0345458984375,
        322.0254821777344,
        567.257080078125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유방암인 폐경",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        554.0345458984375,
        322.0254821777344,
        567.257080078125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "후 여성의 윈격 무재발 생존율에",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        568.4188232421875,
        322.0270690917969,
        595.90576171875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 예후 지표",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        568.4188232421875,
        322.0270690917969,
        595.90576171875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 림프절 전이 양성(4개 이상)인",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        611.3319091796875,
        322.0254821777344,
        638.81884765625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자는 대상으로 하지 않음",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        611.3319091796875,
        322.0254821777344,
        638.81884765625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MammaPrint는 한 시험소에서 환자",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        318.012451171875,
        500.0093078613281,
        388.5323486328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의 원격 전이 위험성을 평가하기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        318.012451171875,
        500.0093078613281,
        388.5323486328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 신선 동결 유방암 검체의 유전",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        318.012451171875,
        500.0093078613281,
        388.5323486328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자 발현을 분석하는 체외 진단용",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        318.012451171875,
        500.0093078613281,
        388.5323486328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성 검사 서비스이다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        318.012451171875,
        500.0093078613281,
        388.5323486328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "림프절",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        332.2199401855469,
        403.8386535644531,
        500.0090026855469,
        417.0611572265625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        403.8386535644531,
        500.0090026855469,
        417.0611572265625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        403.8386535644531,
        500.0090026855469,
        417.0611572265625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종양크기가",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        403.8386535644531,
        500.0090026855469,
        417.0611572265625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5cm 이하, Stage I 또는 II를 가진",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        418.2229309082031,
        500.00946044921875,
        459.9742736816406
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "61세 이하의 유방암 환자를 대상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        418.2229309082031,
        500.00946044921875,
        459.9742736816406
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 검사한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        418.2229309082031,
        500.00946044921875,
        459.9742736816406
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "MammaPrint 결과는 다른 임상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        475.40045166015625,
        500.0090026855469,
        517.2716674804688
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "병리학적인 요소와 함께 예후 지",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        475.40045166015625,
        500.0090026855469,
        517.2716674804688
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표로써, 의사가 사용한다.",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        475.40045166015625,
        500.0090026855469,
        517.2716674804688
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용제한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        92.46988677978516,
        669.2286376953125,
        136.48568725585938,
        682.451171875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처방으로만 사용",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        647.7720947265625,
        322.0254821777344,
        703.90771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "진단, 치료효과를 예측하거나 측정,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        647.7720947265625,
        322.0254821777344,
        703.90771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에게 최적의 치료를 선택할",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        647.7720947265625,
        322.0254821777344,
        703.90771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수 있도록 쓰일 수 없음",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        647.7720947265625,
        322.0254821777344,
        703.90771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "좌동",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        405.0204772949219,
        669.2286376953125,
        427.0885314941406,
        682.451171875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품설명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        730.84130859375,
        133.8471221923828,
        744.0638427734375
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "nCounterⓇ",
      "font_size": 11.030982971191406,
      "font_name": "T19",
      "bbox": [
        154.2364044189453,
        709.384765625,
        322.01495361328125,
        722.6182861328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Dx",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        709.384765625,
        322.01495361328125,
        722.6182861328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "analysis",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        709.384765625,
        322.01495361328125,
        722.6182861328125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "platform 및 ProsignaTM Breast",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        723.76904296875,
        322.02349853515625,
        751.2559814453125
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Cancer",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        723.76904296875,
        322.02349853515625,
        751.2559814453125
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Prognostic",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        723.76904296875,
        322.02349853515625,
        751.2559814453125
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Gene",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        723.76904296875,
        322.02349853515625,
        751.2559814453125
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Signature Assay",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        752.2978515625,
        235.9075927734375,
        765.5203857421875
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 시험소에서 시행되는 70개의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        709.384765625,
        500.0090026855469,
        736.9915771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유전자로",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        709.384765625,
        500.0090026855469,
        736.9915771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구성된",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        709.384765625,
        500.0090026855469,
        736.9915771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RNA",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        709.384765625,
        500.0090026855469,
        736.9915771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전사체",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        709.384765625,
        500.0090026855469,
        736.9915771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마이크로어레이(Microarray) 기반",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        738.033447265625,
        500.0090026855469,
        765.5203857421875
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석(assay)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        738.033447265625,
        500.0090026855469,
        765.5203857421875
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "46",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        64.40509796142578,
        783.3037109375,
        78.93878173828125,
        796.536865234375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 46 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        72.80054473876953,
        796.1296997070312,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험샘플",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "파라핀 포매 유방암 검체",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신선",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동결",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "신선한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태의",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.83131408691406,
        80.67183685302734,
        500.0090026855469,
        101.08649444580078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "유방암 조직 절편",
      "font_size": 11.030982971191406,
      "font_name": "T18",
      "bbox": [
        332.2199401855469,
        94.93624877929688,
        420.1322937011719,
        108.15876007080078
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추출 및",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        92.5898208618164,
        148.2779541015625,
        131.08895874023438,
        161.50047302246094
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증폭 여부",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        87.07280731201172,
        162.6622314453125,
        136.48568725585938,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증폭 필요하지 않음;",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공된 파라핀 포매 유방암 검체",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처리에",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절차;",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "RNA",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추출,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        154.2364044189453,
        126.82140350341797,
        322.0254821777344,
        168.69261169433594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혼성화(hybridization) 과정, 디지",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        169.7344970703125,
        322.0254821777344,
        197.34129333496094
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "털 분석 과정을 포함함",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        154.2364044189453,
        169.7344970703125,
        322.0254821777344,
        197.34129333496094
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증폭 필요함;",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "조직부터 전체 시험을 한 시험소",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 시행; RNA 추출, 라벨링 증",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폭,",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마이크로어레이",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혼성화",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        119.74913787841797,
        500.0091857910156,
        175.88475036621094
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(microarray",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        176.9266357421875,
        500.0090026855469,
        190.14915466308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "hybridization)",
      "font_size": 11.030982971191406,
      "font_name": "T14",
      "bbox": [
        332.2199401855469,
        176.9266357421875,
        500.0090026855469,
        190.14915466308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그리",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        176.9266357421875,
        500.0090026855469,
        190.14915466308594
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고 스캐닝(scanning)을 포함함",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        332.2199401855469,
        191.19105529785156,
        481.89849853515625,
        204.41357421875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        77.11820220947266,
        211.2091827392578,
        419.71929931640625,
        223.14813232421875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        86.59307098388672,
        237.58035278320312,
        538.2682495117188,
        256.327880859375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 내용으로 허가시 고려되어야 할 항목이다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        103.14409637451172,
        260.7150573730469,
        342.10833740234375,
        273.9486083984375
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ (예시 :",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        86.59307098388672,
        278.4556884765625,
        132.35833740234375,
        290.3946533203125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        294.39825439453125,
        537.3788452148438,
        306.3272705078125
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 관리운용기술(System Description)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        96.54767608642578,
        310.4607238769531,
        264.8834533691406,
        322.3897399902344
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 작동모드: 자동화",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        326.4032897949219,
        201.4903106689453,
        338.3323059082031
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 소프트웨어 : 검체 준비 과정(Prep. station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        106.6222152709961,
        342.3458557128906,
        538.0984497070312,
        354.2748718261719
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        358.4083251953125,
        538.148681640625,
        370.33734130859375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        374.35089111328125,
        538.1478271484375,
        386.2799072265625
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 알고리즘으로부터 나온 score를 산출한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        124.01278686523438,
        390.29345703125,
        329.2916259765625,
        402.22247314453125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        106.6222152709961,
        406.3559265136719,
        518.7889404296875,
        418.2849426269531
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        422.2984924316406,
        538.1483154296875,
        434.2275085449219
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 내에서 12 단계를 거쳐 처리된다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        124.01278686523438,
        438.2410583496094,
        301.4667053222656,
        450.1700744628906
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. 검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        106.6222152709961,
        454.30352783203125,
        538.1483154296875,
        466.2325439453125
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요하지 않다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        124.01278686523438,
        470.24609375,
        191.48629760742188,
        482.17510986328125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 품질관리: 품질관리를 위해 아래 항목을 확인한다.",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        106.6222152709961,
        486.18865966796875,
        353.8782958984375,
        498.11767578125
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 항존유전자 표지자의 기하평균 신호 강도",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        502.2511291503906,
        322.26531982421875,
        514.1801147460938
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 50개 유전자 각각의 신호 강도",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        518.1937255859375,
        272.25244140625,
        530.1226806640625
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 음성 대조군의 바탕 신호 강도",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        534.13623046875,
        272.25244140625,
        546.0652465820312
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 양성 대조군의 직선성",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        550.19873046875,
        232.31361389160156,
        562.127685546875
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 표지자(probe) 상호 오염",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        124.01278686523438,
        566.1412353515625,
        244.6674041748047,
        578.0702514648438
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions)",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        101.58494567871094,
        582.0838623046875,
        396.5717468261719,
        594.0228271484375
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 소프트웨어의 성능자료",
      "font_size": 11.99020004272461,
      "font_name": "T22",
      "bbox": [
        56.609317779541016,
        637.703125,
        204.00942993164062,
        652.08740234375
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        661.7967529296875,
        538.2682495117188,
        675.0302734375
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        683.8526611328125,
        538.2227172851562,
        697.086181640625
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        705.7886962890625,
        538.2682495117188,
        719.022216796875
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        74.9593734741211,
        727.7246704101562,
        415.86834716796875,
        740.9581909179688
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "47",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        521.5972900390625,
        783.3037109375,
        532.8837280273438,
        796.536865234375
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        280.40802001953125,
        802.7330322265625,
        314.4545593261719,
        812.6821899414062
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속기관",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.38072204589844,
        135.11178588867188,
        486.33642578125,
        151.0552978515625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분 야",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.38072204589844,
        135.11178588867188,
        486.33642578125,
        151.0552978515625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성 명",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.38072204589844,
        135.11178588867188,
        486.33642578125,
        151.0552978515625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "추천기관",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        109.38072204589844,
        135.11178588867188,
        486.33642578125,
        151.0552978515625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연세대학교 세브란스병원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.16197204589844,
        168.75985717773438,
        275.3702392578125,
        190.50018310546875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.16197204589844,
        168.75985717773438,
        275.3702392578125,
        190.50018310546875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(진단검사의학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        175.8321533203125,
        514.517578125,
        197.69232177734375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최종락",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        175.8321533203125,
        514.517578125,
        197.69232177734375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한진단검사의학회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        175.8321533203125,
        514.517578125,
        197.69232177734375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연세대학교 세브란스병원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.16197204589844,
        210.59414672851562,
        275.3702392578125,
        232.45433044433594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        70.16197204589844,
        210.59414672851562,
        275.3702392578125,
        232.45433044433594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(영상의학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        217.78628540039062,
        502.88494873046875,
        239.64646911621094
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허용민",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        217.78628540039062,
        502.88494873046875,
        239.64646911621094
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한영상의학회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        217.78628540039062,
        502.88494873046875,
        239.64646911621094
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "건국대학교병원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        94.98851776123047,
        252.54827880859375,
        275.3702392578125,
        274.2886047363281
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        94.98851776123047,
        252.54827880859375,
        275.3702392578125,
        274.2886047363281
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(진단검사의학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        259.6205749511719,
        514.517578125,
        281.4807434082031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "윤여민",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        259.6205749511719,
        514.517578125,
        281.4807434082031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한진단검사의학회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        225.47779846191406,
        259.6205749511719,
        514.517578125,
        281.4807434082031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "삼성서울병원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        100.3855972290039,
        294.382568359375,
        275.3702392578125,
        316.24273681640625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        100.3855972290039,
        294.382568359375,
        275.3702392578125,
        316.24273681640625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(병리학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        242.98831176757812,
        301.57470703125,
        500.887451171875,
        323.31500244140625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최윤라",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        242.98831176757812,
        301.57470703125,
        500.887451171875,
        323.31500244140625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한병리학회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        242.98831176757812,
        301.57470703125,
        500.887451171875,
        323.31500244140625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "씨젠의료재단",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        100.3855972290039,
        336.21685791015625,
        275.3702392578125,
        358.0770263671875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        100.3855972290039,
        336.21685791015625,
        275.3702392578125,
        358.0770263671875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(분자진단)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        343.40899658203125,
        519.240966796875,
        365.2691650390625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "노경호",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        343.40899658203125,
        519.240966796875,
        365.2691650390625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한진단검사의학회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        343.40899658203125,
        519.240966796875,
        365.2691650390625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜씨젠",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        115.49740600585938,
        378.1709899902344,
        275.3702392578125,
        400.03118896484375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        115.49740600585938,
        378.1709899902344,
        275.3702392578125,
        400.03118896484375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(분자진단)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        385.3631591796875,
        518.4773559570312,
        407.10345458984375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "고성일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        385.3631591796875,
        518.4773559570312,
        407.10345458984375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국의료기기산업협회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        385.3631591796875,
        518.4773559570312,
        407.10345458984375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지멘스헬시니어스(주)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        80.59632110595703,
        420.0052795410156,
        275.3702392578125,
        441.8654479980469
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        80.59632110595703,
        420.0052795410156,
        275.3702392578125,
        441.8654479980469
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(의료공학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        427.1974182128906,
        518.4773559570312,
        449.0575866699219
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "손종은",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        427.1974182128906,
        518.4773559570312,
        449.0575866699219
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국의료기기산업협회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        427.1974182128906,
        518.4773559570312,
        449.0575866699219
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "휴마시스(주)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        102.54442596435547,
        461.9594421386719,
        275.3702392578125,
        483.6997375488281
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        102.54442596435547,
        461.9594421386719,
        275.3702392578125,
        483.6997375488281
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(컴퓨터공학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        469.0317077636719,
        502.16796875,
        490.8918762207031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안무경",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        469.0317077636719,
        502.16796875,
        490.8918762207031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국바이오협회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        469.0317077636719,
        502.16796875,
        490.8918762207031
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜엔젠바이오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        97.14734649658203,
        503.7937316894531,
        275.3702392578125,
        525.6539306640625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        97.14734649658203,
        503.7937316894531,
        275.3702392578125,
        525.6539306640625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(컴퓨터공학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        510.9858703613281,
        502.16796875,
        532.7261962890625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "홍창범",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        510.9858703613281,
        502.16796875,
        532.7261962890625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국바이오협회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        231.3546142578125,
        510.9858703613281,
        502.16796875,
        532.7261962890625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "㈜바디텍메드",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        97.14734649658203,
        545.7479248046875,
        275.3702392578125,
        567.4882202148438
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "학계",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        97.14734649658203,
        545.7479248046875,
        275.3702392578125,
        567.4882202148438
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(환경공학)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        552.8201904296875,
        502.16796875,
        574.6803588867188
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장덕환",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        552.8201904296875,
        502.16796875,
        574.6803588867188
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한국바이오협회",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        237.23143005371094,
        552.8201904296875,
        502.16796875,
        574.6803588867188
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[전문협의회 위원]",
      "font_size": 15.946965217590332,
      "font_name": "MalgunGothicBold",
      "bbox": [
        233.75331115722656,
        85.01656341552734,
        364.3147888183594,
        106.221435546875
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        527.1143188476562,
        783.3037109375,
        532.8839111328125,
        796.536865234375
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질병의 예후·예측에 사용되는 체외진단용 의료기기",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicBold",
      "bbox": [
        146.56056213378906,
        244.61184692382812,
        479.757080078125,
        263.2657470703125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "허가·심사 가이드라인 (민원인 안내서)",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicBold",
      "bbox": [
        189.73716735839844,
        266.907470703125,
        436.57867431640625,
        285.5613708496094
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA >",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicBold",
      "bbox": [
        117.1764907836914,
        289.3229675292969,
        504.407958984375,
        307.97686767578125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발   행   처",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        325.42864990234375,
        471.8236389160156,
        340.0966796875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        325.42864990234375,
        471.8236389160156,
        340.0966796875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발   행   일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        361.50921630859375,
        254.741943359375,
        376.17724609375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2018년 8월",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        361.50921630859375,
        254.741943359375,
        376.17724609375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발   행   인",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        397.70965576171875,
        230.03500366210938,
        412.377685546875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이선희",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        397.70965576171875,
        230.03500366210938,
        412.377685546875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        433.79022216796875,
        230.03500366210938,
        448.458251953125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오현주",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        433.79022216796875,
        230.03500366210938,
        448.458251953125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편  집  위  원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        500.5572814941406,
        180.14236450195312,
        515.225341796875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<체외진단기기과>",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        460.640869140625,
        292.81683349609375,
        475.30889892578125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진,",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        479.5801696777344,
        521.9984741210938,
        494.2481994628906
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "백승엽, 배성화, 김빛나, 정은지",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        498.63934326171875,
        352.60858154296875,
        513.307373046875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<의료기기연구과>",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        528.6066284179688,
        289.45867919921875,
        543.274658203125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식,",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        552.1009521484375,
        521.9984741210938,
        566.7689819335938
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "김미혜, 김세경, 이정현",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        197.05320739746094,
        571.040283203125,
        310.99114990234375,
        585.7083129882812
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문   의   처",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        103.26403045654297,
        599.44921875,
        513.216796875,
        662.4244384765625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        599.44921875,
        513.216796875,
        662.4244384765625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        599.44921875,
        513.216796875,
        662.4244384765625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화 : 043-719-4652~4665",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        599.44921875,
        513.216796875,
        662.4244384765625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스 : 043-719-4650",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        103.26403045654297,
        599.44921875,
        513.216796875,
        662.4244384765625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 가이드라인은 15년도 식품의약품안전처의 연구개발사업",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        160.59295654296875,
        699.1802368164062,
        458.39093017578125,
        713.8482666015625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구,",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        111.65948486328125,
        718.4791259765625,
        511.2043151855469,
        733.1471557617188
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15172의료평425)의 결과를 활용하였습니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        200.05157470703125,
        737.7780151367188,
        422.81219482421875,
        752.446044921875
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.951866149902344,
      "font_name": "Gulim",
      "bbox": [
        283.2864685058594,
        802.7330322265625,
        311.57611083984375,
        812.6821899414062
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "“내가 지킨 청렴실천 모아지면 청렴사회”",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicBold",
      "bbox": [
        188.8976287841797,
        692.3828125,
        414.9952392578125,
        708.3262939453125
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        110.46013641357422,
        557.5653076171875,
        484.3736267089844,
        574.7843017578125
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        135.04681396484375,
        583.576904296875,
        459.8318176269531,
        600.7958984375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043-719-4652~4665  FAX : 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        152.7971954345703,
        609.5884399414062,
        442.14227294921875,
        626.8074340820312
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "http://www.mfds.go.kr (식품의약품안전처)",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        179.54269409179688,
        635.6847534179688,
        415.27117919921875,
        651.6282348632812
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "http://www.nifds.go.kr (식품의약품안전평가원)",
      "font_size": 11.99020004272461,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        156.27529907226562,
        654.8638305664062,
        438.53857421875,
        670.8073120117188
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018. 8.\n<!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다. | 반드시 협의하여 주시기 바랍니다. | 고려한다. | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다. | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다. | 확립한다. | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다. | 안전 등의 주의사항을 기재한다. | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다. | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다. | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다. 임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다. | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법. | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다. 즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다. | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다. |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다. | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다. | 6) 데이터 불러오기 및 저장을 실행한다. | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다. | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다. | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다. | 등이 밝혀진 검체를 사용할 것을 권장한다. | 아래에 해당하는 사항에 체크하여 주시기 바랍니다. | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1. 배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다. (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다. | 분석 방법을 미리 확립하고 이를 명시한다. | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다. | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다. | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다. | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다. | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다. | 초과)으로 설정하였다. | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. | 2. 목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까? | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다. | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다. | 의료기기로 허가·심사한다. | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다. | 보다 효과적인 방법일 수 있다. | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다. | 한다. 이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다. | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3. 적용 범위 | 4 | 적용되지 않는다. | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30. | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다. | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다. | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다. | 이상의 검체를 시험하도록 권장한다. | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다. | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다. | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다. | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다. 결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다. |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다. | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다. | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다. | 4. 기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다. | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다. | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다. 질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001). | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다. | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다. | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다. | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다. | 확인하였다. | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2. | 9개 | 무색액상 |\n| 기재한다. | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다. | 요구 | 사항 | 번호 | 자료를 제공한다. | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다. | 돕는 결과를 생성하는 알고리즘 포함 여부입니다. | 지침을 제시한다. | 5. 관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2. 정상조직 포함에 따른 ROR score 비교> | 그림 4. RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다. | 있나요? | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다. | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다. | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다. | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. | 알고리즘의 임상적 성능이 떨어질 수 있다. | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다. | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임. | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다. | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다. | 예측할 수 있다. 로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? | 그림 3. RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다. | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다. | 개발한 경우, 조합의료기기로 허가․심사한다. | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다. | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26. | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다. 이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다. | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다. | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다. | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다. | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다. | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다. | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다. | 고려해야할 항목이다. | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다. | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다. | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다. | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다. | 유효성을 동시에 검토해야 한다. | 오류가 나타남 | 권장한다. | 분석 및 임상 데이터 검토가 이뤄져야 한다. | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다. | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다. | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다. | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다. | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가. 작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다. | Rev. 0 |\n| 후보 검사법 | tumor specimens, Nielsen et al. BMC Cancer 2014, 14:177) | 1. 체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다. | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다. | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다. | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1. 사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다. 바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다. 내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다. | 제외)을 제시한다. | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다. | 유전자 | qRT-PCR | 2017.11.10. |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다. | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다. | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요? | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다. | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al. BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다. | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다. | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다. | 필요하다. | 표 1. RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다. | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다. | 예방 등)이 있는 것이 바람직하다. | 내용입니까? | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다. | 고려돼야 한다. | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다. |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다. | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다. | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다. | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다. | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다. | 알고리즘의 검정을 실시한다. 단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다. | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다. | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다. | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2. 공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다. 출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다. | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다. | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다. | 및 알고리즘으로부터 나온 score를 산출한다. | 대해서는 색, 성상, 액성, 냄새 등을 기재한다. | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다. | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다. | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. | 검체에 대한 원인을 분석하여야 한다. | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다. | 자료를 제공하여야 한다. |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다. | 분해능(resolution)에 비하여 큰 차이여야 함 | 다. 검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다. | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다. | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다. | 유전자 수를 기재한다. | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다. | 3. 사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다. | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다. | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가. 추가 검사 수행 | 위양성 결과를 보이는지 확인한다. | 제출자료가 면제될 수 있다. | 각 검체에 혼합하여 사용하였다. | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까? | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다. |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다. | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다. | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다. | 허가받은 알고리즘의 검정을 다시 평가해야 한다. |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다. | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다. | 4. 체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다. |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나. 다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다. <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다. | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 소프트웨어 | 1. 내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다. | 변환할 수 있다. | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다. | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다. | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2. 진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다. 환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다. | 휴마시스(주) | 학계 | 가. 알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다. | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다. |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다. | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다. | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다. | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다. | SRS-3 | 실험하였다. | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다. |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다. | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다. | 관리 계획을 확보하고 있어야 한다. | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다. |\n| 라. 추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다. | 1. 시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바. 품질관리: 품질관리를 위해 아래 항목을 확인한다. | 기능) | 나. 알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다. | <그림 6. 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다. | § | 표준물질 및 내부 표준물질 | 확인한다. | 상세설계에 대한 내용은 아래문서를 참조한다. | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다. | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1. TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. | 다. 알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다. 비밀번호를 누른다. 기 | 기의 “Pulse count”가 0이 된다. | H/W, S/W버전을 확인한다. | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다. | 다시 기기설정화면으로 진입한다. |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다. | 근거를 제시한다.(임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다. | ※ 임상적 정보가 확보된 검체란? | 2. 내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다. | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다. 기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다. | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다. | 1. 체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라. 소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다. |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다. | 강도, pH 등이 기질효과의 주된 요인이다. | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다. | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다. | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다. | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요? | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다. | 및 유효성확인 | 사용해야만 한다. | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다. | 5. 소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. | 수 있는 컬러사진을 첨부한다. | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다. | - 표지자(probe) 상호 오염 | 필요성을 기재한다. | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다. | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다. | 2. 체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다. | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다. | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다. | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다. | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다. | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다. | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까? | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다. |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다. | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다. | 제시(신뢰구간과 함께) 한다. | 소프트웨어를 사용할 수 있도록 한다. |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다. | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다. |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다. | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다. | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다. | 2. 결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다. | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다. | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다. | <그림 5. 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다. | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다. | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다. | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다. | 확인토록 한다. |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다. | 2. RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다. | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다. | 여부를 식약처에 확인받아야 한다. | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3. 체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다. | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다. | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요? | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다. | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다. | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다. | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다. | ① 양성 임상 검체를 이용하여 평가한다. | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다. | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다. | 전까지의 생존 기간 | 하도록 권고한다. | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음. |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다. | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다. | 연구가 부족하다. | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다. | 사용제한 | 좌동 |\n| 기재한다. | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다. | 있는데 식약처의 임상시험 계획 승인 대상인가요? | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다. | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다. | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다. | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다. | 4. 적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다. | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다. | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다. | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다. | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다. | 권고한다. | 구성품의 외관사진 및 구성표를 따로 제시한다. | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다. | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8. 성능에 관한 자료 | 가. 소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다. | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다. |\n| 함을 명시한다. | 일치도 등의 정보를 기재한다. | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다. | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다. | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다. | ※ 예시 : | 것을 권장한다. |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n<!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n<!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018. 8. 22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1. 배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다. 융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다. 진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다. 이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다. 이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다. 서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다. 이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2. 목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3. 적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다. 해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다. 결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나. 체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n<!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다. 알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n<!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다. 체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n<!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n<!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4. 기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우. 검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n<!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n<!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값. 정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다. 온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5. 관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1. 체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다. 국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다. 다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다. 그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n<!-- PAGE_20 -->\n###### 2. 공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3. 사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n<!-- PAGE_21 -->\n###### 가. 사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다. 암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4. 체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가. 알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다. 특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다. 다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n<!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다. 대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다. 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n<!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법. 이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나. 알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다. 알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다. 단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다. 알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n<!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n<!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n<!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n<!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n<!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n<!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n<!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다. 예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n<!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n<!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다. 따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다. 이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n<!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다. 따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n<!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다. 개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다. 이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n<!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라. 체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁. 타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다. 타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n* 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂. 소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다. 소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1. 소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2. 시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3. 검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4. 검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5. 미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1. 소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다. IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n<!-- PAGE_35 -->\n##### 2. 시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다. |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다. | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다. |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다. | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다. | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다. | 제출한다. | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다. |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다. | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다. | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다. | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다. |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다.**\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다. | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다. |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다. | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다. |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다. | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다.**\n| (on-board, reconstitution, openvial/bottle). | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다. | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다. | 는 경우 자사규격 등을 기재한다. |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다. | 경우는 ‘제조원 포장단위’로 기재한다. |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다. | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다. | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다. |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다. |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다. | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다. | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다. | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다. |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다. | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다. | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4. 원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함. |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다. |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다.**\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다. |\n| 요약하여 제시한다. | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다. | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다. | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다. | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함).**\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다.**\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다. | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다. |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다. | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다. |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다. | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다. | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다. |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다.**\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다.**\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다. |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다. |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3. 검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4. 검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다. | 1. 제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다.**\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다. | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다. | 각 구성 시약의 원재료명 또는 성분명을 기재한다. |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다. | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다.**\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다. | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다. | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다. | ① 시험물질 : 반복성 평가와 동일하다. | 결과를 판정하는 기준과 해석을 제시한다. |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2. 제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5. 미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다.**\n| 소프트웨어 | 안전성 등급 |\n**Q3. 체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다.**\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n· MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1. 체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\nA1. 현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n<!-- PAGE_41 -->\n###### A2.\n\n<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n<!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다. 그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3. 체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n<!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다. 이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n<!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4. 체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4. 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다. 또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다. 알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다. 검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n<!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다. 알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다. 만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n<!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n<!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다. 질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다. 로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다. 이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다. 바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다. 성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n<!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4. 체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다. 따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다. 만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다. 유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다. 그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\nNature,\n\n- (2002)\n415(6871):530-6.\"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer. JNCI, (2006) 98(17):1183-1192.\"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6. 체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6. 체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n<!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7. 체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7. 「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다. 여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다. 개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다. 임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.  제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1. 제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1. 제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2. 기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1. 명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2. 분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3. 모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4. 원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5. 제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6. 사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7. 사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8. 사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9. 포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10. 저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11. 시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12. 제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.  기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1. 개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2. 원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3. 사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4. 저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5. 성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6. 체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7. 이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.  성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1. 분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2. 임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6. 상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7. 소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부. 제품 개요\n\n<!-- PAGE_48 -->\n###### 1. 제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다. 유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다. 조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다. 본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부. 신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부. 제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1. 명칭\n\n- 가. 제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나. 제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2. 분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n<!-- PAGE_51 -->\n###### 3. 모양 및 구조\n\n- 가. 모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나. 모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다. 만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n- 가. 원재료는 다음 양식의 표를 사용하여 기재한다.\n보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다. 두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다. 주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다. 소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다. 하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5. 제조방법\n\n- 가. '제조원의 제조방법에 따른다.’라고 기재한다.\n다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다.(대부분의 체외진단용 의료\n\n- 나. 멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6. 사용목적(성능)\n\n- 가. 사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다. 검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나. 성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7. 사용방법\n\n- 가. 검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1. 사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2. BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8. 사용 시 주의사항\n\n- 가. 다음의 사항을 포함하여 기재한다.\n1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9. 포장단위\n\n- 가. 포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10. 저장방법 및 사용기간\n\n- 가. 저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n- ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n<!-- PAGE_60 -->\n###### 11. 시험규격\n\n- 가. 제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n- 나. 시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12. 제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가. 제조원의 제조국, 제조사명 및 주소를 기재한다.\n- 나. 모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다. 다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부. 기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1. 기본원칙\n\n- 가. 기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나. 해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n- 다. 외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다. 다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2. 분석적 성능시험에 관한 자료의 요건\n\n- 가. 인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나. 기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다. 추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3. 임상적 성능시험에 관한 자료의 요건\n\n- 가. 인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나. 임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험. 다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3. 임상적 성능시험에 관한 자료의 요건의 가.\n\n<!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1. 개발경위\n\n- 가. 체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나. 본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다. 해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라. 프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2. 측정원리․방법\n\n- 가. 유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나. 제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n- 다. 제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3. 국내․외에서 사용현황\n\n- 가. 국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1. 원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가. 의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나. 원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다. 프라이머, 프로브에 대한 자료(염기서열)\n- 라. 원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2. 제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가. 제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나. 원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다. 일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1. 허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2. 해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. 완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2. 구성 제품별로 구분하여 안정성 시험 자료\n- 3. 평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4. 안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n- 5. 저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6. 일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7. 제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8. 수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n- 9. 저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n<!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1. 성능시험에 관한 자료는 다음의 자료를 포함한다.\n- 가. 분석적 성능시험에 관한 자료(시험성적서)\n- 나. 임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마. 검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바. 국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사. 소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1. 구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2. 유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n<!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1. 이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부. 성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n<!-- PAGE_69 -->\n###### 1. 분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가. 분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다. 일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다. 계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n- ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n- ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n- 1. 세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n- ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다. 림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다. 림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나. 분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다. 간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n- ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1. 사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다. 정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n30\n\n- - 30 -\n- 2. 사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다. 10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3. 괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다. 괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n- ② 위양성률을 계산한다. 위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n- ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n- ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n- ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다. 5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n- ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다. 동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2. 임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다. 이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다. 가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다. 이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다.(예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다.(예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n- ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n- ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n- ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n- ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다. 경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다. 사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다. 매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다. 삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다. 그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다. ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\nBreast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다. 이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다. 또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\nCTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다. 아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다. 모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군). 점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다. 아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다. 아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3. 완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가. 연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n43\n\n- - 43 -\n- 나. 시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다.(단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n- 다. 시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n<!-- PAGE_87 -->\n###### 4. 완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가. 국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나. 출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5. 검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가. 시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다. 이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나. 검체 취급 및 보관조건에 대한 시험 결과를 제시한다. 이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다. 이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다. 시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6. 상관성 평가\n\n- 가. 일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다. 다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n- ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n- 나. 소프트웨어 : 검체 준비 과정(Prep. station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라. 검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마. 검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7. 소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n- - 2 -",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 236,
        "word_count": 47,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018.  8.\n <!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다. ",
        "original_sentence": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "8.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 1,
        "window_text": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018.  8.\n <!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다.  | 고려한다. ",
        "original_sentence": "8.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "<!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 161,
        "word_count": 40,
        "page_number": 2,
        "window_text": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018.  8.\n <!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다.  | 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다. ",
        "original_sentence": "<!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다. "
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "| 반드시 협의하여 주시기 바랍니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 12,
        "window_text": "<!-- PAGE_1 -->\n### 질병의 예후·예측에 사용되는\n\n<!-- PAGE_1 -->\n### 체외진단용 의료기기 허가·심사 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n<!-- PAGE_1 -->\n###### <  In V itro  D iag no stics M ultivariate Ind e x A ssay, IVD-MIA >\n\n안내서 등록번호\n\n안내서-0882-01\n\n- 2018.  8.\n <!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다.  | 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다. ",
        "original_sentence": "| 반드시 협의하여 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "| 고려한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "8.\n <!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다.  | 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다. ",
        "original_sentence": "| 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 433,
        "word_count": 118,
        "page_number": 2,
        "window_text": "<!-- PAGE_2 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n**[표 시작]**\n\n| 명칭 | F b) PPV의 추정값 [추정 유병률은  × |        | F 관측치가 평균의 양측에 균일하게 분포하면 결과 그래프는 전형적인 종형곡선을 갖는다.  | 반드시 협의하여 주시기 바랍니다.  | 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다. ",
        "original_sentence": "| 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "| 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| 반드시 협의하여 주시기 바랍니다.  | 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다. ",
        "original_sentence": "| 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| 확립한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| 고려한다.  | 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다. ",
        "original_sentence": "| 확립한다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 5,
        "window_text": "| 번호 | 명칭 | 세부구성 | 외관상 특징 | 의료기기 소프트웨어 적합성 확인보고서 | 증폭 필요하지 않음; | 제공된 파라핀 포매 유방암 검체 | 처리에 | 대한 | 절차; | RNA | 추출, | 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | < In Vitro Diagnostics Multivariate Index Assay, IVD-MIA > | MFDS-IVD-MIA-01 | 명칭 : MFDS-IVD-MIA-01 | 버전 : 2.0 | 1EA |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 5) 계산 아이콘을 클릭한다.  | 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다. ",
        "original_sentence": "| Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| 안전 등의 주의사항을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 2,
        "window_text": "| 각 환자의 10년 무원격전이 생존률에 대한 예후 지표를 제공한다.  | 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다. ",
        "original_sentence": "| 안전 등의 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "| 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 2,
        "window_text": "| 확립한다.  | Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다. ",
        "original_sentence": "| 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 10,
        "window_text": "| Low | 487 (47%) | 15 | 96.6% [94.4% - 97.9%] |\n| 제조자와 제조의뢰자가 다른 경우, 구분하여 기재하여야 한다.  | 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법. ",
        "original_sentence": "| 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 34,
        "word_count": 11,
        "page_number": 8,
        "window_text": "| 안전 등의 주의사항을 기재한다.  | 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다. ",
        "original_sentence": "| 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 106,
        "word_count": 19,
        "page_number": 10,
        "window_text": "| 마) 관찰항목, 측정항목, 임상검사항목, 측정기준 및 검사방법 | ㉮ 양성검체 농도, 교차오염 방지, 원재료 농도 변동 등에 대한 자료를 제시한다.  | 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다. ",
        "original_sentence": "임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "| 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 158,
        "word_count": 38,
        "page_number": 13,
        "window_text": "| 유래된 검체를 대상으로 시험한 자료로써 임상적 민감도와 임상적 특이도를 평가한다.  | 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다. ",
        "original_sentence": "| 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법. "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 192,
        "word_count": 40,
        "page_number": 8,
        "window_text": "| 또는 측정 결과의 동등을 평가하는 시험 | 1 | 한다.  임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다. ",
        "original_sentence": "| 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 107,
        "word_count": 27,
        "page_number": 2,
        "window_text": "임상통계학적 모델에 사용한 바이오마커 선정의 근거, 개발 경위, 검사 결과에 | ① 환자 보고 효과측정(patient-reported outcome measures)이 일반적으로 포함된다.  | 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다. ",
        "original_sentence": "즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 8,
        "window_text": "| 반복성 혹은 동시재현성, 검사 간 정밀도, 일간 정밀도, 총 정밀도 등 | (Software Verification & Validation Report) | 소속기관 | 분 야 | 성 명 | 추천기관 | 1개 검체를 알고리즘에 적용하여 구현한 알고리즘이 타당한지 확인하는 방법.  | 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다. ",
        "original_sentence": "| 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "|\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 5,
        "window_text": "| 예측되는 의료기기 | hazard ratio)모델에 따른 위험비(Hazard Ratio), 측정 플랫폼에 따른 유전자 발 | 현의 dynamic range, 유전자 혹은 pathway analysis에 따른 signature 의 특성, | 유전자 상호 간의 상관관계계수(correlation R2) 등 다양한 요소가 존재할 수 있 | 다.  즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다. ",
        "original_sentence": "|\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 135,
        "word_count": 29,
        "page_number": 5,
        "window_text": "즉 유전자 선정, 알고리즘(Risk Score 혹은 아형 구분) 개발 방법론에 따라 | 고유한 특성이 있을 수 있으므로, 유전자 선별 프로세스에 대한 방법론이 제시 | 되는 것이 바람직하다.  | 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다. ",
        "original_sentence": "| 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| 6) 데이터 불러오기 및 저장을 실행한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 5,
        "window_text": "| 유전자 발현에 의한 score를 파악하기 위해서는 장기간에서 의미가 있을 수 있다.  |\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다. ",
        "original_sentence": "| 6) 데이터 불러오기 및 저장을 실행한다. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "| 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 170,
        "word_count": 42,
        "page_number": 12,
        "window_text": "|\n| 제 I부  개요 | 3 | Acceptable | Deviation | Effect | Effect | Safety | Effect |\n| 받고 사용되는 IVD-MIA 제품은 다음과 같습니다.  | 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다. ",
        "original_sentence": "| 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "| ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 49,
        "word_count": 14,
        "page_number": 8,
        "window_text": "| 기관(IRB)의 임상시험계획승인을 받고 실시해야함) | Intermediate | 335 (32%) | 28 | 90.4% [86.3% - 93.3%] | 신청 제품(ProsignaTM Breast |\n| 추출 및 | 다루어 질 것이다.  | 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다. ",
        "original_sentence": "| ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "| 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 90,
        "word_count": 22,
        "page_number": 9,
        "window_text": "| 6) 데이터 불러오기 및 저장을 실행한다.  | 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1. ",
        "original_sentence": "| 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "| 등이 밝혀진 검체를 사용할 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 10,
        "window_text": "| 1 | Reference Sample | 단일구성 | 붉은색캡 바이알내 | 질병의 예후·예측에 사용되는 | 허가 받은 제품(MammaPrint, |\n| 바) 유효성 평가기준, 평가방법 및 해석방법 | 1) 체외진단용 의료기기의 사용목적 | ㉯ 필요에 따라 통계처리 과정에서 로그 변환을 할 수 있다.  | ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다. ",
        "original_sentence": "| 등이 밝혀진 검체를 사용할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 아래에 해당하는 사항에 체크하여 주시기 바랍니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 2,
        "window_text": "| ㉯ 유전자 분석용 시약의 경우 필요에 따라 통계처리 과정에서 로그 변환할 수 있다.  | 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다. ",
        "original_sentence": "| 아래에 해당하는 사항에 체크하여 주시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 283,
        "word_count": 60,
        "page_number": 8,
        "window_text": "| 모델명 | 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific | ② 생존이나 의료자원 사용의 흐름이 포함될 수 있다.  | 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다. ",
        "original_sentence": "| Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 96,
        "word_count": 21,
        "page_number": 5,
        "window_text": "| 등이 밝혀진 검체를 사용할 것을 권장한다.  | 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다. ",
        "original_sentence": "배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "(마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 12,
        "window_text": "| 아래에 해당하는 사항에 체크하여 주시기 바랍니다.  | Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다. ",
        "original_sentence": "(마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "| 분석 방법을 미리 확립하고 이를 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 11,
        "window_text": "| Cancer Prognostic Gene | Description | 진단정확도기준 | Performance | End User |\n| 관련된 유해사례보고 요약 | High | 225 (21%) | 32 | 84.3% [78.4% - 88.6%] | 유전자분석기구 [A22500.01(3)] | 소프트웨어 명칭 및 버전 | MFDS-IVD-MIA-SW(1.00) | 무색액상 |\n| 1) 정확도(Accuracy) | 증폭 여부 | 질병이나 특정 상태로 발전할 위험성이 있는지 예측하는 의료기기 | 1.  배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다. ",
        "original_sentence": "| 분석 방법을 미리 확립하고 이를 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "| Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 128,
        "word_count": 30,
        "page_number": 5,
        "window_text": "배경 | 3 | K062694, K070675) |\n| 체외진단용 의료기기 허가·심사 가이드라인 (민원인 안내서) | reviewer)가 동의할 수 있는 내용이어야 한다.  (마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다. ",
        "original_sentence": "| Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 470,
        "word_count": 116,
        "page_number": 2,
        "window_text": "(마커 선정, 모델 개발, 판단 기준(decision | 환자에 한에서 중요한 예후 인자로 작용한다.  | 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다. ",
        "original_sentence": "| 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 13,
        "window_text": "| 분석 방법을 미리 확립하고 이를 명시한다.  | Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다. ",
        "original_sentence": "| 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 82,
        "window_text": "| Total | 1,047 (100%) | 75 | 혼성화(hybridization) 과정, 디지 | 털 분석 과정을 포함함 | Signature Assay) |\n| 기준 및 합리적인 평가 체계를 다룬 시스템 구축이 필요하다.  | 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. ",
        "original_sentence": "| ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "| Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 176,
        "word_count": 46,
        "page_number": 12,
        "window_text": "| 신뢰의 명시된 수준에서의 불확실성과 함께 하는 물질 | □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | (진단검사의학) | 최종락 | 대한진단검사의학회 | 양성 | 음성 | 전체 | (microarray | hybridization) | 그리 | □ 예 | ■ 아니오 |\n| 2) 효율성과 안전성에 대한 합리적인 확신을 제공하는지의 여부 | 1) 상호 : (주)오송진단시약(주) | 약물의 효능을 정확하게 예측하는 분석법임을 검증 | 유전형과 표현형을 가지며, 배양 중 언제나 그 특성을 유지 | * (예, Gail 인덱스, Framingham 위해도 점수(만성심장질환관련) 등) | - 「의료기기법」제3조 (제조업의 허가의 신청절차) | ※ 예시 : RNA input 양에 따른 Breast Cancer Alarm의 민감도 | ※ 예시 : | ③ 임상 검체의 경우 다양한 임상 상을 포함하는 검체를 포함하여 비교하도록 한다.  | 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2. ",
        "original_sentence": "| Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "| 초과)으로 설정하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 27,
        "window_text": "| 기간)이 각각 다른 경우에는 가장 짧은 제품의 기한을 기재한다.  | ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 초과)으로 설정하였다. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "| 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 177,
        "word_count": 55,
        "page_number": 12,
        "window_text": "| ③ 최종 효과지표로써 의사의 행동 변화와 같은 지표는 불충분하다.  | Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다. ",
        "original_sentence": "| 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "| 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| Cancer Related | Gens primer set | 단일구성 | 파란색캡 바이알내 | Low Priority – | 사용자가 빠르게 여러 번 | 동일 버튼을 누르면 일어날 | 수 | 있는 | 현상을 | 일반적 |\n| 하여야 하는데, 임상적 성능시험으로 검정된 검사 대상을 구체적으로 제시하여야 한다.  | 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 62,
        "word_count": 19,
        "page_number": 5,
        "window_text": "| 초과)으로 설정하였다.  | 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다. ",
        "original_sentence": "목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 118,
        "word_count": 22,
        "page_number": 12,
        "window_text": "| 유효성을 검정 | 2 |\n| 1) 측정 항목 및 검출 항목 | <  In  V itro  D ia g n o stic s M u ltiva ria te  In d e x A ssa y, IVD -M IA > | rule)이 알고리즘 개발의 핵심) | ④ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다. ",
        "original_sentence": "| 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "| 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 176,
        "word_count": 47,
        "page_number": 13,
        "window_text": "| 2.  목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다. ",
        "original_sentence": "| 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "| 의료기기로 허가·심사한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 17,
        "word_count": 3,
        "page_number": 9,
        "window_text": "목적 | 4 | 제품명 | 대상 환자군 | 검사대상 | 진단 기법 | 허가 현황 | 지침서ㆍ안내서가 있습니까?  | 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다. ",
        "original_sentence": "| 의료기기로 허가·심사한다. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "| ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 45,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| 고 스캐닝(scanning)을 포함함 |\n| 2) 정밀도(Precision) | 예시 2) 독립형 소프트웨어(유방암 예후 위험도 측정) | 알고리즘(질량분석기+알고리즘 소프트웨어)만으로 구성된 경우도 있다.  | 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다. ",
        "original_sentence": "| ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "| 보다 효과적인 방법일 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 8,
        "window_text": "| 사용자가 파라메터 버튼을 | 반복적으로 빠르게 누르면 | 화면이 | 느리게 | 움직이며 | Primer | ProsignaTM | Breast | Cancer | 무색액상 |\n| 2) 주소 : 충북 청원군 오송읍 오송생명2로 187 | 사) 개발된 알고리즘의 유효성 평가 방법은 크게 두 가지로 나눌 수 있다.  | 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다. ",
        "original_sentence": "| 보다 효과적인 방법일 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "| 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 345,
        "word_count": 89,
        "page_number": 5,
        "window_text": "| 의료기기로 허가·심사한다.  | ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3. ",
        "original_sentence": "| 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "| 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| ④ 유전자 검사 후 치료효과를 보고하도록 하는 연구 설계만으로는 불충분하다.  | 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 8,
        "window_text": "| 보다 효과적인 방법일 수 있다.  | 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30. ",
        "original_sentence": "이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "| (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 156,
        "word_count": 44,
        "page_number": 8,
        "window_text": "| 양성 | # 진양성 TP | # 위양성 FP | 진양성 + 위양성 |\n**3) 환자의 위험도 수준에 따른 제한(검사 한계, 사용시 주의사항 등)**\n| - 「의료기기법」제29조 (수입업 허가신청 등) | 다) 결과제시 | 방법 X | 체외진단다지표검사용 의료기기 | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 | Prognostic Gene Signature Assay | 는 침윤성 파라핀 포매된 유방암 | 검체를 | 대상으로 | NanoString | set | Y | N | N | N |\n| 어떠한 치료를 받지 않은 환자군으로 대상을 제한하여 알고리즘을 재검정하였습니다.  | 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다. ",
        "original_sentence": "| (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "적용 범위 | 4 | 적용되지 않는다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 5,
        "window_text": "| 한다.  이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다. ",
        "original_sentence": "적용 범위 | 4 | 적용되지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 125,
        "word_count": 36,
        "page_number": 5,
        "window_text": "이때, 제조(수입)업소명은 생략할 수 있고 제품명은 두 개 이상 인정한다.  | (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다. ",
        "original_sentence": "| 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "| 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 143,
        "word_count": 43,
        "page_number": 7,
        "window_text": "| (예, | 체외진단다지표검사용 | 의료기기(IVD-MIA)는 | 변수 | 선택 | 기법을 | 이용하는 | logistic | 일련 | 번호 | 부분품의 명칭 | 부분품 관리번호 | 규격 또는 특성 | 수량 | 비고 | 질병의 발생 및 재발의 위험을 예측하는 의료기기 | 3.  적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다. ",
        "original_sentence": "| 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 8,
        "window_text": "적용 범위 | 4 | 적용되지 않는다.  | 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다. ",
        "original_sentence": "| 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "| 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| 3 | Reference Gens | ■ 제어 | ■ 측정 | ■ 분석 | 제Ⅲ부  Q & A | primer set | 단일구성 | 보라색캡 바이알내 | 전립선 반복 | 유전자 | qRT-PCR | 2015.4.30.  | 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다. ",
        "original_sentence": "| 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| 이상의 검체를 시험하도록 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 10,
        "window_text": "| 2개 |\n| § | 구체적인 사용 검체 | 음성 | # 위음성 FN | # 진음성 TN | 위음성 + 진음성 | (영상의학) | 허용민 | 대한영상의학회 |  | ) |\n| 3) 재현성(Repeatability) | 나) 증례기록 요약 | 명시한다.  | 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다. ",
        "original_sentence": "| 이상의 검체를 시험하도록 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 65,
        "word_count": 17,
        "page_number": 12,
        "window_text": "| 다) 특정상황 하에서 제한적으로 종적 관찰연구가 허용될 수 있다.  | 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다. ",
        "original_sentence": "| 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "| Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| 다만, 일회용으로서 낱개 포장 되어있는 제품은 제외한다.  | 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다. ",
        "original_sentence": "| Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "| □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 112,
        "word_count": 35,
        "page_number": 8,
        "window_text": "| 이상의 검체를 시험하도록 권장한다.  | 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다. ",
        "original_sentence": "| □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "| 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 126,
        "word_count": 27,
        "page_number": 9,
        "window_text": "| 없다고 나타나는가”를 의미(Specificity =  |    | 무색액상 |\n| 멈춤 현상을 일으킨다.  | Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다. ",
        "original_sentence": "| 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 12,
        "window_text": "| Technology, NIST)에서 인증하고 배포한 인증참고물질 | PCA 3 Assay | 아래와 같다.  | □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다. ",
        "original_sentence": "결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "|\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 51,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| □ 진단 | □ 데이터 변환 | □ 데이터 전송 | 사용 | 시 | 일어나지 | 않는 | 생검 결정 | (수입) |\n| 판정 기준치가 수정되었다면 수정된 판정 기준치를 이용하여 재평가가 필요하다.  | 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4. ",
        "original_sentence": "|\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "| 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 78,
        "word_count": 23,
        "page_number": 12,
        "window_text": "| 가능한 특성을 가짐 | - 「의료기기법 시행규칙」제5조 (제조허가의 절차) | 두 제품이 결합돼 새로운 복합적인 기능을 발휘하는 의료기기를 조합의료기기라고 한다) | regression을 적용하여 질병의 유무를 예측한다.  결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다. ",
        "original_sentence": "| 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "| 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 119,
        "word_count": 33,
        "page_number": 7,
        "window_text": "결과가 yes/no로 나오는 경우엔 로지스틱 | 결절 양성 환자의 비율을 보여준다.  |\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다. ",
        "original_sentence": "| 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "| 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "|\n| 별도의 조합의료기기(개별 허가된 사용목적과 다른 새로운 의료기기) 허가가 필요하다.  | 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다. ",
        "original_sentence": "| 4. "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 72,
        "word_count": 18,
        "page_number": 5,
        "window_text": "| 전체 | 진양성 + 위음성 | 위양성 + 진음성 | N | 목 차(Contents) | 것으로 보인다 |\n| 합성된 유전자를 활용한다.  | 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001). ",
        "original_sentence": "기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "| □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 108,
        "word_count": 30,
        "page_number": 1,
        "window_text": "| 다) 기타 임상시험성적의 확인에 필요한 자료 | 기재되어 있어야 함 | § | 검출 · 측정의 대상이 되는 유전자명, 단백질명 | ① 이 경우 무작위대조군 연구를 시행하지 못한 것에 대한 근거가 명확해야한다.  | 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다. ",
        "original_sentence": "| □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "| 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 38,
        "word_count": 7,
        "page_number": 11,
        "window_text": "| 4.  기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다. ",
        "original_sentence": "| 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001). ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 8,
        "window_text": "기본 용어 설명 | 6 | 4 | Reference Gens | 파악하고, 편익과 부작용이 나타나는 시점을 정확히 파악해야한다.  | □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다. ",
        "original_sentence": "질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001). "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 65,
        "word_count": 18,
        "page_number": 5,
        "window_text": "| □ 데이터 수신 | □ 표시 | □ 기타 | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | primer set | 단일구성 | 흰색캡 바이알내 |\n| 맞춤의료 시대를 도래하게 하였다.  | 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다. ",
        "original_sentence": "| [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 회귀분석을 사용하고 생존모델의 경우에는 혹스회귀분석을 사용한다.  질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다. ",
        "original_sentence": "| 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 10,
        "window_text": "질병과 관련있는 | 정보임을 알 수 있다(p < 0.0001).  | [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2. ",
        "original_sentence": "| 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 151,
        "word_count": 39,
        "page_number": 2,
        "window_text": "| [IVD-MIA] 허가·심사 예시 | 유방암의 | 타 장기 |\n| F | 최악의 상황을 고려하여 시험해야 한다.  | 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다. ",
        "original_sentence": "| 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| 소프트웨어로 신청하고자 할 경우, 다음과 같이 허가․심사한다.  | 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. ",
        "original_sentence": "| 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "| (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 227,
        "word_count": 43,
        "page_number": 10,
        "window_text": "| 건국대학교병원 | 학계 | nCounterⓇ Dx 분석 시스템을 사 | 용하는 체외 진단 검사이다.  | 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다. ",
        "original_sentence": "| (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| 9개 | 무색액상 |\n| 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 13,
        "window_text": "| 이러한 | 정성분석은 | 질병의 | 윈격 | 명칭 : MFDS-IVD-MIA-02 | 버전 : 2.0 | 운영환경 |\n| 4) 특이도(Specificity) | 동작 중 측정가능 범위가 | 벗어난 | 파라미터를 잘못 | 있는 내용으로 허가시 고려되어야 할 항목이다.  | 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다. ",
        "original_sentence": "| 9개 | 무색액상 |\n| 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 49,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| 확인하였다.  | (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다. ",
        "original_sentence": "| ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "| - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 116,
        "word_count": 31,
        "page_number": 5,
        "window_text": "| (사유 :                                                                 ) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | □ A | □ B | ■ C | Low Priority – | 알고리즘의 안전한 연산이 | 가능하도록 | 파라미터의 | (진단검사의학) | 윤여민 | 대한진단검사의학회 | 제품명 | 유전자 | qRT-PCR | 2016.11.2.  | 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다. ",
        "original_sentence": "| - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 요구 | 사항 | 번호 | 자료를 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 27,
        "word_count": 9,
        "page_number": 2,
        "window_text": "| 9개 | 무색액상 |\n| 기재한다.  | ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다. ",
        "original_sentence": "| 요구 | 사항 | 번호 | 자료를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 1,
        "window_text": "| ㉮ 검사 장소(기관) 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다.  | 5. ",
        "original_sentence": "| 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 돕는 결과를 생성하는 알고리즘 포함 여부입니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 2,
        "window_text": "| - 「의료기기법 시행규칙」제6조 (제조인증의 절차) | 1) 상호 : MFDS | ① 해당 제품과 측정 원리 및 항목이 가장 유사한 국내 | ② 혼란변수를 최소화하기 위한 단계적 조치를 포함하여야 한다.  | 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다.  | 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2. ",
        "original_sentence": "| 돕는 결과를 생성하는 알고리즘 포함 여부입니다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 지침을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 요구 | 사항 | 번호 | 자료를 제공한다.  | 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다.  | 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4. ",
        "original_sentence": "| 지침을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 9,
        "window_text": "| 허가·심사 가이드라인 (민원인 안내서) | 결과 |\n| 알고리즘으로 구현된 하나의 결과값은 안정성과 유효성을 확보해야 한다.  | 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다.  | 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다. ",
        "original_sentence": "| 5. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 5,
        "window_text": "| 돕는 결과를 생성하는 알고리즘 포함 여부입니다.  | 지침을 제시한다.  | 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요? ",
        "original_sentence": "관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "정상조직 포함에 따른 ROR score 비교> | 그림 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 5,
        "window_text": "| 지침을 제시한다.  | 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다. ",
        "original_sentence": "정상조직 포함에 따른 ROR score 비교> | 그림 4. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 188,
        "word_count": 52,
        "page_number": 5,
        "window_text": "| 5.  관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다. ",
        "original_sentence": "RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "| 있나요? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 43,
        "window_text": "관련 법령 | 13 | 지표와 바이오마커들의 principal component를 이용해 판별 분석을 시행하면 결과를 | 단독 투여된 환자 | <그림 2.  정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다. ",
        "original_sentence": "| 있나요? "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "| 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 10,
        "window_text": "정상조직 포함에 따른 ROR score 비교> | 그림 4.  RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. ",
        "original_sentence": "| 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| 구성하는 다양한 단백질이 형성되는 과정 | 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 10,
        "window_text": "RNA 추출에 대한 재현성 실험 디자인 |\n| 5 | Prep Sol | 3개 바이알로 | 유방암 예후 | 위험도 측정 | 소프트웨어 | · MFDS-IVD-MIA-RM-Software Safety Class | 요구사항 | 시험방법 | 녹색캡 바이알내 | 비고 | 시험자 | 1 | 2 | (제조) |\n| ※ (예시 : | 불가하다.  | 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다. ",
        "original_sentence": "| 구성하는 다양한 단백질이 형성되는 과정 | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 68,
        "word_count": 19,
        "page_number": 2,
        "window_text": "| 있나요?  | 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다. ",
        "original_sentence": "| 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 9,
        "window_text": "| 평가하기 어려운 경우, 검사의 임상적 유효성을 보여주는 임상적 자료를 제출하도록 한다.  | 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임. ",
        "original_sentence": "| 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "| 알고리즘의 임상적 성능이 떨어질 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 8,
        "window_text": "| 구성하는 다양한 단백질이 형성되는 과정 | 평가한다.  | 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다. ",
        "original_sentence": "| 알고리즘의 임상적 성능이 떨어질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 94,
        "word_count": 29,
        "page_number": 8,
        "window_text": "| 비교방법 | □ 예 | ■ 아니오 |\n| 허가·심사시 요구되는 기술문서 작성과 첨부자료 요건의 확인을 목적으로 한다.  | 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다. ",
        "original_sentence": "| 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 55,
        "word_count": 16,
        "page_number": 2,
        "window_text": "| 입력하고 | 계산 아이콘을 | ② 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다. ",
        "original_sentence": "| ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 40,
        "word_count": 13,
        "page_number": 10,
        "window_text": "| 알고리즘의 임상적 성능이 떨어질 수 있다.  | 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "| 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "| <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 90,
        "word_count": 29,
        "page_number": 12,
        "window_text": "| 전이 위험도 |\n| 5) 정량 범위 또는 검출 한계 등의 측정 범위 및 선형선 구간 | ㉯ 장소 간 정밀도를 위해 두 군데 이상의 기관(제조사 포함)에서 평가한다.  | ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3. ",
        "original_sentence": "| <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "| 예측할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| ① 그대로 보고 또는 재검사 필요 여부 | 이해를 돕기 위해 사용되는 것이므로 단순 참고용임.  | 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다. ",
        "original_sentence": "| 예측할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 79,
        "word_count": 16,
        "page_number": 2,
        "window_text": "| 2) 제조국 : 미국 | 1 | ③ 레지스트리 연구 등을 포함한다.  | <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다. ",
        "original_sentence": "로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "| 그림 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 5,
        "window_text": "| <  In  V itro  D ia g n o stics M u ltiva ria te  In d e x A ssa y, IVD -M IA > | 실시한다.  | 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다. ",
        "original_sentence": "| 그림 3. "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 476,
        "word_count": 118,
        "page_number": 9,
        "window_text": "| 예측할 수 있다.  로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다. ",
        "original_sentence": "RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 108,
        "word_count": 26,
        "page_number": 11,
        "window_text": "로지스틱 회귀분석, 혹스회구분석을 이외의 다양한 통계학적 방법들 | 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  | 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26. ",
        "original_sentence": "| ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| 개발한 경우, 조합의료기기로 허가․심사한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| 그림 3.  RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. ",
        "original_sentence": "| 개발한 경우, 조합의료기기로 허가․심사한다. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 82,
        "word_count": 18,
        "page_number": 9,
        "window_text": "RNA 혼합물에 대한 재현성 실험 디자인 | MFDS-IVD-MIA-02 | 구성 | - OS: Windows 7 64bit | - CPU: Core 2 Duo 3.0G 이상 | - RAM : 4Gbyte | - Network : 10/100Mbps | Y | N | N | N | 무색액상 | 1EA |\n| 더블 클릭할 경우, 알고 | 리즘 | 결과치가 산출되는 | - 「의료기기법 시행규칙」제7조 (제조신고의 절차) | 삼성서울병원 | 학계 | 2) Breast Cancer Alarm score의 위험도 추정 | ‘Multiplex PCR Pattern Analysis for Breast Cancer Risk’ 키트의 20개 유전자의 발현량 | 을 알고리즘으로 재해석하여 유방암 예후를 분석하는 소프트웨어 | 재발 위험을 평가하기 위해서 위험 | 군 분류와 구체적인 점수에 필요 | 한 임상적 요인들와 함께 유전자 | 발현 데이터를 이용한다.  | ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다. ",
        "original_sentence": "| System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 118,
        "word_count": 28,
        "page_number": 27,
        "window_text": "| ProsignaTM | Breast | Cancer | 정량값을 하나씩 입력하면 | 오류현상을 | 막을수 | 있을 |\n| 구상의 주요 원동력으로 의료산업에서 전략적인 투자가 확대되고 있다.  | 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다. ",
        "original_sentence": "| (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 63,
        "word_count": 18,
        "page_number": 8,
        "window_text": "| 개발한 경우, 조합의료기기로 허가․심사한다.  | System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다. ",
        "original_sentence": "| 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 39,
        "word_count": 11,
        "page_number": 2,
        "window_text": "| System이 초기화하는 동안 필요한 | 정보를 Controller Firmware로부 | 터 전달받고, 화면에는 진행 상 | 태를 보여준다.  | (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다. ",
        "original_sentence": "| 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| (메인화면->System Log-> | 사용자모드) | 비소세포성 | 폐암 위험도 | (병리학) | 최윤라 | 대한병리학회 | 양성 | 음성 | 전체 | 단백질 | Microarray | 2017.9.26.  | 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다. ",
        "original_sentence": "이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 106,
        "word_count": 29,
        "page_number": 1,
        "window_text": "| 7개 |\n| 2) 임상적 의의 | ③ 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다. ",
        "original_sentence": "| 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 70,
        "word_count": 19,
        "page_number": 10,
        "window_text": "| 제 II부  허가·심사시 고려사항 | 15 | 도 사용 가능하다.  이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다. ",
        "original_sentence": "| 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 51,
        "word_count": 8,
        "page_number": 9,
        "window_text": "이러한 방법으로 생성된 예측 모델의 성능은 민감도와 특이도로 | 비율을 의미한다.  | 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다. ",
        "original_sentence": "| 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| 질병의 예후·예측에 사용되는 체외진단용 의료기기 | 장비를 | 켜고 | Self | Test화면을 |\n| ㉰ 5일 이상, 매일 2회 이상, 매 검사마다 2회 이상 반복 검사를 실시한다.  | 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다. ",
        "original_sentence": "| 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 14,
        "window_text": "| 관련 증빙자료를 함께 제출하여야 함 | 유의성이 있음을 입증하는 자료로 그 타당성이 판단되는 경우 이를 인정할 수 있다.  | 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다. ",
        "original_sentence": "| ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| ④ 2차원 자료를 이용한 후향적 분석은 부적절하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 11,
        "window_text": "| 2) 관리운용기술(System Description) | 대한 실험프로토콜을 제공한다.  | 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다. ",
        "original_sentence": "| ④ 2차원 자료를 이용한 후향적 분석은 부적절하다. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "| 고려해야할 항목이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 14,
        "window_text": "| 3) 주소 : 0000 U.S Highway 000, CA 0000, USA | 평가한다.  | ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다. ",
        "original_sentence": "| 고려해야할 항목이다. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "| 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 66,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| ② 가능한 2개 이상의 회사 제품과 비교 시험할 것을 권장한다.  | ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다. ",
        "original_sentence": "| 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다. "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "| (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 52,
        "word_count": 15,
        "page_number": 15,
        "window_text": "| ④ 2차원 자료를 이용한 후향적 분석은 부적절하다.  | 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다. ",
        "original_sentence": "| (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 85,
        "word_count": 27,
        "page_number": 2,
        "window_text": "| 고려해야할 항목이다.  | 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다. ",
        "original_sentence": "| ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 84,
        "word_count": 18,
        "page_number": 12,
        "window_text": "| 6 | Prep Plate | 3*96well/kit | 흰색의 PP재질 | 음성예측도(NPV)는 96.6%이다.  | (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다. ",
        "original_sentence": "| Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| 유효성을 동시에 검토해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 10,
        "window_text": "| (다운로드 형태) |\n| F | 하한 참고치와 상한 참고치 간의 간격으로 명시되어 있다.  | ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 유효성을 동시에 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "| 오류가 나타남 | 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| ② 재검사는 동일 검체로, 동일 원검체를 다시 처리 또는 재채취 필요 여부 | SRS-1 | (초기 | 화면) | 제 I 부  개 요 | 확인한다.  | Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다. ",
        "original_sentence": "| 오류가 나타남 | 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| 분석 및 임상 데이터 검토가 이뤄져야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 10,
        "window_text": "| Service의 Log화면에서 System | Log를 | 확인, | 초기사용자모드 |\n| reviewer)가 동의할 수 있는 내용이어야 합니다.  | 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다. ",
        "original_sentence": "| 분석 및 임상 데이터 검토가 이뤄져야 한다. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 2,
        "window_text": "| 유효성을 동시에 검토해야 한다.  | 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다. ",
        "original_sentence": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 53,
        "word_count": 21,
        "page_number": 2,
        "window_text": "| 오류가 나타남 | 권장한다.  | 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 126,
        "word_count": 33,
        "page_number": 1,
        "window_text": "| 분석 및 임상 데이터 검토가 이뤄져야 한다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가. ",
        "original_sentence": "| 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 118,
        "word_count": 35,
        "page_number": 15,
        "window_text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다. ",
        "original_sentence": "| [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "| 유전자의 품질(DNA 또는 RNA Quality)을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 8,
        "window_text": "| □ 예 | ■ 아니오 | Lung | 양성 | a | b | a + b | 것으로 보인다.  | 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev. ",
        "original_sentence": "| 유전자의 품질(DNA 또는 RNA Quality)을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 8,
        "window_text": "| 허가·심사 가이드라인 (민원인 안내서) | MammaPrint는 한 시험소에서 환자 | 의 원격 전이 위험성을 평가하기 | 위해 신선 동결 유방암 검체의 유전 | 자 발현을 분석하는 체외 진단용 | 정성 검사 서비스이다.  | [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al. ",
        "original_sentence": "| 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 126,
        "word_count": 24,
        "page_number": 8,
        "window_text": "| [ ]P | [ ]F | [ ]P | [ ]F | (제조) | (시험보고서 | TX-1 참고) |\n| - 「의료기기법 시행규칙」제9조 (기술문서 등의 심사) | 전문가 그룹의 자문 등을 거칠 것을 권장한다.  | 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1. ",
        "original_sentence": "작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| Rev. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 유전자의 품질(DNA 또는 RNA Quality)을 기재한다.  | 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다. ",
        "original_sentence": "| Rev. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "0 |\n| 후보 검사법 | tumor specimens, Nielsen et al. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 12,
        "window_text": "| 발   행   처 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 가.  작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다. ",
        "original_sentence": "0 |\n| 후보 검사법 | tumor specimens, Nielsen et al. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "BMC Cancer 2014, 14:177) | 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 5,
        "window_text": "작동모드: 자동화 | 판단할 수 있으며, cross-validation을 통한 내부 검정(internal validation)을 시행할 수 | 재발률)와 실제 결과(발병 또는 재발)가 어느 정도 일치하는지 확인하는 방법이다.  | Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다. ",
        "original_sentence": "BMC Cancer 2014, 14:177) | 1. "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 160,
        "word_count": 31,
        "page_number": 8,
        "window_text": "| Rev.  0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1. ",
        "original_sentence": "체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 72,
        "word_count": 21,
        "page_number": 5,
        "window_text": "0 |\n| 후보 검사법 | tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다. ",
        "original_sentence": "| ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "| ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 13,
        "window_text": "BMC Cancer 2014, 14:177) | 1.  체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다. ",
        "original_sentence": "| ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "| 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 103,
        "word_count": 28,
        "page_number": 12,
        "window_text": "체외진단다지표 검사용 의료기기(IVD-MIA)의 허가·심사시 | 7 | BCA Risk Score(Software) | CD | Mini Disk | 보드(Boards) | 소프트웨어 버전(Software Version) |\n| ㉱ 각 장소마다 다수의 검사자가 평가에 참여하도록 한다.  | ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다. ",
        "original_sentence": "| 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 89,
        "word_count": 19,
        "page_number": 8,
        "window_text": "| ③ 결과 판독을 위한 알고리즘 제시 | ※ 예시 : 3 종류의 대조군을 사용하여 시험의 각 단계에 이상이 없음을 확인하였다.  | ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다. ",
        "original_sentence": "사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| ③ 비교 제품은 각 제품의 사용방법에 따라서 시험한다.  | 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다. ",
        "original_sentence": "바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 84,
        "word_count": 27,
        "page_number": 10,
        "window_text": "| 씨젠의료재단 | 학계 | <  In V itro  D iag no stics M ultivariate Ind ex A ssay, IV D -M IA  > |\n| Chapter 1.  사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10. ",
        "original_sentence": "내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "| 제외)을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 15,
        "window_text": "사용변수(바이오마커)의 선별 근거 및 선별된 사용변수 | 국제 표준품을 이용하여 측정할 것을 권장) | - 예측도(Predictive values) | 있다.  바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다. ",
        "original_sentence": "| 제외)을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 73,
        "word_count": 18,
        "page_number": 8,
        "window_text": "바이오마커의 선택과 적합 모델의 선정 등 모든 경위를 검토해야 한다.  내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다. ",
        "original_sentence": "| cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "| 유전자 | qRT-PCR | 2017.11.10. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 30,
        "word_count": 6,
        "page_number": 5,
        "window_text": "내부 | 음성 | c | d | c + d | 사용된 SOUP | 버전 |\n| 오마커에 대한 정량범위(직선성)에 대한 성능 시험이 불필요할 수 있다.  | 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요? ",
        "original_sentence": "| 유전자 | qRT-PCR | 2017.11.10. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "|\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 71,
        "word_count": 19,
        "page_number": 2,
        "window_text": "| 제외)을 제시한다.  | cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다. ",
        "original_sentence": "|\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "| DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 12,
        "window_text": "| cancer assay | 위암 예후 | 9개 | (분자진단) | 노경호 | 대한진단검사의학회 | 00화면으로 자동전환 된다.  | 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al. ",
        "original_sentence": "| DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 82,
        "word_count": 25,
        "page_number": 2,
        "window_text": "| 유전자 | qRT-PCR | 2017.11.10.  |\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다. ",
        "original_sentence": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요? "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 8,
        "window_text": "|\n| 관계를 확립하는 일련의 조작 | 번호 | 명칭 | 주요기능 | 성(경향성)을 기반하여 통계적 방법의 알고리즘을 만든다.  | DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다. ",
        "original_sentence": "| ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 77,
        "word_count": 14,
        "page_number": 5,
        "window_text": "| DNA가 제대로 제거되지 않을 경우 간섭반응이 일어남을 확인하였다.  | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다. ",
        "original_sentence": "| - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al. "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 5,
        "window_text": "| □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | Window 7 | 제정 | □ 예 | ■ 아니오 |\n| 어떻게 이루어지나요?  | ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다. ",
        "original_sentence": "BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 8,
        "window_text": "| ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.  | - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다.  | 표 1. ",
        "original_sentence": "| ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "| 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 2,
        "window_text": "| - 「의료기기법 시행규칙」제20조 (임상시험계획의 승인 등) | breast tumor specimens, Nielsen et al.  BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다.  | 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다. ",
        "original_sentence": "| 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| 필요하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 82,
        "window_text": "BMC Cancer 2014, 14:177) | 평가를 수행하도록 한다.  | ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다.  | 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다. ",
        "original_sentence": "| 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 표 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 36,
        "window_text": "| ④ 정량검사의 경우 각 검사를 2회 이상 반복수행을 권장한다.  | 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다.  | 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다. ",
        "original_sentence": "| 표 1. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 125,
        "word_count": 30,
        "page_number": 8,
        "window_text": "| 주요 고려사항 | 15 | 시스템 제어부 | 음성환자의 비율을 보여준다.  | 필요하다.  | 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다.  | 내용입니까? ",
        "original_sentence": "RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "| 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 193,
        "word_count": 49,
        "page_number": 5,
        "window_text": "| 필요하다.  | 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다.  | 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다. ",
        "original_sentence": "| 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다. "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "| 예방 등)이 있는 것이 바람직하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 8,
        "window_text": "| 표 1.  RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다.  | 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다. ",
        "original_sentence": "| 예방 등)이 있는 것이 바람직하다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| 내용입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 9,
        "word_count": 2,
        "page_number": 2,
        "window_text": "RNA input 양에 따른 ROR score 차이점 |\n| ① 논문 등을 참고문헌으로 하거나 직접적인 사용변수 선별 근거를 기술 | (System Control Board) | 1.00 | 국내 유병률을 고려하여야 한다.  | 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다.  | 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다. ",
        "original_sentence": "| 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 63,
        "word_count": 13,
        "page_number": 12,
        "window_text": "| 위음성 결과를 야기할 수 있는 물질 | 발   행   일 | 2018년 8월 | 검정에서 뛰어난 성능을 확인하면, 외부 검정(external validation, 임상시험)을 통해서도 | 전체 | a + c | b + d | n | Network(LANs) | (제조) |\n| 각각의 유전자 발현값을 최소검출한계로 설정하는 것이 보편적이다.  | 예방 등)이 있는 것이 바람직하다.  | 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다. ",
        "original_sentence": "| 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| 고려돼야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 예방 등)이 있는 것이 바람직하다.  | 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다. ",
        "original_sentence": "| 고려돼야 한다. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 8,
        "window_text": "| 내용입니까?  | 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다. ",
        "original_sentence": "| Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "|\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 58,
        "word_count": 12,
        "page_number": 5,
        "window_text": "| 사용자 화면에서 저장 화면을 | 클릭하면, | 사용자설정화면으로 |\n| 음성예측도(NPV)는 94.2%이다.  | 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다. ",
        "original_sentence": "|\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 2,
        "window_text": "| 고려돼야 한다.  | Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다. ",
        "original_sentence": "| 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 10,
        "window_text": "| Prognostic Gene Signature Assay | 는 수술과 함께 국소적인 치료를 | 받은 여성 유방암 환자를 대상으 | 로 한다.  |\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다. ",
        "original_sentence": "| 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 2,
        "window_text": "|\n| 6) 분석적 판별기준(Analytical Cut-off) | 한함) | 방향을 제시하고자 한다.  | 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "| 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 10,
        "window_text": "| 쓰여진 용도에서 안전성과 유효성의 적용 기준 충족 여부를 검토해야 한다.  | 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다. ",
        "original_sentence": "| 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "| 알고리즘의 검정을 실시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 라) 임상적 유용성은 비용효과분석 연구결과 제시가 권고된다.  | 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다. ",
        "original_sentence": "| 알고리즘의 검정을 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 106,
        "word_count": 28,
        "page_number": 9,
        "window_text": "| 본질적 동등품목 비교표)를 이용하여 이미 허가받은 사항과 비교한다.  | 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다. ",
        "original_sentence": "단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "| □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 33,
        "word_count": 11,
        "page_number": 2,
        "window_text": "| 시험이 시행되며 시험 검체의 각 신호를 비교하기 위해 사용되었다.  | 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "| <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 97,
        "word_count": 27,
        "page_number": 5,
        "window_text": "| 알고리즘의 검정을 실시한다.  단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다. ",
        "original_sentence": "| <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 8,
        "window_text": "단, 검정에 대한 성공 기준을 질병 및 대상군에 따라 | 나이, 몸무게, 인종 등의 정보를 종합하여 태아의 유전질환 발생 위험도를 검사) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다. ",
        "original_sentence": "| 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "| ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 112,
        "word_count": 31,
        "page_number": 10,
        "window_text": "| □ 예 | ■ 아니오 | 때문에 제외하는 경우가 많다.  | <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다. ",
        "original_sentence": "| ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 2,
        "window_text": "| <그림 1> 마이크로어레이를 이용한 바이오마커 선별 | <표 6> RNA 추출에 대한 재현성 시험 결과 |\n| ② 선별에 사용된 통계적 분석 방법들을 제시 | 제시한다.  | 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다. ",
        "original_sentence": "공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 51,
        "word_count": 14,
        "page_number": 5,
        "window_text": "| 1 | 데이터의 수집 | 의료기기에서 측정한 데이터를 수집한다.  | ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다. ",
        "original_sentence": "출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 97,
        "word_count": 29,
        "page_number": 14,
        "window_text": "| ㈜씨젠 | 제조 |\n| 2) 임상적 특이도 | 물질만 측정되고 검체 내 다른 물질은 측정되지 않는 분석법의 성능 | - 「의료기기법 시행규칙」제21조 (임상시험기관 지정기준 및 절차 등) | 2.  공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다. ",
        "original_sentence": "| 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 62,
        "word_count": 15,
        "page_number": 9,
        "window_text": "공통 고려사항 | 16 | (분자진단) | 고성일 | 한국의료기기산업협회 | 전환한다.  출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다. ",
        "original_sentence": "| SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 및 알고리즘으로부터 나온 score를 산출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 12,
        "window_text": "출력관련 파라미터를 | 설정하고 M1의 저장 버튼을 3 | 초 누르면 삐삐 소리를 울린다.  | 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다. ",
        "original_sentence": "| 및 알고리즘으로부터 나온 score를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "| 대해서는 색, 성상, 액성, 냄새 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 8,
        "window_text": "| 다시 다른 파라미터로 변경하고 | M1을 | 누르면 | 이전에 | 저장된 |\n| F 역가는 주로 분석물질 농도에 비례 | 취소된 날로부터 1년이 지난 경우 | 명시한다.  | SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. ",
        "original_sentence": "| 대해서는 색, 성상, 액성, 냄새 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "| 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 51,
        "word_count": 12,
        "page_number": 36,
        "window_text": "| SRS-2 | (부가 | 기능) | 데이터 분석 모듈 | 검사용 의료기기(IVD-MIA)임을 명확히 한다.  | 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다. ",
        "original_sentence": "| 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "| 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 142,
        "word_count": 32,
        "page_number": 15,
        "window_text": "| 및 알고리즘으로부터 나온 score를 산출한다.  | 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다. ",
        "original_sentence": "| 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 172,
        "word_count": 53,
        "page_number": 5,
        "window_text": "| 대해서는 색, 성상, 액성, 냄새 등을 기재한다.  | 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다. ",
        "original_sentence": "| 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| 검체에 대한 원인을 분석하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 저장화면에서 사용자가 파라미터를 | 저장 가능하고 재소환시 저장된 | 화면이 나타난다.  | 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다. ",
        "original_sentence": "| 검체에 대한 원인을 분석하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "| 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 66,
        "word_count": 19,
        "page_number": 8,
        "window_text": "| 소프트웨어 개발 규격, 방법 및 개발 툴을 포함한 소프트웨어 개발, 검증, |\n| 반응을 비교하기 위해서 사용되는 체외진단용 시약 | - 임상적 민감도와 특이도(Clinical Sensitivity & Specificity) | 달리 설정해야 한다.  | 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다. ",
        "original_sentence": "| 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| 자료를 제공하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 소프트웨어 | <표 3> DNase 처리 유무에 따른 ROR score 차이 비교 | <표 5> RNA 혼합물에 대한 재현성 시험 결과 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-2 참고) |\n| ㉮ 검사장소 간, 장비 간, 검사자 간, 로트 간 정밀도 자료를 제시한다.  | 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다. ",
        "original_sentence": "| 자료를 제공하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "|  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 108,
        "word_count": 27,
        "page_number": 12,
        "window_text": "| 검체에 대한 원인을 분석하여야 한다.  | 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다. ",
        "original_sentence": "|  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "| 분해능(resolution)에 비하여 큰 차이여야 함 | 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 12,
        "window_text": "| 발   행   인 | 이선희 | ① 연구 설계 또는 자료원에 따른 위계 | (소프트웨어)의 검정을 다시 해야한다.  | 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다. ",
        "original_sentence": "| 분해능(resolution)에 비하여 큰 차이여야 함 | 다. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| 자료를 제공하여야 한다.  |  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다. ",
        "original_sentence": "검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다. "
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 71,
        "word_count": 19,
        "page_number": 2,
        "window_text": "|  |\n| F 양성 일치율(Percent Positive Agreement, PPA) =  × |   | 가) 시험물질 | 마커 또는 다중 바이오마커의 개발까지 요구되고 있다.  | 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다. ",
        "original_sentence": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "| 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 2,
        "window_text": "| 분해능(resolution)에 비하여 큰 차이여야 함 | 다.  검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3. ",
        "original_sentence": "| 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "| 유전자 수를 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 8,
        "window_text": "검체 식별 : 각 검체 식별을 위한 정보는 수동으로 컴퓨터 응용 프로그램에 등록된다.  | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다. ",
        "original_sentence": "| 유전자 수를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "| 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 41,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | 위험관리, 형상관리, 문서화 계획 등은 아래문서를 참조한다.  | 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다. ",
        "original_sentence": "| 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "| 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "| 림프절 | 전이 | 음성, | 종양크기가 | □ 예 | ■아니오 |\n| 사용목적 | - 「의료기기법 시행규칙」제30조 (수입허가 신청 등) | 체외진단용 의료기기 다지표 검사와 비교 시험성적서 첨부를 권장한다.  | 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가. ",
        "original_sentence": "| 3. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 74,
        "word_count": 16,
        "page_number": 2,
        "window_text": "| 유전자 수를 기재한다.  | 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다. ",
        "original_sentence": "사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "| 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 101,
        "word_count": 28,
        "page_number": 8,
        "window_text": "| 2 | 데이터의 저장 및 삭제 | 수집된 데이터를 저장 및 삭제한다.  | 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다. ",
        "original_sentence": "| 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 8,
        "window_text": "| 3.  사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다. ",
        "original_sentence": "| 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "추가 검사 수행 | 위양성 결과를 보이는지 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 8,
        "window_text": "사용목적 설정시 주요 고려사항 | 17 | Breast Cancer Alarm score와 임상적 결과의 상관관계에 따라 확인한다.  | 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까? ",
        "original_sentence": "추가 검사 수행 | 위양성 결과를 보이는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "| 제출자료가 면제될 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 8,
        "window_text": "| 개발 계획 |\n| ④ 통계분석을 통하여 선별된 사용변수들과 선별 시 임상통계 결과들을 제시 | ㉮ 측정하고자 하는 물질을 포함하는 검체나 표준품에 준한 물질을 사용할 수 있다.  | 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다. ",
        "original_sentence": "| 제출자료가 면제될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "| 각 검체에 혼합하여 사용하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 10,
        "window_text": "| 소프트웨어 안전성 등급 | (Software Safety Level) | C | 가.  추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다. ",
        "original_sentence": "| 각 검체에 혼합하여 사용하였다. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 47,
        "word_count": 10,
        "page_number": 2,
        "window_text": "추가 검사 수행 | 위양성 결과를 보이는지 확인한다.  | 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다. ",
        "original_sentence": "| ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 109,
        "word_count": 24,
        "page_number": 10,
        "window_text": "| 제출자료가 면제될 수 있다.  | 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다. ",
        "original_sentence": "| · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "|\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 9,
        "window_text": "| 각 검체에 혼합하여 사용하였다.  | ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다. ",
        "original_sentence": "|\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "| ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 10,
        "window_text": "| ㉮ 무작위대조군 연구(특히 무작위대조군 연구의 메타분석) | 정리한 자료입니까?  | · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다. ",
        "original_sentence": "| ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "| (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 9,
        "window_text": "| · MFDS-IVD-MIA-SDP : Software Development Plan | 5cm 이하, Stage I 또는 II를 가진 | 61세 이하의 유방암 환자를 대상 | 으로 검사한다.  |\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다. ",
        "original_sentence": "| (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| 허가받은 알고리즘의 검정을 다시 평가해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 15,
        "window_text": "|\n| 정상적으로 사용했을 경우 결과에 대한 신뢰성을 제공 | 정량값 판정 등의 기준을 제시한다.  | ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4. ",
        "original_sentence": "| 허가받은 알고리즘의 검정을 다시 평가해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "|\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 106,
        "word_count": 29,
        "page_number": 9,
        "window_text": "| ① 검체는 적용하고자 하는 대상 인구집단을 반영하여야 한다.  | (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다. ",
        "original_sentence": "|\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "| 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 68,
        "word_count": 23,
        "page_number": 5,
        "window_text": "| (의료공학) | 손종은 | 한국의료기기산업협회 |\n| 제시하여야 한다.  | 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나. ",
        "original_sentence": "| 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "| 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "| 허가받은 알고리즘의 검정을 다시 평가해야 한다.  |\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다. ",
        "original_sentence": "| 4. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 2,
        "window_text": "|\n| ※ 예시 : ∼ 유방암 조직에 대한 유방암 관련 58개의 유전자의 발현량을 ∼ | 림프노드 전이유무 | BCA Score Range | 위험 수준 | number) 등으로 설정한다.  | 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다. ",
        "original_sentence": "체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "|  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 72,
        "word_count": 19,
        "page_number": 12,
        "window_text": "| 편 집 위 원 장 | 오현주 | 3 | 데이터의 표시 | 수집된 데이터를 요약, 일, 주, 월, 년 등으로 표시한다.  | 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "|  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 40,
        "word_count": 11,
        "page_number": 8,
        "window_text": "| 4.  체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "<부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 2,
        "window_text": "체외진단다지표 검사용 의료기기(IVD-MIA)의 성능 평가 | 17 | 소프트웨어 요구사항 수립, 위험통제 수단수립 및 위험분석 재평가, 소프트 | 값으로 나타난다.  |  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1. ",
        "original_sentence": "<부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 55,
        "word_count": 14,
        "page_number": 2,
        "window_text": "|  |\n| F 음성 일치율(Percent Negative Agreement, PNA) =  × |    | 나.  다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. ",
        "original_sentence": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 2,
        "window_text": "다른 방법이나 표지자의 이용 | 대해 보다 상세한 이해를 돕고자 한다.  <부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "| 소프트웨어 | 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 36,
        "window_text": "<부록 참고> | - 「의료기기법 시행규칙」제42조 (용기 등의 기재사항) | 분석법의 반응과 측정되는 특성과의 관계를 설정하는데 사용 가능 | 기기 내에서 12 단계를 거쳐 처리된다.  | ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다. ",
        "original_sentence": "| 소프트웨어 | 1. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 131,
        "word_count": 37,
        "page_number": 8,
        "window_text": "| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다. ",
        "original_sentence": "내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "| 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 76,
        "word_count": 18,
        "page_number": 9,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다. ",
        "original_sentence": "| 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "| 변환할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 8,
        "window_text": "| 소프트웨어 | 1.  내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2. ",
        "original_sentence": "| 변환할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "| ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 52,
        "word_count": 20,
        "page_number": 2,
        "window_text": "내분비보조치료만 받은 호르몬 | 수용체 양성, 림프절 전이 음성, | Stage 1 또는 2 유방암인 폐경 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 |\n| ㉯ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다. ",
        "original_sentence": "| ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "| 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 158,
        "word_count": 33,
        "page_number": 8,
        "window_text": "| 대한 자료를 제출 | 분석하여 재현성을 평가하는 시험(정밀도는 반복성, 재현성, 강건성을 포함한다) | 시험항목을 설정할 수 있다.  | 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다. ",
        "original_sentence": "| 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 12,
        "window_text": "| 변환할 수 있다.  | ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가. ",
        "original_sentence": "| 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 80,
        "word_count": 23,
        "page_number": 2,
        "window_text": "| ㉯ 무작위 배정 단일암 연구 | 구분 | 작성 | 검토 | 승인 |  |\n| 수 있다.  | 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다. ",
        "original_sentence": "진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| 1) Breast Cancer Alarm score 또는 Breast Cancer Alarm risk group의 유의성 확인 | Positive Predictive Value(PPV) =  |   | 웨어 요구사항 검증방법 등 요구사항 관련 내용은 아래문서를 참조한다.  | 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다. ",
        "original_sentence": "환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "| 휴마시스(주) | 학계 | 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 8,
        "window_text": "| 알고리즘 | 검정에서 | 피험자에 |\n| Chapter 2.  진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다. ",
        "original_sentence": "| 휴마시스(주) | 학계 | 가. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 64,
        "word_count": 18,
        "page_number": 5,
        "window_text": "진단 방법(알고리즘) 개발 과정 및 통계모델에 대한 설명과 분석 결과 | 구분하는 경우 | 요구사항 분석 | 0-60 | 저위험군 |\n| 다.  환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다. ",
        "original_sentence": "알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "| 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 213,
        "word_count": 46,
        "page_number": 13,
        "window_text": "환자의 임상상태나 진단명 검토 | ※ 상기 시험을 아래의 정보가 함께 제시돼야 한다.  | 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다. ",
        "original_sentence": "| 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "|\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 11,
        "window_text": "| 휴마시스(주) | 학계 | 가.  알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다. ",
        "original_sentence": "|\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "| 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 9,
        "window_text": "알고리즘 설계 및 내부 검정(평가) | 17 | 대장암 등)에 대한 소인, 예후를 예측하는데 도움을 줄 수 있다.  | 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다. ",
        "original_sentence": "| 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 13,
        "window_text": "| 파라미터를 입력한 알고리즘의 | 산술식의 결과와 소프트웨어에서 | 산출된 | 결과가 | 일치하는지를 | <체외진단기기과> | · MFDS-IVD-MIA-SRS : Software Requirement Specification | 대한 바이오마커의 정량 또는 | 정성 결과를 알고리즘으로 산 | 출하였을 때, 소프트웨어의 파 | 라미터를 입력한 값과 동일한 | 결과가 나타난다.  |\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다. ",
        "original_sentence": "| 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "| 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 65,
        "word_count": 20,
        "page_number": 5,
        "window_text": "|\n| ㉰ 정량검사의 경우 측정범위의 낮은값, 중간값, 높은값을 모두 포함하도록 한다.  | 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다. ",
        "original_sentence": "| 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "| SRS-3 | 실험하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 17,
        "word_count": 4,
        "page_number": 5,
        "window_text": "| 결정하는데 사용되는 측정물질의 정량값 | * (예, CFTR 유전자형 분석 등) | ※ 예시 : | 그 결과 자료(raw data)를 제출한다.  | 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다. ",
        "original_sentence": "| SRS-3 | 실험하였다. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "| ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 12,
        "window_text": "| 되고 영향을 받는 경우는 간섭물질을 희석하여 재검사한다.  | 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다. ",
        "original_sentence": "| ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "|\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "| 하는 방법을 상세히 기재하고 | 4 | 디바이스 등록 및 해제 | 연동되는 의료기기를 등록 및 해제할 수 있다.  | SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다. ",
        "original_sentence": "|\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 200,
        "word_count": 57,
        "page_number": 5,
        "window_text": "| SRS-3 | 실험하였다.  | ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라. ",
        "original_sentence": "| (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "| 관리 계획을 확보하고 있어야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| ㉰ 무작위 배정 없는 대조군 연구 | 유병율을 고려하여 통계적으로 타당한 근거를 제시한다.  |\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다. ",
        "original_sentence": "| 관리 계획을 확보하고 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "| 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 145,
        "word_count": 39,
        "page_number": 2,
        "window_text": "|\n| 림프노드 전이 음성 | - 「의료기기법 시행규칙」제43조 (첨부문서의 기재사항) | 필요하지 않다.  | (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1. ",
        "original_sentence": "| 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "|\n| 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| (컴퓨터공학) | 안무경 | 한국바이오협회 | 61-100 | 중간 위험군 |   | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| F 총 일치율(Overall percent agreement) =  × |  | 항원 결정기를 가진 항원과 항체가 반응하는 현상 | (주 | 고려할 것을 권장한다.  | 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바. ",
        "original_sentence": "|\n| 라. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 244,
        "word_count": 59,
        "page_number": 8,
        "window_text": "| 관리 계획을 확보하고 있어야 한다.  | 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다. ",
        "original_sentence": "추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "| 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| 성명 | 김○○ | 이○○ | 박○○ | 소프트웨어 구현은 요구사항을 구현하기 위한 각 아키텍처 설계와 이에 대한 | <그림 3> LOOCV 개념도 | MammaPrint 결과는 다른 임상 | 병리학적인 요소와 함께 예후 지 | 표로써, 의사가 사용한다.  |\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 9,
        "window_text": "|\n| 라.  추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다. ",
        "original_sentence": "시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "품질관리: 품질관리를 위해 아래 항목을 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 10,
        "window_text": "추적 검사 수행 | <그림 5 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 과정> | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | 이원규, 류승렬, 우승민, 이용경, 서두원, 정재연, 김현홍, 손미진, | □ 예(☞지침서) | ■ 아니오 |\n| F 다른 양의 분석물질을 갖는 보정물질은 보정 곡선을 설정하는데 사용 가능 | ㉱ 정성검사의 경우 음성, 양성, 판정기준치 주변값의 검체를 모두 포함하도록 한다.  | 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6. ",
        "original_sentence": "품질관리: 품질관리를 위해 아래 항목을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "| 기능) | 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 11,
        "word_count": 4,
        "page_number": 27,
        "window_text": "| 1.  시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다. ",
        "original_sentence": "| 기능) | 나. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 64,
        "word_count": 18,
        "page_number": 5,
        "window_text": "시험 방법에 대한 재현성 시험(추출된 RNA 혼합물을 사용하여 시험) | 나) 시험방법 | 바.  품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다. ",
        "original_sentence": "알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "| <그림 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 5,
        "window_text": "품질관리: 품질관리를 위해 아래 항목을 확인한다.  | 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다. ",
        "original_sentence": "| <그림 6. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 9,
        "window_text": "| 기능) | 나.  알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다. ",
        "original_sentence": "림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "| § | 표준물질 및 내부 표준물질 | 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 29,
        "word_count": 9,
        "page_number": 7,
        "window_text": "알고리즘 외부 검정(평가) | 20 | ㉱ 코호트 연구 또는 환자-대조군 연구 | 3차 선별을 추가할 수도 있다.  | <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| § | 표준물질 및 내부 표준물질 | 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "| 상세설계에 대한 내용은 아래문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| <그림 6.  림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1. ",
        "original_sentence": "| 상세설계에 대한 내용은 아래문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "| 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 136,
        "word_count": 31,
        "page_number": 5,
        "window_text": "림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율> |\n| 해 알고리즘의 검정을 계획합니다.  | § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. ",
        "original_sentence": "| 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "| 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| § | 표준물질 및 내부 표준물질 | 확인한다.  | 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다. ",
        "original_sentence": "| 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "(공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 201,
        "word_count": 48,
        "page_number": 2,
        "window_text": "| 상세설계에 대한 내용은 아래문서를 참조한다.  | 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다. ",
        "original_sentence": "(공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 124,
        "word_count": 36,
        "page_number": 5,
        "window_text": "| 101-160 | 고위험군 |\n| 확인한 자료 또는 이를 공증한 자료 | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 으로써, 치료 방향의 선정에 도움이 될 수 있다.  | 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다. ",
        "original_sentence": "TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "| 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "| 대한 기술 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다. ",
        "original_sentence": "| 다. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 204,
        "word_count": 50,
        "page_number": 2,
        "window_text": "(공무원용) |\n| - 「의료기기법 시행규칙」제44조 (기재사항의 표시방법) | 편  집  위  원 | - 항존유전자 표지자의 기하평균 신호 강도 | 소프트웨어 구현 | 백승엽, 배성화, 김빛나, 정은지 |\n| 개발 | 림프노드 전이 양성 | ㈜엔젠바이오 | 학계 | · MFDS-IVD-MIA-SA : Software Architecture | <그림 1.  TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다. ",
        "original_sentence": "알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "비밀번호를 누른다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 11,
        "word_count": 2,
        "page_number": 36,
        "window_text": "TransATAC 임상 연구 결과> | 0-60 | 저위험군 |\n| 2) 임상검체를 이용한 시험시 유의 사항 | ※ 예시 : ∼ 정량 PCR법으로 ∼ | ① 전체 결과 및 특이 환자 그룹이 있다면 그룹별 결과를 제시한다.  | 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다. ",
        "original_sentence": "비밀번호를 누른다. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "기 | 기의 “Pulse count”가 0이 된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 12,
        "window_text": "| 다.  알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다. ",
        "original_sentence": "기 | 기의 “Pulse count”가 0이 된다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "| H/W, S/W버전을 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 15,
        "window_text": "알고리즘 내부 및 외부 검정시 고려사항 | 21 | 서명 | <알고리즘 도출 및 내부 검정단계의 고려사항> | (컴퓨터공학) | 홍창범 | 한국바이오협회 |\n| ② 알고리즘 개발 모델과 discovery set에 대한 설명 | 생물학적 물질로부터 분리하는 것 | 보드(Boards) | Version | Remarks | 기기설정화면에서 초기화 버튼을 | 누른다.  비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다. ",
        "original_sentence": "| H/W, S/W버전을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "| 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 57,
        "word_count": 16,
        "page_number": 15,
        "window_text": "비밀번호를 누른다.  기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다.",
        "original_sentence": "| 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "| 다시 기기설정화면으로 진입한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 15,
        "window_text": "기 | 기의 “Pulse count”가 0이 된다.  | H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다. ",
        "original_sentence": "| 다시 기기설정화면으로 진입한다. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "|\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 50,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| H/W, S/W버전을 확인한다.  | 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란? ",
        "original_sentence": "|\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "| 근거를 제시한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 사용자 화면에서 광조사 파라미 | 터를 최소 설정하여 안전한 곳 | 에서 1시간 shot을 한다.  | 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란?  | 2. ",
        "original_sentence": "| 근거를 제시한다."
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "(임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 232,
        "word_count": 61,
        "page_number": 9,
        "window_text": "| 다시 기기설정화면으로 진입한다.  |\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란?  | 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다. ",
        "original_sentence": "(임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "| ※ 임상적 정보가 확보된 검체란? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 10,
        "window_text": "|\n| (1-3개 림프노드) | 없는 경우 합성 유전자를 사용하여 평가할 것을 권장한다.  | 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란?  | 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다. ",
        "original_sentence": "| ※ 임상적 정보가 확보된 검체란? "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "| 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| 근거를 제시한다. (임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란?  | 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 98,
        "word_count": 28,
        "page_number": 8,
        "window_text": "(임상적 민감도 참고) | - 50개 유전자 각각의 신호 강도 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | · MFDS-IVD-MIA-SDS : Software Design Specification | 61-160 | 고위험군 |\n| 구분 | SRS-4 | (기기 | 버전 | 확인 | 및 | § | 검체 채취 방법, 처리 방법, 저장 방법 등 채취하는 검체에 대한 정보 | 확립한다.  | ※ 임상적 정보가 확보된 검체란?  | 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다. ",
        "original_sentence": "내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "| - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 153,
        "word_count": 40,
        "page_number": 9,
        "window_text": "| ※ 임상적 정보가 확보된 검체란?  | 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1. ",
        "original_sentence": "| - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 54,
        "word_count": 12,
        "page_number": 12,
        "window_text": "| 2.  내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라. ",
        "original_sentence": "기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다. "
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "| <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 151,
        "word_count": 33,
        "page_number": 9,
        "window_text": "내분비보조치료만 받은 호르몬 | 수용체 양성, | 림프절 전이 양성 |  | ■ 예(☞안내서) | □ 아니오 |\n| ㉮ 반복 측정한 결과의 일치도를 %로 표기하여 비교한다.  | - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
        "original_sentence": "| <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "| 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| - 「의료기기 허가․신고․심사 등에 관한 규정」 | 제공하는 의료기기 | <표 9> 림프절 양성 환자의 각 위험군에 대한 원격 무재발 생존율 요약 | 미발표 연구, 회사자료, 가이드라인, 전문가 의견 등 | 시스템의 H/W, S/W버전은 초 | 기설정 버전과 동일하다.  기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 48,
        "word_count": 8,
        "page_number": 8,
        "window_text": "기기 | 설정화면에서 광조사 된 pulse | count는 사용자화면에서 카운터와 | 동일하다.  | <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라. "
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 92,
        "word_count": 23,
        "page_number": 2,
        "window_text": "| <의료기기연구과> | Negative Predictive Value(NPV) =  |    |\n| ③ 알고리즘에 사용된 사용변수의 선별 경위 및 사용된 통계분석법에 대한 설명 | 정의하여 임상적 유용성(clinical utility)을 분명하게 해야 합니다.  | 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다. ",
        "original_sentence": "소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "(민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 145,
        "word_count": 32,
        "page_number": 8,
        "window_text": "| 1.  체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다. ",
        "original_sentence": "(민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "|\n| 서로 다른 경우 가장 짧은 기한으로 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 30,
        "word_count": 9,
        "page_number": 13,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)를 구성하는 바이오마커의 선택 및 | 라.  소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다. ",
        "original_sentence": "|\n| 서로 다른 경우 가장 짧은 기한으로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "| 강도, pH 등이 기질효과의 주된 요인이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 10,
        "window_text": "소프트웨어 허가·심사시 고려사항 | 27 | - 음성 대조군의 바탕 신호 강도 | 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다. ",
        "original_sentence": "| 강도, pH 등이 기질효과의 주된 요인이다. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "| ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 12,
        "window_text": "(민원인용) |\n| 연구 조직에서 시행된 국제적인 임상시험 | 품질관리시스템 하에서 실시된 시험자료 | 소프트웨어 검증 | 일자 | 2018.08.01 | 2018.08.02 | 2018.08.03 | 첨부자료로 제출된 검증 및 유효성확인 보고서를 확인한다.  |\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요? ",
        "original_sentence": "| ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "| PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 176,
        "word_count": 52,
        "page_number": 11,
        "window_text": "|\n| 서로 다른 경우 가장 짧은 기한으로 기재한다.  | 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다. ",
        "original_sentence": "| PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "| - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 122,
        "word_count": 33,
        "page_number": 8,
        "window_text": "| 강도, pH 등이 기질효과의 주된 요인이다.  | ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다. ",
        "original_sentence": "| - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "| (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 27,
        "window_text": "| ㈜바디텍메드 | 학계 | 정보 및 ROR score은 아래 표와 같다.  | PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다. ",
        "original_sentence": "| (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요? "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "| * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 118,
        "word_count": 31,
        "page_number": 8,
        "window_text": "| PC부 | <그림 2> 통계적 방법을 이용한 알고리즘 도출 | [ ]P | [ ]F | [ ]P | [ ]F | (시험보고서 | TX-3 참고) |\n| ④ 도출된 알고리즘의 계산식, 선별된 각 사용변수가 검사 결과에 미치는 영향을 기술 | 임상통계학적 모델 개발 경위, 검사 결과에 대한 판단 기준을 고려한다.  | - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5. ",
        "original_sentence": "| * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "| 및 유효성확인 | 사용해야만 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 22,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| - 양성 대조군의 직선성 | 조기 난소암 환자의 5년 재발위험을 점수화로 나타내는 제품을 개발하고자 할 | 경우, 최초 검체 채취 후 5년간 재발여부 및 치료정보를 포함한 임상정보가 확 | 인되는 검체를 의미한다.  | (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. ",
        "original_sentence": "| 및 유효성확인 | 사용해야만 한다. "
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "| (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 204,
        "word_count": 48,
        "page_number": 5,
        "window_text": "| (PC BOARD) | Rev 1.0 | 김미정, 임천일, 고동현, 이정주, 이승일, 이승열, 이승노, 김형식, |\n| 왜 명확히 설정해야 하나요?  | * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다. ",
        "original_sentence": "| (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "| 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 9,
        "window_text": "| * (예, 염색체 복제 수 결정 등) | ② 임상문헌의 내적타당도 확보를 위한 평가항목 | - Likelihood ratios | § | 반응 조건 및 분석 조건 | 바이어스(bias, 편향성)를 제시한다.  | 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다. ",
        "original_sentence": "| 5. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 75,
        "word_count": 20,
        "page_number": 5,
        "window_text": "| 및 유효성확인 | 사용해야만 한다.  | (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다. ",
        "original_sentence": "소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "| 수 있는 컬러사진을 첨부한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 8,
        "window_text": "| (1-3개), Stage | 2 | 유방암인 폐경 | · Software Verification & Validation | (환경공학) | 장덕환 | 한국바이오협회 | Number of |\n| - 「의료기기 품목 및 품목별 등급에 관한 규정」 | Risk Group | Number of | Patients (%) | 검체를 검사하여 분석적 민감도를 판정한다.  | 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다. ",
        "original_sentence": "| 수 있는 컬러사진을 첨부한다. "
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "| Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 172,
        "word_count": 33,
        "page_number": 12,
        "window_text": "| 5.  소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다. ",
        "original_sentence": "| Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "| - 표지자(probe) 상호 오염 | 필요성을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 12,
        "window_text": "소프트웨어 검증 및 유효성 확인 보고서 작성 예시 | 28 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2. ",
        "original_sentence": "| - 표지자(probe) 상호 오염 | 필요성을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "| Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 145,
        "word_count": 38,
        "page_number": 8,
        "window_text": "| 수 있는 컬러사진을 첨부한다.  | Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. ",
        "original_sentence": "| Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "| 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 228,
        "word_count": 61,
        "page_number": 10,
        "window_text": "| Estimated Percent Without Distant | Recurrence at 10 years [95% CI] |\n| 가능한 서류 등) | (출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11)) | 방법을 미리 확립하고 이를 명시한다.  | - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다. ",
        "original_sentence": "| 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| - 표지자(probe) 상호 오염 | 필요성을 기재한다.  | Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 176,
        "word_count": 35,
        "page_number": 8,
        "window_text": "| Events Through |\n| ⑤ 알고리즘을 통하여 계산되는 분류, 점수, 지수 등의 환산법 등에 대한 설명 | 후 여성의 윈격 무재발 생존율에 | 대한 예후 지표 | 김미혜, 김세경, 이정현 |\n| 본 민원인 안내서(가이드라인)을 참고하시면 됩니다.  | 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 12,
        "window_text": "| 관리기준 | 초기화) | ㉮ 효과지표 명시 : 선정한 효과지표의 중요성과 1차 및 2차 효과지표 종류 | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 에 의하여 실시한 것으로 판단되는 자료 | 해당 소프트웨어 시스템에 대한 미해결 문제점(버그 또는 결함, 이상 현상) | 10 Years | □ 예 | ■ 아니오 |\n| 1) 최초의 알고리즘을 사용목적에 부합하도록 설계하였는지를 평가한다.  | 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다. ",
        "original_sentence": "| (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "| § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 7,
        "window_text": "| 2.  체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다. ",
        "original_sentence": "| § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "| 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 2,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)의 목적에 따라 민감도, 특이도, 양성 | (※ 출처 : Prisigna 510(k)자료, p17-18, O. System Descriptions) | 시스템 제어부 |\n| - 「의료기기 안정성시험 기준」 | ③ 선택한 비교평가 방법을 명시하고, 선택한 사유를 기술한다.  | (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다. ",
        "original_sentence": "| 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 88,
        "word_count": 19,
        "page_number": 8,
        "window_text": "| (System Control Board) | Rev 1.0 | 비교한 결과, 영향을 거의 미치지 않음을 확인하였다.  | § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 8,
        "window_text": "| § | 비특이적 반응이 발생할 가능성과 억제 방법 | Set)를 통하여 알고리즘을 평가한다.  | 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다. ",
        "original_sentence": "| 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "| test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 46,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 상태 등 검체가 제대로 관리되었는지의 여부를 확인한다.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다. ",
        "original_sentence": "| test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "| 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 2,
        "window_text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 |\n| ⑥ 알고리즘에 대한 성능평가 및 통계학적 유의성 | 및 사용기간(유효기간) 등이 포함되도록 한다.  | 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다. ",
        "original_sentence": "| 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "| <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 62,
        "word_count": 17,
        "page_number": 2,
        "window_text": "| 전신에 퍼져있는 암세포에 작용하는 치료 방법 | 확인하는 과정을 제공한다.  | test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다. ",
        "original_sentence": "| <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "|\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 10,
        "window_text": "| test, 카이제곱 (χ2) p-value에 대한 자유도의 임계값을 보여준다.  | 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다. ",
        "original_sentence": "|\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "| 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 137,
        "word_count": 33,
        "page_number": 5,
        "window_text": "| 소프트웨어 배포 | 민원인을 구속하는 내용이 있습니까?  | <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다. ",
        "original_sentence": "| 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "| 제시(신뢰구간과 함께) 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| <표 4> 재현성 시험에 사용된 RNA 혼합물 정보 | 목록 및 잔여위험 평가여부는 아래 문서를 참조한다.  |\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. ",
        "original_sentence": "| 제시(신뢰구간과 함께) 한다. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "| 소프트웨어를 사용할 수 있도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 8,
        "window_text": "|\n| 분석법임을 입증하는 과정 | (높은 농도의 X물질은 분석물질의 결과를 감소시킴) | 반복 측정한다.  | 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다. ",
        "original_sentence": "| 소프트웨어를 사용할 수 있도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "|\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 89,
        "word_count": 22,
        "page_number": 8,
        "window_text": "| 제III부  Q & A | 35 | Low | 158 (41%) | 7 | 94.2% [88.1% - 97.2%] | 예측도, 음성예측도, AUC(Area Under the Curve), C-index 등을 이용한 성능 | 평가를 제시한다.  | 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다. ",
        "original_sentence": "|\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "| 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 5,
        "window_text": "| 제시(신뢰구간과 함께) 한다.  | 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다. ",
        "original_sentence": "| 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187. "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 102,
        "word_count": 19,
        "page_number": 5,
        "window_text": "| 소프트웨어를 사용할 수 있도록 한다.  |\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다. ",
        "original_sentence": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "|\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 58,
        "word_count": 14,
        "page_number": 8,
        "window_text": "|\n| 환자에서의 건강이나 건강의 손상 정도를 평가하기 위한 목적 | 농도별 고, 중, 저 표준물질을 포함하여 사용하도록 권장하고 해당 표준물질명을 기재한다.  | 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2. ",
        "original_sentence": "|\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "| · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 107,
        "word_count": 17,
        "page_number": 10,
        "window_text": "| 문   의   처 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187.  | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다. ",
        "original_sentence": "| · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "| 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 152,
        "word_count": 36,
        "page_number": 12,
        "window_text": "| 식품의약품안전평가원 의료기기심사부 체외진단기기과 | 전화 : 043-719-4652~4665 | 팩스 : 043-719-4650 | 각각의 판정 기준 점수는 40점과 60점이다.  |\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다. ",
        "original_sentence": "| 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "| 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "|\n| 포함한다)을 검토하여 타당하다고 인정할 수 있는 시험자료 | 통계적으로 타당한 근거를 제시한다.  | · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| · MFDS-IVD-MIA-Release : Software Release |\n| ⑦ discovery set에서의 internal validation의 결과의 순으로 기술하시면 됩니다.  | 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5. ",
        "original_sentence": "결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "| High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 270,
        "word_count": 74,
        "page_number": 5,
        "window_text": "| 생명과학 연구를 차세대에 이르도록 하여 오믹스를 질적, 양적 변화를 가져옴) | USB 부 | TEL : 043-719-4652~4665  FAX : 043-719-4650 | ※ 림프절 전이 양성(4개 이상)인 | 환자는 대상으로 하지 않음 |\n| 기록하여야 한다.  | 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다. ",
        "original_sentence": "| High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "| 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 44,
        "word_count": 8,
        "page_number": 12,
        "window_text": "| 2.  결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다. ",
        "original_sentence": "| 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| <그림 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 9,
        "window_text": "결과의 재현성을 위해 분석 검체는 아래의 조건을 만족하여야 한다.  | High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다. ",
        "original_sentence": "| <그림 5. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 39,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| High | 224 (59%) | 46 | 75.8% [68.9% - 81.4%] | § | 오염으로 인하여 발생할 오판 가능성과 오염을 제거하는 방안 | (USB | BOARD) | Rev 1.0 | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | Likelihood ratio positive =  |   |  |  |    |  |  |\n| ④ 결과가 불일치하는 경우 불일치의 원인분석에 대한 자료를 제출한다.  | 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다. ",
        "original_sentence": "림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "| 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 109,
        "word_count": 27,
        "page_number": 2,
        "window_text": "| 혈장/혈청/FFPE에 해당 물질을 일정 농도로 spiking하여 사용한다.  | <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다. ",
        "original_sentence": "| 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "| 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 82,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| <그림 5.  림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다. ",
        "original_sentence": "| 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "| (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 13,
        "window_text": "림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율> | 크다.  | 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2. ",
        "original_sentence": "| (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "| 확인토록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 전향적 연구여부 등 | 소프트웨어 유지보수 프로세스, 소프트웨어 문제해결 프로세스에 따라 유지 보수 계획 수립, |\n| 수 없는 결과가 제공되는 특징을 보이기도 하는 체외진단용 의료기기이다.  | 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다. ",
        "original_sentence": "| 확인토록 한다. "
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "|\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 48,
        "word_count": 14,
        "page_number": 8,
        "window_text": "| 가) 시험물질 | 용 의료기기(In Vitro Diagnostics Multivariate Index Assay, IVD-MIA))라고 한다.  | (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다. ",
        "original_sentence": "|\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "| 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "| (1) 저농도 표준물질인 경우, 정량 및 정성검출한계를 근거로 하여 설정한다.  | 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 확인토록 한다.  |\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
        "original_sentence": "RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "| <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 110,
        "word_count": 29,
        "page_number": 5,
        "window_text": "|\n| 의한 증폭 방해를 동정하기 위한 목적으로 사용 | 이상 반복 검사를 권장한다.  | 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3. ",
        "original_sentence": "| <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "| 여부를 식약처에 확인받아야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 2,
        "window_text": "| 2.  RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다. ",
        "original_sentence": "| 여부를 식약처에 확인받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 2,
        "window_text": "RNA 추출에 대한 재현성 시험(파라핀 포매 유방암 검체로 시험) | 군을 어떤 방법으로 선별하였는지 확인해야 한다.  | <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다. ",
        "original_sentence": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "| <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 91,
        "word_count": 24,
        "page_number": 10,
        "window_text": "| <부 록> | 침윤성 유방암 환자의 재발위험 예측 및 예후 검사(IVD-MIA) 제품 | 허가·심사 예시 | 41 | 과정의 강건성 등을 기준으로 삼아 계속해서 바이오마커를 필터링할 수 있다.  | 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요? ",
        "original_sentence": "| <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 84,
        "word_count": 13,
        "page_number": 8,
        "window_text": "| 여부를 식약처에 확인받아야 한다.  | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "| (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 105,
        "word_count": 28,
        "page_number": 5,
        "window_text": "| 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다. ",
        "original_sentence": "| (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "| <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 97,
        "word_count": 18,
        "page_number": 8,
        "window_text": "| <표 7> ABCSG-8 임상 검정 연구에서 일차 분석 요약 |\n| F 정량 PCR에서 검출반응은 형광신호가 축적되는 것을 인식하는 방식으로 이루어짐 | 3.  체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다. ",
        "original_sentence": "| <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요? "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "| ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 10,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)에서 주어진 테스트 데이터를 학습하면서 | (overfitting)에 대한 평가를 반드시 수행하여야 한다.  | (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다. ",
        "original_sentence": "| ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "| 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 66,
        "word_count": 19,
        "page_number": 8,
        "window_text": "| (가) 50% 이상의 암조직을 포함하는 검체여야 함 | Total | 382 (100%) | 53 | 문제 보고 및 수정분석, 구현 내용, 문제해결 검증 내용은 아래 문서를 참조한다.  | <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다. ",
        "original_sentence": "| 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "| ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 95,
        "word_count": 28,
        "page_number": 8,
        "window_text": "| <표 2> Breast Cancer Alarm score 범위 및 위험도 분류 | http://www.mfds.go.kr (식품의약품안전처) |\n| 어떻게 이루어지나요?  | ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다. ",
        "original_sentence": "| ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "| 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 82,
        "word_count": 22,
        "page_number": 10,
        "window_text": "| ㉰ 측정범위를 포함하는 두 가지 이상의 농도의 물질을 선택한다.  | 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다. ",
        "original_sentence": "| 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "| (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 14,
        "window_text": "| 받아 승인하였음을 확인한 자료 또는 이를 공증한 자료 | 넘지 않는 결과를 보인 최대 간섭 물질 농도를 기재한다.  | ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다. ",
        "original_sentence": "| (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "| ① 양성 임상 검체를 이용하여 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 10,
        "window_text": "| ㉰ 중재에 대한 명시 : 중재에 사용된 약제 또는 방법, 대상 환자 포함 범위 |\n| 변수가 검사 결과에 영향을 끼칠 수 있으므로 검사대상을 명확히 설정해야 합니다.  | 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다. ",
        "original_sentence": "| ① 양성 임상 검체를 이용하여 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "| 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 145,
        "word_count": 39,
        "page_number": 12,
        "window_text": "| 측정하고 검체 내 다른 물질은 측정되지 않는 분석법의 능력 | 일치하는 결과 | 다) 결과제시 | 임상적 성능)이 우선적으로 검정되어야 한다.  | (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "| 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "| 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 174,
        "word_count": 41,
        "page_number": 10,
        "window_text": "| (2) 표준물질의 농도는 정밀도, 직선성, 최소검출한계를 고려하여 선정한다.  | ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다. ",
        "original_sentence": "| 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "| 전까지의 생존 기간 | 하도록 권고한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 12,
        "window_text": "| ① 양성 임상 검체를 이용하여 평가한다.  | 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. ",
        "original_sentence": "| 전까지의 생존 기간 | 하도록 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "| (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 88,
        "word_count": 16,
        "page_number": 9,
        "window_text": "| 전원공급부 | Likelihood ratio negative =  |   |  |  |    |  |  |\n| (Power Supply BOARD) | Rev 1.0 | 과적합(overfitting)이 | 생길 | 수 | 있다.  | 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다. ",
        "original_sentence": "| (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "|\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 123,
        "word_count": 33,
        "page_number": 10,
        "window_text": "| 과적합을 | 방지하기 | 위해 | 내부 | 검정 | · MFDS-IVD-MIA-Maintenance : Software Maintenance | 처방으로만 사용 | 진단, 치료효과를 예측하거나 측정, | 환자에게 최적의 치료를 선택할 | 수 있도록 쓰일 수 없음 |\n| 같이 저장방법과 사용기간을 기재한다.  | 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다. ",
        "original_sentence": "|\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "| * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 12,
        "window_text": "| 전까지의 생존 기간 | 하도록 권고한다.  | (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다. ",
        "original_sentence": "| * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "| (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 56,
        "word_count": 8,
        "page_number": 12,
        "window_text": "| (암 조직 주변 정상세포가 50% 이상이면 안됨) | http://www.nifds.go.kr (식품의약품안전평가원) | 상기 사항에 대하여 확인하였음.  |\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다. ",
        "original_sentence": "| (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "| 연구가 부족하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 12,
        "window_text": "|\n| ※ 예시 : | Null Model | Alternate Model | ΔLR χ2 | χ2 Critical Value |\n| ㉱ 정량검사의 경우 측정범위의 낮은 값, 중간 값, 높은 값을 모두 포함하도록 한다.  | * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다. ",
        "original_sentence": "| 연구가 부족하다. "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "| · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 108,
        "word_count": 20,
        "page_number": 10,
        "window_text": "| * (예, creatinine clearance, 콜레스테롤 비율 결정, 사구체 여과율 등) | ① 시험방법, 통계방법 등에 대한 자세한 실험프로토콜을 제공한다.  | (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요? ",
        "original_sentence": "| · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "| 사용제한 | 좌동 |\n| 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 22,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| (internal validation)을 통하여 성능의 비편향성(unbias) 평가를 권고한다.  | 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다. ",
        "original_sentence": "| 사용제한 | 좌동 |\n| 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "| 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 8,
        "window_text": "| 연구가 부족하다.  | · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다. ",
        "original_sentence": "| 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "| 있는데 식약처의 임상시험 계획 승인 대상인가요? ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 8,
        "window_text": "| · MFDS-IVD-MIA-PR : Software Problem Resolution | (Degrees of freedom) | χ2 p-value |\n| 방법 등)을 상세하게 기재한다.  | 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. ",
        "original_sentence": "| 있는데 식약처의 임상시험 계획 승인 대상인가요? "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "| (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 78,
        "word_count": 22,
        "page_number": 14,
        "window_text": "| 사용제한 | 좌동 |\n| 기재한다.  | 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다. ",
        "original_sentence": "| (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다. "
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "| 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 2,
        "window_text": "| 허가규정 제29조(첨부자료의 요건) ① 기술문서 등의 심사를 위한 첨부자료의 요건은 | 다음 각 호와 같다.  | 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다. ",
        "original_sentence": "| 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "| 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 76,
        "word_count": 20,
        "page_number": 8,
        "window_text": "| 있는데 식약처의 임상시험 계획 승인 대상인가요?  | (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4. ",
        "original_sentence": "| 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "| (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 152,
        "word_count": 36,
        "page_number": 5,
        "window_text": "| (나) 괴사, 염증, 유방관 상피 내암 존재 시 암 조직은 최소 10%이상 암 세포를 포함해야 함 | 또는 바이오마커를 1차 선별한다.  | 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다. ",
        "original_sentence": "| (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "| (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 141,
        "word_count": 36,
        "page_number": 8,
        "window_text": "| 2018년 8월 22일 |\n| 검토하고, 자료를 제시하여야 한다.  | 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다. ",
        "original_sentence": "| (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "| 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 5,
        "window_text": "| 경계 사이클 수는 초기 검체량과 반비례의 관계를 가짐 | ② 불일치한 검체에 대해 원인을 분석한 자료를 제출하고, 해석을 제시한다.  | (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다. ",
        "original_sentence": "| 4. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 156,
        "word_count": 29,
        "page_number": 12,
        "window_text": "| (제품 개요, 신청서 기재항목, 기술문서 제출자료, 성능시험 등) | 소프트웨어 위험관리 프로세스에 따라 위해상황, 위험통제수단, 위험통제 수단의 검증, 소프트 | 전원제어부 |\n| ㉲ 정성검사의 경우 음성, 양성, 판정기준치 주변 값의 검체를 모두 포함하도록 한다.  | (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다. ",
        "original_sentence": "적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "| - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 69,
        "word_count": 16,
        "page_number": 12,
        "window_text": "| (Power Control Board) | Rev 1.0 | 제품 또는 확진검사방법으로 확인된 자료나 양성임을 확인 가능한 서류 등) |\n| 확률 범위 내에서 분포할 것으로 예상되는 구간 | 일치하는 결과 | 대한 교차반응에 대한 자료를 제공한다.  | 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다. ",
        "original_sentence": "| - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다. "
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "| “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 113,
        "word_count": 33,
        "page_number": 11,
        "window_text": "| 4.  적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다. ",
        "original_sentence": "| “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "| 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 10,
        "window_text": "적절한 internal validation 방법은 split-sample, cross-validation including | (다) H&E 염색 슬라이드에서 암 면적은 4mm2이상 이어야 함 | 반복 시험하여 ROR score에 따른 위험 그룹 분류에 대한 결과를 비교하였다.  | - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다. ",
        "original_sentence": "| 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "| CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 110,
        "word_count": 30,
        "page_number": 5,
        "window_text": "| - AUC(Area Under the ROC Curve) | 웨어 변경의 위험관리에 관한 내용은 아래 문서를 참조한다.  | “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다. ",
        "original_sentence": "| CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "| 권고한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| “내가 지킨 청렴실천 모아지면 청렴사회” |\n| ※ 사용 장비 및 적용 프로그램 모드의 선택 등 상세한 예시 기재 필요 | ㉮ 시행기관의 특성에 맞게 20개 이상의 검체에 대해 1회 이상 평가한다.  | 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8. ",
        "original_sentence": "| 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "| 구성품의 외관사진 및 구성표를 따로 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 항체를 이용한 리간드-결합 분석 | 하게 측정되고 검출된다는 걸 증명하는 시험성적서를 제시해야 한다.  | CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가. ",
        "original_sentence": "| 구성품의 외관사진 및 구성표를 따로 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "| 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 79,
        "word_count": 18,
        "page_number": 5,
        "window_text": "| CTS | CTS + Breast Cancer | Alarm score | 53.49 | 3.84 (df = 1) | p < 0.0001 |\n| (온도 등) 및 유의사항 등을 병기하여야 한다.  | 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다. ",
        "original_sentence": "| 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "| 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 8,
        "window_text": "| 권고한다.  | 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다. ",
        "original_sentence": "| 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "성능에 관한 자료 | 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 15,
        "word_count": 5,
        "page_number": 8,
        "window_text": "| 구성품의 외관사진 및 구성표를 따로 제시한다.  | 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다. ",
        "original_sentence": "성능에 관한 자료 | 가. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 330,
        "word_count": 80,
        "page_number": 5,
        "window_text": "| 본 가이드라인은 15년도 식품의약품안전처의 연구개발사업 |\n| ㉳ 제품 내에 포함된 정도관리물질을 이용한 평가를 포함하는 것을 권장한다.  | 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다. ",
        "original_sentence": "소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "| 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 7,
        "window_text": "| 양성으로 나온 검사 결과 | 환자의 원격 재발률에 대한 점수 및 위험도를 제공하는 체외진단용 의료기기 | 전 위 t(9;22)(q34;q11)가 발생한 경우 필라델피아 염색체가 관찰된다) | 8.  성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다. ",
        "original_sentence": "| 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "|\n| 함을 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 15,
        "window_text": "성능에 관한 자료 | 가.  소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다. ",
        "original_sentence": "|\n| 함을 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "| 일치도 등의 정보를 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 9,
        "window_text": "소프트웨어가 내장되어 있거나 단독으로 사용되는 경우에는 별표 13에 따른 별지 | · MFDS-IVD-MIA-RM : Software Risk Management | 시험 결과(Test Results) | (결함률) |\n| 계획승인을 받고 실시해야함) | (라) 전체 암 면적은 최소 24mm2이상이 되어야 함 | nCounterⓇ | Dx | analysis | 담당자 | 확  인(부서장) | 한 시험소에서 시행되는 70개의 | 유전자로 | 구성된 | RNA | 전사체 | 우 승 민 |\n| ※ 소프트웨어 조작방법 예시 : | 계산값에 대해 95% 검출되는지를 시험을 통해 재확인한다.  | 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다. ",
        "original_sentence": "| 일치도 등의 정보를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "| ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 45,
        "word_count": 13,
        "page_number": 5,
        "window_text": "| 진단을 위해 하나의 검사에서 복수의 알고리즘이 적용될 수도 있다.  |\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다. ",
        "original_sentence": "| ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "| (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 61,
        "word_count": 11,
        "page_number": 8,
        "window_text": "|\n| 함을 명시한다.  | 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다. ",
        "original_sentence": "| (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "| 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 110,
        "word_count": 26,
        "page_number": 13,
        "window_text": "| 일치도 등의 정보를 기재한다.  | ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "| 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "| ※ 예시 : | 것을 권장한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 20,
        "word_count": 7,
        "page_number": 10,
        "window_text": "| ㉯ 정상 검체보다 20% 이상 높은 검체에 대해 1회 이상 검사를 실시한다.  | (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n",
        "original_sentence": "| ※ 예시 : | 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "|\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 121,
        "word_count": 30,
        "page_number": 5,
        "window_text": "| (맞춤 의료를 위한 체외진단다지표검사(IVD-MIA)의료기기 평가기술 개발 연구, | 제외)을 제시한다.  | 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n",
        "original_sentence": "|\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| 소프트웨어 형상관리 프로세스에 따라 소프트웨어 식별, 변경관리, 상태기록에 관한 내용은 | Defect Rate | Pass | Fail | Total |\n| 목록을 제시하고 자료를 제공한다.  | ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 136,
        "word_count": 31,
        "page_number": 1,
        "window_text": "| ※ 예시 : | 것을 권장한다.  |\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n",
        "original_sentence": "지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 102,
        "word_count": 21,
        "page_number": 3,
        "window_text": "|\n| CTS | CTS + Risk Groups | 34.12 | 5.99 (df = 2) | p < 0.0001 |\n\n**[표 끝]**\n\n질병의 예후·예측에 사용되는\n\n등록대상\n\n여부\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018. ",
        "original_sentence": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 104,
        "word_count": 26,
        "page_number": 3,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8. ",
        "original_sentence": "또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "<!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 309,
        "word_count": 59,
        "page_number": 3,
        "window_text": "지침서ㆍ안내서\n\n기타 확인\n\n사항\n\n이 원 규\n\n이 안내서는 질병의 예후·예측에 사용되는 체외진단용 의료기기의 허가·심사 시 요구되는 신청서\n\n작성 방법 및 제출자료 요건을 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것\n\n입니다.\n\n 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "<!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 241,
        "word_count": 41,
        "page_number": 3,
        "window_text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식(‘~하여야 한다’\n\n등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는 사항이 아님을 알려드립니다.\n\n 또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "8. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 3,
        "word_count": 1,
        "page_number": 1,
        "window_text": "또한, 본 안내서는 현재의 과학적·기술적 사실 및 유효한 법규를 토대로 작성되었으므로\n\n이후 최신 개정 법규 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n <!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다. ",
        "original_sentence": "8. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 100,
        "word_count": 25,
        "page_number": 5,
        "window_text": "<!-- PAGE_3 -->\n###### ※ 민원인 안내서란 대내외적으로 법령 또는 고시·훈령·예규 등을 알기 쉽게 풀어서\n\n<!-- PAGE_3 -->\n###### 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것(식품\n\n<!-- PAGE_3 -->\n###### 의약품안전처 지침서등의 관리에 관한 규정 제2조)\n\n<!-- PAGE_3 -->\n###### ※ 본 민원인 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전평가원\n\n<!-- PAGE_3 -->\n###### 의료기기심사부 체외진단기기과에 문의하시기 바랍니다.\n\n <!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다. ",
        "original_sentence": "22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 307,
        "word_count": 50,
        "page_number": 7,
        "window_text": "<!-- PAGE_3 -->\n###### - 전화번호 : 043-719-4654~4665\n\n<!-- PAGE_3 -->\n###### - 팩스번호 : 043-719-4650\n\n<!-- PAGE_4 -->\n###### 제·개정 이력서\n\n<!-- PAGE_4 -->\n###### 제․개정번호\n\n<!-- PAGE_4 -->\n###### 승인일자\n\n<!-- PAGE_4 -->\n###### 주요 내용\n\n안내서-0882-01\n\n- 2018.  8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다. ",
        "original_sentence": "배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 341,
        "word_count": 72,
        "page_number": 7,
        "window_text": "8.  22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다. ",
        "original_sentence": "융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 114,
        "word_count": 24,
        "page_number": 7,
        "window_text": "22\n<!-- PAGE_5 -->\n### 목  차\n\n3\n\n- - 3 -\n<!-- PAGE_7 -->\n##### 제  I 부  개요\n\n<!-- PAGE_7 -->\n###### 1.  배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다. ",
        "original_sentence": "진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 483,
        "word_count": 105,
        "page_number": 7,
        "window_text": "배경\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 1990년에 시작된 인간게놈프로젝트(Human Genome Project)로 유전자 정보해석\n\n<!-- PAGE_7 -->\n###### 분야의 경쟁이 시작되었으며, 2000년대 생명공학기술(Biotechnology, BT) 및 정보\n\n<!-- PAGE_7 -->\n###### 기술(Information Technology, IT)의 발달과 융합으로 생물정보학, 유전체학 및\n\n<!-- PAGE_7 -->\n###### 단백체학이 급속히 성장할 수 있었다.  융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n",
        "original_sentence": "이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 363,
        "word_count": 69,
        "page_number": 7,
        "window_text": "융합 학문의 발달로 인한 유전체 및 단백질\n\n<!-- PAGE_7 -->\n###### 분석 기술의 향상은 개개인의 질병 진단과 치료를 빠르고 정확하게 하여, 개인\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 이용한 진단은 맞춤의료 시대를 여는 핵심적인 열쇠이며, 혁신 의약품\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 바이오마커를 통한 진단검사는 질병의 발병 여부를 확인하고 중증도를 판단하는\n\n<!-- PAGE_7 -->\n###### 단계를 지나, 질병의 진행 상태, 재발 가능성을 모니터링하기도 한다.  진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2. ",
        "original_sentence": "이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 170,
        "word_count": 37,
        "page_number": 7,
        "window_text": "진단검사를\n\n<!-- PAGE_7 -->\n###### 활용하여 치료 효과를 예측하고, 치료 방법을 선정하는 등 과거에는 기대할 수\n\n<!-- PAGE_7 -->\n###### 없었던 부분을 개척하고 있다.  이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3. ",
        "original_sentence": "서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 84,
        "word_count": 20,
        "page_number": 8,
        "window_text": "이에 따라 질병의 예후를 진단할 수 있는 바이오\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 질병 진단에서 바이오마커를 효과적으로 사용할 경우, 질병의 병리학적 소인을 파악\n\n<!-- PAGE_7 -->\n###### 하고 질환 발병 가능성을 예측하는 것이 가능하며, 이를 통해 질병의 예방 및\n\n<!-- PAGE_7 -->\n###### 조기 치료를 할 수 있을 뿐만 아니라 치료 약물 투약 후 환자의 예후를 예측함\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 최근 이러한 개인 맞춤의료를 위해 다양한 바이오마커에 대한 분석 측정값을\n\n<!-- PAGE_7 -->\n###### 특정 알고리즘(Algorithm)으로 이용하여 분석함으로써, 기존의 단독 바이오마커를\n\n<!-- PAGE_7 -->\n###### 이용한 진단의 단점을 보완할 수 있는 다양한 진단법이 등장하고 있다.  이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n",
        "original_sentence": "이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 256,
        "word_count": 44,
        "page_number": 8,
        "window_text": "이러한 진\n\n<!-- PAGE_7 -->\n###### 단법을 통해 2개 이상의 바이오마커를 이용한 환자 상태의 진단, 질병의 재발율,\n\n<!-- PAGE_7 -->\n###### 환자의 생존률 등의 예후·예측에 사용되는 체외진단용 의료기기(체외진단다지표검사\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)는 여러 가지 바이오마커 측정 시약과\n\n<!-- PAGE_7 -->\n###### 측정값을 종합해서 분석하는 특정 알고리즘으로 구성되어 있으며, 복수의 바이오마커\n\n<!-- PAGE_7 -->\n###### 외에도 임상 정보를 포함하여 알고리즘을 개발할 수 있다.  서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다. ",
        "original_sentence": "<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 991,
        "word_count": 170,
        "page_number": 8,
        "window_text": "서로 다른 상태에 대한\n\n<!-- PAGE_7 -->\n###### §\n\n<!-- PAGE_7 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 분석을 통해 제시된 결과는\n\n4\n\n- - 4 -\n<!-- PAGE_8 -->\n###### 개인별 맞춤 진단 및 치료에 이용할 수 있다.  이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다. ",
        "original_sentence": "목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 8,
        "window_text": "이러한 결과는 환자의 치료 효과\n\n<!-- PAGE_8 -->\n###### 증대는 물론 불필요한 치료 등을 예측하고 방지할 수 있다는 장점이 있다.\n\n <!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나. ",
        "original_sentence": "적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n"
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 351,
        "word_count": 59,
        "page_number": 8,
        "window_text": "<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 해외에서는 이미 여러 종류의 체외진단다지표검사용 의료기기(IVD-MIA)들을\n\n<!-- PAGE_8 -->\n###### 개발하여 사용하고 있으므로, 이러한 흐름에 발맞춰 우리나라도 체외진단다지표\n\n<!-- PAGE_8 -->\n###### 검사용 의료기기(IVD-MIA)의 안전성과 유효성을 확보하고 허가·심사에 대한 평가\n\n<!-- PAGE_8 -->\n###### 2.  목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n",
        "original_sentence": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 86,
        "word_count": 17,
        "page_number": 8,
        "window_text": "목적\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본\n\n<!-- PAGE_8 -->\n###### 민원인\n\n<!-- PAGE_8 -->\n###### 안내서(가이드라인)는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 또한, 본 민원인 안내서는 체외진단다지표검사용 의료기기(IVD-MIA)의 개발 및\n\n<!-- PAGE_8 -->\n###### 상업화\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기의\n\n<!-- PAGE_8 -->\n###### 수입,\n\n<!-- PAGE_8 -->\n###### 판매를\n\n<!-- PAGE_8 -->\n###### 계획하고\n\n<!-- PAGE_8 -->\n###### 있는\n\n<!-- PAGE_8 -->\n###### 기업들에게\n\n<!-- PAGE_8 -->\n###### 허가·심사를\n\n<!-- PAGE_8 -->\n###### 위한\n\n<!-- PAGE_8 -->\n###### 필수적\n\n<!-- PAGE_8 -->\n###### 고려사항들에\n\n<!-- PAGE_8 -->\n###### 대해\n\n<!-- PAGE_8 -->\n###### 검토할\n\n<!-- PAGE_8 -->\n###### 수\n\n<!-- PAGE_8 -->\n###### 있도록\n\n<!-- PAGE_8 -->\n###### §\n\n<!-- PAGE_8 -->\n###### 본 민원인 안내서(가이드라인) 내용 안에 부록으로 유방암 예후를 예측하는 제품을\n\n<!-- PAGE_8 -->\n###### 예시로 설명함으로써 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(IVD-MIA)의 허가·심사에\n\n<!-- PAGE_8 -->\n###### 3.  적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다. ",
        "original_sentence": "해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 105,
        "word_count": 20,
        "page_number": 8,
        "window_text": "적용범위\n\n<!-- PAGE_8 -->\n###### 가.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n",
        "original_sentence": "결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 46,
        "word_count": 6,
        "page_number": 8,
        "window_text": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_8 -->\n###### 의료기기(In\n\n<!-- PAGE_8 -->\n###### Vitro\n\n<!-- PAGE_8 -->\n###### Diagnostic\n\n<!-- PAGE_8 -->\n###### Multivariate\n\n<!-- PAGE_8 -->\n###### Index\n\n<!-- PAGE_8 -->\n###### Assay,\n\n<!-- PAGE_8 -->\n###### IVD-MIA)는 환자의 질병이나 상태를 진단하거나 질병의 치료, 완화, 처치, 예방,\n\n<!-- PAGE_8 -->\n###### 예후, 예측을 위하여 해석 함수를 사용한다.  해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "<!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 127,
        "word_count": 24,
        "page_number": 8,
        "window_text": "해석 함수는 다양한 지표(수치)들을\n\n<!-- PAGE_8 -->\n###### 결합하여 환자 특이적인 결과(위험군 분류, 점수, 인덱스 등)를 도출한다.  결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다. ",
        "original_sentence": "<!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 275,
        "word_count": 50,
        "page_number": 8,
        "window_text": "결과의\n\n<!-- PAGE_8 -->\n###### 유도(derivation) 과정은 명확히 알 수 없으며, 최종 사용자가 독자적으로 입증할\n\n<!-- PAGE_8 -->\n###### 나.  체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n",
        "original_sentence": "알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 106,
        "word_count": 19,
        "page_number": 8,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)에 해당되는 의료기기는 다음과 같다.\n\n <!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n",
        "original_sentence": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "<!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 256,
        "word_count": 56,
        "page_number": 9,
        "window_text": "<!-- PAGE_8 -->\n###### 1) 환자의 임상정보(나이, 성별, 몸무게 등)와 바이오마커 지표(대사율, 유전자 발현\n\n<!-- PAGE_8 -->\n###### 정도, 유전자형 등)를 알고리즘의 입력값으로 사용한다.  알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4. ",
        "original_sentence": "<!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 47,
        "word_count": 6,
        "page_number": 8,
        "window_text": "알고리즘은 입력값을\n\n<!-- PAGE_8 -->\n###### 분석하여 결과(위험군 분류, 점수, 인덱스 등)를 제시하고, 환자의 상태(질병\n\n<!-- PAGE_8 -->\n###### 진단\n\n<!-- PAGE_8 -->\n###### 또는\n\n<!-- PAGE_8 -->\n###### 위험도에\n\n<!-- PAGE_8 -->\n###### 따른\n\n<!-- PAGE_8 -->\n###### 분류\n\n<!-- PAGE_8 -->\n###### 등)를\n\n<!-- PAGE_8 -->\n###### 진단한다.\n\n <!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "<!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 1277,
        "word_count": 258,
        "page_number": 9,
        "window_text": "<!-- PAGE_8 -->\n###### 체외진단다지표검사용\n\n5\n\n- - 5 -\n<!-- PAGE_9 -->\n###### 의료기기(IVD-MIA)의 대표적인 분석검사법들은 다음과 같다.\n\n <!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n",
        "original_sentence": "<!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n"
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "<!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 724,
        "word_count": 138,
        "page_number": 9,
        "window_text": "<!-- PAGE_9 -->\n###### - 다수의 유전자 발현 양상을 분석하고 종합하여 특정 암종의 예후를 예측하는\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### - 다수의 면역 분석 시험에서 얻은 정량적인 결과들을 종합하여 환자가 어떤\n\n<!-- PAGE_9 -->\n###### - 환자의 나이, 성별, 다양한 유전자 발현 양상을 종합하여 질병의 진단 또는\n\n<!-- PAGE_9 -->\n###### 다.  체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n",
        "original_sentence": "<!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 1202,
        "word_count": 206,
        "page_number": 10,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)에서 제외되는 의료기기는 다음과 같다.\n\n <!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값. ",
        "original_sentence": "기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 613,
        "word_count": 105,
        "page_number": 10,
        "window_text": "<!-- PAGE_9 -->\n###### 1) 의료기기 사용에서 충분한 경험과 훈련이 필요하나 사용 미숙으로 인하여\n\n<!-- PAGE_9 -->\n###### 임상의가 다르게 해석할 수 있는 다양한 검사를 환자 개인의 특정 결과로\n\n<!-- PAGE_9 -->\n###### 종합하여 판독을 쉽게 하는 의료기기\n\n* (예, 표준 산모 삼중검사: 임신 4개월째 AFP, hCG, estriol 측정을 기본으로 산모의\n\n<!-- PAGE_9 -->\n###### 2) 표현형과의 연관성이 확립된 유전자형을 확인하는 목적의 의료기기로 독특한\n\n<!-- PAGE_9 -->\n###### 판독 기능(알고리즘)을 포함하지 않지만 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 의료기기\n\n<!-- PAGE_9 -->\n###### 3) 염색체 수 이상을 확인하는 의료기기로 독특한 해석 기능을 포함하지 않지만\n\n<!-- PAGE_9 -->\n###### 임상의들\n\n<!-- PAGE_9 -->\n###### 스스로\n\n<!-- PAGE_9 -->\n###### 판단할\n\n<!-- PAGE_9 -->\n###### 수\n\n<!-- PAGE_9 -->\n###### 있도록\n\n<!-- PAGE_9 -->\n###### 개별\n\n<!-- PAGE_9 -->\n###### 변수들에\n\n<!-- PAGE_9 -->\n###### 대한\n\n<!-- PAGE_9 -->\n###### 표준적인\n\n<!-- PAGE_9 -->\n###### 해석을\n\n<!-- PAGE_9 -->\n###### 4) 비록 여러\n\n<!-- PAGE_9 -->\n###### 가지 변수들을 측정하여 하나의\n\n<!-- PAGE_9 -->\n###### 결과를 계산해 낼 수\n\n<!-- PAGE_9 -->\n###### 있으나,\n\n<!-- PAGE_9 -->\n###### 독특한 해석 기능을 포함하지 않으며 임상의들 스스로 판단할 수 있는 개별\n\n<!-- PAGE_9 -->\n###### 변수들에 대한 표준적인 해석을 제공하는 일반적인 임상수치 계산을 위한\n\n<!-- PAGE_9 -->\n###### 의료기기\n\n<!-- PAGE_9 -->\n###### 5) 알고리즘을 이용하여 임상의들이 스스로 표준 범위를 벗어나는 결과들, 약물\n\n<!-- PAGE_9 -->\n###### 상호작용 가능성, 보충 시험의 기회 등 특이적 임상 변수들에 기초하여 환자\n\n<!-- PAGE_9 -->\n###### 치료\n\n<!-- PAGE_9 -->\n###### 결과의\n\n<!-- PAGE_9 -->\n###### 구분.\n\n <!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n",
        "original_sentence": "검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n"
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "<!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 352,
        "word_count": 58,
        "page_number": 10,
        "window_text": "<!-- PAGE_9 -->\n###### 질병등록정보의\n\n<!-- PAGE_9 -->\n###### 생성,\n\n<!-- PAGE_9 -->\n###### 환자특이적인\n\n<!-- PAGE_9 -->\n###### 정보를\n\n<!-- PAGE_9 -->\n###### 종합보고서\n\n<!-- PAGE_9 -->\n###### 형태로 요약, 환자에 대한 처치 및 질병의 결과 등을 추적하기 위해 저장된\n\n6\n\n- - 6 -\n<!-- PAGE_10 -->\n###### 임상 정보들을 분석하여 임상적인 결정을 돕는 의료기기\n\n<!-- PAGE_10 -->\n###### 6) 상호 검토된 간행물, 실질적 가이드라인 등을 통해 널리 보급되어 임상에서\n\n<!-- PAGE_10 -->\n###### 일반적으로\n\n<!-- PAGE_10 -->\n###### 자유롭게\n\n<!-- PAGE_10 -->\n###### 사용되고\n\n<!-- PAGE_10 -->\n###### 있고\n\n<!-- PAGE_10 -->\n###### 임상의\n\n<!-- PAGE_10 -->\n###### 자신들의\n\n<!-- PAGE_10 -->\n###### 의학적\n\n<!-- PAGE_10 -->\n###### 지식과\n\n<!-- PAGE_10 -->\n###### 의학계에서 일반적으로 통용되는 정보들을 이용하여 계산하고 해석할 수 있는\n\n<!-- PAGE_10 -->\n###### 일반적인 인구통계학적 위해도 계산법\n\n<!-- PAGE_10 -->\n###### 4.  기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다. ",
        "original_sentence": "<!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n"
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "<!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 9706,
        "word_count": 1705,
        "page_number": 10,
        "window_text": "기본 용어 설명\n\n<!-- PAGE_10 -->\n###### ※ 본 민원인 안내서(가이드라인)에서 사용되는 용어의 정의는 동 가이드라인의\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 간섭물질(Interfering\n\n<!-- PAGE_10 -->\n###### substances)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 임상\n\n<!-- PAGE_10 -->\n###### 검체에\n\n<!-- PAGE_10 -->\n###### 존재하는\n\n<!-- PAGE_10 -->\n###### 내부물질(혈액\n\n<!-- PAGE_10 -->\n###### 구성요소, acidic polysaccharides) 또는 외부물질(항응고제 등)로 위양성 또는\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 강건성(Robustness) : 검출될 수 있는 분석 물질의 최소량 분석과정에서 작지만\n\n<!-- PAGE_10 -->\n###### 미묘한 파라미터의 변화가 생겼을 때 그것에 영향을 받지 않는 것을 의미하며\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 교차반응(Cross-reactivity)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 항원\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 공유되었거나,\n\n<!-- PAGE_10 -->\n###### 유사한\n\n<!-- PAGE_10 -->\n###### 또는\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 기질효과(Matrix\n\n<!-- PAGE_10 -->\n###### effect)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 측정하고자\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 분석물질\n\n<!-- PAGE_10 -->\n###### 이외에\n\n<!-- PAGE_10 -->\n###### 검체의\n\n<!-- PAGE_10 -->\n###### 특성이\n\n<!-- PAGE_10 -->\n###### 분석물질의 측정에 영향을 미치는 경우.  검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5. ",
        "original_sentence": "<!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 3480,
        "word_count": 651,
        "page_number": 14,
        "window_text": "검체의 점성, 표면장력, 혼탁도, 이온\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 내부\n\n<!-- PAGE_10 -->\n###### 대조물질(Internal\n\n<!-- PAGE_10 -->\n###### control)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 동일한\n\n<!-- PAGE_10 -->\n###### 검체\n\n<!-- PAGE_10 -->\n###### 튜브에\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하지\n\n<!-- PAGE_10 -->\n###### 않는\n\n<!-- PAGE_10 -->\n###### 염기서열을\n\n<!-- PAGE_10 -->\n###### 넣어서\n\n<!-- PAGE_10 -->\n###### 목표로\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 염기서열과\n\n<!-- PAGE_10 -->\n###### 동시에\n\n<!-- PAGE_10 -->\n###### 증폭되게\n\n<!-- PAGE_10 -->\n###### 하는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1. ",
        "original_sentence": "정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n"
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 702,
        "word_count": 131,
        "page_number": 15,
        "window_text": "<!-- PAGE_10 -->\n###### Thermal cycler의 오작동, 시약의 적절성, 중합효소의 활성 또는 방해물질에\n\n<!-- PAGE_10 -->\n###### §\n\n<!-- PAGE_10 -->\n###### 대조물질(Control/Control\n\n<!-- PAGE_10 -->\n###### material)\n\n<!-- PAGE_10 -->\n###### :\n\n<!-- PAGE_10 -->\n###### 정도\n\n<!-- PAGE_10 -->\n###### 관리를\n\n<!-- PAGE_10 -->\n###### 위해\n\n<!-- PAGE_10 -->\n###### 이용되는\n\n<!-- PAGE_10 -->\n###### 물질.\n\n <!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다. ",
        "original_sentence": "<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 1339,
        "word_count": 254,
        "page_number": 16,
        "window_text": "<!-- PAGE_10 -->\n###### 면역분석법, 면역측정법(Immunoassay) 분석물질에 결합 가능한 특이 항원이나\n\n<!-- PAGE_10 -->\n###### ☞ 항체를 사용하여 물질을 측정하는 검사법으로 면역분석법은 경쟁적 또는\n\n<!-- PAGE_10 -->\n###### 비경쟁적, 고체상 또는 액체상, 동위원소 또는 비동위원소, 항원표지 또는\n\n<!-- PAGE_10 -->\n###### 항체표지, 단일 또는 이중 부위, 균질적 또는 비균질적 방법일 수 있음\n\n7\n\n- - 7 -\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 동등성 평가에 대한 시험 또는 동등성 시험(Concordance study) : 체외진단의\n\n<!-- PAGE_11 -->\n###### 감지 또는 측정의 정확성을 담보하기 위해 적절한 대조 체외진단(기준이 되는\n\n<!-- PAGE_11 -->\n###### 측정법 또는 임상시험에서 사용된 측정법 등)과 해당 체외진단의 판정 일치율\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 바이오마커(Biomarker) : 생체 내에 존재하는 생물학적 표지물질로써 질병의\n\n<!-- PAGE_11 -->\n###### 진단, 예후, 치료에 대한 반응 등을 나타내거나 예측할 수 있는 물질로 측정\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 발현(Expression) : 유전자를 구성하는 유전 정보, 즉 유전자에 의해 생물을\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정(Calibration) : 특별한 조건하에서 측정 기기나 측정 시스템이 나타내는 값\n\n<!-- PAGE_11 -->\n###### 또는\n\n<!-- PAGE_11 -->\n###### 측정물질이나\n\n<!-- PAGE_11 -->\n###### 참고물질에\n\n<!-- PAGE_11 -->\n###### 의한\n\n<!-- PAGE_11 -->\n###### 값과\n\n<!-- PAGE_11 -->\n###### 표준물질에\n\n<!-- PAGE_11 -->\n###### 상응하는\n\n<!-- PAGE_11 -->\n###### 값\n\n<!-- PAGE_11 -->\n###### 사이의\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 보정물질(Calibrator / Calibration material) :\n\n<!-- PAGE_11 -->\n###### 측정과정을\n\n<!-- PAGE_11 -->\n###### 보정하거나\n\n<!-- PAGE_11 -->\n###### 검체의\n\nF 보정물질에서\n\n분석물질\n\n양은\n\n그의\n\n제조과정에서\n\n확인된\n\n한계(limit)\n\n내에\n\n있으며,\n\nF 보정물질은 국가 또는 국제 표준물질이나 참고물질에 소급성(traceability)을 가져야 함\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석물질(Analyte) : 검사에 사용되는 물질 또는 구성요소\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석법 검증(Analytical test validation) : 분석법에 대한 적절한 정도 관리 등을\n\n<!-- PAGE_11 -->\n###### 행하여\n\n<!-- PAGE_11 -->\n###### 어떤\n\n<!-- PAGE_11 -->\n###### 분석법이\n\n<!-- PAGE_11 -->\n###### 분석\n\n<!-- PAGE_11 -->\n###### 대상물을\n\n<!-- PAGE_11 -->\n###### 정확하게\n\n<!-- PAGE_11 -->\n###### 측정하고,\n\n<!-- PAGE_11 -->\n###### 그\n\n<!-- PAGE_11 -->\n###### 결과를\n\n<!-- PAGE_11 -->\n###### 높은\n\n<!-- PAGE_11 -->\n###### 재현성으로 얻을 수 있음을 확인함으로써 사용 목적에 맞는 신뢰할 수 있는\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 분석적\n\n<!-- PAGE_11 -->\n###### 특이도(Analytical\n\n<!-- PAGE_11 -->\n###### specificity)\n\n<!-- PAGE_11 -->\n###### :\n\n<!-- PAGE_11 -->\n###### 검사에서\n\n<!-- PAGE_11 -->\n###### 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는\n\n<!-- PAGE_11 -->\n###### 물질만\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 신뢰구간(Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이 정해진\n\n<!-- PAGE_11 -->\n###### §\n\n<!-- PAGE_11 -->\n###### 양성 예측도(Positive Predictive Value, PPV) : 표적 질환(진단 정확도 기준으로\n\n<!-- PAGE_11 -->\n###### 결정되는)을 가지고 있는 환자에서 양성 결과를 보이는 비율\n\n8\n\n- - 8 -\nF a)\n\n양성\n\n예측도(PPV)는\n\n반드시\n\n관심대상\n\n조건(진단\n\n정확도\n\n기준으로\n\n결정되는)의\n\n유병률에 맞추어 해석\n\n  \n\n은  ×\n\n  \n\n\n\n로 계산\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 에이비씨에스지 임상시험(Austrian Breast & Colorectal Cancer Study Group,\n\n<!-- PAGE_12 -->\n###### ABCSG clinical test) : 유방암과 직장암을 연구하기위해 설립된 호주 최대의\n\n§\n\n<!-- PAGE_12 -->\n###### 오믹스(Omics) : 유전체학(Genomics)이나 단백체학(Proteomics) 등 생물 데이터\n\n<!-- PAGE_12 -->\n###### 전체를\n\n<!-- PAGE_12 -->\n###### 집약하여\n\n<!-- PAGE_12 -->\n###### 해석하는\n\n<!-- PAGE_12 -->\n###### 연구\n\n영역(초고속\n\n유전자\n\n서열\n\n분석\n\n기술의\n\n발전은\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 무재발\n\n<!-- PAGE_12 -->\n###### 생존률(Distant\n\n<!-- PAGE_12 -->\n###### Recurrence-Free\n\n<!-- PAGE_12 -->\n###### Survival,\n\n<!-- PAGE_12 -->\n###### DRFS)\n\n<!-- PAGE_12 -->\n###### :\n\n<!-- PAGE_12 -->\n###### 원격\n\n<!-- PAGE_12 -->\n###### 재발\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위양성(False positive, FP) : 질병이나 증상이 없는 음성 환자나 음성 검체에서\n\n<!-- PAGE_12 -->\n###### §\n\n<!-- PAGE_12 -->\n###### 위음성(False negative, FN) : 질병이나 증상이 있는 양성 환자나 양성 검체에서\n\n<!-- PAGE_12 -->\n###### 음성으로 나온 검사 결과\n\n9\n\n- - 9 -\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 판정기준치(Clinical cut-off) : 체외진단다지표검사용 의료기기에서의 임상\n\n<!-- PAGE_13 -->\n###### 판정치는 알고리즘 산출값의 결과로 검사대상자를 정상(비위험군)과 비정상(위험군)을\n\n<!-- PAGE_13 -->\n###### 구분하는 기준값을 의미\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 검증(Clinical test validation) : 민감도(질병 또는 표현형이 있을 때의\n\n<!-- PAGE_13 -->\n###### 양성율),\n\n<!-- PAGE_13 -->\n###### 특이도(질병\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 표현형이\n\n<!-- PAGE_13 -->\n###### 없을\n\n<!-- PAGE_13 -->\n###### 때의\n\n<!-- PAGE_13 -->\n###### 음성율)\n\n<!-- PAGE_13 -->\n###### 등의\n\n<!-- PAGE_13 -->\n###### 정보에\n\n<!-- PAGE_13 -->\n###### 따라\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 민감도(Clinical sensitivity) : 특정질환을 가지고 있는 사람들 중 검사\n\n<!-- PAGE_13 -->\n###### 결과가 양성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 유효성(Clinical efficacy) : 체외진단다지표검사용 의료기기(IVD-MIA)의\n\n<!-- PAGE_13 -->\n###### 임상적\n\n<!-- PAGE_13 -->\n###### 유효성이란\n\n<!-- PAGE_13 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_13 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_13 -->\n###### 이용하여\n\n<!-- PAGE_13 -->\n###### 바이오마커에 대해 수행한 시험이 환자의 질병 또는 다른 환자의 상태에 대한\n\n<!-- PAGE_13 -->\n###### 판단 근거를 제공할 수 있는 성능\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 임상적 특이도(Clinical specificity) : 특정질환을 가지고 있지 않은 사람들 중\n\n<!-- PAGE_13 -->\n###### 검사 결과가 음성으로 나오는 비율\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 재현성(Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의 결과값\n\n<!-- PAGE_13 -->\n###### 사이의 일치도의 근접성\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정밀도(Precision)\n\n<!-- PAGE_13 -->\n###### 시험:\n\n<!-- PAGE_13 -->\n###### 동일\n\n<!-- PAGE_13 -->\n###### 검체를\n\n<!-- PAGE_13 -->\n###### 일정기간\n\n<!-- PAGE_13 -->\n###### 동안\n\n<!-- PAGE_13 -->\n###### 반복\n\n<!-- PAGE_13 -->\n###### 측정한\n\n<!-- PAGE_13 -->\n###### 결과를\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 정확도(Accuracy)\n\n<!-- PAGE_13 -->\n###### 시험: 표준물질의\n\n<!-- PAGE_13 -->\n###### 목표\n\n<!-- PAGE_13 -->\n###### 결과와\n\n<!-- PAGE_13 -->\n###### 실측 결과(정량검사의\n\n<!-- PAGE_13 -->\n###### 경우\n\n<!-- PAGE_13 -->\n###### 결과 값과 bias)를 제시하고, 양성 및 음성대조물질의 제조방법, 설정 농도 및\n\n<!-- PAGE_13 -->\n###### 반복 측정 결과를 기술하는 시험\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 직선성(Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례하는 결과를\n\n<!-- PAGE_13 -->\n###### 제공할 수 있는 능력\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진단\n\n<!-- PAGE_13 -->\n###### 검사(Diagnostic\n\n<!-- PAGE_13 -->\n###### test)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 특정\n\n<!-- PAGE_13 -->\n###### 질환의\n\n<!-- PAGE_13 -->\n###### 진단,\n\n<!-- PAGE_13 -->\n###### 예방,\n\n<!-- PAGE_13 -->\n###### 치료\n\n<!-- PAGE_13 -->\n###### 또는\n\n<!-- PAGE_13 -->\n###### 개개의\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진양성(True\n\n<!-- PAGE_13 -->\n###### Positive,\n\n<!-- PAGE_13 -->\n###### TP)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 양성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 양성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 진음성(True\n\n<!-- PAGE_13 -->\n###### Negative,\n\n<!-- PAGE_13 -->\n###### TN)\n\n<!-- PAGE_13 -->\n###### :\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 환자나\n\n<!-- PAGE_13 -->\n###### 음성\n\n<!-- PAGE_13 -->\n###### 검체에서\n\n<!-- PAGE_13 -->\n###### 검사의\n\n<!-- PAGE_13 -->\n###### 음성판정이\n\n<!-- PAGE_13 -->\n###### §\n\n<!-- PAGE_13 -->\n###### 참고물질/참고제작(Reference Material, RM / Reference preparation)\n\n<!-- PAGE_13 -->\n###### 1) 하나 또는 그 이상의 특성값이 충분히 균일하고 기구의 보정, 측정 방법의\n\n<!-- PAGE_13 -->\n###### 평가 또는 물질에 값을 할당하기 위해서 사용되는 물질\n\n10\n\n- - 10 -\n<!-- PAGE_14 -->\n###### 2)\n\n<!-- PAGE_14 -->\n###### 인증참고물질(Certified\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### CRM)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 기술적으로\n\n<!-- PAGE_14 -->\n###### 입증된\n\n<!-- PAGE_14 -->\n###### 과정으로\n\n<!-- PAGE_14 -->\n###### 공인되었고\n\n<!-- PAGE_14 -->\n###### 인증서나\n\n<!-- PAGE_14 -->\n###### 다른\n\n<!-- PAGE_14 -->\n###### 인증기관에서\n\n<!-- PAGE_14 -->\n###### 발행된\n\n<!-- PAGE_14 -->\n###### 서류가\n\n<!-- PAGE_14 -->\n###### 있거나\n\n<!-- PAGE_14 -->\n###### 추적 가능한 하나 또는 그 이상의 값을 갖는 참고 물질\n\n<!-- PAGE_14 -->\n###### a) 인증참고물질(CRM)은 인증서가 있는 참고물질로써 하나 또는 그 이상의\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 절차에\n\n<!-- PAGE_14 -->\n###### 따라\n\n<!-- PAGE_14 -->\n###### 공인되며,\n\n<!-- PAGE_14 -->\n###### 그\n\n<!-- PAGE_14 -->\n###### 절차는\n\n<!-- PAGE_14 -->\n###### 특성값이\n\n<!-- PAGE_14 -->\n###### 표현되는\n\n<!-- PAGE_14 -->\n###### 단위의\n\n<!-- PAGE_14 -->\n###### 정확한\n\n<!-- PAGE_14 -->\n###### 구현에\n\n<!-- PAGE_14 -->\n###### 대한\n\n<!-- PAGE_14 -->\n###### 추적을\n\n<!-- PAGE_14 -->\n###### 할\n\n<!-- PAGE_14 -->\n###### 수\n\n<!-- PAGE_14 -->\n###### 있고,\n\n<!-- PAGE_14 -->\n###### 그것에\n\n<!-- PAGE_14 -->\n###### 대해\n\n<!-- PAGE_14 -->\n###### 각\n\n<!-- PAGE_14 -->\n###### 공인된\n\n<!-- PAGE_14 -->\n###### 값은\n\n<!-- PAGE_14 -->\n###### b)\n\n<!-- PAGE_14 -->\n###### 표준참고물질(Standard\n\n<!-- PAGE_14 -->\n###### Reference\n\n<!-- PAGE_14 -->\n###### Material,\n\n<!-- PAGE_14 -->\n###### SRM)은\n\n<!-- PAGE_14 -->\n###### 인증참고물질(CRM)의\n\n<!-- PAGE_14 -->\n###### 하나로써\n\n<!-- PAGE_14 -->\n###### 국립표준기술\n\n<!-- PAGE_14 -->\n###### 연구소(National\n\n<!-- PAGE_14 -->\n###### Institute\n\n<!-- PAGE_14 -->\n###### of\n\n<!-- PAGE_14 -->\n###### Science\n\n<!-- PAGE_14 -->\n###### and\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 측정가능범위(Analytical measurement range, AMR) : 일상적인 측정 과정의\n\n<!-- PAGE_14 -->\n###### 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤 검사법이 검체에서 직접\n\n<!-- PAGE_14 -->\n###### 측정할 수 있는 분석물질 값의 범위\n\n§\n\n최소검출한계(Limit of detection) : 일관되게 검출되는 최소 농도 값(표준물질,\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 특이도/분석적\n\n<!-- PAGE_14 -->\n###### 특이도(Specificity/Analytical\n\n<!-- PAGE_14 -->\n###### specificity)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 측정하고자\n\n<!-- PAGE_14 -->\n###### 하는\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 판정기준치(Cut-off\n\n<!-- PAGE_14 -->\n###### value)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 정성검사에서\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 이상을\n\n<!-- PAGE_14 -->\n###### 양성으로,\n\n<!-- PAGE_14 -->\n###### 경계치\n\n<!-- PAGE_14 -->\n###### 미만을 음성으로 판정하는 경계값.  정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다. ",
        "original_sentence": "온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 305,
        "word_count": 56,
        "page_number": 17,
        "window_text": "정량검사에서는 측정 결과가 임상적 또는\n\n<!-- PAGE_14 -->\n###### 분석적\n\n<!-- PAGE_14 -->\n###### 결정점(Decision\n\n<!-- PAGE_14 -->\n###### point)의\n\n<!-- PAGE_14 -->\n###### 위나\n\n<!-- PAGE_14 -->\n###### 아래에\n\n<!-- PAGE_14 -->\n###### 있는지(양성\n\n<!-- PAGE_14 -->\n###### 또는\n\n<!-- PAGE_14 -->\n###### 음성)\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 핵산추출(Nucleic\n\n<!-- PAGE_14 -->\n###### acid\n\n<!-- PAGE_14 -->\n###### extraction)\n\n<!-- PAGE_14 -->\n###### :\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### 증폭하고\n\n<!-- PAGE_14 -->\n###### 분석하기\n\n<!-- PAGE_14 -->\n###### 위해\n\n<!-- PAGE_14 -->\n###### 핵산을\n\n<!-- PAGE_14 -->\n###### ※ 부록에 사용된 용어\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 경계 사이클(Threshold cycle, Ct) : 형광 신호 값이 배경(baseline) 값을 넘어서\n\n<!-- PAGE_14 -->\n###### 감지되는 시점의 사이클 수(cycle number)\n\nF 경계 사이클(Ct)은 배경값 수준의 형광신호를 벗어난 사이클 수를 의미하는 것으로\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 바이어스(Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n<!-- PAGE_14 -->\n###### §\n\n<!-- PAGE_14 -->\n###### 상관계수(Correlation coefficient, r) : 측정된 데이터에 대한 두 개의 무작위\n\n<!-- PAGE_14 -->\n###### 변수의 공분산(covariance)과 그들의 표준편차의 곱의 비(ratio)\n\n11\n\n- - 11 -\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 선별검사(Screening test) : 특정질환의 증상이 없어 의학적 주의를 받지 못하는\n\n<!-- PAGE_15 -->\n###### 사람들 중에 해당질환의 고위험군을 발견하여 추가적인 관찰이나 직접적 예방\n\n<!-- PAGE_15 -->\n###### 활동을 하기 위한 체계적인 검사\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 세포주(Cell line) : 세포 배양을 통해 지속적으로 수를 증가시키는 세포들이며,\n\n<!-- PAGE_15 -->\n###### 세포주를\n\n<!-- PAGE_15 -->\n###### 구성하는\n\n<!-- PAGE_15 -->\n###### 세포들이\n\n<!-- PAGE_15 -->\n###### 한\n\n<!-- PAGE_15 -->\n###### 가지\n\n<!-- PAGE_15 -->\n###### 클론에서\n\n<!-- PAGE_15 -->\n###### 유래하므로\n\n<!-- PAGE_15 -->\n###### 모두\n\n<!-- PAGE_15 -->\n###### 동일한\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 수송 안정성 실험(Transport stability test) : 제품 운송 도중 발생 가능한 환경\n\n<!-- PAGE_15 -->\n###### 변화가 제품 성능에 미치는 영향을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 실시간 안정성 실험(Real time stability) : 시약을 정상적인 상황에서 일반적인\n\n<!-- PAGE_15 -->\n###### 보관 상황과 시약의 사용하는 환경에서의 안정성을 평가하는 실험\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 역가(Titer)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 주어진\n\n<!-- PAGE_15 -->\n###### 시스템에서\n\n<!-- PAGE_15 -->\n###### 정해진\n\n<!-- PAGE_15 -->\n###### 결과를\n\n<!-- PAGE_15 -->\n###### 내는데\n\n<!-- PAGE_15 -->\n###### 필요한\n\n<!-- PAGE_15 -->\n###### 희석율에\n\n<!-- PAGE_15 -->\n###### 상당하는 수치 또는 방사면역측정법에서 주어진 조건하에 방사표지 분석물질의\n\n<!-- PAGE_15 -->\n###### 특정 백분율이 결합하는 항체의 희석율\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 예후(Distanct Metastasis Prognosis) : 환자의 상태나 질병의 결과에 대한 예측\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 인간 표피 증식 인자 수용체(Human Epithelial Receptor, HER) : 유방암에서\n\n<!-- PAGE_15 -->\n###### 높은 활동을 보이는 단백질로 ERBB2 유전자에 암호화되어 있으며, 유방암에서\n\n<!-- PAGE_15 -->\n###### HER의 과발현은 질병 재발을 더 높게 하고 더 나쁜 예후를 보여줌\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 임상적 보고가능 범위(Clinically Reportable Range, CRR) : 분석 측정범위를\n\n<!-- PAGE_15 -->\n###### 연장하기 위해 검체에 대한 희석, 농축, 또는 기타 전처리를 하여 정량 결과\n\n<!-- PAGE_15 -->\n###### 값으로 보고할 수 있는 분석물질 값의 범위\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 재현성 조건(Reproducibility condition) : 동일한 방법과 동일한 검사 품목으로\n\n<!-- PAGE_15 -->\n###### 다른 검사실에서 다른 사용자가 다른 장비를 사용하여 검사 결과를 얻는 조건\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전사물(Transcript) : DNA에서 RNA 중합효소의 작용으로 합성되는 RNA\n\n<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전위(Translocation) : 염색체의 일부가 위치를 바꾸어 이동하는 현상\n\nF (예, 만성골수백혈병 환자에서는 9번 염색체와 22번 염색체의 각각에서 일정 부분이\n\n절 단 된\n\n후\n\n두\n\n조 각 이\n\n서 로\n\n위 치 를\n\n바 꾸 어\n\n이 동 하 는\n\n현 상 이\n\n일 어 난 다 .\n\n <!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n",
        "original_sentence": "관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 775,
        "word_count": 125,
        "page_number": 19,
        "window_text": "<!-- PAGE_15 -->\n###### §\n\n<!-- PAGE_15 -->\n###### 전이(Metastasis)\n\n<!-- PAGE_15 -->\n###### :\n\n<!-- PAGE_15 -->\n###### 장기\n\n<!-- PAGE_15 -->\n###### 내지\n\n<!-- PAGE_15 -->\n###### 조직에\n\n<!-- PAGE_15 -->\n###### 발생한\n\n<!-- PAGE_15 -->\n###### 암병소를\n\n<!-- PAGE_15 -->\n###### 원발소라\n\n<!-- PAGE_15 -->\n###### 하며,\n\n<!-- PAGE_15 -->\n###### 원발소에서 암세포가 떠나 다른 장기, 조직에 붙어 증식하는 상태\n\n12\n\n- - 12 -\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 정규분포(Normal distribution) : 가우시안 분포라고 불리며 측정값을 곡선의\n\n<!-- PAGE_16 -->\n###### x축에, 관측치의 빈도를 곡선의 y축에 표시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 조합의료기기 : 2가지 이상의 의료기기가 모여 하나의 의료기기가 되는 것으로써\n\n<!-- PAGE_16 -->\n###### 복합적인 기능을 발휘하는 의료기기\n\nF (예, 의료용 진동기와 온열기의 기능이 결합된 의료기기가 있다.  온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 155,
        "word_count": 29,
        "page_number": 19,
        "window_text": "온열과 진동 기능이\n\n동시에 동작할 경우, 각각의 기능들의 합이 아닌 새로운 복합 기능을 보이는데 위와 같이\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 중합효소(polymerase) : 핵산의 중합반응을 일으키는 효소\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 참고구간(Reference interval) : 상하 두 개의 참고 한계치 내의 간격\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 측정 시스템의 민감도(Sensitivity of a measuring system) : 측정 시스템 표시\n\n<!-- PAGE_16 -->\n###### 도수의 변화 및 측정된 양의 값의 변화계수\n\nF 측정시스템의 민감도는 측정된 양의 크기에 의존하며 측정된 양의 값 변경은 반드시\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 탐색자(Probe) : 상보적 염기서열을 가지고 있는 특정 DNA나 RNA를 동정하는\n\n<!-- PAGE_16 -->\n###### 목적으로 사용하는 단일가닥 핵산\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프라이머(Primer) : DNA 중합효소와 nucleotide triphosphates와 같이 목표 DNA에\n\n<!-- PAGE_16 -->\n###### 상보적으로 결합하여 DNA 합성을 시작할 수 있게 하는 Oligonucleotide\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 프로빗 분석(Probit Analysis) : 여러 단위의 스트레스 또는 자극을 적용한 후,\n\n<!-- PAGE_16 -->\n###### 장비 또는 알고리즘의 이상 여부를 파악하는 통계적 분석\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항암화학요법(Chemotherapy)\n\n<!-- PAGE_16 -->\n###### :\n\n<!-- PAGE_16 -->\n###### 항암제를\n\n<!-- PAGE_16 -->\n###### 사용하여\n\n<!-- PAGE_16 -->\n###### 암을\n\n<!-- PAGE_16 -->\n###### 치료하는\n\n<!-- PAGE_16 -->\n###### 요법으로\n\n<!-- PAGE_16 -->\n###### §\n\n<!-- PAGE_16 -->\n###### 항원(Antigen) : 체내 항체 생성을 유발하고 항체와 특이적으로 결합할 수 있는 물질\n\n13\n\n- - 13 -\n<!-- PAGE_17 -->\n###### 5.  관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n",
        "original_sentence": "국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 95,
        "word_count": 21,
        "page_number": 19,
        "window_text": "관련 법령\n\n<!-- PAGE_17 -->\n###### §\n\n<!-- PAGE_17 -->\n###### 본 민원인 안내서(가이드라인)은 권고 사항이지만, 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_17 -->\n###### 식품의약품안전처의 품목 분류상 체외진단용 의료기기의 일종이므로, 의료기기법 아래에서\n\n<!-- PAGE_18 -->\n# 제Ⅱ부  허가·심사시 고려사항\n\n15\n\n- - 15 -\n<!-- PAGE_19 -->\n##### 제 Ⅱ 부  허가·심사시 고려사항\n\n<!-- PAGE_19 -->\n###### 1.  체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n",
        "original_sentence": "다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 298,
        "word_count": 52,
        "page_number": 19,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA) 허가·심사시 주요 고려 사항\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 기본 구성은 체외진단다지표검사\n\n<!-- PAGE_19 -->\n###### 시약(이하, 다지표시약)과 분석장비 및 알고리즘으로 구성되어 있으며, 분석장비와\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 인체에서 유래된 검체를 사용하는 체외진단다지표검사용 의료기기(IVD-MIA)는\n\n<!-- PAGE_19 -->\n###### 제품 구성과 무관하게 다중 마커를 검출해 정량하는 시스템의 성능을 보장해야 하고,\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능과 함께 알고리즘의 임상적\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)를 명확히 검정하고 표시기재(label)에\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 해외에서 수입되는 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 검사를\n\n<!-- PAGE_19 -->\n###### 구성하는 바이오마커들에 대한 인종유전학적(ethnogenetic) 부분 등을 반드시 고려\n\n<!-- PAGE_19 -->\n###### 해야 한다.  국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2. ",
        "original_sentence": "<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 282,
        "word_count": 52,
        "page_number": 19,
        "window_text": "국내 환자군을 대상으로 하는 임상시험 수행을 통하여 해당 검사의\n\n<!-- PAGE_19 -->\n###### 구성요소인 알고리즘이 한국인에게도 적합한 것인지에 대한 검증과 최적화\n\n<!-- PAGE_19 -->\n###### (optimization)를 수행하는 것을 권고한다.  다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n",
        "original_sentence": "그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 232,
        "word_count": 37,
        "page_number": 20,
        "window_text": "다만, 각 바이오마커들에 대한 인종적인\n\n<!-- PAGE_19 -->\n###### 차이가 없다는 검증 자료가 있는 경우에는 위에 언급된 사항에 대한 생략이 가능하다.\n\n <!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n",
        "original_sentence": "16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "<!-- PAGE_20 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 20,
        "window_text": "<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 이미 허가된 체외진단검사에 알고리즘을 추가하여 체외진단다지표검사용 의료\n\n<!-- PAGE_19 -->\n###### 기기(IVD-MIA)로 허가 받거나 체외진단다지표검사용 의료기기(IVD-MIA)에 새로운\n\n<!-- PAGE_19 -->\n###### 표시기재(label) 사항을 추가하는 경우, 바이오마커들의 분석적 성능 자료는 상황에\n\n<!-- PAGE_19 -->\n###### 따라 이전에 시험한 분석적 성능시험 자료로 갈음할 수 있다.  그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3. ",
        "original_sentence": "<!-- PAGE_20 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 152,
        "word_count": 27,
        "page_number": 20,
        "window_text": "그렇지만 사용목적이\n\n<!-- PAGE_19 -->\n###### 추가되거나 변경된 경우엔, 임상적 성능시험을 통하여 알고리즘 검정을 필히 수행\n\n<!-- PAGE_19 -->\n###### §\n\n<!-- PAGE_19 -->\n###### 다만, 이미 허가된 체외진단다지표검사용 의료기기(IVD-MIA)를 새로운 환자군에 적용\n\n<!-- PAGE_19 -->\n###### 하고자 하는 경우, 새로운 환자군에 알고리즘이 임상적으로 유효한지 반드시\n\n<!-- PAGE_19 -->\n###### 검토해야 한다.\n\n 16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n",
        "original_sentence": "공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 345,
        "word_count": 60,
        "page_number": 20,
        "window_text": "16\n\n- - 16 -\n<!-- PAGE_20 -->\n###### leave-one-out cross validation, bootstrap 등이 있는데 일부 데이터(training\n\n<!-- PAGE_20 -->\n###### set)를 이용하여 알고리즘을 개발하고, 나머지 데이터(testing set)를 이용하여\n\n<!-- PAGE_20 -->\n###### 검정(validation)하는 방법 등을 권고한다.\n\n <!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 331,
        "word_count": 65,
        "page_number": 20,
        "window_text": "<!-- PAGE_20 -->\n###### 2.  공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다. ",
        "original_sentence": "※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 146,
        "word_count": 25,
        "page_number": 21,
        "window_text": "공통 고려사항\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 확보를 위해 위험 요소 기반의\n\n<!-- PAGE_20 -->\n###### 접근법을 적용하는 것이 타당하다.\n\n <!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4. ",
        "original_sentence": "사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "<!-- PAGE_21 -->\n###### 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 21,
        "window_text": "<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘을 수식으로 제공하지 않고\n\n<!-- PAGE_20 -->\n###### 1) 동일 제조원에서 체외진단용 시약과 소프트웨어(CD, USB 또는 앱)를 같이\n\n<!-- PAGE_20 -->\n###### 2) 허가된 체외진단용 의료기기(시약, 장비)를 이용하여 알고리즘만을 개발한 경우, 시약과\n\n<!-- PAGE_20 -->\n###### 장비가 알고리즘 개발 당시와 동일함을 확인하고, 알고리즘(소프트웨어)만을 허가․\n\n<!-- PAGE_20 -->\n###### 심사한다.\n\n ※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가. ",
        "original_sentence": "<!-- PAGE_21 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 461,
        "word_count": 82,
        "page_number": 21,
        "window_text": "※ 알고리즘 개발 후, 시약 또는 장비의 변경이 결과값에 영향을 줄 경우, 해당 알고리즘\n\n<!-- PAGE_20 -->\n###### §\n\n<!-- PAGE_20 -->\n###### 허가·심사를 신청하는 체외진단다지표검사용 의료기기(IVD-MIA)는 검사가 의도\n\n<!-- PAGE_20 -->\n###### 하는 결과(위험성, 재발가능성 등)를 명확히 제시해야 하며, 체외진단다지표검사용\n\n<!-- PAGE_20 -->\n###### 의료기기(IVD-MIA)를 적용할 수 있는 대상 환자군을 정확히 정의할 것을 권고한다\n\n17\n\n- - 17 -\n<!-- PAGE_21 -->\n###### 3.  사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n",
        "original_sentence": "사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 68,
        "word_count": 15,
        "page_number": 21,
        "window_text": "사용목적 설정시 주요 고려사항\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 사용목적 설정은 일반적인 체외진단용\n\n<!-- PAGE_21 -->\n###### 의료기기와 유사하나 다음의 사항을 특히 고려하여야 한다.\n\n <!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다. ",
        "original_sentence": "암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 60,
        "word_count": 9,
        "page_number": 21,
        "window_text": "<!-- PAGE_21 -->\n###### 가.  사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 355,
        "word_count": 60,
        "page_number": 21,
        "window_text": "사용목적\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 특정 유전자에 대한 검사를 실시하는 경우 특정 코돈이나 유전자 변이 영역 등\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)임을 명확히 하도록 관련 진단기기의\n\n<!-- PAGE_21 -->\n###### 일반 명칭을 기재하고, 체외진단다지표검사용 의료기기(IVD-MIA)의 필요성\n\n<!-- PAGE_21 -->\n###### (적용 여부 판정, 부작용 예측, 투여량 결정 등)을 명시하여 체외진단다지표\n\n<!-- PAGE_21 -->\n###### §\n\n<!-- PAGE_21 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)로 신청된 품목은 적용 질병명을 분명히\n\n<!-- PAGE_21 -->\n###### 기입한다.  암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n",
        "original_sentence": "알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 181,
        "word_count": 36,
        "page_number": 22,
        "window_text": "암 조직을 검사 대상으로 하는 경우엔 적응 암종(폐암, 유방암, 위암,\n\n<!-- PAGE_21 -->\n###### 4.  체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다. ",
        "original_sentence": "18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 538,
        "word_count": 115,
        "page_number": 22,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)의 성능 평가\n\n<!-- PAGE_21 -->\n###### 가.  알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다. ",
        "original_sentence": "특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다. "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 279,
        "word_count": 48,
        "page_number": 23,
        "window_text": "알고리즘 설계 및 내부 검정(평가)\n\n<!-- PAGE_21 -->\n###### 2) 바이오마커들의 선별 방법을 평가하기 위하여 질환과 유전자 및 바이오마커 후보\n\n<!-- PAGE_21 -->\n###### 가) 데이터 기반의 생물정보학(Bioinformatics)을 이용하여 질환과 관련 있는 유전자\n\n<!-- PAGE_21 -->\n###### (미국)국립생물공학정보센터(www.ncbi.nlm.nih.gov./geo/info)는 특정 질환에\n\n<!-- PAGE_21 -->\n###### 대한 마이크로어레이, 염기서열분석 데이터를 웹상에 공개하고 있으며, 이 자료들을\n\n<!-- PAGE_21 -->\n###### 이용할 수 있다.\n\n 18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n",
        "original_sentence": "다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "<!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 110,
        "word_count": 20,
        "page_number": 23,
        "window_text": "18\n\n- - 18 -\n(출처; 맞춤 의료를 위한 체외진단다지표검사(IVD-MIA) 의료기기 평가기술 개발연구 보고서(2015.11))\n\n<!-- PAGE_22 -->\n###### 나) 1차 선별한 수많은 바이오마커 후보군에 대해 데이터 처리 및 필터링을 통하여\n\n<!-- PAGE_22 -->\n###### 2차 선별한다.  특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n",
        "original_sentence": "<!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 184,
        "word_count": 29,
        "page_number": 23,
        "window_text": "특정 질환에 대한 임상적 정보가 확보된 충분한 수의 검체군\n\n<!-- PAGE_22 -->\n###### 으로 2차 선별된 바이오마커들을 이용하여 통계적 방법으로 알고리즘을 만들거나\n\n<!-- PAGE_22 -->\n###### 다) 환자 상태와 선별된 바이오마커가 가진 의미의 일치성, 패턴 간의 일관성, 검사\n\n19\n\n- - 19 -\n※ 유전자들의 2차 선별, 혹은 3차 선별 시 선별의 기준 및 방법\n\n유전자를\n\n선별할\n\n수\n\n있는\n\n근거는\n\n유전자의\n\n콕스비례위험비(cox\n\nproportional\n\n<!-- PAGE_23 -->\n###### 라) 각 단계에서의 바이오마커 선별과 필터링을 적용한 기준이 사용목적이나 성능에\n\n<!-- PAGE_23 -->\n###### 부합한 논리성을 가져야 하고, 과도한 필터링으로 바이오마커의 수가 줄게 되면\n\n<!-- PAGE_23 -->\n###### 3) 이처럼 여러 단계의 필터링을 거쳐 바이오마커를 최종 선별하고, 임상 정보를 가진\n\n<!-- PAGE_23 -->\n###### 질환자의 잔여검체를 충분히 확보한다.  다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법. ",
        "original_sentence": "대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 355,
        "word_count": 60,
        "page_number": 23,
        "window_text": "다음으론 선별된 바이오마커와 질환과의 연관\n\n<!-- PAGE_23 -->\n###### 4) 1차로 만들어진 알고리즘은 내부 검정(알고리즘 산출에 사용된 검체군으로\n\n<!-- PAGE_23 -->\n###### 검정)을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 모델의\n\n<!-- PAGE_23 -->\n###### 바이어스(bias,\n\n<!-- PAGE_23 -->\n###### 편향성)를\n\n<!-- PAGE_23 -->\n###### 확인한다.\n\n <!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나. ",
        "original_sentence": "과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 74,
        "word_count": 18,
        "page_number": 24,
        "window_text": "<!-- PAGE_23 -->\n###### 알고리즘의\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### 5) 내부 검정에서 교차검정 기법을 사용한다.  대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다. ",
        "original_sentence": "20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "<!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 390,
        "word_count": 80,
        "page_number": 24,
        "window_text": "대표적인 교차검정 기법으로는 Leave\n\n<!-- PAGE_23 -->\n###### one out cross validation(LOOCV), k-fold cross validation 등이 있으며, 내부\n\n<!-- PAGE_23 -->\n###### 검정을 통하여 모델이 과적합(overfitting)이 되었는지 확인해야 한다.  과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다. ",
        "original_sentence": "<!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 102,
        "word_count": 22,
        "page_number": 24,
        "window_text": "과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 되었을\n\n<!-- PAGE_23 -->\n###### 경우,\n\n<!-- PAGE_23 -->\n###### dropout\n\n<!-- PAGE_23 -->\n###### 기법\n\n<!-- PAGE_23 -->\n###### 등\n\n<!-- PAGE_23 -->\n###### 다양한\n\n<!-- PAGE_23 -->\n###### 방법을\n\n<!-- PAGE_23 -->\n###### 통하여\n\n<!-- PAGE_23 -->\n###### 과적합\n\n<!-- PAGE_23 -->\n###### (overfitting) 문제를 개선함으로써 개발된 초기 알고리즘을 최적화할 수 있다.\n\n 20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n",
        "original_sentence": "이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 127,
        "word_count": 20,
        "page_number": 24,
        "window_text": "20\n\n- - 20 -\n<!-- PAGE_24 -->\n###### 이러한 최적화 과정은 반드시 그 절차와 방법이 기록되어야 한다.\n\n <!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다. ",
        "original_sentence": "알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 73,
        "word_count": 15,
        "page_number": 24,
        "window_text": "<!-- PAGE_24 -->\n###### 가) Leave One Out Cross Validation(LOOCV) - 알고리즘 산출에 사용된 검체 중에서\n\n<!-- PAGE_24 -->\n###### 1개의 검체를 제외한 나머지 검체를 통해 알고리즘 모델을 구현하고, 제외한\n\n<!-- PAGE_24 -->\n###### 이후 나머지 검체들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의\n\n<!-- PAGE_24 -->\n###### 군집으로 나누어 k개의 model을 만들고, 각 모델을 만들 때 한 개의 군을 제외한\n\n<!-- PAGE_24 -->\n###### 나머지 검체군에 대해 알고리즘을 적용하여 구현된 알고리즘이 타당한지 확인하는 방\n\n<!-- PAGE_24 -->\n###### 법.  이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n",
        "original_sentence": "알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 76,
        "word_count": 17,
        "page_number": 24,
        "window_text": "이후 나머지 군집들로 위와 같은 타당성 검사를 반복 수행하여 알고리즘의 유효\n\n<!-- PAGE_24 -->\n###### 성을 검정\n\n<!-- PAGE_24 -->\n###### 나.  알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n",
        "original_sentence": "단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 25,
        "window_text": "알고리즘의 외부 검정(평가)\n\n<!-- PAGE_24 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 검사결과가 환자의 임상데이터를\n\n<!-- PAGE_24 -->\n###### 구분하는 능력을 평가한다.  알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n",
        "original_sentence": "21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 357,
        "word_count": 68,
        "page_number": 25,
        "window_text": "알고리즘 계산으로 도출되는 분류, 점수, 지수 등이\n\n<!-- PAGE_24 -->\n###### 임상적 유효성이 있는지 확인한다.  단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n",
        "original_sentence": "알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "<!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 237,
        "word_count": 45,
        "page_number": 25,
        "window_text": "단, 내부 검정에 모집된 검체를 사용하지 않고\n\n<!-- PAGE_24 -->\n###### 반드시 새로 모집한 검체로 평가해야 한다.\n\n 21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n",
        "original_sentence": "<!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "<!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 354,
        "word_count": 70,
        "page_number": 25,
        "window_text": "21\n\n- - 21 -\n<!-- PAGE_25 -->\n###### 다.  알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n",
        "original_sentence": "<!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "<!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 278,
        "word_count": 46,
        "page_number": 25,
        "window_text": "알고리즘의 내부 및 외부 검정시 고려사항\n\n<!-- PAGE_25 -->\n###### 1) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가\n\n<!-- PAGE_25 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)는 적용하고자 하는 질병 대상 환자의\n\n<!-- PAGE_25 -->\n###### 검체로 바이오마커(유전체 및 단백질 등)들의 발현 정도, 비율, 돌연변이 등에\n\n<!-- PAGE_25 -->\n###### 대한 수치 등을 검사하고 특정 알고리즘으로 계산한 결과와 환자의 질병 또는\n\n<!-- PAGE_25 -->\n###### 어떤 상태와 일치하는 정도를 임상통계학적 신뢰성을 근거로 평가하여야 한다.\n\n <!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n",
        "original_sentence": "<!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "<!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 328,
        "word_count": 65,
        "page_number": 25,
        "window_text": "<!-- PAGE_25 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 안전성 및 유효성 평가는 검사를\n\n<!-- PAGE_25 -->\n###### 구성하는 검체, 통계모델링, 임상적 유용성, 바이오마커들에 대한 측정, 사용\n\n<!-- PAGE_25 -->\n###### 방향, 분석 방법, 임상 성능 등을 고려한 전체적인 성능으로 검토할 것을\n\n<!-- PAGE_25 -->\n###### 권고한다.\n\n <!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "<!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 120,
        "word_count": 24,
        "page_number": 25,
        "window_text": "<!-- PAGE_25 -->\n###### 다) 사용 목적에 해당하는 환자군을 포함하고 사용 목적 및 대상 질병을 뒷받침하는\n\n<!-- PAGE_25 -->\n###### 라) 단순히 검사 결과만을 제공하는 것이 아니라 임상적 시사성(처치, 수술, 치료,\n\n<!-- PAGE_25 -->\n###### 마) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가를 위한 시험은 전향적\n\n<!-- PAGE_25 -->\n###### 시험이 가장 이상적이나 해당 체외진단다지표검사용 의료기기(IVD-MIA) 적용 대상인\n\n<!-- PAGE_25 -->\n###### 환자군을 시험 후에 사용 목적에 반영할 수 있는 후향적 시험도 적용 가능하다.\n\n <!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다. ",
        "original_sentence": "<!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 142,
        "word_count": 39,
        "page_number": 8,
        "window_text": "<!-- PAGE_25 -->\n###### 바) 체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발과정에 다음 사항들을\n\n<!-- PAGE_25 -->\n###### - 알고리즘 발견 세트(Discovery Set)에서 도출한 알고리즘의 구성(사용변수가 포함된\n\n<!-- PAGE_25 -->\n###### 함수식, 결과 해석 방법 등)을 확립하고, 알고리즘 도출에 사용된 검체군으로\n\n<!-- PAGE_25 -->\n###### 내부 검정(Internal validation)을 실시한다.\n\n <!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n",
        "original_sentence": "22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "<!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 199,
        "word_count": 42,
        "page_number": 26,
        "window_text": "<!-- PAGE_25 -->\n###### - 내부 검정을 만족하면 새로운 검체군으로 모집한 외부 검정 세트(Validation\n\n<!-- PAGE_25 -->\n###### ※ 내부 검정과 검정 세트를 통한 연구는 의료기기 임상시험계획승인대상\n\n<!-- PAGE_25 -->\n###### - 바이오마커의 선택 및 알고리즘 발견 세트(Discovery Set)에서 임상통계학을\n\n<!-- PAGE_25 -->\n###### 기반으로 하는 모델 개발 경위, 검사 결과에 대한 판단 기준 등의 자료는\n\n<!-- PAGE_25 -->\n###### 허가·심사자료 중 개발경위의 자료로 요구된다.\n\n <!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n",
        "original_sentence": "<!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "<!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 113,
        "word_count": 22,
        "page_number": 26,
        "window_text": "<!-- PAGE_25 -->\n###### - 외부 검정 세트에 사용하는 검체군의 크기(수)는 임상통계학적으로 추산된\n\n<!-- PAGE_25 -->\n###### 검체 수 이상을 가지고 시행하는 것이 바람직하다.\n\n 22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다. ",
        "original_sentence": "<!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 145,
        "word_count": 29,
        "page_number": 26,
        "window_text": "22\n\n- - 22 -\n(예, 대장암 진단을 위한 선별 검사 목적의 제품인 경우에는 민감도, 특이도 등 각\n\n각의 성능에 대한 정확한 평가 기준을 설정할 수 있도록 충분한 대장암 환자와\n\n비교 환자(기타 암, 양성 환자 등), 정상인을 확보해야 한다.\n\n <!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다. ",
        "original_sentence": "예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "<!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 329,
        "word_count": 61,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### - 발견 세트에서 내부 검정된 알고리즘과 검정 세트에서 외부 검정된 알고리즘\n\n<!-- PAGE_26 -->\n###### 의 통계적 유의성이 동등하게 확보되었으나, 일부 수치(예, 상수 등)가 다를\n\n<!-- PAGE_26 -->\n###### 경우엔 임상통계학적 검증을 통하여 알고리즘 수정을 고려할 수 있다.\n\n <!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n",
        "original_sentence": "<!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "<!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 157,
        "word_count": 30,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### 아) 알고리즘을 구성하는 바이오마커의 정성 또는 정량값에 대한 임상적 의미와\n\n<!-- PAGE_26 -->\n###### 알고리즘 결과값의 일관성을 평가한다.  예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n",
        "original_sentence": "<!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 85,
        "word_count": 19,
        "page_number": 26,
        "window_text": "예를 들어, 발현량이 높으면 예후가\n\n<!-- PAGE_26 -->\n###### 좋다고 알려진 바이오마커의 발현량이 높은 경우에 알고리즘의 결과값(Index)\n\n<!-- PAGE_26 -->\n###### 도 좋은 예후로 나타나는지 확인하여 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n",
        "original_sentence": "따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 127,
        "word_count": 26,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### 자) 다른 방법은 알고리즘으로 환자의 질환 예후를 예측한 위험도(발병률 또는\n\n<!-- PAGE_26 -->\n###### 카) 두 가지 방법 모두 검정 측면에서 매우 중요하며 다음 항목들에 대한 평가가\n\n<!-- PAGE_26 -->\n###### Sensitivity와\n\n<!-- PAGE_26 -->\n###### Specificity는\n\n<!-- PAGE_26 -->\n###### 두\n\n<!-- PAGE_26 -->\n###### 가지의\n\n<!-- PAGE_26 -->\n###### 결과를\n\n<!-- PAGE_26 -->\n###### 다룬다.\n\n <!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n",
        "original_sentence": "이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "<!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 241,
        "word_count": 49,
        "page_number": 26,
        "window_text": "<!-- PAGE_26 -->\n###### 질환의\n\n<!-- PAGE_26 -->\n###### 재발\n\n<!-- PAGE_26 -->\n###### 유․무를 기준으로 나누고, 알고리즘 분석을 통해 재발 고위험, 저위험\n\n<!-- PAGE_26 -->\n###### 두 그룹으로 나눈다.  따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n",
        "original_sentence": "<!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 9,
        "window_text": "따라서 재발이 된 그룹과 안 된 그룹, 재발 고위험군과\n\n<!-- PAGE_26 -->\n###### 저위험군으로 나눠지면 총 4가지 그룹이 만들어진다.  이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n",
        "original_sentence": "따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 71,
        "word_count": 15,
        "page_number": 8,
        "window_text": "이 4가지 그룹의 각 수를\n\n<!-- PAGE_26 -->\n###### 이용하면 AUC(Area Under the ROC Curve)를 제외한 아래의 성능 항목을\n\n<!-- PAGE_26 -->\n###### 평가할 수 있다.\n\n <!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다. ",
        "original_sentence": "민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 107,
        "word_count": 23,
        "page_number": 11,
        "window_text": "<!-- PAGE_26 -->\n###### <그림 4 민감도와 특이도 계산>\n\n23\n\n- - 23 -\n∙ 민감도(Sensitivity) - “실제로 병에 걸린 사람들 중에서 얼마나 정확하게 병에\n\n<!-- PAGE_27 -->\n#### 걸린 것으로 나타났는가”를 의미(Sensitivity = \n\n \n\n\n\n)\n\n민감도는\n\n치명적인\n\n병을\n\ntest하거나\n\n고위험군을\n\n선별하는\n\n경우\n\n중요하게\n\n고려해야할\n\n사항이다.\n\n 따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n",
        "original_sentence": "∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 224,
        "word_count": 43,
        "page_number": 27,
        "window_text": "따라서,\n\n이런\n\n경우에는\n\n알고리즘을\n\n통해\n\n치료를\n\n받아야 하는 고위험군을 매우 잘 규정해야 한다.\n\n 민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n",
        "original_sentence": "특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 524,
        "word_count": 104,
        "page_number": 27,
        "window_text": "민감도는 실제 재발(또는 발병)한 사람들 중 알고리즘 분석결과 재발(또는\n\n발병)할 것이라고 구분한 사람의 비율을 의미한다.\n\n ∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다. ",
        "original_sentence": "∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 27,
        "window_text": "∙ 특이도(Specificity) - “실제로 병이 없는 사람들 중에서 얼마나 정확하게 병이\n\n어떤 질병에 대한 저위험군을 선별하여 과도한 치료의 불필요성을 제시할\n\n경우의 고려 대상이다.\n\n 특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다. ",
        "original_sentence": "따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 178,
        "word_count": 42,
        "page_number": 29,
        "window_text": "특이도는 민감도와 반대되는 의미로, 실제 재발(또는 발병) 하지 않은 사람들 중\n\n알고리즘\n\n분석결과\n\n재발(또는\n\n발병)하지\n\n않을\n\n것이라고\n\n구분한\n\n사람의\n\n<!-- PAGE_27 -->\n###### 민감도, 특이도 또는 위양성, 위음성은 모두 분모가 실질적인 참값(ture\n\n<!-- PAGE_27 -->\n###### nature)인데 예측도는 분모에 알고리즘으로 구분한 결과가 들어간다.\n\n ∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n",
        "original_sentence": "24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "<!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 318,
        "word_count": 63,
        "page_number": 29,
        "window_text": "∙ 양성 예측도(Positive Predictive Value, PPV) - 알고리즘을 통하여 재발할 것으로\n\n예측되는 대상을 분모로 하고 실제 재발한 환자를 분자로 계산하여, 알고리즘\n\n민감도에 대한 예측도를 나타냄\n\n∙ 음성 예측도(Negative predictive value, NPV) - 알고리즘을 통하여 재발이 안 될\n\n것으로 예측되는 대상을 분모로 하고 실제 재발 안 된 정상인을 분자로 계산하여,\n\n알고리즘 특이도에 대한 예측도를 나타냄\n\n<!-- PAGE_27 -->\n###### Likelihood ratio는 위양성 오류비율(false positive error rate)에 대한 제품의\n\n<!-- PAGE_27 -->\n###### 민감도 비율과 위음성 오류비율에 대한 제품의 특이도 비율을 계산\n\n<!-- PAGE_27 -->\n###### ROC curve의 아래 면적으로 진단 정확도를 의미하고 0.5 ~ 1.0사이의\n\n<!-- PAGE_27 -->\n###### 값에서 1에 근접할수록 이상적인 성능이라 하겠다.  따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n",
        "original_sentence": "<!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 77,
        "word_count": 18,
        "page_number": 29,
        "window_text": "따라서 예후 예측에\n\n<!-- PAGE_27 -->\n###### 대한 정확도를 AUC로 평가할 수 있다.\n\n 24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라. ",
        "original_sentence": "개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 147,
        "word_count": 29,
        "page_number": 29,
        "window_text": "24\n\n- - 24 -\n◎ 어떤 경우에나 적용 가능한 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n다지표검사용 의료기기 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야\n\n25\n\n- - 25 -\n<!-- PAGE_29 -->\n###### ※ 상기 사항을 종합한 제품개발과정을 <그림 3>과 같이 정리하였다.\n\n <!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁. ",
        "original_sentence": "이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 214,
        "word_count": 35,
        "page_number": 30,
        "window_text": "<!-- PAGE_29 -->\n###### 가) 체외진단다지표검사용 의료기기(IVD-MIA)의 평가 시험을 수행할 때, 시험의\n\n<!-- PAGE_29 -->\n###### 신뢰성을 확보하기 위해 사용 검체의 채취 시기, 병변의 질, 고정 상태 및 저장\n\n<!-- PAGE_29 -->\n###### 나) 체외진단다지표검사용 의료기기(IVD-MIA)의 임상적 성능 평가 기준은 대상 질병의\n\n<!-- PAGE_29 -->\n###### 특성, 환자 수(현실적으로 확인 가능한 증례 수), 신뢰 구간 등을 감안하여\n\n<!-- PAGE_29 -->\n###### 검토해야 한다.  개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다. ",
        "original_sentence": "26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "<!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 246,
        "word_count": 51,
        "page_number": 30,
        "window_text": "개발 과정에서 사용한 양성 또는 음성 검체 일부를 가지고\n\n<!-- PAGE_29 -->\n###### 임상적 성능시험을 수행할 수 있다.  이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n",
        "original_sentence": "<!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 366,
        "word_count": 70,
        "page_number": 31,
        "window_text": "이때, 그 타당성은 식약처에 문의하기를\n\n<!-- PAGE_29 -->\n###### 다) 체외진단다지표검사용 의료기기의 평가를 위한 후향적 시험에서 대상 환자군을\n\n<!-- PAGE_29 -->\n###### 명확히 제시하여 검체 수집의 편향성을 배제해야 한다.\n\n 26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 159,
        "word_count": 31,
        "page_number": 31,
        "window_text": "26\n\n- - 26 -\n<!-- PAGE_30 -->\n###### ○ 체외진단다지표검사용 의료기기(IVD-MIA)의 분석적 성능평가(Analytical Validation)\n\n<!-- PAGE_30 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 결과 타당성을 확보하기 위해 다음과\n\n<!-- PAGE_30 -->\n###### 같은 분석적 성능 시험이 요구된다.\n\n <!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다. ",
        "original_sentence": "타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 76,
        "word_count": 16,
        "page_number": 31,
        "window_text": "<!-- PAGE_30 -->\n###### 개별 바이오마커의 정량값 모두가 알고리즘 분석에 필수적이지 않다면, 각 바이\n\n<!-- PAGE_30 -->\n###### 분석적 판별기준을 설정하였다면, 설정근거와 임상적 성능시험으로 검정된 결과를\n\n<!-- PAGE_30 -->\n###### 분석적 성능시험의 측정(검출) 방법을 변경할 경우, 변경 전과 변경 후에서 동일\n\n27\n\n- - 27 -\n<!-- PAGE_31 -->\n###### 라.  체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n",
        "original_sentence": "타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "* 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 271,
        "word_count": 62,
        "page_number": 31,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)의 소프트웨어에 대한 허가·심사시 고려사항\n\n<!-- PAGE_31 -->\n###### ※ 알고리즘을 단순히 수식으로 제공하지 않고 소프트웨어로 제공할 경우, 아래의 사항을\n\n<!-- PAGE_31 -->\n###### ➀ 동일 제조원에서 체외진단용 시약, 장비, 소프트웨어 모두를 시스템으로 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 장비, 시약, 소프트웨어(알고리즘) 모두 하나의 시스템으로 개발된 것으로 조합\n\n<!-- PAGE_31 -->\n###### 2) 소프트웨어 개발 전에 장비와 시약의 허가를 받고 시스템에서 사용하고 있더라도,\n\n<!-- PAGE_31 -->\n###### ➁.  타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1. ",
        "original_sentence": "* 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 157,
        "word_count": 27,
        "page_number": 31,
        "window_text": "타사의 체외진단용 시약 또는 장비를 이용하고 소프트웨어만을 개발한 경우\n\n<!-- PAGE_31 -->\n###### 1) 소프트웨어(알고리즘)를 단독으로 허가하나, 타사의 시약과 장비를 같이 사용했을\n\n<!-- PAGE_31 -->\n###### 때의 성능으로 심사가 이루어져야 한다.  타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2. ",
        "original_sentence": "소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 199,
        "word_count": 40,
        "page_number": 31,
        "window_text": "타사의 시약과 장비에서 알고리즘의 결과\n\n<!-- PAGE_31 -->\n###### 판정에 영향을 주는 중대한 변경*이 없어야 한다.\n\n * 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3. ",
        "original_sentence": "소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "<!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 349,
        "word_count": 75,
        "page_number": 31,
        "window_text": "* 중대한 변경 : 시약의 원재료 주성분 변경, 바이오마커의 정량값의 변경, 기댓값의\n\n변경으로 정성결과의 변경 등, 기존 결과와 다른 결과로 인하여 알고리즘 결과값에\n\n영향을 주는 변경\n\n<!-- PAGE_31 -->\n###### (ㄱ) 알고리즘 개발 이후 타사의 시약과 장비에 중대한 변경이 있는 경우, 이미\n\n<!-- PAGE_31 -->\n###### (ㄴ) 타사의 장비나 시약의 변경을 관찰하는 방법과 변경할 경우에 대한 위험\n\n<!-- PAGE_31 -->\n###### ➂.  소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4. ",
        "original_sentence": "<!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 45,
        "word_count": 6,
        "page_number": 34,
        "window_text": "소프트웨어의 허가·심사시 성능 평가\n\n<!-- PAGE_31 -->\n###### 1)「의료기기 허가·신고·심사 등에 관한 규정」(이하 ‘허가규정’) 제29조(첨부자료의 요건)에서\n\n<!-- PAGE_31 -->\n###### 요구하고 있는 소프트웨어에 관한 첨부자료는 다음과 같다.  소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5. ",
        "original_sentence": "소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 55,
        "word_count": 8,
        "page_number": 34,
        "window_text": "소프트웨어의 명칭,\n\n<!-- PAGE_31 -->\n###### 버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성 확인을 할 수\n\n<!-- PAGE_31 -->\n###### 있는 자료, 의료기기 소프트웨어 적합성 확인보고서(별지 제13호 서식)에 대하여 허가·\n\n<!-- PAGE_31 -->\n###### 심사 시 검토가 이루어져야 한다.\n\n <!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1. ",
        "original_sentence": "시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 34,
        "window_text": "<!-- PAGE_31 -->\n###### 2) 소프트웨어는 알고리즘의 구현을 위한 수단일 뿐이므로 알고리즘의 성능(시스템 전체의\n\n제13호 서식의 적합성 확인보고서와 소프트웨어 검증 및 유효성 확인 자료를\n\n제출하여야 하고, (이하 생략)\n\n28\n\n- - 28 -\n<!-- PAGE_32 -->\n###### <작성 예시>\n\n<!-- PAGE_32 -->\n##### 소프트웨어 검증 및 유효성확인 보고서\n\n29\n\n- - 29 -\n<!-- PAGE_33 -->\n###### 개정 이력(Revision History)\n\n날짜\n\n개정 버전\n\n승인자\n\n설명\n\n30\n\n- - 30 -\n<!-- PAGE_34 -->\n###### 1.  소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다. ",
        "original_sentence": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 67,
        "word_count": 11,
        "page_number": 34,
        "window_text": "소개(Introduction)\n\n<!-- PAGE_34 -->\n###### 2.  시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n",
        "original_sentence": "검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 35,
        "window_text": "시스템 정보(System Information)\n\n<!-- PAGE_34 -->\n###### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2. ",
        "original_sentence": "미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1. "
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 134,
        "word_count": 21,
        "page_number": 35,
        "window_text": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n<!-- PAGE_34 -->\n###### 4.  검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다. ",
        "original_sentence": "소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 120,
        "word_count": 20,
        "page_number": 35,
        "window_text": "검증 & 유효성 확인(Verification & Validation)\n\n<!-- PAGE_34 -->\n###### 5.  미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다. ",
        "original_sentence": "IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "<!-- PAGE_35 -->\n##### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 35,
        "window_text": "미해결 오류 (Unresolved Anomalies)\n\n31\n\n- - 31 -\n<!-- PAGE_35 -->\n##### 1.  소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다. ",
        "original_sentence": "<!-- PAGE_35 -->\n##### 2. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 277,
        "word_count": 53,
        "page_number": 35,
        "window_text": "소개(Introduction)\n\n<!-- PAGE_35 -->\n###### 본 문서는 ㈜MFDS에서 제조한 유방암 예후 위험도를 예측하는 체외진단다지표 검사용\n\n<!-- PAGE_35 -->\n###### 의료기기(IVD-MIA)를 다룬다.  IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다. ",
        "original_sentence": "시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "|\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 61,
        "word_count": 18,
        "page_number": 8,
        "window_text": "IVD-MIA 중에서 알고리즘을 구현한 소프트웨어에 대한\n\n<!-- PAGE_35 -->\n###### 검증 및 검정(verification and validation)을 하여 소프트웨어의 적합성을 확인하려 한다.\n\n <!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다. ",
        "original_sentence": "|\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "| 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 13,
        "window_text": "<!-- PAGE_35 -->\n##### 2.  시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다. ",
        "original_sentence": "| 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "|\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 85,
        "word_count": 21,
        "page_number": 12,
        "window_text": "시스템 정보(System Information)\n\n<!-- PAGE_35 -->\n###### 1) 소프트웨어 버전(Software Version)\n\n(Data Analysis Module(GUI))\n\n- 1.00\n<!-- PAGE_35 -->\n###### 2) 하드웨어 버전(Hardware Version)\n\n32\n\n- - 32 -\n**[표 시작]**\n\n| 사) 시험방법 | 3) 임상평가 | 2) 주요설비 | ① 동일 검체를 일정기간 동안 반복 측정한 결과를 분석하여 정밀도 자료를 제시한다.  |\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다. ",
        "original_sentence": "|\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "| 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 13,
        "window_text": "|\n| --- | --- | --- | --- |\n| 1) 작용원리 : 해당 의료기기의 작용원리를 기재한다.  | 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다. ",
        "original_sentence": "| 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "| 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 130,
        "word_count": 37,
        "page_number": 10,
        "window_text": "| 자사 표준물질을 제작하여 사용할 경우, 다음의 자료를 제출한다.  |\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다. ",
        "original_sentence": "| 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "| 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 15,
        "window_text": "|\n| 연번 | ❍ 원재료 | 1) 최소검출한계(Limit of detection) |\n| ① 양성과 음성의 판정기준치를 결정한 근거 자료를 제시한다.  | 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다. ",
        "original_sentence": "| 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "| 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 69,
        "word_count": 22,
        "page_number": 8,
        "window_text": "| 편차로 표시하되, 주성분 이외의 성분의 경우 “적량”으로 표시 가능하다.  | 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다. ",
        "original_sentence": "| 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "|\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 44,
        "word_count": 13,
        "page_number": 10,
        "window_text": "| 바) 원심분리 조건 등을 포함한 검체 전처리과정 등 |\n| 1) 표준물질의 농도별 설정 기준을 입증할 수 있는 시험 자료 및 결과 해석 자료 | 8) 다른 의료기기와 결합하여 사용하는 경우, 적절한 조합에 대한 정보를 제공한다.  | 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다. ",
        "original_sentence": "|\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "| 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 2,
        "window_text": "| 제출한다.  | 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다.",
        "original_sentence": "| 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "| 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 66,
        "word_count": 14,
        "page_number": 5,
        "window_text": "| 2 |\n| 소프트웨어 | ❍ 제조방법 | ※ 예시 : 본 제품의 측정은 아래와 같은 네 가지 주요 과정으로 이루어진다.  |\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다. ",
        "original_sentence": "| 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "| 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 132,
        "word_count": 34,
        "page_number": 8,
        "window_text": "|\n| 2) 검체 종류 : 해당 제품에 적용이 가능한 검체의 종류를 기술한다.  | 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다. ",
        "original_sentence": "| 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "|\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 78,
        "word_count": 14,
        "page_number": 12,
        "window_text": "| 가) 일반사항 | 특히, 중합효소의 경우, 활성도(U/uL 등)를 기재하고 단위의 정의도 제시한다.  | 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다. ",
        "original_sentence": "|\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다."
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "**\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 107,
        "word_count": 30,
        "page_number": 5,
        "window_text": "| 3 | AptoDetectTM- |\n**사용목적**\n| 9) 일회용의 경우 재사용하지 않도록 주의사항을 기재한다.  | 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다. ",
        "original_sentence": "**\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "| 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 112,
        "word_count": 27,
        "page_number": 2,
        "window_text": "| 기준에 의하여 실시한 시험자료 또는 이에 준하는 것으로 인정되는 시험자료 |\n| 2) 표준물질 관리방법 및 관리기록서(정도관리 포함) | 5) 소프트웨어 주요기능 | ① FFPE 처리된 유방암 조직에서 RNA 추출 | 하여야 한다.  |\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다. ",
        "original_sentence": "| 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다. "
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "|\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 5,
        "window_text": "|\n**❍ 사용목적(성능)**\n| TID-1 | 소프트웨어 |\n**open vial/bottle stability) 안정성 자료를 포함한다. **\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다.",
        "original_sentence": "|\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "| ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 8,
        "window_text": "**\n| 5) 규격 | 운영환경 | 4) 이미 허가받은 제품과의 동등비교 | ② RNA 교잡반응 | 3) 연구 인력구성 | ② 사용 검체의 종류가 다양하다면 검체의 종류별로 자료를 제출한다.  | 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle). ",
        "original_sentence": "| ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "|\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 88,
        "word_count": 23,
        "page_number": 2,
        "window_text": "| 소프트웨어를 추가로 제공할 경우에 한함) |\n**❍ 사용방법**\n| 3) 검사항목 | 4 | nProfiler I stomach | 다만, 다음의 어느 하나에 해당하는 경우에는 그러하지 아니하다.  |\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다. ",
        "original_sentence": "|\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "| 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 8,
        "window_text": "|\n| (독립형 | 인정범위 1)∼4) 중 어느 하나)에 해당하는 자료 |\n| 다양한 임상결과를 보이는 질환으로 예후 인자의 역할이 매우 중요하다.  | ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다. ",
        "original_sentence": "| 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다."
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "**\n| (on-board, reconstitution, openvial/bottle). ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 50,
        "word_count": 5,
        "page_number": 12,
        "window_text": "| ③ 검체에 영향을 줄 수 있는 간섭물질의 목록을 작성하고 각 간섭물질별 자료를 제출한다.  |\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다. ",
        "original_sentence": "**\n| (on-board, reconstitution, openvial/bottle). "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "| 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 70,
        "word_count": 18,
        "page_number": 5,
        "window_text": "|\n| 소프트웨어에 | ❍ 사용 시 주의사항 | 2) 검사 전 준비사항 | ③ 형광표지자를 이용한 각 유전자들의 정량(Scanning) | 방법을 기재한다.  | 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다. ",
        "original_sentence": "| 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "| ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 124,
        "word_count": 34,
        "page_number": 11,
        "window_text": "| 및 활성도를 확인 할 수 있는 자료 |\n**가) 검사하고자 하는 유전자에 대해 기재한다. **\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다. ",
        "original_sentence": "| ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "| 는 경우 자사규격 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 13,
        "window_text": "**\n| (on-board, reconstitution, openvial/bottle).  | 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. ",
        "original_sentence": "| 는 경우 자사규격 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "|\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 2,
        "window_text": "| 나) 반복성 | 4) 시험자의 연구경력 | ④ 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 비교한다.  | ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다. ",
        "original_sentence": "|\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "| 경우는 ‘제조원 포장단위’로 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 13,
        "window_text": "| ③ 결과제시 |\n| 1) 시험항목 | ④ 각 유전자의 정량값을 알고리즘으로 분석한 후, 결과값(Index Score) 도출 | 시험 전 시약 조제가 필요한 경우 조제 방법, 검사에 필요한 기구 및 조건 등을 기재한다.  | 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다. ",
        "original_sentence": "| 경우는 ‘제조원 포장단위’로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "|\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 139,
        "word_count": 34,
        "page_number": 8,
        "window_text": "| 는 경우 자사규격 등을 기재한다.  |\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다. ",
        "original_sentence": "|\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "|\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 138,
        "word_count": 38,
        "page_number": 8,
        "window_text": "|\n**❍ 포장단위**\n| TID-2 | ① 실험방법 및 기타 세부사항 | ※ 프라이머, 프로브 등은 제출된 근거자료에 따라 염기서열을 “별도규격”으로 작성한다.  | 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다. ",
        "original_sentence": "|\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "| 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 178,
        "word_count": 41,
        "page_number": 8,
        "window_text": "| 경우는 ‘제조원 포장단위’로 기재한다.  |\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다. ",
        "original_sentence": "| 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "| 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 33,
        "word_count": 9,
        "page_number": 8,
        "window_text": "|\n| ❍ 저장방법 및 사용기간 | ⑤ 결과값(Index Score) 판단표에 따라 다음의 위험그룹에서 해당되는 그룹을 판정 | 가) 적용되는 체외진단분석용 장비의 제조사 및 모델명 기재 | 가) 완제품의 최종 품질관리에 따른 성능시험을 포함한다.  |\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다. ",
        "original_sentence": "| 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "|\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 119,
        "word_count": 34,
        "page_number": 5,
        "window_text": "|\n| - 미국 허가 제품 | 2) 동일한 제조(수입)업자가 허가(신고) 취하 후 동일한 제품을 허가(신고)하는 경우 |\n| 다) 결과판독 | 지멘스헬시니어스(주) | 학계 |\n| 및 냉동 및 해동된 검체의 사용 가능성 및 제한점 등을 포함한다.  | 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다. ",
        "original_sentence": "|\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "|\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 108,
        "word_count": 29,
        "page_number": 5,
        "window_text": "| 나) 검사 시약(키트)의 사용조건(온도 또는 습도 등) 기재 |\n| ❍ 시험규격 | 1) 식약처장이 지정한 시험검사기관에서 발급한 시험성적서 |\n**6) 비고**\n**❍ 제조원(수입 또는 제조공정 전부 위탁의 경우)**\n| 기기는 비멸균의료기기에 해당됨) | ⑥ 검사과정에서 판정기준치를 산정하는 방법을 명시한다.  | 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다. ",
        "original_sentence": "|\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "| 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 15,
        "window_text": "| 비고란에는 각 구성시약의 총량 및 수량 등을 기재한다.  |\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다. ",
        "original_sentence": "| 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "| 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 8,
        "window_text": "|\n**4) 측정원리**\n| ❍ 허가조건 | 2) 시험기준 | 웨어의 회사명, 모델명, 허가 번호 등을 기재 |\n| TID-3 | 나) 시험물질 |\n| 라) 결과제시 | ⑦ 각 검체별로 3번 반복검사를 시행한다.  |\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다. ",
        "original_sentence": "| 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "| ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 10,
        "window_text": "|\n| 1) 4등급 체외진단용 의료기기의 시험 | 소프트웨어 | 7) 소프트웨어 원재료 | 라) 필요한 경우, 보정물질에 대한 설명 및 방법을 기재 | 가) 측정에 사용된 검사원리를 명시한다.  | 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4. ",
        "original_sentence": "| ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "|\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 49,
        "word_count": 12,
        "page_number": 8,
        "window_text": "| 보관조건(온도, 습도, 차광, 밀폐 등), 사용기간(유효기간) 등을 명기하여야 한다.  | 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함. ",
        "original_sentence": "|\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "| ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 104,
        "word_count": 25,
        "page_number": 10,
        "window_text": "| 품질관리 시험의 단계를 확인할 수 있는 자료) |\n**❍ 비고**\n| 입증하는 자료를 제출한다.  | ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다. ",
        "original_sentence": "| ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "| 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 2,
        "window_text": "| ❍ 다양한 농도를 포함한 양성 임상 검체와 패널을 이용하여 평가한다.  |\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다.",
        "original_sentence": "| 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 9,
        "window_text": "|\n| 허가·신고·심사 등에 관한 규정 또는 이와 동등이상 규격의 멸균방법을 기재한다.  | ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다. ",
        "original_sentence": "원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "|\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 5,
        "window_text": "| ② 결과제시방법 | 관한 자료 및 내부 검정(Internal Validation) 결과 자료 |\n| 조건 변화에 따른 결과의 변화를 제시하고 평가에 사용된 만족기준을 함께 기록한다.  | 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다. ",
        "original_sentence": "|\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "|\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 8,
        "window_text": "| 마) 소프트웨어의 사용전 준비사항을 기재 |\n**4.  원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다. ",
        "original_sentence": "|\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다."
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "**\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 5,
        "window_text": "원재료**\n| 5) 정도관리 | 붙여 상품명을 기재하는 것은 동일제조사 제품에 한하여 가능함.  |\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다. ",
        "original_sentence": "**\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "|\n| 요약하여 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 15,
        "window_text": "|\n**아) 결과제시**\n| 3) 시험방법 | 1) 식약처장이 지정한 임상시험기관에서 시험한 자료 | 제출한다.  |\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다. ",
        "original_sentence": "|\n| 요약하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "| 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 86,
        "word_count": 20,
        "page_number": 11,
        "window_text": "|\n**가) 사용자가 정도관리를 할 수 있는 방법을 제시한다. **\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함).",
        "original_sentence": "| 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "| ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 105,
        "word_count": 24,
        "page_number": 11,
        "window_text": "**\n| TID-4 | 분석적 성능시험에 관한 자료에는 다음의 평가항목을 포함할 수 있습니다.  |\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다.",
        "original_sentence": "| ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "| 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 63,
        "word_count": 21,
        "page_number": 2,
        "window_text": "|\n| 요약하여 제시한다.  | 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다. ",
        "original_sentence": "| 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "| 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함).",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 90,
        "word_count": 22,
        "page_number": 8,
        "window_text": "| 2) 외국자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 | ① 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과값을 제시한다.  | ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다. ",
        "original_sentence": "| 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함)."
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "**\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 106,
        "word_count": 23,
        "page_number": 11,
        "window_text": "| ③ 시험물질 | 등의 자료 |\n**1) 간섭반응**\n| 1) 분석적 민감도(판정기준치(cut-off value), 최소검출한계, 측정 범위 등) | ② 경향이 있다면 경향을 기술한다.  | 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다. ",
        "original_sentence": "**\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다."
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "**\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 89,
        "word_count": 26,
        "page_number": 5,
        "window_text": "| 일련번호 | 명칭 | 배합목적 | 원재료명 또는 성분명 | 분량 | 규격 | 비교 |\n| 점수를 제공 한다.  | 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다. ",
        "original_sentence": "**\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "| 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 73,
        "word_count": 16,
        "page_number": 5,
        "window_text": "| 미치지 않는 시험 및 잔여검체로 실시하는 시험은 제외) | 있는 자료도 포함 |\n**다) 시험방법**\n**(Index Score) 판단표에 대한 설명 포함). **\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다. ",
        "original_sentence": "| 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "|\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 79,
        "word_count": 22,
        "page_number": 8,
        "window_text": "**\n**2) 분석적 특이도(교차반응 등)**\n**❍ 개발경위, 측정원리․방법 및 국내·외 사용현황에 관한 자료**\n**다) 정도관리결과가 적합하지 않을 때 제시할 수 있는 대책을 기술한다. **\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다. ",
        "original_sentence": "|\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "| 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 44,
        "word_count": 11,
        "page_number": 8,
        "window_text": "**\n| 시험자 직급 | 시험자 성명 | 시험 일자 | 서명 | 비고 | 3) 시약의 조제가 필요할 경우 조제 후 보관조건 및 사용기간(유효기간)을 기재한다.  | 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다. ",
        "original_sentence": "| 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "|\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 13,
        "window_text": "| 3) 정밀도(반복, 재현성 등) | 나) 표준물질의 목표 결과와 실측 결과(정량검사의 경우 결과값과 bias)경우를 제시한다.  |\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. ",
        "original_sentence": "|\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "| 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 8,
        "window_text": "|\n| ❍ 원재료 및 제조방법에 관한 자료 | 2) 교차반응 | 하기 위한 중요한 요소이기 때문에 해당하는 내용을 원재료에 기재하여야 한다.  | 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다.",
        "original_sentence": "| 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "| 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 결과를 확인할 수 없는 시험 | 소프트웨어만을 사용하도록 분명히 기재한다.  |\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다.",
        "original_sentence": "| 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "|\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 121,
        "word_count": 26,
        "page_number": 5,
        "window_text": "|\n| ※ 별도 포장판매 구성품이 있을 경우에는 원재료를 함께 기재한다.  | 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. ",
        "original_sentence": "|\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "|\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 71,
        "word_count": 23,
        "page_number": 2,
        "window_text": "| 도움을 주기 위함으로, 진단을 사용목적으로 하지 않는다.  | 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다. ",
        "original_sentence": "|\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다."
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "**\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 95,
        "word_count": 17,
        "page_number": 5,
        "window_text": "| 소프트웨어 | 사용과정에 대한 신뢰도를 보여주는 지표가 된다.  |\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다. ",
        "original_sentence": "**\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다."
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "**\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 267,
        "word_count": 72,
        "page_number": 8,
        "window_text": "|\n| 연구원 | 김○○ | 2014.9.1 |\n| 4) 정확도(위험도를 측정하는 제품의 경우, 일반적으로 해당없음) | 유지보수 | 다) 시약의 표준화(standardization)를 위해 사용된 방법을 기술한다.  |\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3. ",
        "original_sentence": "**\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "|\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 83,
        "word_count": 24,
        "page_number": 8,
        "window_text": "|\n| 1) 국내 | ❍ 사용목적에 관한 자료 | 가) 일반사항 | ※ 예시 : |\n**① 시험물질 :　반복성 평가와 동일하다. **\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4. ",
        "original_sentence": "|\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "|\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 156,
        "word_count": 40,
        "page_number": 12,
        "window_text": "**\n| 및 문제해결 | 책임연구원 | 이○○ | 2014.9.1 |\n**라) 보정물질(calibrator)의 설정농도, 소급성(traceability)에 대해 기술한다. **\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다. ",
        "original_sentence": "|\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "|\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 97,
        "word_count": 17,
        "page_number": 36,
        "window_text": "**\n| ※ 예시 : 상관성 평가에 대한 시험수행 및 결과는 없음 단, 아래 표와 같은 기허가된 | 1) 명칭 | 4) 과학논문인용색인(Science Citation Index)에 등재된 전문학회지에 게재된 자료 |\n| ❍ 사용기간 또는 유효기간에 관한 자료 | 작용원리 등이 동등하지 아니한 체외진단용 의료기기의 시험에 한함) |\n| 1) 업체명 및 주소 | ② 시험방법 |\n| 시험 결과 | 마) 양성 및 음성대조물질의 제조방법, 설정 농도 및 반복 측정 결과를 기술한다.  |\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1. ",
        "original_sentence": "|\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3. "
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 281,
        "word_count": 53,
        "page_number": 36,
        "window_text": "|\n| 소프트웨어 | 체외진단용 의료기기 다지표 검사와의 유사점 및 차이점에 대한 표를 제시함 |\n| ❍ 성능시험에 관한 자료 | 비교할 수 있다.  |\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다.",
        "original_sentence": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4. "
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 253,
        "word_count": 63,
        "page_number": 5,
        "window_text": "|\n**2) 시험성적서 일련번호 및 각 페이지와 전체 페이지번호**\n**위험관리**\n**총 시험 횟수**\n| ❍ 취급자 안전에 관한 자료 | 원리 및 정성 또는 정량 등)에 대한 근거자료 | 나) 시험물질 | 되어 하나의 사용목적을 달성하는 경우에는 세트별로 구분하여 기재한다.  |\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다. ",
        "original_sentence": "검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "| 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "|\n**3) 시험검사품의 모델명, 상품명(해당 경우에 한함)**\n**(Total Test Cases)**\n\n**[표 끝]**\n\n<!-- PAGE_36 -->\n##### 3.  검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 68,
        "word_count": 19,
        "page_number": 10,
        "window_text": "검사 장비 & 검사 도구(Test Equipments & Tools)\n\n구분\n\n테스트 & 툴\n\n목적\n\n장비관리번호\n\n비고\n\n1\n\nVisual Studio 2018\n\n프로그램 컴파일러\n\n2\n\nIAR Embedded workbench IDE\n\n프로그램 다운로드\n\n3\n\nIAR 에뮬레이터\n\n프로그램 디버거\n\n4\n\nPersonal Computer\n\n프로그램 개발\n\n5\n\nPower Meter\n\nPower 측정\n\n6\n\nFluorescence scan\n\n신호 측정\n\n<!-- PAGE_36 -->\n##### 4.  검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다. ",
        "original_sentence": "제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "**\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 56,
        "word_count": 17,
        "page_number": 2,
        "window_text": "검증 및 유효성 확인(Verification & Validation)\n\n33\n\n- - 33 -\n**[표 시작]**\n\n| No | 이상현상 | Explanation -Disposition |\n| --- | --- | --- |\n**1) 검체준비 및 저장방법**\n| 3) 원재료명 및 성분명 | 성적서 | 가) 일반사항 | 품목명 | ③ 분석물질 음성 검체 + 간섭물질 | ① 교차반응 평가에 사용된 양성물질의 종류, 농도, 측정한 원시 자료를 제시한다.  | 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다. ",
        "original_sentence": "**\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "| 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 94,
        "word_count": 25,
        "page_number": 5,
        "window_text": "| 1.  제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다.",
        "original_sentence": "| 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "| 각 구성 시약의 원재료명 또는 성분명을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 8,
        "window_text": "제조의뢰자 |\n| 연세대학교 세브란스병원 | 학계 | 가) 검체대상 및 채취방법 등 |\n**① 정성검사는 생략할 수 있다. **\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다. ",
        "original_sentence": "| 각 구성 시약의 원재료명 또는 성분명을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "|\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 82,
        "word_count": 22,
        "page_number": 2,
        "window_text": "**\n| 4) 결과판정 | 5) 사용한 검체 및 키트의 처리 및 폐기 방법 및 주의사항을 기재한다.  | 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다. ",
        "original_sentence": "|\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "| 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 131,
        "word_count": 36,
        "page_number": 10,
        "window_text": "| 3) 제조국에서 사용되지 않는 경우는 그 사유 | 2) 임상결과 | ④ 분석물질 음성 검체(간섭물질 없음) | ② 교차반응을 보이는 물질의 종류와 빈도를 제시한다.  | 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다. ",
        "original_sentence": "| 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다."
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "**\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 8,
        "window_text": "| 각 구성 시약의 원재료명 또는 성분명을 기재한다.  |\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다. ",
        "original_sentence": "**\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "| 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 170,
        "word_count": 37,
        "page_number": 5,
        "window_text": "|\n| ❍ 명칭(제품명, 품목명, 모델명) | 실시한 자료 |\n| 1) 시험규격 설정에 관한 자료로 시험방법과 기준결과 값 등의 내용을 포함한다.  | 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다. ",
        "original_sentence": "| 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "| 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 83,
        "word_count": 21,
        "page_number": 10,
        "window_text": "| 사용형태 | □ 내장형 | ■ 독립형 |\n**나) 검체 종류별 사용 가능한 항응고제**\n| 바) 시험물질 | 다) 재현성 | 1) 시험시설개요 |\n**국제 표준물질 혹은 타사 표준물질을 구매하여 사용한 경우 아래의 자료를 제출한다. **\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2. ",
        "original_sentence": "| 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "| ① 시험물질 : 반복성 평가와 동일하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 10,
        "window_text": "**\n| ❍ 분류번호(등급) | 2) 제조사의 CoA 및 시험방법에 관한 자료 등을 포함한다.  | 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5. ",
        "original_sentence": "| ① 시험물질 : 반복성 평가와 동일하다. "
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "| 결과를 판정하는 기준과 해석을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 9,
        "window_text": "| 연세대학교 세브란스병원 | 학계 | ➀「감염병의 예방 및 관리에 관한 시행규칙」 제4조제9호에 해당하는 기관 | 1 | (※ 출처 : Prosigna 510(k) 자료, p3, Substantial Equivalence Information) |\n| 4) 분량 | 등 심사의뢰서’를 작성하여야 한다.  | 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다.",
        "original_sentence": "| 결과를 판정하는 기준과 해석을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "|\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 114,
        "word_count": 31,
        "page_number": 5,
        "window_text": "| 다) 사용하는 검체의 종류별 필요 분량 | 1 | Progensa |\n**자료도 가능)**\n| 측정항목에 대한 임상적 배경을 포함하여 기재한다.  | ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3. ",
        "original_sentence": "|\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2. "
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 189,
        "word_count": 41,
        "page_number": 37,
        "window_text": "| ① 시험물질 : 반복성 평가와 동일하다.  | 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다.",
        "original_sentence": "제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5. "
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 241,
        "word_count": 46,
        "page_number": 38,
        "window_text": "| 결과를 판정하는 기준과 해석을 제시한다.  |\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n",
        "original_sentence": "미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다."
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "**\n| 소프트웨어 | 안전성 등급 |\n**Q3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 5,
        "window_text": "|\n| ❍ 모양 및 구조-외형 | ➁「혈액관리법」 제6조제3항에 따라 허가받은 공급혈액원 |\n**라) 검체 보관조건, 방법 및 사용기간 등**\n| 가) 일반사항 | 나) 시험방법 | ② 시험방법 | 2.  제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1. ",
        "original_sentence": "**\n| 소프트웨어 | 안전성 등급 |\n**Q3. "
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 104,
        "word_count": 17,
        "page_number": 8,
        "window_text": "제조자 |\n**❍ 모양 및 구조-작용원리**\n**➂ 의료기기법 제10조제3항에 따라 식약처장이 지정한 의료기기 임상시험기관**\n| 3) 판정기준치(cut-off value) | 마) 냉동 및 해동된 검체의 사용 가능성 및 제한점 | 2 | GenesWell™ BCT |\n\n**[표 끝]**\n\n<!-- PAGE_37 -->\n##### 5.  미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다."
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "**\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 42,
        "word_count": 8,
        "page_number": 15,
        "window_text": "미해결 오류(Unresolved Anomalies)\n\n34\n\n- - 34 -\n<!-- PAGE_38 -->\n###### <작성 예시>\n\n<!-- PAGE_38 -->\n###### <별지제13호서식>\n\n(품목분류번호)\n\n소프트웨어\n\n**[표 시작]**\n\n| 소프트웨어 | 기능적 특성 | (중복선택 가능) |\n| --- | --- | --- |\n**예측하거나 예후를 보기 위한 체외진단다지표검사용 의료기기(IVD-MIA)’의 예이다. **\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "· MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 96,
        "word_count": 16,
        "page_number": 40,
        "window_text": "**\n| 소프트웨어 | 안전성 등급 |\n**Q3.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n",
        "original_sentence": "· MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1. "
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 46,
        "word_count": 7,
        "page_number": 8,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 개발은**\n**⑦ 경계범위(gray zone 또는 equivocal zone)가 있을 경우 이를 설정한 근거를 제시한다. **\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n"
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "A1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 36,
        "window_text": "**\n\n**[표 끝]**\n\n소프트웨어\n\n형상관리\n\n아래 문서를 참조한다.\n\n · MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n",
        "original_sentence": "A1. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 141,
        "word_count": 31,
        "page_number": 40,
        "window_text": "· MFDS-IVD-MIA-CM : Software Configuration Management\n\n36\n\n- - 36 -\n<!-- PAGE_40 -->\n###### Q1.  체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n",
        "original_sentence": "현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n"
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 223,
        "word_count": 34,
        "page_number": 41,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA) 진단법의 예를 들면 무엇이 있나요?\n\n A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다. ",
        "original_sentence": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n"
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "<!-- PAGE_41 -->\n###### A2.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 29,
        "word_count": 5,
        "page_number": 41,
        "window_text": "A1.  현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n",
        "original_sentence": "<!-- PAGE_41 -->\n###### A2.\n\n"
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 562,
        "word_count": 95,
        "page_number": 41,
        "window_text": "현재 국내에는 4개의 IVD-MIA 제품이 제조(수입) 허가 되어 있으며, 미국에서 허가를\n\n<!-- PAGE_40 -->\n###### - 국내 허가 제품(수입1, 제조 3)\n\n37\n\n- - 37 -\n<!-- PAGE_41 -->\n###### Q2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3. ",
        "original_sentence": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "<!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 430,
        "word_count": 70,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단(Multiplex\n\n<!-- PAGE_41 -->\n###### assays)과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기\n\n<!-- PAGE_41 -->\n###### (IVD-MIA)의 가장 큰 차이점은 무엇인가요?\n\n <!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n",
        "original_sentence": "<!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다. "
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 238,
        "word_count": 45,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### A2.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다. ",
        "original_sentence": "그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 159,
        "word_count": 26,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단은\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 단순히\n\n<!-- PAGE_41 -->\n###### 양성과\n\n<!-- PAGE_41 -->\n###### 음성으로\n\n<!-- PAGE_41 -->\n###### 구분할\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있는\n\n<!-- PAGE_41 -->\n###### 기준인\n\n<!-- PAGE_41 -->\n###### cut-off\n\n<!-- PAGE_41 -->\n###### 수치를\n\n<!-- PAGE_41 -->\n###### 이용하여\n\n<!-- PAGE_41 -->\n###### 검사\n\n<!-- PAGE_41 -->\n###### 결과를\n\n<!-- PAGE_41 -->\n###### 도출합니다.\n\n <!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n",
        "original_sentence": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3. "
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 260,
        "word_count": 45,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 이에\n\n<!-- PAGE_41 -->\n###### 반해,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_41 -->\n###### 다수의\n\n<!-- PAGE_41 -->\n###### 바이오마커에\n\n<!-- PAGE_41 -->\n###### 대한\n\n<!-- PAGE_41 -->\n###### 측정값을\n\n<!-- PAGE_41 -->\n###### 입력값으로\n\n<!-- PAGE_41 -->\n###### 하여\n\n<!-- PAGE_41 -->\n###### 특정\n\n<!-- PAGE_41 -->\n###### 알고리즘의\n\n<!-- PAGE_41 -->\n###### 수식을\n\n<!-- PAGE_41 -->\n###### 계산합니다.  그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "<!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 168,
        "word_count": 28,
        "page_number": 41,
        "window_text": "그 결과 질병의 위험도나 환자의 상태와 예후를 예측할 수 있고\n\n<!-- PAGE_41 -->\n###### 예측\n\n<!-- PAGE_41 -->\n###### 결과는\n\n<!-- PAGE_41 -->\n###### 임상의의\n\n<!-- PAGE_41 -->\n###### 판단을\n\n<!-- PAGE_41 -->\n###### 도울\n\n<!-- PAGE_41 -->\n###### 수\n\n<!-- PAGE_41 -->\n###### 있습니다.\n\n <!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4. ",
        "original_sentence": "<!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 434,
        "word_count": 72,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 일반적인\n\n<!-- PAGE_41 -->\n###### 다중진단과\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA)의 가장 큰 차이점은 임상의의 판단을\n\n<!-- PAGE_41 -->\n###### A3.  체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다. ",
        "original_sentence": "이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "<!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 256,
        "word_count": 43,
        "page_number": 41,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)를 위한 알고리즘의 개발은 일반적으로\n\n<!-- PAGE_41 -->\n###### 후향적 연구로 진행되며, 검정은 전향적 연구 또는 전향적 연구에서 모아진\n\n<!-- PAGE_41 -->\n###### 검체를\n\n<!-- PAGE_41 -->\n###### 이용하는\n\n<!-- PAGE_41 -->\n###### 것이\n\n<!-- PAGE_41 -->\n###### 가장\n\n<!-- PAGE_41 -->\n###### 이상적입니다.\n\n <!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다. ",
        "original_sentence": "<!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4. "
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 70,
        "word_count": 10,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 하지만,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)의 적용 환자군을 특정하면 후향적 시험으로 검증을 대체할\n\n<!-- PAGE_41 -->\n###### 수 있습니다.  이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4. "
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 116,
        "word_count": 16,
        "page_number": 41,
        "window_text": "이 경우 임상통계학적 가설과 결과 변수(바이오마커 분석으로부터\n\n<!-- PAGE_41 -->\n###### 얻은\n\n<!-- PAGE_41 -->\n###### 결과치)가\n\n<!-- PAGE_41 -->\n###### 명확해야\n\n<!-- PAGE_41 -->\n###### 하며,\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_41 -->\n###### 의료기기(IVD-MIA)를\n\n<!-- PAGE_41 -->\n###### 적용할\n\n<!-- PAGE_41 -->\n###### 대상\n\n<!-- PAGE_41 -->\n###### 환자군\n\n<!-- PAGE_41 -->\n###### 또한\n\n<!-- PAGE_41 -->\n###### 명확하게\n\n<!-- PAGE_41 -->\n###### 정의돼야\n\n<!-- PAGE_41 -->\n###### 합니다.\n\n <!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 60,
        "word_count": 12,
        "page_number": 41,
        "window_text": "<!-- PAGE_41 -->\n###### 또한,\n\n<!-- PAGE_41 -->\n###### 결과\n\n<!-- PAGE_41 -->\n###### 변수와의\n\n<!-- PAGE_41 -->\n###### 통계적 연관성뿐만 아니라 어떤 목적(intended use)을 위해 사용할 것인지도\n\n<!-- PAGE_41 -->\n###### 체외진단다지표검사용 의료기기(IVD-MIA) 알고리즘 개발을 위한 고려사항들은\n\n<!-- PAGE_41 -->\n###### Q4.  체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다. ",
        "original_sentence": "또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다. "
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 243,
        "word_count": 43,
        "page_number": 41,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)에 사용되는 알고리즘의 검정은\n\n<!-- PAGE_41 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다. ",
        "original_sentence": "알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 137,
        "word_count": 30,
        "page_number": 42,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)의 알고리즘 개발을 위해 사용된 검체군의\n\n<!-- PAGE_41 -->\n###### 검정은 허용기준(acceptability criteria)을 충족해야 합니다.  또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n",
        "original_sentence": "검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "<!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 178,
        "word_count": 33,
        "page_number": 42,
        "window_text": "또한, 알고리즘은 독립\n\n<!-- PAGE_41 -->\n###### 적인 검체를 이용해 검정을 진행합니다.  알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n",
        "original_sentence": "<!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 93,
        "word_count": 18,
        "page_number": 42,
        "window_text": "알고리즘의 검정을 시행하기 이전에 알\n\n<!-- PAGE_41 -->\n###### 고리즘의 핵심 구성 요소인 사용변수(바이오마커),\n\n<!-- PAGE_41 -->\n###### 통계모델\n\n<!-- PAGE_41 -->\n###### 개발,\n\n<!-- PAGE_41 -->\n###### 판단\n\n<!-- PAGE_41 -->\n###### 기준\n\n<!-- PAGE_41 -->\n###### (decision rule) 등이 결정돼야 합니다.  검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다. ",
        "original_sentence": "알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 432,
        "word_count": 74,
        "page_number": 42,
        "window_text": "검체군은 알고리즘으로 예측하고자 하는\n\n38\n\n- - 38 -\n<!-- PAGE_42 -->\n###### 그룹의 유의성을 보장할 수 있는 충분한 수를 이용하여 임상적 성능시험을 수행\n\n<!-- PAGE_42 -->\n###### 하여야 합니다.\n\n <!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다. ",
        "original_sentence": "만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "<!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 135,
        "word_count": 27,
        "page_number": 42,
        "window_text": "<!-- PAGE_42 -->\n###### 예를 들어, 대장암 진단을 위한 체외진단다지표검사용 의료기기(IVD-MIA)에서 민감도와\n\n<!-- PAGE_42 -->\n###### 특이도의 정확한 측정을 위해 충분한 수의 대장암 환자와 대조환자 검체를 가지고\n\n<!-- PAGE_42 -->\n###### 시험해야 합니다.  알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다. ",
        "original_sentence": "<!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "<!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 268,
        "word_count": 50,
        "page_number": 42,
        "window_text": "알고리즘 검정을 위한 검체군의 data pre-processing 단계는 개발\n\n<!-- PAGE_42 -->\n###### 단계와 무관하게 진행할 수 있어야 합니다.  만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다. ",
        "original_sentence": "<!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 135,
        "word_count": 25,
        "page_number": 42,
        "window_text": "만약 알고리즘 개발 단계에서 사용했던\n\n<!-- PAGE_42 -->\n###### 검체의\n\n<!-- PAGE_42 -->\n###### 정보를\n\n<!-- PAGE_42 -->\n###### 이용해야\n\n<!-- PAGE_42 -->\n###### 한다면(예,\n\n<!-- PAGE_42 -->\n###### gene\n\n<!-- PAGE_42 -->\n###### expression\n\n<!-- PAGE_42 -->\n###### microarray\n\n<!-- PAGE_42 -->\n###### 실험에서\n\n<!-- PAGE_42 -->\n###### development data를 이용하여 새로운 sample을 normalization 해야 하는 경우),\n\n<!-- PAGE_42 -->\n###### 이 단계의 결과를 모르는 모든 검체가 편중되지 않도록 적용 가능한지 확인해야 합니다.\n\n <!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다. ",
        "original_sentence": "질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다. "
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 11,
        "window_text": "<!-- PAGE_42 -->\n###### 어떤 경우에나 적용할 수 있는 최적의 알고리즘이 존재하지 않으므로, 체외진단\n\n<!-- PAGE_42 -->\n###### 다지표검사 알고리즘의 검정을 시행하기 이전에 다음 사항을 유의해야 합니다.\n\n <!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n",
        "original_sentence": "로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다. "
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 341,
        "word_count": 55,
        "page_number": 42,
        "window_text": "<!-- PAGE_42 -->\n###### 임상통계학적 모델에 사용한 바이오마커의 선정의 근거, 개발 경위, 검사 결과에\n\n<!-- PAGE_42 -->\n###### 대한 판단 기준을 명시할 것을 권고하며, 이러한 내용은 과학적 검토자(scientific\n\n<!-- PAGE_42 -->\n###### 질병의 유무를 예측하는 체외진단다지표검사의 경우엔 변수 선택 기법을 이용한\n\n<!-- PAGE_42 -->\n###### logistic regression을 적용할 수 있습니다.  질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4. ",
        "original_sentence": "이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 67,
        "word_count": 15,
        "page_number": 42,
        "window_text": "질병과 관련 있는 지표와 바이오마커들의\n\n<!-- PAGE_42 -->\n###### 주성분(principal component, PC)을 이용해 판별 분석을 시행하면 결과를 예측할 수 있\n\n<!-- PAGE_42 -->\n###### 습니다.  로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다. ",
        "original_sentence": "바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다. "
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 131,
        "word_count": 24,
        "page_number": 42,
        "window_text": "로지스틱 회귀분석 이외의 다양한 통계학적 방법들도 사용 가능합니다.  이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다. ",
        "original_sentence": "성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n"
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "<!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 195,
        "word_count": 30,
        "page_number": 42,
        "window_text": "이러한\n\n<!-- PAGE_42 -->\n###### 방법으로\n\n<!-- PAGE_42 -->\n###### 생성된\n\n<!-- PAGE_42 -->\n###### 예측\n\n<!-- PAGE_42 -->\n###### 모델의\n\n<!-- PAGE_42 -->\n###### 성능은\n\n<!-- PAGE_42 -->\n###### cross-validation을\n\n<!-- PAGE_42 -->\n###### 통하여\n\n<!-- PAGE_42 -->\n###### 내부\n\n<!-- PAGE_42 -->\n###### 검정\n\n<!-- PAGE_42 -->\n###### (internal validation 임상시험)이 시행되어야 합니다.  바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다. ",
        "original_sentence": "<!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 176,
        "word_count": 32,
        "page_number": 42,
        "window_text": "바이오마커의 선택과 적합 모\n\n<!-- PAGE_42 -->\n###### 델의 선정 등 모든 경위를 검정에 사용합니다.  성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 131,
        "word_count": 26,
        "page_number": 42,
        "window_text": "성공적인 결과를 확인한 경우(성공\n\n<!-- PAGE_42 -->\n###### 기준은 질병 및 대상군에 따라 정의), 외부 검정(external validation 임상시험)을 통\n\n<!-- PAGE_42 -->\n###### Q5.\n\n <!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n",
        "original_sentence": "따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다. "
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 137,
        "word_count": 30,
        "page_number": 42,
        "window_text": "<!-- PAGE_42 -->\n###### 체외진단다지표검사용\n\n<!-- PAGE_42 -->\n###### 의료기기(IVD-MIA)는\n\n<!-- PAGE_42 -->\n###### 검사\n\n<!-- PAGE_42 -->\n###### 대상(환자,\n\n<!-- PAGE_42 -->\n###### 피험자)을\n\n<!-- PAGE_42 -->\n###### A4.  체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6.",
        "original_sentence": "만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 151,
        "word_count": 29,
        "page_number": 42,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)는 다수의 바이오마커들에 대해 각각의\n\n<!-- PAGE_42 -->\n###### 검사 결과를 도출하지 않고, 각 검사 결과를 임상통계학적 분석 알고리즘을 이용\n\n<!-- PAGE_42 -->\n###### 하여 새로운 값(수치), 지수(인덱스), 분류 등으로 제시합니다.  따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer. ",
        "original_sentence": "유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 148,
        "word_count": 22,
        "page_number": 11,
        "window_text": "따라서, 환자군의\n\n<!-- PAGE_42 -->\n###### 예를 들면, 유방암 예후진단검사는 보통 유전자의 전사 수준과 단백질 발현 정도를\n\n<!-- PAGE_42 -->\n###### 관찰하여 유방암의 예후를 예측하는 검사입니다.  만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192.",
        "original_sentence": "그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n"
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "Nature,\n\n- (2002)\n415(6871):530-6.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 34,
        "word_count": 4,
        "page_number": 5,
        "window_text": "만약 이 검사의 알고리즘 개발과\n\n<!-- PAGE_42 -->\n###### 검정 검체군에 화학요법을 받은 환자가 포함된다면, 유전적 요소와 화학적 요소가\n\n<!-- PAGE_42 -->\n###### 유전자 발현 양상에 영향을 줄 수 있습니다.  유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6. ",
        "original_sentence": "Nature,\n\n- (2002)\n415(6871):530-6."
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "\"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 283,
        "word_count": 48,
        "page_number": 43,
        "window_text": "유전적 요소만이 검사 결과에 영향을\n\n<!-- PAGE_42 -->\n###### 줘야하는 예후진단검사에서 화학적 요소가 반영된다면 체외진단다지표검사용 의료기기\n\n39\n\n- - 39 -\n<!-- PAGE_43 -->\n###### (IVD-MIA)에 문제가 있는 것입니다.  그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6. ",
        "original_sentence": "\"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer. "
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "JNCI, (2006) 98(17):1183-1192.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 30,
        "word_count": 3,
        "page_number": 5,
        "window_text": "그러한 이유로 MammaPrint 제품은 알고리즘\n\n개발 단계와 첫 검정에서 환자들의 화학요법 여부를 고려하지 않았습니다(\"Gene\n\nexpression\n\nprofiling\n\npredicts\n\nclinical\n\noutcome\n\nof\n\nbreast\n\ncancer.\n\n Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n",
        "original_sentence": "JNCI, (2006) 98(17):1183-1192."
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "\"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 69,
        "word_count": 13,
        "page_number": 43,
        "window_text": "Nature,\n\n- (2002)\n415(6871):530-6. \"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7. ",
        "original_sentence": "\"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6. "
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 73,
        "word_count": 12,
        "page_number": 43,
        "window_text": "\"에서 다변량비례 위험분석결과, MammaPrint의 Hazard Ratio(위험비)와 더불어\n\n암의 크기, 림프절 전이 여부, chemotherapy 여부 등이 예후진단에 영향을 끼칠 수 있는\n\n유의한 인자임을 밝히고 있음) 이후 두 번째 알고리즘 임상 검정(\"Validation and\n\nclinical utility of a 70-gene prognostic signature for women with node-negative breast\n\n<!-- PAGE_43 -->\n###### cancer.  JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7. ",
        "original_sentence": "체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6. "
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 8,
        "window_text": "JNCI, (2006) 98(17):1183-1192. \"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다. ",
        "original_sentence": "체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "<!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 169,
        "word_count": 38,
        "page_number": 43,
        "window_text": "\"의 TRNASBIG trial 및 FDA 510(k))에서는 수술 후\n\n<!-- PAGE_43 -->\n###### Q6.  체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다. ",
        "original_sentence": "<!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7. "
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 70,
        "word_count": 10,
        "page_number": 43,
        "window_text": "체외진단다지표검사(IVD-MIA) 알고리즘 개발경위 작성을 위한 간략한 예시가\n\n<!-- PAGE_43 -->\n###### A6.  체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 94,
        "word_count": 17,
        "page_number": 43,
        "window_text": "체외진단다지표검사 알고리즘 개발 경위의 간단한 예시는 다음과 같습니다.\n\n <!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.  ",
        "original_sentence": "「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 143,
        "word_count": 31,
        "page_number": 43,
        "window_text": "<!-- PAGE_43 -->\n###### ③ 통계 분석 결과로 사용변수들을 선별한 기준을 구체적인 수치 등을 사용하여 기술\n\n<!-- PAGE_43 -->\n###### ① 우선 검사의 사용 목적 및 검사법, 판단 기준에 대한 요약과 세부적인 내용에\n\n<!-- PAGE_43 -->\n###### Q7.  체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1. ",
        "original_sentence": "여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 134,
        "word_count": 26,
        "page_number": 44,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)를 이용한 임상시험을 계획하고\n\n<!-- PAGE_43 -->\n###### A7.  「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.  ",
        "original_sentence": "개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.  ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 170,
        "word_count": 37,
        "page_number": 45,
        "window_text": "「의료기기 허가·신고 심사 등에 관한 규정」제33조제2항제5호다목에는 식약처의\n\n<!-- PAGE_43 -->\n###### 임상시험 계획 승인 대상을 정하고 있습니다.  여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1. ",
        "original_sentence": "임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.  "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 116,
        "word_count": 9,
        "page_number": 46,
        "window_text": "여기에는 ‘이미 확릭된 의학적 진단\n\n<!-- PAGE_43 -->\n###### 방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험 결과를 확인할\n\n40\n\n- - 40 -\n<!-- PAGE_44 -->\n###### 수 없는 시험’이 포함됩니다.  개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2. ",
        "original_sentence": "제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.  ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 140,
        "word_count": 9,
        "page_number": 46,
        "window_text": "개발중인 IVD-MIA는 기존의 의학적 진단방법 또는\n\n<!-- PAGE_44 -->\n###### 허가·인증된 의료기기가 없는 경우가 대부분으로 식약처의 임상시험 계획 승인\n\n<!-- PAGE_44 -->\n###### 대상일 수 있습니다.  임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.  ",
        "original_sentence": "제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.  "
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 76,
        "word_count": 13,
        "page_number": 46,
        "window_text": "임상시험을 실시하기 전에 식약처 관련 부서(체외진단기기과)와\n\n<!-- PAGE_45 -->\n###### <부 록>\n\n<!-- PAGE_45 -->\n###### <침윤성 유방암 환자의 재발 위험 예측 및 예후 검사>\n\n2\n\n- - 2 -\n목   차\n\n<!-- PAGE_46 -->\n###### 제Ⅰ부.   제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1. ",
        "original_sentence": "신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 112,
        "word_count": 10,
        "page_number": 46,
        "window_text": "제품 개요 ··············································································· 4\n\n<!-- PAGE_46 -->\n###### 1.  제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2. ",
        "original_sentence": "제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.  ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 125,
        "word_count": 9,
        "page_number": 46,
        "window_text": "제품 개요 ···································································································· 4\n\n<!-- PAGE_46 -->\n###### 제Ⅱ부.   신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3. ",
        "original_sentence": "기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.  "
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 76,
        "word_count": 13,
        "page_number": 46,
        "window_text": "신청서 기재 항목 및 기술문서 제출자료 ······················· 5\n\n<!-- PAGE_46 -->\n###### 1.  제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4. ",
        "original_sentence": "제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 144,
        "word_count": 8,
        "page_number": 46,
        "window_text": "제조허가 및 수입허가 신청서 ··································································5\n\n<!-- PAGE_46 -->\n###### 2.  기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5. ",
        "original_sentence": "명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 131,
        "word_count": 8,
        "page_number": 46,
        "window_text": "기술문서에 관한 자료 ················································································5\n\n<!-- PAGE_46 -->\n###### 제Ⅲ부.   제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6. ",
        "original_sentence": "분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 133,
        "word_count": 10,
        "page_number": 46,
        "window_text": "제조허가 및 수입허가 신청서 기재 항목 ······················· 6\n\n<!-- PAGE_46 -->\n###### 1.  명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7. ",
        "original_sentence": "모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 141,
        "word_count": 8,
        "page_number": 46,
        "window_text": "명칭 ·············································································································· 6\n\n<!-- PAGE_46 -->\n###### 2.  분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8. ",
        "original_sentence": "원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 138,
        "word_count": 7,
        "page_number": 46,
        "window_text": "분류번호(등급) ··························································································· 7\n\n<!-- PAGE_46 -->\n###### 3.  모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9. ",
        "original_sentence": "제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 131,
        "word_count": 7,
        "page_number": 46,
        "window_text": "모양 및 구조 ······························································································ 7\n\n<!-- PAGE_46 -->\n###### 4.  원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10. ",
        "original_sentence": "사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 138,
        "word_count": 7,
        "page_number": 46,
        "window_text": "원재료 ·········································································································· 9\n\n<!-- PAGE_46 -->\n###### 5.  제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11. ",
        "original_sentence": "사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 127,
        "word_count": 9,
        "page_number": 46,
        "window_text": "제조방법 ······································································································11\n\n<!-- PAGE_46 -->\n###### 6.  사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12. ",
        "original_sentence": "사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 139,
        "word_count": 7,
        "page_number": 46,
        "window_text": "사용목적(성능) ···························································································11\n\n<!-- PAGE_46 -->\n###### 7.  사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.  ",
        "original_sentence": "포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 120,
        "word_count": 9,
        "page_number": 46,
        "window_text": "사용방법 ······································································································13\n\n<!-- PAGE_46 -->\n###### 8.  사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1. ",
        "original_sentence": "저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 137,
        "word_count": 7,
        "page_number": 46,
        "window_text": "사용 시 주의사항 ······················································································14\n\n<!-- PAGE_46 -->\n###### 9.  포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2. ",
        "original_sentence": "시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12. "
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.  ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 102,
        "word_count": 17,
        "page_number": 47,
        "window_text": "포장단위 ······································································································15\n\n<!-- PAGE_46 -->\n###### 10.  저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3. ",
        "original_sentence": "제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.  "
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 180,
        "word_count": 22,
        "page_number": 47,
        "window_text": "저장방법 및 사용기간 ············································································15\n\n<!-- PAGE_46 -->\n###### 11.  시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4. ",
        "original_sentence": "기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 72,
        "word_count": 13,
        "page_number": 47,
        "window_text": "시험규격 ····································································································16\n\n<!-- PAGE_46 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5. ",
        "original_sentence": "개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 107,
        "word_count": 11,
        "page_number": 47,
        "window_text": "제조원(수입 또는 제조공정 전부 위탁의 경우) ·······························16\n\n3\n\n- - 3 -\n<!-- PAGE_47 -->\n###### 제Ⅳ부.   기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6. ",
        "original_sentence": "원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 47,
        "window_text": "기술문서 등의 심사를 위한 제출자료 ···························18\n\n<!-- PAGE_47 -->\n###### ※ 기본원칙 및 성능시험 자료의 요건 ·····················································18\n\n<!-- PAGE_47 -->\n###### 1.  개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7. ",
        "original_sentence": "사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 92,
        "word_count": 10,
        "page_number": 47,
        "window_text": "개발경위, 측정원리·방법 및 국내․외 사용현황에 관한 자료 ········21\n\n<!-- PAGE_47 -->\n###### 2.  원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.  ",
        "original_sentence": "저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 121,
        "word_count": 9,
        "page_number": 47,
        "window_text": "원재료 및 제조방법에 관한 자료 ··························································22\n\n<!-- PAGE_47 -->\n###### 3.  사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1. ",
        "original_sentence": "성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 85,
        "word_count": 12,
        "page_number": 47,
        "window_text": "사용목적에 관한 자료 ··············································································22\n\n<!-- PAGE_47 -->\n###### 4.  저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2. ",
        "original_sentence": "체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.  ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 107,
        "word_count": 11,
        "page_number": 47,
        "window_text": "저장방법과 사용기간(유효기간)에 관한 자료 ·····································23\n\n<!-- PAGE_47 -->\n###### 5.  성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3. ",
        "original_sentence": "이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.  "
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 97,
        "word_count": 10,
        "page_number": 47,
        "window_text": "성능시험에 관한 자료 ··············································································23\n\n<!-- PAGE_47 -->\n###### 6.  체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4. ",
        "original_sentence": "성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 111,
        "word_count": 10,
        "page_number": 47,
        "window_text": "체외진단용 의료기기의 취급자 안전에 관한 자료 ····························24\n\n<!-- PAGE_47 -->\n###### 7.  이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5. ",
        "original_sentence": "분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 111,
        "word_count": 10,
        "page_number": 47,
        "window_text": "이미 허가받은 제품과 비교한 자료 ······················································24\n\n<!-- PAGE_47 -->\n###### 제Ⅴ부.   성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6. ",
        "original_sentence": "임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 78,
        "word_count": 13,
        "page_number": 47,
        "window_text": "성능에 관한 세부사항 ····················································· 25\n\n<!-- PAGE_47 -->\n###### 1.  분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7. ",
        "original_sentence": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 78,
        "word_count": 13,
        "page_number": 47,
        "window_text": "분석적 성능시험에 관한 자료 ································································25\n\n<!-- PAGE_47 -->\n###### 2.  임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부. ",
        "original_sentence": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 76,
        "word_count": 14,
        "page_number": 47,
        "window_text": "임상적 성능시험에 관한 자료 ································································36\n\n<!-- PAGE_47 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1. ",
        "original_sentence": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 134,
        "word_count": 8,
        "page_number": 47,
        "window_text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료 ··················42\n\n<!-- PAGE_47 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다. ",
        "original_sentence": "상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 133,
        "word_count": 14,
        "page_number": 48,
        "window_text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료 ··················43\n\n<!-- PAGE_47 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다. ",
        "original_sentence": "소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부. "
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "제품 개요\n\n<!-- PAGE_48 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 48,
        "window_text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료 ············43\n\n<!-- PAGE_47 -->\n###### 6.  상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다. ",
        "original_sentence": "제품 개요\n\n<!-- PAGE_48 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 411,
        "word_count": 89,
        "page_number": 48,
        "window_text": "상관성 평가 ································································································43\n\n<!-- PAGE_47 -->\n###### 7.  소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부. ",
        "original_sentence": "제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 465,
        "word_count": 88,
        "page_number": 48,
        "window_text": "소프트웨어 성능 자료 ··············································································46\n\n4\n\n- - 4 -\n<!-- PAGE_48 -->\n##### 제Ⅰ부.  제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부. ",
        "original_sentence": "유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 209,
        "word_count": 48,
        "page_number": 48,
        "window_text": "제품 개요\n\n<!-- PAGE_48 -->\n###### 1.  제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1. ",
        "original_sentence": "조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다. "
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 243,
        "word_count": 51,
        "page_number": 48,
        "window_text": "제품에 대한 개요\n\n<!-- PAGE_48 -->\n###### 본 가이드라인은 가상의 제품(모델명 : Breast Cancer Alarm)으로 ‘호르몬 수용체\n\n<!-- PAGE_48 -->\n###### 양성(HR+)과 림프절 전이 3개 이하의 조기 유방암 여성 환자(Stage I 또는 Stage\n\n<!-- PAGE_48 -->\n###### II)에 대한 다중 유전자 분석 알고리즘으로 10년 내 원격 전이 등 재발 위험을\n\n<!-- PAGE_48 -->\n###### 유방암은 유방 내에만 머무는 양성 종양과 달리 유방 밖으로 퍼져 생명을 위협할 수\n\n<!-- PAGE_48 -->\n###### 있는 악성 종양으로써, 암이 기원한 세포의 종류 및 침윤 정도 등에 따라 다양하게\n\n<!-- PAGE_48 -->\n###### 분류된다.  유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가. ",
        "original_sentence": "본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부. "
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 216,
        "word_count": 47,
        "page_number": 49,
        "window_text": "유방암은 선진국형 질병으로 미국의 경우 가장 흔한 암으로 보고되었으며,\n\n<!-- PAGE_48 -->\n###### 유방암 예후 예측인자로는 종양의 크기 및 림프절 전이의 유무, 종양의 병리학적\n\n<!-- PAGE_48 -->\n###### 분화도가\n\n<!-- PAGE_48 -->\n###### 있으며,\n\n<!-- PAGE_48 -->\n###### 호르몬\n\n<!-- PAGE_48 -->\n###### 수용체(HR,\n\n<!-- PAGE_48 -->\n###### 에스트로겐\n\n<!-- PAGE_48 -->\n###### 수용체\n\n<!-- PAGE_48 -->\n###### 또는\n\n<!-- PAGE_48 -->\n###### 프로게스테론\n\n<!-- PAGE_48 -->\n###### 수용체)와 인간 표피 증식 인자 수용체(HER2)의 양성 유무가 예후 예측 및 치료의\n\n<!-- PAGE_48 -->\n###### 결정에 중요한 역할을 한다.  조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n",
        "original_sentence": "신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부. "
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 50,
        "word_count": 11,
        "page_number": 50,
        "window_text": "조기 유방암 환자 중 HR 양성, HER2 음성, 림프절\n\n<!-- PAGE_48 -->\n###### 전이 3개 이하의 환자 중 70 ~ 80%는 원격 전이의 확률이 매우 적지만 기존 유방암\n\n<!-- PAGE_48 -->\n###### 진단 가이드라인으로는 판별이 어려워 대다수의 환자가 수술 후 항암화학요법을\n\n<!-- PAGE_48 -->\n###### 처방 받고 있다.  본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n",
        "original_sentence": "제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "명칭\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 2,
        "window_text": "본 제품을 이용하여 유방암 조직에서 다중 유전자 분석은 60종의\n\n<!-- PAGE_48 -->\n###### 유전자 전사(Transcript)량에 유전자별 가중치를 부여하여 원격 전이 예후에 관한\n\n<!-- PAGE_48 -->\n###### 단, 본 제품은 환자의 치료반응성에 대한 예측 또는 이상적 치료를\n\n<!-- PAGE_48 -->\n###### 선택하는데\n\n5\n\n- - 5 -\n<!-- PAGE_49 -->\n##### 제Ⅱ부.  신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나. ",
        "original_sentence": "명칭\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 31,
        "word_count": 5,
        "page_number": 8,
        "window_text": "신청서 기재 항목 및 기술문서 제출자료\n\n<!-- PAGE_49 -->\n###### 1\n\n<!-- PAGE_49 -->\n###### 제조허가 및 수입허가 신청서\n\n<!-- PAGE_49 -->\n###### 2\n\n<!-- PAGE_49 -->\n###### 기술문서에 관한 자료\n\n❍ 이미 허가받은 제품과 비교한 자료\n\n6\n\n- - 6 -\n<!-- PAGE_50 -->\n##### 제Ⅲ부.  제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n",
        "original_sentence": "제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 113,
        "word_count": 18,
        "page_number": 8,
        "window_text": "제조허가 및 수입허가 신청서 기재 항목\n\n<!-- PAGE_50 -->\n###### 1.  명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2. ",
        "original_sentence": "1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 5,
        "window_text": "명칭\n\n- 가.  제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n",
        "original_sentence": "3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 8,
        "window_text": "제조(수입)업소명, 품목류명, 모델명을 각각 기재한다.\n 1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3. ",
        "original_sentence": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n"
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 207,
        "word_count": 50,
        "page_number": 51,
        "window_text": "1) 제품명을 기재하는 경우에는 “제조(수입)업소명·제품명”, “품목명”, “모델명”을 각각 기재\n\n2) 제품명을 기재하지 아니하는 경우에는 “제조(수입)업소명·품목명”, “모델명”을 각각 기재한다.\n\n 3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가. ",
        "original_sentence": "1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 8,
        "window_text": "3) 동일제품에 대하여 두개 이상의 다른 상품명(또는 모델명) 부여는(수출용 의료기기 제외)\n\n- 나.  제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나. ",
        "original_sentence": "분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "<!-- PAGE_51 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 51,
        "window_text": "제품명은 이미 허가(신고)를 받거나 받았었던 의료기기의 제품명과 동일하여서는 아니 된다.\n 1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다. ",
        "original_sentence": "<!-- PAGE_51 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "모양 및 구조\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 8,
        "window_text": "1) 허가(신고)가 취소된 의료기기와 사용목적, 작용원리 및 원재료 등이 동일한 의료기기로써\n\n3) 서로 다른 수입업자가 제조원이 같은 동일한 제품을 수입하는 경우에 수입업소명을 병기하여\n\n※ 다만, 기허가 제품과 사용목적이 유사하여 허가 받은 제품의 상품명에 문자, 단어, 숫자 등을\n\n※ 예시 :\n\n7\n\n- - 7 -\n<!-- PAGE_51 -->\n###### 2.  분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n",
        "original_sentence": "모양 및 구조\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 128,
        "word_count": 28,
        "page_number": 8,
        "window_text": "분류번호(등급)\n\n- 가.「의료기기 품목 및 품목별 등급에 관한 규정」에 따라 해당제품의 품목분류번호와 등급을\n기재한다.\n\n <!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n",
        "original_sentence": "모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 47,
        "word_count": 13,
        "page_number": 10,
        "window_text": "<!-- PAGE_51 -->\n###### 3.  모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가. ",
        "original_sentence": "모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 297,
        "word_count": 49,
        "page_number": 8,
        "window_text": "모양 및 구조\n\n- 가.  모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n",
        "original_sentence": "만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 160,
        "word_count": 39,
        "page_number": 8,
        "window_text": "모양 및 구조 - 작용원리\n해당 체외진단다지표검사용 의료기기(IVD-MIA)의 해당 제품에 적용되는 적용한 작용원리와\n\n2) 임상적 배경 : 해당 의료기기를 이용한 검사결과의 임상적 의의를 기재한다(알고리즘 및 결과값\n\n- 나.  모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다. ",
        "original_sentence": "2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 8,
        "window_text": "모양 및 구조 – 외형\n1) 구성 : 구성품의 외관사진을 포함한 구성표를 기재한다.  만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "원재료는 다음 양식의 표를 사용하여 기재한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 15,
        "window_text": "만일 체외진단다지표검사용 의료기기\n\n(IVD-MIA)와 보관조건의 차이로 다른 포장의 구성품을 포함하고자 할 경우, 별도포장\n\n본 검사는 RNA 추출 키트, Breast Cancer Alarm 시약(Reference Sample, Primer Set, Prep\n\n8\n\n- - 8 -\nPack,\n\nCartridge(s)\n\nand\n\nPrep\n\nPlate),\n\n검체와\n\nprobe의\n\n혼성화(hybridization)\n\n및\n\n디지털\n\n분석기인 NanoString nCounter® Dx Analysis System으로 구성되어 있다.\n\n 2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다. ",
        "original_sentence": "원재료는 다음 양식의 표를 사용하여 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 2,
        "window_text": "2) 외관설명 : 고형의 구성제품에 대해서는 모양․구조․중량 등을 기재하고, 액상 또는 분말의 시약에\n\n3) 외형사진 : 제품을 육안으로 식별할 수 있도록 제품의 전체 및 구성하는 체외동반진단기기를 확인할\n\n9\n\n- - 9 -\n4) 소프트웨어 구조 : 소프트웨어의 구조도를 기재한다.\n\n - 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다. ",
        "original_sentence": "보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 69,
        "word_count": 19,
        "page_number": 14,
        "window_text": "- 가.  원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다. ",
        "original_sentence": "두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 117,
        "word_count": 27,
        "page_number": 10,
        "window_text": "원재료는 다음 양식의 표를 사용하여 기재한다.\n 보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5. ",
        "original_sentence": "※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 141,
        "word_count": 31,
        "page_number": 23,
        "window_text": "보조시약을 포함하여 해당 구성시약별로 일반명칭을 기재한다.  두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가. ",
        "original_sentence": "주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 113,
        "word_count": 22,
        "page_number": 8,
        "window_text": "두 세트 이상이 함께 사용\n\n10\n\n- - 10 -\n2) 배합목적\n\n원재료의 특성에 맞게 각 성분의 배합목적을 기재한다.\n\n ※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n",
        "original_sentence": "소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다. "
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 224,
        "word_count": 49,
        "page_number": 55,
        "window_text": "※ 예시 : 주성분, 반응보조제, 보존제, 반응안정제, 반응정지제 등\n\n분량란에는 각 성분의 분량(역가, 소요량 등) 및 단위(mL, mg, v/v, w/v, w/w 등)를 기재하고\n\n범위를 설정할 수 있다.  주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다.",
        "original_sentence": "하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "제조방법\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "주성분(중합효소, 역전사효소, 프라이머 및 프로브 등)의 분량은 농도와\n\n규격란에 원재료에 대한 규격이 있는 경우 당해 규격(KP, USP 등)을 기재하고, 규격이 없\n\n소프트웨어 원재료 표를 작성하여 소프트웨어 명칭, 버전, 운영환경 등을 기재한다.  소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나. ",
        "original_sentence": "제조방법\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "'제조원의 제조방법에 따른다.’라고 기재한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 26,
        "word_count": 4,
        "page_number": 8,
        "window_text": "소프\n\n트웨어가 특정 하드웨어에서만 작동할 수 있도록 개발되었다면 내장형 소프트웨어에 해당되며\n\n기술문서에 기재된 하드웨어의 사양이 소프트웨어의 운영환경이므로 별도의 운영환경을\n\n작성하지 않아도 된다.  하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6. ",
        "original_sentence": "'제조원의 제조방법에 따른다.’라고 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 33,
        "word_count": 6,
        "page_number": 2,
        "window_text": "하지만 소프트웨어가 일반PC 등 범용적인 하드웨어에서 작동하\n\n도록 개발되었다면 독립형 소프트웨어에 해당되며 운영환경은 소프트웨어가 정상적으로 작동\n\n11\n\n- - 11 -\n예시 1) 내장형 소프트웨어(유방암 예후 위험도 측정)\n\n일련\n\n번호\n\n부분품의 명칭\n\n부분품 관리번호\n\n규격 또는 특성\n\n수량\n\n비고\n\n유방암 예후\n\n위험도 측정\n\n소프트웨어\n\n<!-- PAGE_55 -->\n###### 5.  제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가. ",
        "original_sentence": "다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다."
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "(대부분의 체외진단용 의료\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 8,
        "window_text": "제조방법\n\n- 가.  '제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다. ",
        "original_sentence": "(대부분의 체외진단용 의료\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 79,
        "word_count": 13,
        "page_number": 55,
        "window_text": "'제조원의 제조방법에 따른다.’라고 기재한다.\n 다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n",
        "original_sentence": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "사용목적(성능)\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 8,
        "window_text": "다만, 멸균의료기기의 경우에는 해당사항을 부가하여 기재한다. (대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나. ",
        "original_sentence": "사용목적(성능)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 63,
        "word_count": 15,
        "page_number": 2,
        "window_text": "(대부분의 체외진단용 의료\n\n- 나.  멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7. ",
        "original_sentence": "사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 205,
        "word_count": 48,
        "page_number": 13,
        "window_text": "멸균의료기기의 제조방법의 경우 멸균방법은 식약처장이 인정하는 멸균의료기기의 멸균방법(의료기기\n<!-- PAGE_55 -->\n###### 6.  사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가. ",
        "original_sentence": "검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 418,
        "word_count": 111,
        "page_number": 8,
        "window_text": "사용목적(성능)\n\n- 가.  사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n",
        "original_sentence": "- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 214,
        "word_count": 40,
        "page_number": 57,
        "window_text": "사용목적에는 약 이름 및 검사대상, 검체 종류, 검사항목, 측정원리, 정성 또는 정량 등을\n구체적으로 기재한다.  검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1. ",
        "original_sentence": "성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "사용방법\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "검사에 사용되는 특정 장비가 있다면 ‘사용방법’항에 해당 장비/\n\n포르말린 고정 후 파라핀 포매된 여성 유방암환자의 침습적 유방암 조직에서 유방암 관련 58개의\n\n유전자의 발현량을 정량 PCR법으로 측정하고, 각 유전자 발현에 가중치를 달리한 알고리즘(수식)으로\n\n본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은 아래와 같다.\n\n - - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2. ",
        "original_sentence": "사용방법\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 105,
        "word_count": 22,
        "page_number": 2,
        "window_text": "- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n12\n\n- - 12 -\n단독 투여된 환자\n\n- - 호르몬 수용체 양성, 림프절 전이 양성(1~3개), 유방암 병기 II 로 보조적 내분비 치료만 단\n독 투여된 환자\n\n1) 검사대상 : 체외진단다지표검사용 의료기기(IVD-MIA)의 경우, 해당 검사대상이 명확\n\n※ 예시 : 본 검사법 사용 대상은 국소 영역 치료 및 수술을 받은 여성 환자로, 구체적인 조건은\n\n- - 호르몬 수용체 양성, 림프절 전이 음성, 유방암 병기 I 또는 II로 보조적 내분비 치료만\n나) 검사하고자 하는 유전자 또는 단백질 마커가 5개 이상인 경우, 포괄적으로 기재하고\n\n5) 임상적 의의: 의약품의 적용 질환 명을 기재하여야 하며, 의약품 투여에서 동반진단의\n\n- 나.  성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n",
        "original_sentence": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 118,
        "word_count": 30,
        "page_number": 10,
        "window_text": "성능\n1) 분석적 성능으로 검출한계(FFPE level/RNA level), 분석적 특이도, 정밀도(재현성, 반복성),\n\n직선성/측정범위, 측정소급성, 검체안정성, 판별기준\n\n또는\n\n결과값(Index Score)등을\n\n2) 임상적 성능으로 신청제품과 이미 허가 받은 제품 또는 고식적 검사법과의(양성, 음성)\n\n13\n\n- - 13 -\n<!-- PAGE_57 -->\n###### 7.  사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n",
        "original_sentence": "※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1. "
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 50,
        "word_count": 14,
        "page_number": 10,
        "window_text": "사용방법\n\n- 가.  검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n",
        "original_sentence": "사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 212,
        "word_count": 43,
        "page_number": 8,
        "window_text": "검체준비 및 저장방법, 검사 전 준비사항, 검사과정, 결과판정 및 정도관리, 장비(해당 장비의\n제조사, 모델명) 등을 아래와 같이 포함하여 체외동반진단기기 중심으로 사용방법을 기술한다.\n\n ※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n",
        "original_sentence": "BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 5,
        "window_text": "※ 조직검체에서 유전자를 추출할 경우, 유전자 추출에 사용되는 시약의 상품명과 필요에 따라서는 추출된\n\n다) 필요한 경우, 체외동반진단기기의 성능과 판정에 영향을 줄 수 있는 기기 및 소프트\n\n※ 예시 : 1.  사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n",
        "original_sentence": "14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 62,
        "word_count": 11,
        "page_number": 5,
        "window_text": "사용 전 매뉴얼을 숙지하고 기기의 올바른 사용을 위해 의학적 지식을 가진 자가\n\n- 2.  BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8. ",
        "original_sentence": "3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 58,
        "window_text": "BCA Risk Score 프로그램의 접근통제 기능을 부여하고, 인가된 사용자에 한하여 본\n3) 검사과정의 시험방법이 구분되어 있는 경우엔 각각을 구분하여 검사과정(반응 시간, 온도\n\n조건, 세척과정 및 건조조건, 소프트웨어 조작방법 등) 및 결과판독과정(파장, 판독시간,\n\n1) 데스크탑의 아이콘을 더블클릭하여 본 소프트웨어 플랫폼을 시작하면 로그온 다이얼로그가\n\n나타난다.\n\n 14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가. ",
        "original_sentence": "4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 324,
        "word_count": 61,
        "page_number": 12,
        "window_text": "14\n\n- - 14 -\n2) 로그인 네임과 패스워드를 입력하고 [Log In] 버튼을 클릭하면 데이터베이스가 열린다.\n\n 3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n",
        "original_sentence": "고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 76,
        "word_count": 16,
        "page_number": 58,
        "window_text": "3) Settings > Profile로 들어가서 기본정보(나이, 림프절 전이수, 종양의 크기)를 입력한다.\n\n 4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n",
        "original_sentence": "나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "사용 시 주의사항\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 2,
        "window_text": "4) 측정된 파라미터(바이오마커들의 정량 또는 정성 정보)를 입력한다.\n\n 고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n",
        "original_sentence": "사용 시 주의사항\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "다음의 사항을 포함하여 기재한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 2,
        "window_text": "고위험성, 저위험성, 미확정(indeterminate), 무효(invalid) 등의 예측되는 모든 경우의 시험\n\n가) 미확정(indeterminate), 또는 무효(invalid) 결과를 어떻게 처리해야 하는지에 대한\n\n나) 환자검체의 검사결과를 판독하기 전에 확인해야 할 대조물질과 보정결과 확인절차를\n\n다) 검사의 검출한계 또는 정량한계 등에 따른 보고가능범위를 제시하고, 정량검사인 경우,\n\n라) 알고리즘을 수식으로 제공할 경우, 각 바이오마커의 정성 또는 정량결과를 수식에 대입\n\n마) 알고리즘을 소프트웨어로 제공할 경우, 해당 소프트웨어의 사용방법을 추가로 기재한다.\n\n 나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9. ",
        "original_sentence": "다음의 사항을 포함하여 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 185,
        "word_count": 42,
        "page_number": 8,
        "window_text": "나) 제공하는 정도관리물질과 그 물질의 목표값이 있을 경우, 제시된 기준값에 적합함을\n\n<!-- PAGE_58 -->\n###### 8.  사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가. ",
        "original_sentence": "1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 111,
        "word_count": 27,
        "page_number": 5,
        "window_text": "사용 시 주의사항\n\n- 가.  다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10. ",
        "original_sentence": "3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 133,
        "word_count": 32,
        "page_number": 59,
        "window_text": "다음의 사항을 포함하여 기재한다.\n 1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가. ",
        "original_sentence": "6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "포장단위\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "1) 체외진단용 의료기기로 사용해야 함과 해당 분야 교육을 받은 전문가(의료인포함)가 사용해야\n\n2) 해당 제품의 분석 결과만으로 치료적 결정이나 치료 방법을 선택하는데 직접적으로 사용해서는\n\n15\n\n- - 15 -\n안되며, 다른 임상적 정보와 함께 해당 분야 교육을 받은 전문가(의료인포함)를 통해 해석되어야\n\n함을 명시한다.\n\n 3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n",
        "original_sentence": "포장단위\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 75,
        "word_count": 15,
        "page_number": 59,
        "window_text": "3) 일반적인 실험실 안전지침 및 생물학적 위험물질(검체, 감염 가능성 물질 및 폐기물 등) 취급 시\n\n4) 체외진단용 의료기기의 원재료 중 유해물질이 포함될 경우 이에 대한 경고사항을 기재한다.\n\n 6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n",
        "original_sentence": "포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "저장방법 및 사용기간\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 8,
        "window_text": "6) 경고사항을 포함하여 검체 및 키트 취급 및 보관상의 주의사항(온도, 습도의 영향 등)을\n\n7) 임상 적용 대상 및 미적용 대상을 포함하여 적용상의 주의사항 및 결과 판정상 주의사항을\n\n<!-- PAGE_59 -->\n###### 9.  포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11. ",
        "original_sentence": "저장방법 및 사용기간\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 398,
        "word_count": 86,
        "page_number": 8,
        "window_text": "포장단위\n\n- 가.  포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가. ",
        "original_sentence": "저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "- ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 168,
        "word_count": 41,
        "page_number": 9,
        "window_text": "포장단위는 취급상 용이한 최소 단위로 기재하되 제조의 경우 ‘자사포장단위’, 수입의\n<!-- PAGE_59 -->\n###### 10.  저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n",
        "original_sentence": "- ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "<!-- PAGE_60 -->\n###### 11. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 60,
        "window_text": "저장방법 및 사용기간\n\n- 가.  저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나. ",
        "original_sentence": "<!-- PAGE_60 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "시험규격\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "저장방법은 제품의 특성을 고려하여 안정성이 보장될 수 있도록 검증된 자료에 의한 구체적인\n1) 키트 또는 세트의 제품인 경우, 구성품별로 보관조건을 기재하고, 사용기간(유효기간)이\n\n2) 일회용 의료기기가 아닐 경우, 개봉 후 시약의 저장방법(온도, 습도, 차광, 밀폐, 보관용기 등)\n\n4) 전자민원 접수시 ‘저장방법’ 항은 ‘사용기간에 따름’으로 표기하고 ‘사용기간’ 항에 아래 표와\n\n가) 저장방법은 의료기기의 특성을 고려하여 안정성이 보장될 수 있도록 구체적인 보관조건\n\n나) 사용기간(유효기간)은 다음 각 호의 어느 하나에 해당하는 경우에는 식약처장이 고시한\n\n「의료기기의 안정성시험 기준」(식품의약품안전처 고시)에 따라 저장방법 및 사용기간\n\n16\n\n- - 16 -\n(유효기간) 설정하여 기재한다.\n\n - ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n",
        "original_sentence": "시험규격\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 99,
        "word_count": 22,
        "page_number": 8,
        "window_text": "- ① 멸균의료기기\n- ② 시간이 경과됨에 따라 원재료 등의 물리화학적 변화로 인한 안전성 또는 성능의 변화가\n다) 키트 또는 세트 제품인 경우에는 구성품별 보관온도 등을 각각 기재하고 사용기간(유효\n\n라) 일회용의 경우, 개봉 후 시약의 저장방법 및 사용기간(유효기간) 등이 포함되도록 기재한다.\n\n <!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n",
        "original_sentence": "제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "<!-- PAGE_60 -->\n###### 11.  시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 195,
        "word_count": 41,
        "page_number": 13,
        "window_text": "시험규격\n\n- 가.  제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가. ",
        "original_sentence": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 54,
        "word_count": 12,
        "page_number": 8,
        "window_text": "제품의 품질관리에 적정을 기할 수 있도록 제품의 특성에 따라 성능 등을 고려하여, 제조\n단위별·제조단계별로 안전성·성능을 검증하기 위하여 적용할 수 있는 시험규격을 명시한다.\n\n - 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n",
        "original_sentence": "가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 85,
        "word_count": 20,
        "page_number": 60,
        "window_text": "- 나.  시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나. ",
        "original_sentence": "나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12. "
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 8,
        "window_text": "시험규격은 제조사의 품질관리시험 자료에 따라 자사가 설정한 시험항목, 시험기준, 시험\n나) 분석적 성능시험(민감도, 특이도, 정밀도 등)을 포함하는 것을 권장하나, 제조사에서\n\n가) 시험결과의 적부판정의 기준이 되는 기준치의 허용 범위를 명확히 기재하여야 하며\n\n시험결과가 온도․습도 등 주위조건에 영향을 받는 경우에는 그 조건을 명시하여야한다.\n\n 가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다. ",
        "original_sentence": "제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "제조원의 제조국, 제조사명 및 주소를 기재한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 15,
        "window_text": "가) 시험방법은 순서에 따라 시험결과를 정확히 산출할 수 있도록 구체적, 개조식으로 기재한다.\n\n 나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n",
        "original_sentence": "제조원의 제조국, 제조사명 및 주소를 기재한다.\n"
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "나) 표준물질이 사용된 경우, 고, 중, 저 위험도 그룹을 포함한 각각 최소 3개 이상의 표준물질과\n\n<!-- PAGE_60 -->\n###### 12.  제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 5,
        "window_text": "제조원(수입 또는 제조공정 전부 위탁의 경우)\n\n- 가.  제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1. ",
        "original_sentence": "모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다. "
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 13,
        "window_text": "제조원의 제조국, 제조사명 및 주소를 기재한다.\n - 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가. ",
        "original_sentence": "다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 47,
        "word_count": 12,
        "page_number": 62,
        "window_text": "- 나.  모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나. ",
        "original_sentence": "※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부. "
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 118,
        "word_count": 24,
        "page_number": 62,
        "window_text": "모든 제조공정을 위탁하여 제조하는 경우에는 제조의뢰자와 제조자의 상호와 주소를 모두\n17\n\n- - 17 -\n기재한다.  다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n",
        "original_sentence": "기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "기본원칙\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "다만, 제조자가 외국회사일 경우에는 제조국을 추가로 기재한다.\n\n ※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다. ",
        "original_sentence": "기본원칙\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 9,
        "window_text": "※ 예시\n\n18\n\n- - 18 -\n<!-- PAGE_62 -->\n##### 제Ⅳ부.  기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다. ",
        "original_sentence": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_709",
      "text": "해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 708,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 11,
        "window_text": "기술문서 등 심사를 위한 제출자료\n\n<!-- PAGE_62 -->\n###### ※\n\n<!-- PAGE_62 -->\n###### 기본원칙 및 성능시험 자료의 요건\n\n<!-- PAGE_62 -->\n###### 1.  기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2. ",
        "original_sentence": "해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_710",
      "text": "- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 709,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "기본원칙\n\n- 가.  기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가. ",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_711",
      "text": "외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 710,
        "window_size": 3,
        "char_count": 67,
        "word_count": 16,
        "page_number": 2,
        "window_text": "기술문서 등의 심사를 받고자 하는 자는 시행규칙 별지 제7호 서식에 따라 ‘의료기기 기술문서\n- 나.  해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나. ",
        "original_sentence": "외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_712",
      "text": "다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 711,
        "window_size": 3,
        "char_count": 61,
        "word_count": 14,
        "page_number": 62,
        "window_text": "해당 제품의 특성상 첨부 자료의 일부가 불필요한 경우, 그 사유를 구체적으로 기재하여야 한다.\n - 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다. ",
        "original_sentence": "다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_713",
      "text": "분석적 성능시험에 관한 자료의 요건\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 712,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 8,
        "window_text": "- 다.  외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3. ",
        "original_sentence": "분석적 성능시험에 관한 자료의 요건\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_714",
      "text": "인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 713,
        "window_size": 3,
        "char_count": 269,
        "word_count": 59,
        "page_number": 9,
        "window_text": "외국의 자료는 주요사항을 발췌한 한글요약문 및 원문을 첨부하여야 하며, 필요한 경우에\n한하여 번역물을 요구할 수 있다.  다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가. ",
        "original_sentence": "인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_715",
      "text": "기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 714,
        "window_size": 3,
        "char_count": 192,
        "word_count": 50,
        "page_number": 5,
        "window_text": "다만, 영어 외의 외국어 자료는 공증된 전체 번역문을 첨부\n\n<!-- PAGE_62 -->\n###### 2.  분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나. ",
        "original_sentence": "기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_716",
      "text": "추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 715,
        "window_size": 3,
        "char_count": 311,
        "word_count": 68,
        "page_number": 63,
        "window_text": "분석적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n",
        "original_sentence": "추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_717",
      "text": "임상적 성능시험에 관한 자료의 요건\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 716,
        "window_size": 3,
        "char_count": 26,
        "word_count": 7,
        "page_number": 8,
        "window_text": "인정범위\n2) 해당 의료기기에 대하여 경제협력기구(OECD) 회원국에 허가 당시 제출되어 평가된 시험에\n\n관한 자료로써 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출받아 승인하였음을\n\n3)「의료기기 제조·수입 및 품질관리기준」또는 이와 동등 이상의 규격에 따른 제조사의\n\n4) 대학 또는 연구기관 등 국내·외의 전문기관에서 시험한 것으로서 해당 전문기관의 장이\n\n발급하고 그 내용(전문기관의 시험시설 개요, 주요설비, 연구인력 구성, 시험자의 연구경력 등을\n\n- 나.  기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n",
        "original_sentence": "임상적 성능시험에 관한 자료의 요건\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_718",
      "text": "인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 717,
        "window_size": 3,
        "char_count": 121,
        "word_count": 27,
        "page_number": 5,
        "window_text": "기재내용\n4) 시험일자 및 시험성적서 발급일자\n\n19\n\n- - 19 -\n5) 시험책임자의 서명 또는 직인\n\n6) 시험기준 및 시험방법 단, 규격이 없는 경우 이에 대한 설정 사유\n\n7) 시험 검사품 채취 및 방법에 대한 사항(시험을 위한 별도의 전처리가 필요한 경우에 한함)\n\n8) 시험환경요인(시험결과에 영향을 주는 경우에 한함)\n\n- 다.  추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험. ",
        "original_sentence": "인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_719",
      "text": "임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 718,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 2,
        "window_text": "추가 기재내용(대학 또는 연구기관 등 국내외 전문기관에서 시험한 자료의 경우)\n전문기관의 명칭, 주소, 인증현황, 검사기능 분야, 연구 인력구성, 주요설비 목록 등이\n\n시험검사에 사용된 장비명칭, 장비사양, 검·교정 기록서 등에 대한 사항이 기재되고\n\n시험검사를 실시한 전문기관 담당부서에 속한 연구 인력들에 대한 정보가 기재하여야 함\n\n시험검사를 실시한 시험자가 해당 검사를 하기에 적합한 전공, 경력 등을 가지고 있는지에\n\n대해 기재하고, 해당 전문기관에서 규정한 요건에 적합한 시험자가 시험하였는지에\n\n<!-- PAGE_63 -->\n###### 3.  임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n",
        "original_sentence": "임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_720",
      "text": "1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 719,
        "window_size": 3,
        "char_count": 389,
        "word_count": 92,
        "page_number": 5,
        "window_text": "임상적 성능시험에 관한 자료의 요건\n\n- 가.  인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3. ",
        "original_sentence": "1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_721",
      "text": "2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 720,
        "window_size": 3,
        "char_count": 140,
        "word_count": 33,
        "page_number": 10,
        "window_text": "인정범위\n의료기기 임상시험\n\n3) 해당 의료기기에 대하여 경제협력개발개구(OECD) 회원국에 허가 당시 제출되어 평가된\n\n임상적 성능 시험자료로서 해당 정부 또는 정부가 허가 업무를 위임한 등록기관이 제출\n\n- 나.  임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n",
        "original_sentence": "2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험. "
      }
    },
    {
      "chunk_id": "chunk_722",
      "text": "다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 721,
        "window_size": 3,
        "char_count": 293,
        "word_count": 63,
        "page_number": 5,
        "window_text": "임상적 성능시험 자료의 인정범위 중 1)및 2)의 자료는 다음의 사항을 포함하여야 한다.\n 1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1. ",
        "original_sentence": "다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_723",
      "text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 722,
        "window_size": 3,
        "char_count": 193,
        "word_count": 45,
        "page_number": 10,
        "window_text": "1) 임상시험방법\n\n가) 피험자의 선정기준, 제외기준 및 목표한 피험자의 수\n\n20\n\n- - 20 -\n나) 사용방법과 그 설정 사유\n\n다) 비교시험용 의료기기를 사용하는 경우, 그 선택사유\n\n라) 병용사용의 유무\n\n가) 임상시험의 성적(임상례 계획수, 실제 대상수, 완료된 수, 중도 탈락자 수 및 이유 등을 포함)\n\n해당 적응증에 대한 의료기기의 유효율이 의학적·한의학적 원리에 기준하여 임상적\n\n가) 제출되는 ‘이미 허가받은 제품과 비교한 자료([별지 제5호 서식］의 체외진단용 의료기기의\n\n나) 규정 [별표 8］‘체외진단용 의료기기의 기술문서 등 제출 자료의 범위’ 판단 표에 따라\n\n❍ 아래의 1)부터 4)중 어느 하나에 해당하는 경우, 임상적 성능시험에 관한 자료를 제출하여야 한다.\n\n 2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가. ",
        "original_sentence": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3. "
      }
    },
    {
      "chunk_id": "chunk_724",
      "text": "임상적 성능시험에 관한 자료의 요건의 가.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 723,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 8,
        "window_text": "2) 인체로부터 검체를 채취하는 방법의 위해도가 큰 시험(검체의 채취방법이 인체의 피부, 점막,\n\n안구, 요도를 침투 또는 관통하거나, 외이도, 외비공, 인두, 직장 또는 자궁경부를 넘어서 귀,\n\n코, 입, 항문관 또는 질에 들어가는 침습적인 시험.  다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나. ",
        "original_sentence": "임상적 성능시험에 관한 자료의 요건의 가.\n\n"
      }
    },
    {
      "chunk_id": "chunk_725",
      "text": "<!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 724,
        "window_size": 3,
        "char_count": 111,
        "word_count": 21,
        "page_number": 65,
        "window_text": "다만, 정맥채혈 등 피험자에게 중대한 위험을\n\n3) 이미 확립된 의학적 진단방법 또는 허가·인증받은 체외진단용 의료기기로 임상적 성능시험의\n\n4) 의약품 등과 함께 동반하여 진단하는 시험(다만, 이미 허가·인증받은 의료기기와 사용목적,\n\n(※ 상기의 1)부터 4)까지는 식약처장의 임상시험계획승인 및 임상시험기관(IRB)의 임상시험\n\n21\n\n- - 21 -\n❍ 상기의 1)부터 4)까지에 해당하지 않는 임상시험의 경우에는 아래의 가)부터 다)까지 중 어느 하나에\n\n해당하는 임상적 성능시험에 관한 자료로 제출하여야 한다.\n\n (※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다. ",
        "original_sentence": "<!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_726",
      "text": "개발경위\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 725,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 8,
        "window_text": "(※ 하기의 가)부터 나)까지는 식약처장의 임상시험계획승인은 제외되고, 임상적 성능시험 실시\n\n가) 다음 각 단의 어느 하나에 해당하는 기관에서 별표 14 임상적 성능시험 관리기준에 의하여\n\n나) 외국 자료로서 그 내용을 검토하여 실시기관의 신뢰성이 인정되고 별표 14 임상적 성능시험 관리\n\n다) 임상적 성능시험에 관한 자료 요건(상기의 3.  임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라. ",
        "original_sentence": "개발경위\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_727",
      "text": "체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 726,
        "window_size": 3,
        "char_count": 54,
        "word_count": 10,
        "page_number": 8,
        "window_text": "임상적 성능시험에 관한 자료의 요건의 가.\n\n <!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2. ",
        "original_sentence": "체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_728",
      "text": "본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 727,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 8,
        "window_text": "<!-- PAGE_65 -->\n###### 1\n\n<!-- PAGE_65 -->\n###### 개발경위, 측정원리·방법 및 국내외 사용현황에 관한 자료\n\n<!-- PAGE_65 -->\n###### 1.  개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가. ",
        "original_sentence": "본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_729",
      "text": "해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 728,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 2,
        "window_text": "개발경위\n\n- 가.  체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나. ",
        "original_sentence": "해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_730",
      "text": "프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 729,
        "window_size": 3,
        "char_count": 60,
        "word_count": 13,
        "page_number": 65,
        "window_text": "체외진단다지표검사용 의료기기(IVD-MIA)의 바이오마커 선별 근거 및 알고리즘 개발에\n- 나.  본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n",
        "original_sentence": "프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_731",
      "text": "측정원리․방법\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 730,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 8,
        "window_text": "본 제품의 임상적 적용에 대한 설명 자료 및 개발배경이 포함된 논문, 문헌, 기초연구결과\n- 다.  해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다. ",
        "original_sentence": "측정원리․방법\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_732",
      "text": "유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 731,
        "window_size": 3,
        "char_count": 36,
        "word_count": 10,
        "page_number": 10,
        "window_text": "해당 제품의 적응증에 준하여 연관 질병의 발생빈도, 치료 등을 구분하여 관련된 설명 자료\n- 라.  프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n",
        "original_sentence": "유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_733",
      "text": "제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 732,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 8,
        "window_text": "프라이머, 프로브, 표적 등을 설정한 방법과 설정근거 자료\n<!-- PAGE_65 -->\n###### 2.  측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3. ",
        "original_sentence": "제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_734",
      "text": "- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 733,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "측정원리․방법\n\n- 가.  유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가. ",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_735",
      "text": "제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 734,
        "window_size": 3,
        "char_count": 40,
        "word_count": 12,
        "page_number": 9,
        "window_text": "유전자 발현량을 측정하는 방법 및 원리를 설명하는 자료\n- 나.  제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n",
        "original_sentence": "제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_736",
      "text": "22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 735,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 66,
        "window_text": "제품개발 및 자사제품 성능에 관련된 문헌자료(국문 요약본 포함)를 제출한다.\n - 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1. ",
        "original_sentence": "22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_737",
      "text": "국내․외에서 사용현황\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 736,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 8,
        "window_text": "- 다.  제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가. ",
        "original_sentence": "국내․외에서 사용현황\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_738",
      "text": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 737,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 2,
        "window_text": "제품 검사 원리에 대한 기술 및 관련 외국 규정 등의 자료를 제출한다.\n 22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나. ",
        "original_sentence": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n"
      }
    },
    {
      "chunk_id": "chunk_739",
      "text": "1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 738,
        "window_size": 3,
        "char_count": 189,
        "word_count": 44,
        "page_number": 66,
        "window_text": "22\n\n- - 22 -\n<!-- PAGE_66 -->\n###### 3.  국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다. ",
        "original_sentence": "1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_740",
      "text": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 739,
        "window_size": 3,
        "char_count": 35,
        "word_count": 10,
        "page_number": 8,
        "window_text": "국내․외에서 사용현황\n\n- 가.  국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라. ",
        "original_sentence": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_741",
      "text": "의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 740,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 8,
        "window_text": "국내․외에서 사용현황에 관해 제출할 자료는 다음의 사항을 포함한다.\n 1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2. ",
        "original_sentence": "의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_742",
      "text": "원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 741,
        "window_size": 3,
        "char_count": 61,
        "word_count": 11,
        "page_number": 12,
        "window_text": "1) 외국의 판매 또는 허가현황 및 제조품목허가 경위 등과 관련된 자료\n\n2) 사용 시 보고된 측정오류: 외국에서 시판 중인 제품의 경우, 제품 안전성 및 성능과\n\n<!-- PAGE_66 -->\n###### 2\n\n<!-- PAGE_66 -->\n###### 원재료 및 제조방법에 관한 자료\n\n<!-- PAGE_66 -->\n###### 1.  원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가. ",
        "original_sentence": "원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_743",
      "text": "프라이머, 프로브에 대한 자료(염기서열)\n- 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 742,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 9,
        "window_text": "원재료의 성분 또는 분량을 확인할 수 있는 근거자료\n\n- 가.  의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나. ",
        "original_sentence": "프라이머, 프로브에 대한 자료(염기서열)\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_744",
      "text": "원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 743,
        "window_size": 3,
        "char_count": 44,
        "word_count": 9,
        "page_number": 66,
        "window_text": "의료기기의 성분과 분량을 확인할 수 있는 자료\n- 나.  원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다. ",
        "original_sentence": "원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_745",
      "text": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 744,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 8,
        "window_text": "원료물질의 주반응 시약 중 중합효소(bacteria) 혹은 역전사효소의 기원(AMV, M-MLV등)\n- 다.  프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1. ",
        "original_sentence": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_746",
      "text": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 745,
        "window_size": 3,
        "char_count": 54,
        "word_count": 14,
        "page_number": 8,
        "window_text": "프라이머, 프로브에 대한 자료(염기서열)\n- 라.  원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2. ",
        "original_sentence": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_747",
      "text": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 746,
        "window_size": 3,
        "char_count": 51,
        "word_count": 13,
        "page_number": 8,
        "window_text": "원료물질의 품질 확인 근거자료\n<!-- PAGE_66 -->\n###### 2.  제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. ",
        "original_sentence": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_748",
      "text": "일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 747,
        "window_size": 3,
        "char_count": 118,
        "word_count": 23,
        "page_number": 66,
        "window_text": "제조공정의 흐름도를 포함한 제조공정에 관한 자료\n\n- 가.  제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2. ",
        "original_sentence": "일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_749",
      "text": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 748,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 2,
        "window_text": "제조공정의 흐름을 파악할 수 있는 자료를 제출(제조공정상의 제조 단계별 시험 및 완제품\n- 나.  원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3. ",
        "original_sentence": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_750",
      "text": "해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 749,
        "window_size": 3,
        "char_count": 129,
        "word_count": 24,
        "page_number": 67,
        "window_text": "원료물질의 제조방법을 간략하게 기술하고, 이를 구매한 경우 확인할 수 있는 자료를\n- 다.  일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4. ",
        "original_sentence": "해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_751",
      "text": "완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 750,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 8,
        "window_text": "일부구성제품이 OEM제조품인 경우, 구성품의 제조원(제조자의 상호와 주소)을 확인할 수\n<!-- PAGE_66 -->\n###### 3\n\n<!-- PAGE_66 -->\n###### 사용목적에 관한 자료\n\n- 1.  허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n",
        "original_sentence": "완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_752",
      "text": "구성 제품별로 구분하여 안정성 시험 자료\n- 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 751,
        "window_size": 3,
        "char_count": 28,
        "word_count": 8,
        "page_number": 2,
        "window_text": "허가신청서에 기재한 해당 제품의 사용목적의 세부 사항(검사대상, 검체종류, 검사항목, 측정\n- 2.  해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5. ",
        "original_sentence": "구성 제품별로 구분하여 안정성 시험 자료\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_753",
      "text": "평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 752,
        "window_size": 3,
        "char_count": 57,
        "word_count": 12,
        "page_number": 13,
        "window_text": "해당제품의 제품설명서(instructions for user)\n23\n\n- - 23 -\n<!-- PAGE_67 -->\n###### 4\n\n<!-- PAGE_67 -->\n###### 저장방법과 사용기간(유효기간)에 관한 자료\n\n- 1.  완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6. ",
        "original_sentence": "평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_754",
      "text": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 753,
        "window_size": 3,
        "char_count": 43,
        "word_count": 9,
        "page_number": 8,
        "window_text": "완제품 및 개봉 후 의료기기의 안정성에 관한 자료로서 저장방법, 사용기간 등에 대한 시험\n- 2.  구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7. ",
        "original_sentence": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n"
      }
    },
    {
      "chunk_id": "chunk_755",
      "text": "- 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 754,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 9,
        "window_text": "구성 제품별로 구분하여 안정성 시험 자료\n- 3.  평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8. ",
        "original_sentence": "- 5. "
      }
    },
    {
      "chunk_id": "chunk_756",
      "text": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 755,
        "window_size": 3,
        "char_count": 63,
        "word_count": 16,
        "page_number": 5,
        "window_text": "평가계획, 시험간격, 허용기준, 결과 등의 내용이 포함된 시험성적서(추적성이 확보되는 별도의\n- 4.  안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n",
        "original_sentence": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6. "
      }
    },
    {
      "chunk_id": "chunk_757",
      "text": "일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 756,
        "window_size": 3,
        "char_count": 69,
        "word_count": 11,
        "page_number": 8,
        "window_text": "안정성 시험 시에는 식약처「의료기기의 안정성 시험 기준」의 내용을 참고한다.\n - 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9. ",
        "original_sentence": "일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_758",
      "text": "제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 757,
        "window_size": 3,
        "char_count": 53,
        "word_count": 11,
        "page_number": 13,
        "window_text": "- 5.  저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n",
        "original_sentence": "제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_759",
      "text": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 758,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 8,
        "window_text": "저장 및 사용기간(유효기간)에 대한 시험은 완제품 3 lots, 개봉 후 1 lot 이상의 시험성적서를\n- 6.  일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1. ",
        "original_sentence": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n"
      }
    },
    {
      "chunk_id": "chunk_760",
      "text": "- 9. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 759,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 13,
        "window_text": "일회용으로 낱개 포장되어 있는 체외동반진단기기를 제외하고, 개봉 후(on-board, reconstitution,\n- 7.  제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n",
        "original_sentence": "- 9. "
      }
    },
    {
      "chunk_id": "chunk_761",
      "text": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 760,
        "window_size": 3,
        "char_count": 53,
        "word_count": 10,
        "page_number": 9,
        "window_text": "제품사용방법과 관련하여\n해당되는 경우, 개봉후의 유효기간에 관한\n\n자료를\n\n포함한다\n\n- 8.  수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가. ",
        "original_sentence": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_762",
      "text": "<!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 761,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 67,
        "window_text": "수송 조건(환경 및 운반조건 변화)을 고려한 안정성 자료의 제출을 권장한다.\n - 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나. ",
        "original_sentence": "<!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_763",
      "text": "성능시험에 관한 자료는 다음의 자료를 포함한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 762,
        "window_size": 3,
        "char_count": 27,
        "word_count": 6,
        "page_number": 15,
        "window_text": "- 9.  저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n",
        "original_sentence": "성능시험에 관한 자료는 다음의 자료를 포함한다.\n"
      }
    },
    {
      "chunk_id": "chunk_764",
      "text": "- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 763,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 8,
        "window_text": "저장방법 및 사용기간(유효기간)에 대한 시험자료는 시험성적서의 인정범위 내의 자료이어야 한다.\n <!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n",
        "original_sentence": "- 가. "
      }
    },
    {
      "chunk_id": "chunk_765",
      "text": "분석적 성능시험에 관한 자료(시험성적서)\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 764,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 11,
        "window_text": "<!-- PAGE_67 -->\n###### 5\n\n<!-- PAGE_67 -->\n###### 성능시험에 관한 자료\n\n- 1.  성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다. ",
        "original_sentence": "분석적 성능시험에 관한 자료(시험성적서)\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_766",
      "text": "임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 765,
        "window_size": 3,
        "char_count": 90,
        "word_count": 19,
        "page_number": 8,
        "window_text": "성능시험에 관한 자료는 다음의 자료를 포함한다.\n - 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라. ",
        "original_sentence": "임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_767",
      "text": "다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 766,
        "window_size": 3,
        "char_count": 137,
        "word_count": 36,
        "page_number": 67,
        "window_text": "- 가.  분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마. ",
        "original_sentence": "다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_768",
      "text": "1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 767,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 10,
        "window_text": "분석적 성능시험에 관한 자료(시험성적서)\n- 나.  임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바. ",
        "original_sentence": "1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_769",
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 768,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 5,
        "window_text": "임상적 성능시험에 관한 자료\n체외동반진단기기의 성능 및 유효성을 입증하기 위하여 사람에서 유래된 검체를 대상으로\n\n시험한 자료로서 다음의 평가항목을 포함한다.\n\n 다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사. ",
        "original_sentence": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_770",
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 769,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 11,
        "window_text": "다만, 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고 판단\n\n24\n\n- - 24 -\n되는 경우, 식약처장은 국내에 거주하는 한국인으로부터 유래한 검체를 대상으로 한 자료를\n\n추가 제출할 것을 요구 할 수 있다.\n\n 1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1. ",
        "original_sentence": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_771",
      "text": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 770,
        "window_size": 3,
        "char_count": 40,
        "word_count": 12,
        "page_number": 10,
        "window_text": "1) 임상적 민감도\n\n2) 임상적 특이도\n\n- 다.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2. ",
        "original_sentence": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바. "
      }
    },
    {
      "chunk_id": "chunk_772",
      "text": "국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 771,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 9,
        "window_text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료(3배치 1회 이상 또는 1배치 3회 이상)\n- 라.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n",
        "original_sentence": "국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사. "
      }
    },
    {
      "chunk_id": "chunk_773",
      "text": "소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 772,
        "window_size": 3,
        "char_count": 131,
        "word_count": 27,
        "page_number": 68,
        "window_text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n- 마.  검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1. ",
        "original_sentence": "소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_774",
      "text": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 773,
        "window_size": 3,
        "char_count": 106,
        "word_count": 18,
        "page_number": 13,
        "window_text": "검체 보관 및 취급상(온도, 습도 등)의 조건 설정 근거 자료\n- 바.  국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n",
        "original_sentence": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_775",
      "text": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 774,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 15,
        "window_text": "국내·외 허가 제품과의 상관성 시험에 대한 시험성적서\n- 사.  소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부. ",
        "original_sentence": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n"
      }
    },
    {
      "chunk_id": "chunk_776",
      "text": "<!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 775,
        "window_size": 3,
        "char_count": 76,
        "word_count": 16,
        "page_number": 68,
        "window_text": "소프트웨어 적합성 확인보고서와 소프트웨어 검증 및 유효성 화인 자료(알고리즘이 포함된\n<!-- PAGE_68 -->\n###### 6\n\n<!-- PAGE_68 -->\n###### 체외진단용 의료기기의 취급자 안전에 관한 자료\n\n- 1.  구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n",
        "original_sentence": "<!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_777",
      "text": "이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 776,
        "window_size": 3,
        "char_count": 108,
        "word_count": 21,
        "page_number": 2,
        "window_text": "구성시약 중 인간혈액 유래물질이 포함되었을 경우에는 사람면역결핍 바이러스(HIV), C형\n간염바이러스(HCV), B형간염바이러스(HBV)가 음성 또는 불활성화하여 감염력이 없음을\n\n- 2.  유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1. ",
        "original_sentence": "이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_778",
      "text": "25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 777,
        "window_size": 3,
        "char_count": 41,
        "word_count": 10,
        "page_number": 69,
        "window_text": "유해물질(독성, 가연성 등) 등 취급자 안전 및 적합성을 확인한 자료를 제출한다.\n <!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가. ",
        "original_sentence": "25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부. "
      }
    },
    {
      "chunk_id": "chunk_779",
      "text": "성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 778,
        "window_size": 3,
        "char_count": 169,
        "word_count": 26,
        "page_number": 2,
        "window_text": "<!-- PAGE_68 -->\n###### 7\n\n<!-- PAGE_68 -->\n###### 이미 허가받은 제품과 비교한 자료\n\n- 1.  이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다. ",
        "original_sentence": "성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_780",
      "text": "<!-- PAGE_69 -->\n###### 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 779,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 69,
        "window_text": "이미 허가받은 제품과 명칭(품목명, 모델명), 제조(수입)업소명, 제조원 및 소재지, 허가번호,\n사용목적, 작용원리, 원재료, 성능 등을 비교한 [별지 제5호서식］의 비교표를 기재해야 한다.\n\n 25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다. ",
        "original_sentence": "<!-- PAGE_69 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_781",
      "text": "분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 780,
        "window_size": 3,
        "char_count": 52,
        "word_count": 14,
        "page_number": 2,
        "window_text": "25\n\n- - 25 -\n<!-- PAGE_69 -->\n##### 제Ⅴ부.  성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n",
        "original_sentence": "분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_782",
      "text": "분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 781,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 11,
        "window_text": "성능에 관한 세부사항\n\n성능에 관한 상세사항은 상기 가상의 예시 제품(Breast Cancer Alarm)과 유사한 “ProsignaTM\n\nBreast Cancer Prognostic Gene Signature Assy (미국 FDA-Approved, K130010)”의 성능을 예시로\n\n설명하였다.\n\n <!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n",
        "original_sentence": "분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_783",
      "text": "일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 782,
        "window_size": 3,
        "char_count": 380,
        "word_count": 90,
        "page_number": 10,
        "window_text": "<!-- PAGE_69 -->\n###### 1.  분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n",
        "original_sentence": "일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다. "
      }
    },
    {
      "chunk_id": "chunk_784",
      "text": "계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 783,
        "window_size": 3,
        "char_count": 152,
        "word_count": 39,
        "page_number": 11,
        "window_text": "분석적 성능시험에 관한 자료\n\n※ 분석적 성능시험에 관한 자료의 작성 시 권장사항\n\n- 가.  분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1. ",
        "original_sentence": "계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_785",
      "text": "- ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 784,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 10,
        "window_text": "분석적 민감도\n- ① 표준물질, 국제표준품을\n이용하여 측정할 것을 권장하며,\n\n일관되게 검출되는 최소\n\n농도값으로 설정할 수 있다.  일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n",
        "original_sentence": "- ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_786",
      "text": "- ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 785,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 8,
        "window_text": "일관성 있게 검출이 가능한 핵산 농도 혹은 전체 검체 중\n\n- ②\n표준물질, 국제표준품을\n\n구할 수\n\n없는 항목이나\n\n아형의\n\n경우에는 국내·외 허가된\n\n- ③ 정량검사에서 최소정량한계와 최소검출한계가 같다면, 정량범위의 근거자료로 대체할\n- ① 유전형이 실험적으로 검증되어 있는 암세포주(cancer cell line)나 검증된 암세포주가\n- ② 체외진단용 의료기기 다지표 검사 시험물질의 비율을 최소 5단계 이상 계대 희석한\n- ① 추정되는 검출한계의 주변 농도 근처 농도 중의 최소 3개의 희석 검체는 검체 당 24회\n- ② 총 시험 건수 중 95%에서 양성으로 판정될 수 있는 검체의 농도를 프로빗 분석(probit\nanalysis)으로 산정하여 최소검출한계를 결정한다.  계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다. ",
        "original_sentence": "- ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n"
      }
    },
    {
      "chunk_id": "chunk_787",
      "text": "- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 786,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 36,
        "window_text": "계산된 값이 실제로 측정되지 않은\n\n농도라면 실제 측정 농도 중 계산값과 가장 가까운 높은 값의 농도로 결정하거나,\n\n26\n\n- - 26 -\n라) 결과제시\n\n- ① 통계적으로 유효한 검출 한계치와 설정에 사용된 검체의 종류, 검체수, 반복회수,\n계산법을 함께 제시한다.\n\n - ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n",
        "original_sentence": "- 1. "
      }
    },
    {
      "chunk_id": "chunk_788",
      "text": "세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 787,
        "window_size": 3,
        "char_count": 692,
        "word_count": 150,
        "page_number": 5,
        "window_text": "- ② 검체 유형별(검체의 종류 및 양), 종류별로 설정된 최소검출한계를 제시한다.\n - ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다. ",
        "original_sentence": "세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n"
      }
    },
    {
      "chunk_id": "chunk_789",
      "text": "- ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 788,
        "window_size": 3,
        "char_count": 245,
        "word_count": 56,
        "page_number": 13,
        "window_text": "- ③ 체외진단용 의료기기 다지표 검사의 최소검출한계는 IU/(m)L로 표기하는 것을 권장한다.\n - 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n",
        "original_sentence": "- ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다. "
      }
    },
    {
      "chunk_id": "chunk_790",
      "text": "림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 789,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 12,
        "window_text": "- 1.  세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나. ",
        "original_sentence": "림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_791",
      "text": "28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 790,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 5,
        "window_text": "세 개의 위험군(low/ intermediate/ high)을 포함하면서 20에서 82까지 넓은 재발위험(risk\nof recurrence;ROR) 점수(score)를 가지는 13개의 유방암 RNA 추출물을 총 5개의 농도(62.5,\n\n125, 250, 500, 625 ng), 2 반복, 2 Lot으로 시험을 시행하고, 각 농도에서의 ROR score 차이를\n\nROR score 차이를 SD 및 90% 신뢰구간으로 확인한 결과, 125 ~ 500 ng의 RNA input양을\n\n(출처: Prosigna Packet INSERT 자료 p11-12 RNA Input)\n\n(한 슬라이드 당 암 면적이 4mm2 일 때 6장이 필요함)\n\n- (마) RNA 양은 최소 125 ng 이상이어야 함\n27\n\n- - 27 -\n- (바) RNA 농도는 12.5 ng/ul 이상이어야 함(흡광도 260nm 파장)\n- (사) RNA 순도는 1.7에서 2.3 범위 내에 들어와야 함(OD 260/280 nm ratio)\n2) 측정범위(Measurement range)\n\n※ 예시 : ROR score는 50개 유전자의 발현 정도로 계산되므로, 직선성 시험은 본 검사법에\n\n- ② 측정항목, 측정원리, 판독방법 등에 따라 판정기준치의 설정 방법이 달라질 수 있으므로\n- ③ 판정기준치가 최소검출한계의 산출을 근거로 설정된 경우에는 해당 자료로 대신할 수 있다.\n - ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다. ",
        "original_sentence": "28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다. "
      }
    },
    {
      "chunk_id": "chunk_792",
      "text": "림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 791,
        "window_size": 3,
        "char_count": 139,
        "word_count": 36,
        "page_number": 11,
        "window_text": "- ④ 판정기준치가 공란한계의 산출을 근거로 설정된 경우 결과 분포 및 설정 방법을\n- ⑤ 분자유전 제품의 판정기준치는 실시간중합효소연쇄반응에서 Ct값 또는 카피수(copy\n※ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한 임상적\n\n※ 예시 : ROR score는 침습적 유방암 환자의 10년 무원격전이 확률을 보여주는 것으로 림프절\n\n전이 음성과 림프절 전이 양성에 따라 위험군이 다르게 분류된다.  림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n",
        "original_sentence": "림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_793",
      "text": "이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 792,
        "window_size": 3,
        "char_count": 309,
        "word_count": 66,
        "page_number": 5,
        "window_text": "림프절 전이 음성은\n\n저위험, 중위험, 고위험군 으로 나뉘고, 림프절 전이 양성은 저위험, 고위험군 으로 나뉜다.\n\n 28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n",
        "original_sentence": "이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_794",
      "text": "분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 793,
        "window_size": 3,
        "char_count": 196,
        "word_count": 51,
        "page_number": 8,
        "window_text": "28\n\n- - 28 -\n위험군 분류에 대한 판정기준은 TransATAC 임상 연구 결과를 토대로 설정되었다.  림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1. ",
        "original_sentence": "분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_795",
      "text": "간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 794,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 8,
        "window_text": "림프절 전이\n\n양성 및 음성 그룹에서 10년 내 원격 전이 위험도를 확인한 결과, 림프절 전이 음성인 경우\n\n10년 내 원격 전이 위험도가 10% 일 때 ROR score가 42인 반면 림프절 전이 양성인 경우에는\n\nROR score가 25였다.\n\n 이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다. ",
        "original_sentence": "간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_796",
      "text": "29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 795,
        "window_size": 3,
        "char_count": 74,
        "word_count": 20,
        "page_number": 9,
        "window_text": "이 결과를 바탕으로 림프절 전이 음성인 경우 ROR 점수 40 이하는 저위험군(10년 내 원격\n\n전이\n\n위험도가\n\n10%\n\n이하)으로,\n\nROR\n\n점수\n\n41-60는\n\n중위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n10%-20%)으로, ROR 점수 61-100는 고위험군( 10년 내 원격 전이 위험도가 20% 초과)으로\n\n설정하였으며, 림프절 전이 양성인 경우 ROR 점수 40을 기준으로 40 이하는 저위험군(10년 내\n\n원격\n\n전이\n\n위험도 20% 이하)으로,\n\n40\n\n초과는\n\n고위험군(10년\n\n내\n\n원격\n\n전이\n\n위험도가\n\n20%\n\n- 나.  분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n",
        "original_sentence": "29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_797",
      "text": "- ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 796,
        "window_size": 3,
        "char_count": 308,
        "word_count": 78,
        "page_number": 10,
        "window_text": "분석적 특이도\n가) 간섭반응을 일으킬 수 있는 물질을 시험한 뒤, 결과를 제시하고, 이를 주의사항에 반드시\n\n나) 간섭반응은 검체의 유형, 측정항목, 측정원리, 처리시약 등에 따라 다양하므로 해당 검사\n\n(핵산 증폭검사법)의 잠재적 간섭 물질 등 시험 결과에 영향을 줄 수 있는 인자에 대해\n\n다) 간섭 물질은 검체 내부 또는 외부 요인일 수 있다.  간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2. ",
        "original_sentence": "- ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_798",
      "text": "사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 797,
        "window_size": 3,
        "char_count": 66,
        "word_count": 16,
        "page_number": 9,
        "window_text": "간섭 물질의 가능성 있는 모든 물질의\n\n라) 종양 세포 검체의 상태를 반영하는 지표를 포함하도록 한다.\n\n 29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다. ",
        "original_sentence": "사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_799",
      "text": "정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 798,
        "window_size": 3,
        "char_count": 96,
        "word_count": 22,
        "page_number": 5,
        "window_text": "29\n\n- - 29 -\n마) 각 분석물질에 대한 각 간섭물질의 영향을 평가하기 위해 다음과 같은 4가지 형태의\n\n세트를 준비한다.\n\n - ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3. ",
        "original_sentence": "정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_800",
      "text": "30\n\n- - 30 -\n- 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 799,
        "window_size": 3,
        "char_count": 18,
        "word_count": 7,
        "page_number": 5,
        "window_text": "- ① 분석물질 약양성 검체(간섭물질 없음)\n- ② 분석물질 약양성 검체 + 간섭물질\n측정대상이 되는 검체와 동일한 기질의 검체를 이용하거나 임상검체를 구하기 힘들 경우\n\n- ① 검체의 종류, 간섭물질의 종류, 간섭물질의 농도, 분석물질의 농도, 검체의 제조 방법에\n- ⑤ 분석물질(해당 항원·항체·표적 유전자 등)이 음성이고, 간섭물질을 포함한 검체도 검사하여\n- ⑥ 높은 농도의 간섭물질에 영향을 받지 않는 경우는 더 이상의 평가를 시행하지 않아도\n- ③ 간섭 가능한 물질만 포함된 검체의 실측한 자료를 바탕으로 배경 한계와 검출 한계를\n- 1.  사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다. ",
        "original_sentence": "30\n\n- - 30 -\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_801",
      "text": "사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 800,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 9,
        "window_text": "사람 유방암 조직에는 정상 조직이 함께 산재해 있으므로 정상 조직에 대한 간섭 반응을\nROR score로 확인하였다.  정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n",
        "original_sentence": "사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_802",
      "text": "10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 801,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 10,
        "window_text": "정상조직이 50 ~ 95%까지 포함된 13개의 파라핀 포매 유방암\n\n검체로 시험을 시행한 결과, 50% 이상의 정상 조직이 포함된 경우 간섭반응이 일어남을\n\n확인하였다.\n\n 30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n",
        "original_sentence": "10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_803",
      "text": "괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 802,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 9,
        "window_text": "30\n\n- - 30 -\n- 2.  사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다. ",
        "original_sentence": "괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_804",
      "text": "괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 803,
        "window_size": 3,
        "char_count": 200,
        "word_count": 46,
        "page_number": 10,
        "window_text": "사람의 genomic DNA에 대한 간섭 반응을 ROR score로 확인하였다.  10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n",
        "original_sentence": "괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_805",
      "text": "31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 804,
        "window_size": 3,
        "char_count": 48,
        "word_count": 14,
        "page_number": 5,
        "window_text": "10개의 파라핀 포매\n유방암 검체로 시험 중 DNase I 처리 단계를 생략하여 ROR score를 확인한 결과, genomic\n\n- 3.  괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n",
        "original_sentence": "31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n"
      }
    },
    {
      "chunk_id": "chunk_806",
      "text": "- ② 위양성률을 계산한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 805,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 12,
        "window_text": "괴사, 출혈, 유관 상피 암종의 오염에 대한 간섭반응을 확인하였다.  괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n",
        "original_sentence": "- ② 위양성률을 계산한다. "
      }
    },
    {
      "chunk_id": "chunk_807",
      "text": "위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 806,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 8,
        "window_text": "괴사, 출혈, 유관 상피\n암종을 포함하는 11개의 파라핀 포매 유방암 검체의 간섭물질 유무에 따른 ROR score\n\n다른 관련성 있는 유전자와 측정의 대상이 되는 Target 유전자와 상동성이 높은 유전형에\n\n교차반응을 일으킬 수 있는 유전자를 포함하는 검체를 이용하여 교차반응성을 평가하며,\n\n임상적으로 나타날 수 있는 고농도를 사용할 것을 권장한다.\n\n 31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n",
        "original_sentence": "위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n"
      }
    },
    {
      "chunk_id": "chunk_808",
      "text": "라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 807,
        "window_size": 3,
        "char_count": 182,
        "word_count": 44,
        "page_number": 5,
        "window_text": "31\n\n- - 31 -\n다) 시험방법\n\n- ① 준비된 시험물질을 3회 반복 측정한다.\n - ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n",
        "original_sentence": "라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n"
      }
    },
    {
      "chunk_id": "chunk_809",
      "text": "- ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 808,
        "window_size": 3,
        "char_count": 112,
        "word_count": 28,
        "page_number": 8,
        "window_text": "- ② 위양성률을 계산한다.  위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다. ",
        "original_sentence": "- ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n"
      }
    },
    {
      "chunk_id": "chunk_810",
      "text": "32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 809,
        "window_size": 3,
        "char_count": 71,
        "word_count": 23,
        "page_number": 5,
        "window_text": "위양성을 보이는 검체에 대해 원인을 분석 조사한다.\n 라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n",
        "original_sentence": "32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n"
      }
    },
    {
      "chunk_id": "chunk_811",
      "text": "- ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 810,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 15,
        "window_text": "라) 결과제시\n\n3) 정밀도(반복, 재현성, 안정성 등)\n\n- ② 단일 기관에서 실시한 정밀도(반복성)와 다수의 기관에서 실시한 재현성으로 구분하여\n- ③ 각 평가 수행기관은 평가를 시행하기 전에 검사방법에 익숙해지는 시기를 거친 다음\n- ㉮ 측정하고자 하는 물질을 포함하는 임상검체나 표준품에 준한 물질을 사용할 수 있다.\n - ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n",
        "original_sentence": "- ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n"
      }
    },
    {
      "chunk_id": "chunk_812",
      "text": "- ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 811,
        "window_size": 3,
        "char_count": 148,
        "word_count": 33,
        "page_number": 8,
        "window_text": "- ㉯ 임상 검체를 구할 수 없는 경우에는 측정하고자 하는 물질(유전자)을 포함하지 않는\n- ④ 시험방법\n- ㉮ 시행기관은 검사특성에 맞추어 일정기간동안 매일 반복 측정하는 계획을 수립하여 시행한다.\n 32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n",
        "original_sentence": "- ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다. "
      }
    },
    {
      "chunk_id": "chunk_813",
      "text": "5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 812,
        "window_size": 3,
        "char_count": 129,
        "word_count": 30,
        "page_number": 5,
        "window_text": "32\n\n- - 32 -\n- ㉯ 20일 이상 동안 매일 2회의 run, 각 run 당 2회 이상 반복 측정 하는 것을 권장한다.\n - ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n",
        "original_sentence": "5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_814",
      "text": "(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 813,
        "window_size": 3,
        "char_count": 600,
        "word_count": 98,
        "page_number": 9,
        "window_text": "- ⑤ 결과제시\n- ㉮ 시험결과 및 정밀도를 나타내는 다음 지표들을 제시한다.\n - ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다. ",
        "original_sentence": "(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_815",
      "text": "35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 814,
        "window_size": 3,
        "char_count": 81,
        "word_count": 18,
        "page_number": 5,
        "window_text": "- ㉯ 체외진단용 의료기기 다지표 검사의 경우 필요에 따라 통계처리 과정에서 로그\n세 개의 위험 그룹(low/ intermediate/ high)을 대표하는 43개의 파라핀 포매 유방암 검체를\n\n5개 그룹의 RNA 혼합물로 나누어 반복, 재현성 시험을 시행하였다.  5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2. ",
        "original_sentence": "35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_816",
      "text": "㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 815,
        "window_size": 3,
        "char_count": 48,
        "word_count": 11,
        "page_number": 76,
        "window_text": "5개 그룹에 대한 임상적\n\n33\n\n- - 33 -\n각 RNA 혼합물을 3lot의 Breast Cancer Alarm을 사용하여 장소 3곳, 장소별 두 명의\n\n실험자, 하루에 3번의 시험을 시행하여 ROR score를 비교하였다.\n\n (※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다. ",
        "original_sentence": "㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_817",
      "text": "- ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 816,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 9,
        "window_text": "(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature\n\nAssay\n\nand\n\nnCounter\n\nAnalysis\n\nSystem\n\nusing\n\nformalin-fixed\n\nparaffin-embedded\n\n림프절 전이 양성, 음성을 다 포함하면서 호르몬 수용체 양성인 43개의 파라핀 포매 유방암\n\n검체를 세 곳의 장소, 총 3Lot의 RNA isolation kit(각 장소별 1Lot), 1개의 reagent kit, 2번\n\n34\n\n- - 34 -\n(※ 출처 : Analytical Validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene\n\nSignature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast\n\n4) 강건성(robustness)\n\n분석과정의 강건성은 방법적 변수의 고의적 변동에 대한 안정성을 보여줌으로써 일상적인\n\n㉰ 검사 시 양성과 음성을 교대로 배치하여 검정한다.\n\n 35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다. ",
        "original_sentence": "- ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다. "
      }
    },
    {
      "chunk_id": "chunk_818",
      "text": "동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 817,
        "window_size": 3,
        "char_count": 525,
        "word_count": 116,
        "page_number": 80,
        "window_text": "35\n\n- - 35 -\n㉱ 원재료(e.g., MgCl2, primer, probe, dNTP, etc) 농도 변동에 대해 1회 이상 검증한다.\n\n ㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다. ",
        "original_sentence": "동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_819",
      "text": "임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 818,
        "window_size": 3,
        "char_count": 166,
        "word_count": 37,
        "page_number": 2,
        "window_text": "㉲ 여러 추출법이 적용되는 경우 다양한 추출법이 평가에 포함되도록 계획을 수립한다.\n\n - ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다.",
        "original_sentence": "임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_820",
      "text": "이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 819,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 9,
        "window_text": "- ③ 결과제시\n파라핀 포매 유방암 검체로부터 추출한 RNA에 대한 안정성을 전향적으로 확인하였다.  동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다.",
        "original_sentence": "이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_821",
      "text": "가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 820,
        "window_size": 3,
        "char_count": 218,
        "word_count": 49,
        "page_number": 10,
        "window_text": "동일\n\n검체에서\n\n12개월\n\n간\n\n주기적으로\n\nRNA를\n\n추출하여\n\nROR\n\nscore를\n\n비교한\n\n결과,\n\nROR\n\nscore에서 유의한 차이는 없으며, RNA는 권장 보관 방법 하에서 약 9개월간 안정함을\n\n☞ 아래 항목은 Breast Cancer Alarm에 삽입되어 있는 내용으로 분석적 성능시험 시\n\n- ㉮ 58개 유전자에 대한 발현량을 이미 알고 있는 양성 대조군으로, 검체와 독립적으로\n- ㉯ 검체의 준비 및 교잡반응의 적절성을 확인하기 위하여 일련의 6개의 양성대조군을\n㉰ RNA가 오염되지 않음을 보장하기 위하여 일련의 8개의 음성 대조군을 사용하여\n\n(※ 출처 : Prosigna 510(k) 자료, p8-9, Controls)\n\n5) 정확도\n\n가) WHO international reference standard 물질 등 국제표준품, 상용 패널, 제조사 제조\n\n표준물질 등 특성이 명시되어 있는 물질을 사용하여 평가할 것을 권장하며 최소 2회\n\n36\n\n- - 36 -\n<!-- PAGE_80 -->\n###### 2.  임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n",
        "original_sentence": "가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_822",
      "text": "이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 821,
        "window_size": 3,
        "char_count": 134,
        "word_count": 34,
        "page_number": 8,
        "window_text": "임상적 성능시험에 관한 자료\n\n✽ 임상적 성능시험에 관한 자료 작성 시 준수 사항\n\n❍ 체외진단용\n\n의료기기\n\n다지표\n\n검사의\n\n성능\n\n및\n\n유효성을\n\n입증하기\n\n위하여\n\n사람에서\n\n❍ 판정기준치의 설정이 임상적 판정기준치(민감도, 특이도)를 바탕으로 한 경우, 타당한\n\n임상적 근거를 제시한다.  이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n",
        "original_sentence": "이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다."
      }
    },
    {
      "chunk_id": "chunk_823",
      "text": "(예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 822,
        "window_size": 3,
        "char_count": 142,
        "word_count": 35,
        "page_number": 8,
        "window_text": "이 경우, 실험 대상 인구에 대한 자료(인구통계/ 선택기준/\n\n배제기준, 전체 숫자)와 ROC 분석 등과 같은 통계적 방법 등을 제시한다.  가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n",
        "original_sentence": "(예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다."
      }
    },
    {
      "chunk_id": "chunk_824",
      "text": "(예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 823,
        "window_size": 3,
        "char_count": 159,
        "word_count": 42,
        "page_number": 8,
        "window_text": "가급적\n\n독립적인 두 개 이상의 임상 시험을 근거로 설정될 것을 권장하며, 임상평가를 토대로\n\n❍ 질병의\n\n진단이\n\n검사의\n\n주된\n\n목적이\n\n아니어서\n\n임상적\n\n민감도와\n\n임상적\n\n특이도를\n\n❍ 민족적 요인의 차이가 있어 외국 임상적 성능 시험을 그대로 적용하기가 어렵다고\n\n판단되는\n\n경우,\n\n국내에서\n\n우리나라\n\n사람\n\n유래의\n\n검체를\n\n대상으로\n\n한\n\n자료를\n\n추가\n\n제출해야 한다.  이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n",
        "original_sentence": "(예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n"
      }
    },
    {
      "chunk_id": "chunk_825",
      "text": "- ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 824,
        "window_size": 3,
        "char_count": 564,
        "word_count": 152,
        "page_number": 2,
        "window_text": "이러한 경우, 한국인 인구집단을 포함하여 수행한 결과이어야 하며,\n\n❍ 임상적 민감도 및 특이도 평가 중 결과가 불일치한 경우, 아래의 방법 등으로 불일치한\n\n❍ 임상 검체인 경우, 양성 또는 음성임을 확인한 방법을 기술한 자료를 제출한다. (예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n",
        "original_sentence": "- ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_826",
      "text": "나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 825,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 82,
        "window_text": "(예,\n\n기허가 진단제품 또는 확진검사방법 등으로 확인하였음을 기술한 자료나 양성임을 확인\n\n1) 임상적 민감도 평가를 위해 시험해야할 일반적인 권장 검사의 목적, 유병율을 고려하여\n\n- ② 양성 임상 검체인 경우, 이를 확인할 수 있는 자료를 제출한다. (예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다. ",
        "original_sentence": "나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_827",
      "text": "- ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 826,
        "window_size": 3,
        "char_count": 324,
        "word_count": 76,
        "page_number": 8,
        "window_text": "(예, 기허가 진단\n- ③ 양성 검체는 각 질환의 다양한 임상단계 및 아형(유전자형, 변이체등)이 포함되는\n※ 권장사항 : 종양의 모든 병기가 포함된 검체를 이용한 평가가 권장됨\n\n37\n\n- - 37 -\n나) 시험방법\n\n- ① 양성으로 규명된 검체를 양성으로 판정한 비율을 산정한다.\n - ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다. ",
        "original_sentence": "- ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n"
      }
    },
    {
      "chunk_id": "chunk_828",
      "text": "- ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 827,
        "window_size": 3,
        "char_count": 104,
        "word_count": 29,
        "page_number": 5,
        "window_text": "- ② 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ③ 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사등의 원인\n- ① 질환이 있음과 없음(‘임상적 참값’)을 규명한 방법, 대상군(환자 선택기준 및 제외기준,\n환자 수), 질환단계, 아형(유전형, 변이체 등), 검체의 종류 등 검체에 대한 상세한\n\n- ④ 계산된 민감도 및 95% 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n- ② 임상적 특이도 평가를 위해 시험해야할 일반적인 권장 검체 수는 검사의 목적,\n- ① 피험자 선정/제외 기준, 검체 종류와 수, 시험 상 주의사항, 통계분석법 등을 미리\n- ② 평가 전에 결과 해석에 대한 알고리즘 및 불일치한 경우 추가 검사 등의 원인 분석\n- ④ 양성 결과를 보인 경우 임상소견 확인 및 확진 검사를 시행하여 진양성 유무를\n- ③ 계산된 특이도 및 95%의 신뢰구간(측정원리상 95% 이상 설정이 어려운 제품 등은\n38\n\n- - 38 -\n3) 임상적 유용성\n\n가) 유전자 검사에 따른 편익과 안전성 측면에서 개선효과를 입증해야한다.\n\n 나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다. ",
        "original_sentence": "- ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_829",
      "text": "- ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 828,
        "window_size": 3,
        "char_count": 92,
        "word_count": 23,
        "page_number": 10,
        "window_text": "나) 임상적 유용성은 환자관점에서 검사의 편익과 위해 측정에 대한 평가를 포함하여야 한다.\n\n - ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n",
        "original_sentence": "- ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다. "
      }
    },
    {
      "chunk_id": "chunk_830",
      "text": "경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 829,
        "window_size": 3,
        "char_count": 157,
        "word_count": 38,
        "page_number": 8,
        "window_text": "- ⑤ 2차 데이터베이스는 자료수집원이 될 수 있으나, 이 경우 보조적으로 전향적 자료수집이\n㉲ 기타 임상연구(case series), 전문가 심사(peer-review)가 되지 않는 연구 또는\n\n- ㉯ 연구 설계에 대해 분명한 명시: 효과지표에 대한 분명한 정의, 눈가림 여부,\n㉱\n\n자료분석\n\n관련\n\n사항\n\n:\n\n연구의\n\n질을\n\n담보할\n\n수\n\n있는\n\n충분한\n\n정보\n\n여부,\n\n효과지표에 따른 적절한 자료 사용 여부, 명시적 및 적절한 분석법인가에 대한\n\n여부, 탈락과 잠재적 바이어스에 대한 설명, 바이어스와 혼란변수의 평가, 점\n\n추정 결과와 95% 신뢰구간 제시 여부.\n\n - ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n",
        "original_sentence": "경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_831",
      "text": "사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 830,
        "window_size": 3,
        "char_count": 109,
        "word_count": 24,
        "page_number": 12,
        "window_text": "- ③ 비용효과분석 관련 이슈\n39\n\n- - 39 -\n- ㉮ 분석관점 : 유전자 검사가 아닌 경우 대부분 보험자관점에서 연구되지만 유전자\n검사 관련해서 사회적 관점이 요구될 수 있다.\n\n - ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다. ",
        "original_sentence": "사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_832",
      "text": "매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 831,
        "window_size": 3,
        "char_count": 223,
        "word_count": 39,
        "page_number": 10,
        "window_text": "- ㉯ 분석기간 : 대부분 단기간 평가되고 있으나 무증상의 환자에서 특정질환과 연관된\n㉰ 대조 시약의 선정 : 유전자 검사에는 표준검사법이 존재하지 않고 다양하다.  경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다. ",
        "original_sentence": "매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_833",
      "text": "선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 832,
        "window_size": 3,
        "char_count": 198,
        "word_count": 36,
        "page_number": 12,
        "window_text": "경우에\n\n따라 비특이적 검사인 비유전자 검사를 실시 후에 유전자 검사를 수행하는 것이\n\n㉱\n\n임상적\n\n경로의\n\n이해\n\n:\n\n임상적\n\n경로에서\n\n유전자\n\n검사\n\n효과가\n\n있는\n\n지점을\n\n㉲ 비용 : 유전자 검사에 소요되는 비용뿐 아니라 검사로 인해 야기되는 부작용\n\n비용 포함한다.  사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n",
        "original_sentence": "선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_834",
      "text": "개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 833,
        "window_size": 3,
        "char_count": 99,
        "word_count": 19,
        "page_number": 8,
        "window_text": "사회적 관점에서 유전자 검사로 인해 항암제를 받지 않아도\n\n되는 환자에서 시간절약 비용(대부분 연구에서는 포함하지 않았으나 많게는\n\n3배까지 비용절약이 있다는 연구가 있었음)을 고려할 수 있다.  매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다. ",
        "original_sentence": "개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_835",
      "text": "삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 834,
        "window_size": 3,
        "char_count": 78,
        "word_count": 22,
        "page_number": 10,
        "window_text": "매우 배우기\n\n어려운 검사법인 경우 직원교육비용을 포함하는 것이 가능하지만 일회성이기\n\n㉳ 삶의 질 측정 : 질환 특이적 연구방법(예, European Organization for Research\n\nand Treatment of Cancer quality-of-life questionnaires)은 유전자 관련 효용을\n\n선별하는데 효과적이지만 질환 특이적이기 때문에 상호비교성에 제한이 있다.\n\n 선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n",
        "original_sentence": "삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_836",
      "text": "그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 835,
        "window_size": 3,
        "char_count": 72,
        "word_count": 16,
        "page_number": 9,
        "window_text": "선호도에\n\n기반한\n\n간접측정법(the\n\nEuroQol\n\nfive-dimensional\n\n[EQ-5D]\n\nquestionnaire)은 일반적 건강상태에 대한 측정법이므로 상호비교성은 개선되나\n\n건강과 관련되지 않은 유전자 검사에 따른 건강상태의 변화, 예를 들어 유전자\n\n발현에 의한 score를 가지고 살아가는 것 등에 대한 효용은 선별하지 못 한다.\n\n 개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n",
        "original_sentence": "그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_837",
      "text": "※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 836,
        "window_size": 3,
        "char_count": 83,
        "word_count": 17,
        "page_number": 10,
        "window_text": "개인적 효용(personal utility) 연구 방법은 환자의 웰빙상태에 대해 효과적이고,\n\n비유전적 효용을 선별하는데 효과적이지만 유전자 효용 정보 선별에는 제한이\n\n있다.  삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다. ",
        "original_sentence": "※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다. "
      }
    },
    {
      "chunk_id": "chunk_838",
      "text": "ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 837,
        "window_size": 3,
        "char_count": 128,
        "word_count": 29,
        "page_number": 8,
        "window_text": "삶의 질 측정에서 환자대상 연구와 일반인대상 연구 결과는 매우 차이가\n\n㉴ 효과 측정 : 환자 및 의사에 대한 행동변화를 연구할 수 있다.  그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다. ",
        "original_sentence": "ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_839",
      "text": "또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 838,
        "window_size": 3,
        "char_count": 121,
        "word_count": 21,
        "page_number": 5,
        "window_text": "그러나 이에 대한\n\n㉵ 이질적 환자군 고려에 대한 문제 : 소집단 분석(sub-group analysis)이 요구될 수 있다.\n\n ※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n",
        "original_sentence": "또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_840",
      "text": "Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 839,
        "window_size": 3,
        "char_count": 133,
        "word_count": 26,
        "page_number": 10,
        "window_text": "※ 예시 :\n\nBreast Cancer Alarm을 통한 ROR\n\nscore의 임상적 유용성을 입증하기 위하여\n\nABSCG 임상 시험을 시행하였다.  ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n",
        "original_sentence": "Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다. "
      }
    },
    {
      "chunk_id": "chunk_841",
      "text": "이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 840,
        "window_size": 3,
        "char_count": 104,
        "word_count": 20,
        "page_number": 8,
        "window_text": "ABSCG 임상 시험은 호르몬 수용체 양성인 폐경 후 조기\n\n유방암 환자를 대상으로 수술 후 보조요법으로 Anastrozole와 Tamoxifen을 단독 혹은\n\n40\n\n- - 40 -\n병용\n\n투여한\n\n군을\n\n대상으로\n\n하였다.\n\n 또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다. ",
        "original_sentence": "이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다. "
      }
    },
    {
      "chunk_id": "chunk_842",
      "text": "또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 841,
        "window_size": 3,
        "char_count": 127,
        "word_count": 21,
        "page_number": 10,
        "window_text": "또한\n\n림프절\n\n음성\n\n및\n\n림프절\n\n양성(1-3개)\n\n유방암\n\n환자군 각각에서 위험 군에 따라 10년 내 원격 무재발 생존율(Distant Recurrence-Free\n\nSurvival, DRFS)를 확인하였다.\n\n Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다. ",
        "original_sentence": "또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_843",
      "text": "림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 842,
        "window_size": 3,
        "char_count": 519,
        "word_count": 103,
        "page_number": 12,
        "window_text": "Breast Cancer Alarm은 ABSCG 임상에서 후향적 의무 기록 조사가 가능한 1,000 명의\n\n조직\n\n시료를\n\n다변량\n\ncox의\n\n비례\n\n위험\n\n모형을\n\n사용하여\n\n원격\n\n무재발\n\n생존율의\n\n위험비(HR)을 비교 평가하였다.  이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군). ",
        "original_sentence": "림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_844",
      "text": "CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 843,
        "window_size": 3,
        "char_count": 149,
        "word_count": 24,
        "page_number": 8,
        "window_text": "이때 다변량 변수로 Breast Cancer Alarm Score 외에\n\n나이,\n\n종양의\n\n등급,\n\n종양의\n\n크기,\n\n림프절\n\n상태\n\n그리고\n\n보조요법을\n\n사용하여\n\n비교\n\n평가하였다.  또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다. ",
        "original_sentence": "CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다. "
      }
    },
    {
      "chunk_id": "chunk_845",
      "text": "아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 844,
        "window_size": 3,
        "char_count": 192,
        "word_count": 38,
        "page_number": 5,
        "window_text": "또한, 임상 예후 정보에 Breast Cancer Alarm score를 추가하여 Breast Cancer\n\nAlarm score의 유의성을 판별하기 위하여 우도비 검정(Likelihood ratio test)을 사용하였다.\n\n 림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다. ",
        "original_sentence": "아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다. "
      }
    },
    {
      "chunk_id": "chunk_846",
      "text": "모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군). ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 845,
        "window_size": 3,
        "char_count": 174,
        "word_count": 36,
        "page_number": 8,
        "window_text": "림프절 음성 유방암(Node-negative breast cancer) 환자를 대상으로 고위험군으로 분류된\n\n환자에서 실제로 10년 내 원격전이가 발생한 환자의 비율인 양성예측도(PPV)는 15.7%,\n\n저위험군으로\n\n분류된\n\n환자\n\n중\n\n실제로\n\n10년\n\n내\n\n원격전이가\n\n없는\n\n환자의\n\n비율인\n\n림프절 양성 환자 중 고위험군으로 분류된 환자 중 10년 내 원격 재발이 일어난 비율인\n\n양성예측도(PPV)는\n\n- 24.2%이었으며,\n저위험군\n\n중\n\n원격\n\n재발이\n\n일어나지\n\n않는\n\n비율인\n\n양성 및 음성예측도를 적용할 수 없을 경우 다음과 같이 원격 무재발생존율의 위험도는\n\n아래의 표는 (1) 임상정보 기반 예후 진단 점수(Clinical treatment score; CTS)에 연속 변수로\n\nBreast Cancer Alarm score을 추가 하거나 또는 (2) Breast Cancer Alarm score을 기반으로\n\n한 위험군을 추가한 cox 비례위험 모형을 사용하여 ABCSG-8 임상을 분석한 결과이다.\n\n CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3. ",
        "original_sentence": "모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군). "
      }
    },
    {
      "chunk_id": "chunk_847",
      "text": "점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 846,
        "window_size": 3,
        "char_count": 130,
        "word_count": 25,
        "page_number": 8,
        "window_text": "CTS만으로 구성되어저 있는 귀무모형(null model)을 귀무모형에 Breast Cancer Alarm의\n\n모델을 더한 대립모형(alternate model)에 대해 우도비 검정을 사용하여 Breast Cancer\n\nAlarm 모델의 통계적 유의성을 판단하였다.  아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가. ",
        "original_sentence": "점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다. "
      }
    },
    {
      "chunk_id": "chunk_848",
      "text": "아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 847,
        "window_size": 3,
        "char_count": 482,
        "word_count": 95,
        "page_number": 86,
        "window_text": "아래 표는 검정통계량(test statistic), α=0.05\n\n41\n\n- - 41 -\n임상정보\n\n기반\n\n예후\n\n진단\n\n점수(Clinical\n\nTreatment\n\nScore,\n\nCTS)는\n\n의사가\n\n처방을\n\n결정하는데 있어서 임상 및 치료 연관 변수(환자 나이, 종양의 등급, 종양의 크기, 림프절\n\n상태, 보조 요법)의 최적화된 조합이다.  모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n",
        "original_sentence": "아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다. "
      }
    },
    {
      "chunk_id": "chunk_849",
      "text": "아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 848,
        "window_size": 3,
        "char_count": 141,
        "word_count": 28,
        "page_number": 86,
        "window_text": "모든 조합 중에서 세 가지 변수(나이, 치료요법\n\n그리고 종양의 등급)는 유용한 변수가 아니지만, 종양의 병기(stage)는 결절음성 유방암\n\n위의 표를 보면, Breast Cancer Alarm score 점수를 변수로 사용하거나 점수를 기반으로\n\n한 위험군 분류를 변수로 사용한다(고위험군 또는 저위험군).  점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나. ",
        "original_sentence": "아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_850",
      "text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 849,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 8,
        "window_text": "점수와 위험군 분류 모두\n\n원격\n\n무재발\n\n생존율(Distant\n\nRecurrence\n\nFree\n\nSurvival,\n\nDRFS)에\n\n대해\n\n주요한\n\n예후\n\n림프절 음성 환자에서의 위험도 예측에 대한 결과는 아래의 표와 그림과 같다.  아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다.",
        "original_sentence": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_851",
      "text": "연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 850,
        "window_size": 3,
        "char_count": 84,
        "word_count": 20,
        "page_number": 5,
        "window_text": "아래의 표와\n\n그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은 림프절\n\n42\n\n- - 42 -\n<!-- PAGE_86 -->\n###### Risk Group\n\n<!-- PAGE_86 -->\n###### Number of\n\n<!-- PAGE_86 -->\n###### Patients (%)\n\n<!-- PAGE_86 -->\n###### Number of Events\n\n<!-- PAGE_86 -->\n###### Through\n\n<!-- PAGE_86 -->\n###### 10 Years\n\n<!-- PAGE_86 -->\n###### Estimated Percent Without\n\n<!-- PAGE_86 -->\n###### Recurrence at 10 years\n\n<표 8> 림프절 음성 환자의 각 위험군에 대한 원격 무재발 생존율 요약\n\n림프절 양성 유방암 환자에서의 위험도 예측에 대한 결과는 아래의 그림과 표와 같다.  아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n",
        "original_sentence": "연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_852",
      "text": "43\n\n- - 43 -\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 851,
        "window_size": 3,
        "char_count": 18,
        "word_count": 7,
        "page_number": 5,
        "window_text": "아래의\n\n표와 그림은 ABCSG-8 임상시험에서 10년 동안 각 위험 군에서 원격 재발이 일어나지 않은\n\n(※ 출처 : Prosigna 510(k) 자료, p10-14, Clinical studies)\n\n<!-- PAGE_86 -->\n###### 3.  완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다. ",
        "original_sentence": "43\n\n- - 43 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_853",
      "text": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다.",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 852,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 8,
        "window_text": "완제품의 품질관리 시험성적서 또는 시험에 관한 자료\n\n- 가.  연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n",
        "original_sentence": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다."
      }
    },
    {
      "chunk_id": "chunk_854",
      "text": "(단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 853,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 11,
        "window_text": "연속적인 3회(3배치 1회 이상 또는 1배치 3회)에 대해 시험규격에 따른 시험 성적서 또는\n시험에 관한 자료를 제출하여 제품의 균일성을 제시한다.\n\n 43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4. ",
        "original_sentence": "(단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_855",
      "text": "- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 854,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "43\n\n- - 43 -\n- 나.  시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가. ",
        "original_sentence": "- 다. "
      }
    },
    {
      "chunk_id": "chunk_856",
      "text": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 855,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 8,
        "window_text": "시험규격 설정에 따른 시험 기준 및 방법에 관한 자료와 품질관리물질(표준물질 등)이\n사용된 경우, 이에 관한 자료를 제출 한다. (단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나. ",
        "original_sentence": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n"
      }
    },
    {
      "chunk_id": "chunk_857",
      "text": "<!-- PAGE_87 -->\n###### 4. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 856,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 87,
        "window_text": "(단, 표준물질에 관한 자료와 중복될 경우 이를\n\n생략한다.)\n\n - 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5. ",
        "original_sentence": "<!-- PAGE_87 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_858",
      "text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 857,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 8,
        "window_text": "- 다.  시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가. ",
        "original_sentence": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_859",
      "text": "국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 858,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 8,
        "window_text": "시험 항목은 품질의 동등성을 입증할 수 있는 항목(민감도, 특이도, 정밀도 등)을 권장한다.\n <!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다. ",
        "original_sentence": "국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_860",
      "text": "출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 859,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 87,
        "window_text": "<!-- PAGE_87 -->\n###### 4.  완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나. ",
        "original_sentence": "출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_861",
      "text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 860,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 8,
        "window_text": "완제품 품질관리 시험에 사용된 표준물질에 관한 자료\n\n- 가.  국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다. ",
        "original_sentence": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_862",
      "text": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 861,
        "window_size": 3,
        "char_count": 69,
        "word_count": 17,
        "page_number": 8,
        "window_text": "국제 표준품 또는 기타 사용된 표준물질의 확인서(certificate)\n- 나.  출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다. ",
        "original_sentence": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_863",
      "text": "이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 862,
        "window_size": 3,
        "char_count": 35,
        "word_count": 11,
        "page_number": 10,
        "window_text": "출처 및 근거 자료\n<!-- PAGE_87 -->\n###### 5.  검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다. ",
        "original_sentence": "이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_864",
      "text": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 863,
        "window_size": 3,
        "char_count": 30,
        "word_count": 8,
        "page_number": 9,
        "window_text": "검체보관 및 취급상(온도, 습도 등)의 조건 설정 근거자료\n\n- 가.  시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6. ",
        "original_sentence": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_865",
      "text": "이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 864,
        "window_size": 3,
        "char_count": 78,
        "word_count": 22,
        "page_number": 8,
        "window_text": "시험결과를 근거로 하여, 검사에 이용할 수 있는 검체의 취급방법, 보관 조건 및 방법,\n사용기한, 주의사항 등을 기재한다.  이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가. ",
        "original_sentence": "이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_866",
      "text": "이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 865,
        "window_size": 3,
        "char_count": 45,
        "word_count": 12,
        "page_number": 15,
        "window_text": "이는 원심분리 조건 등을 포함한 검체 전 처리 과정\n\n- 나.  검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다. ",
        "original_sentence": "이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_867",
      "text": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 866,
        "window_size": 3,
        "char_count": 83,
        "word_count": 19,
        "page_number": 87,
        "window_text": "검체 취급 및 보관조건에 대한 시험 결과를 제시한다.  이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n",
        "original_sentence": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_868",
      "text": "상관성 평가\n\n- 가. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 867,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 8,
        "window_text": "이는 제시된 시간, 온도, 습도 등의\n항목에 대해 유효하다고 제시된 구간 중 몇 단계에 대해 동일한 검사 결과를 보임을 입\n\n증해야 한다.  이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n",
        "original_sentence": "상관성 평가\n\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_869",
      "text": "일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 868,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 2,
        "window_text": "이 시험은 제시된 구간의 양측 한계치 이상에서 평가된 결과이어야 하며\n\n- 다.  시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n",
        "original_sentence": "일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_870",
      "text": "다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 869,
        "window_size": 3,
        "char_count": 110,
        "word_count": 25,
        "page_number": 13,
        "window_text": "시험에 사용된 방법, 검체 수, 검체 범위, 표준 농도, 계산법, 통계처리법, 허용기준, 결과 등을\n<!-- PAGE_87 -->\n###### 6.  상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n",
        "original_sentence": "다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_871",
      "text": "3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 870,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 87,
        "window_text": "상관성 평가\n\n- 가.  일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나. ",
        "original_sentence": "3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_872",
      "text": "44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 871,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 5,
        "window_text": "일반사항\n외 허가된 체외진단용 의료기기와의 상관성을 확인할 수 있는 비교 시험성적서를 포함\n\n하여야 한다.  다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나.  소프트웨어 : 검체 준비 과정(Prep. ",
        "original_sentence": "44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_873",
      "text": "- ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 872,
        "window_size": 3,
        "char_count": 787,
        "word_count": 163,
        "page_number": 89,
        "window_text": "다만, 측정원리 및 측정항목이 새로운 경우 동일목적으로 사용되는 제품과\n\n2) 성능시험 과정에서 기허가 제품과 비교검사를 실시하였다면 그 자료를 정리하여 상관성\n\n검사의 결과로 제시할 수 있다.\n\n 3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나.  소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n",
        "original_sentence": "- ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_874",
      "text": "- 나. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 873,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "3) 추가적으로 상관성 평가가 필요할 경우 아래의 원칙을 따른다.\n\n 44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나.  소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라. ",
        "original_sentence": "- 나. "
      }
    },
    {
      "chunk_id": "chunk_875",
      "text": "소프트웨어 : 검체 준비 과정(Prep. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 874,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 10,
        "window_text": "44\n\n- - 44 -\n가) 시험물질 검체\n\n- ① 다양한 역가의 표준물질과 통계적으로 해석 가능한 임상 검체수를 포함하여 비교\n시험을 수행한다.\n\n - ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나.  소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마. ",
        "original_sentence": "소프트웨어 : 검체 준비 과정(Prep. "
      }
    },
    {
      "chunk_id": "chunk_876",
      "text": "station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 875,
        "window_size": 3,
        "char_count": 46,
        "word_count": 7,
        "page_number": 11,
        "window_text": "- ② 임상 검체는 기 허가된 방법이거나 여타 검증된 방법으로 검사되어 검체의 이력\n- ④ 정량검사의 임상 검체는 측정범위 내의 다양한 농도가 포함되도록 하고 최소 40개\n외 허가 제품과의 비교시험을\n\n- ⑤ 결과가 불일치하는 경우 다른 검사를 통해 불일치의 원인을 분석하고 이에 대한\n체외진단용 의료기기 다지표 검사의 분석알고리즘을 이용하여 결과를 판정하는 기준과\n\n- ② 정량검사에 대해서는 기울기, 절편(신뢰구간과 함께), 상관계수 및 의학적 결정치에서의\n- ③ 정성 또는 반정량검사에 대해서는 양성과 음성 검체에 대한 비교검사와의 % 일치도를\n45\n\n- - 45 -\n<!-- PAGE_89 -->\n###### 유사점 및 차이점\n\n항 목\n\nProsigna\n\nMammaPrint\n\n제품설명\n\nplatform 및 ProsignaTM Breast\n\nCancer\n\nPrognostic\n\nGene\n\nSignature Assay\n\n마이크로어레이(Microarray) 기반\n\n분석(assay)\n\n46\n\n- - 46 -\n시험샘플\n\n파라핀 포매 유방암 검체\n\n신선\n\n동결\n\n또는\n\n신선한\n\n상태의\n\n유방암 조직 절편\n\n증폭 필요함;\n\n조직부터 전체 시험을 한 시험소\n\n에서 시행; RNA 추출, 라벨링 증\n\n폭,\n\n마이크로어레이\n\n혼성화\n\n☞ 아래 항목은 Prosigna™ Breast Cancer Prognostic Gene Signature Assay에 삽입되어\n\n1) 시험기기: nCounter Dx Analysis System은 Prep Station 5s와 Digital Analyzer 5s을 포함한다.\n\n - 나.  소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7. ",
        "original_sentence": "station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n"
      }
    },
    {
      "chunk_id": "chunk_877",
      "text": "준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 876,
        "window_size": 3,
        "char_count": 114,
        "word_count": 24,
        "page_number": 10,
        "window_text": "- 나.  소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n",
        "original_sentence": "준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라. "
      }
    },
    {
      "chunk_id": "chunk_878",
      "text": "검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 877,
        "window_size": 3,
        "char_count": 58,
        "word_count": 16,
        "page_number": 10,
        "window_text": "소프트웨어 : 검체 준비 과정(Prep.  station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n 47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n",
        "original_sentence": "검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마. "
      }
    },
    {
      "chunk_id": "chunk_879",
      "text": "검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7. ",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 878,
        "window_size": 3,
        "char_count": 77,
        "word_count": 17,
        "page_number": 90,
        "window_text": "station) 과 디지털 분석(Digital Analyzer) 과정으로 나뉜다.\n 준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n 47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n - - 2 -",
        "original_sentence": "검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_880",
      "text": "소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 879,
        "window_size": 3,
        "char_count": 207,
        "word_count": 39,
        "page_number": 9,
        "window_text": "준비 과정의 소프트웨어는 검체 교잡반응(hybridazation)을 자동화 하는 것이고, 디지털 분석은\n\n검체에서 나오는 다양한 신호를 분리하고 측정하는 신호 해독, 원 데이터 저장, 알고리즘\n\n- 라.  검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n 47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n - - 2 -",
        "original_sentence": "소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_881",
      "text": "47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 880,
        "window_size": 3,
        "char_count": 88,
        "word_count": 19,
        "page_number": 91,
        "window_text": "검체 추출 및 처리: 파라핀 포매 검체에서 RNA 추출은 독립적으로 시행되며, 이 후 RNA는\n- 마.  검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n 47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n - - 2 -",
        "original_sentence": "47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_882",
      "text": "- - 2 -",
      "metadata": {
        "source": "질병의+예후·예측에+사용되는+체외진단용+의료기기+허가심사+가이드라인.pdf",
        "chunk_index": 881,
        "window_size": 3,
        "char_count": 7,
        "word_count": 4,
        "page_number": 36,
        "window_text": "검교정 : 기기의 설치, 검교정, 보전에 관련된 부분은 제조사가 수행하며, 사용자 교정은\n<!-- PAGE_90 -->\n###### 7.  소프트웨어의 성능자료\n\n소프트웨어(알고리즘)에 대한 성능자료는 「의료기기 허가·신고·심사 등에 관한 규정」\n\n(이하 허가규정) 제29조(첨부자료의 요건)에서 요구하고 있는 자료로 소프트웨어의 명칭,\n\n버전, 운영환경, 구조 등을 포함하여 주요기능을 검증하고 유효성확인을 할 수 있는 자료, 의료기기\n\n소프트웨어 적합성 확인보고서(별지 제13호 서식)를 제출해야 한다.\n\n 47\n\n- - 47 -\n<!-- PAGE_91 -->\n###### [전문협의회 위원]\n\n1\n\n- - 1 -\n15172의료평425)의 결과를 활용하였습니다.\n\n - - 2 -",
        "original_sentence": "- - 2 -"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 882,
    "avg_chunk_length": 126.04195011337869,
    "min_chunk_length": 3,
    "max_chunk_length": 9706,
    "total_characters": 111169,
    "total_words": 23319,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 3709,
    "heading_count": 1097,
    "paragraph_count": 803,
    "list_item_count": 237,
    "table_cell_count": 1572,
    "tables_detected": 8,
    "chunks_generated": 882
  }
}